







A Thesis Submitted for the Degree of PhD at the University of Warwick 
 







Copyright and reuse:                     
This thesis is made available online and is protected by original copyright.  
Please scroll down to view the document itself.  
Please refer to the repository record for this item for information to help you to cite it. 
Our policy information is available from the repository home page.  
 


























Role of maternal ethnicity, adverse risk 
factors and gestational diabetes on offspring 







A thesis submitted in partial fulfillment of the requirements for the 
degree of                                                                                                  










Table of contents 
List of illustrations ............................................................................................................................ 1 
List of tables ..................................................................................................................................... 5 
Acknowledgements .......................................................................................................................... 8 
Declaration ....................................................................................................................................... 9 
Abstract .......................................................................................................................................... 10 
List of abbreviations ....................................................................................................................... 11 
Chapter 1 ........................................................................................................................................ 12 
Childhood obesity: the global epidemic ......................................................................................... 12 
1.1 Introduction .......................................................................................................................... 13 
1.2 Body Mass Index (BMI) ....................................................................................................... 14 
1.3 Childhood obesity adverse outcomes ................................................................................... 16 
1.4 Causes of childhood obesity ................................................................................................. 20 
1.4.1 Diet and Lifestyle .......................................................................................................... 20 
1.4.2 Genetics ......................................................................................................................... 22 
1.4.3 Intrauterine programming .............................................................................................. 23 
1.4.4 Role of maternal factors on the pathogenesis of childhood obesity .............................. 25 
1.4.5 Prematurity .................................................................................................................... 44 
1.4.6 Small for gestational age (SGA) and Low Birth Weight (LBW) .................................. 45 
1.4.7 Feeding pattern .............................................................................................................. 46 
1.5 Adipose tissue: A complex cell system ................................................................................ 48 
1.5.1 Function and types ......................................................................................................... 48 
               1.5.1.1 White Adipose Tissue…………………………………………………………...50 
               1.5.1.2 Brown Adipose Tissue…………………………………………………………..51 
               1.5.1.3 Beige (Brown in White)…………………………………………………………52  
1.5.2 Adipose tissue as an endocrine organ ............................................................................ 53 
1.6 Body composition during early stages of life ....................................................................... 69 
1.6.1 Infant body composition reference data ........................................................................ 70 
1.6.2 Body composition data using ADP ............................................................................... 72 
1.6.3 Body composition measurement methods during infancy ............................................. 74 
1.6.3.4 Multicompartment model ........................................................................................... 77 
        1.6.3.5 Dual Energy X-ray absorptiometry (DXA)…………………………………….........77 
        1.6.3.6 Magnetic Resonance Imaging (MRI)………………………………………………...78 
        1.6.3.7 Air Displacement Plethysmography (ADP)………………………………………….79 
                 1.6.3.7.1 Operating Principles………………………………………………………….81 
                 1.6.3.7.2 Calculating FM and FFM…………………………………………………….82 
                  1.6.3.7.3 Test procedure……………………………………………………………….83 
                  1.6.3.7.4 ADP validation……………………………………………………...……….85  




1.7.1 Hypothesis ..................................................................................................................... 88 
1.7.2 Research Questions ....................................................................................................... 88 
1.7.3 Outcomes and criteria .................................................................................................... 88 
1.7.4 Inclusion criteria ............................................................................................................ 88 
1.7.5 Exclusion criteria ........................................................................................................... 89 
1.8 Summary .............................................................................................................................. 89 
1.9 References ............................................................................................................................ 91 
CHAPTER 2 ................................................................................................................................. 112 
Role of cord blood leptin, adiponectin and infant body composition: Systematic Review and Meta-
analysis ......................................................................................................................................... 112 
2.1.1 Leptin in pregnancy and early post natal life............................................................... 113 
2.1.2 Adiponectin in pregnancy and early post natal life ..................................................... 118 
Figure 2.4: Role of adiponectin during pregnancy; Adopted from Aye et al (64) ....................... 121 
2.2 Cord blood adipocytokines and body composition up to 5 years of age: a systematic review 
and meta-analysis ..................................................................................................................... 122 
2.2.1 Background .................................................................................................................. 122 
2.2.2 Hypothesis ................................................................................................................... 123 
2.2.3 Research Questions ..................................................................................................... 123 
2.2.4 Methods ....................................................................................................................... 124 
2.2.5 Results ......................................................................................................................... 127 
2.2.6 Discussion.................................................................................................................... 137 
2.3 Closing Remarks ................................................................................................................ 140 
Chapter 3 ...................................................................................................................................... 148 
The impact of Gestational Diabetes Mellitus on infant body composition .................................. 148 
3.1 Introduction ........................................................................................................................ 149 
3.2 The role of maternal adverse/risk outcomes on offspring's body composition: Prospective, 
longitudinal cohort study .......................................................................................................... 149 
3.2.1 Hypothesis ................................................................................................................... 149 
3.2.2 Research Questions ..................................................................................................... 149 
3.2.3 Outcomes and criteria .................................................................................................. 150 
3.2.4 Study design ................................................................................................................ 150 
3.2.5 Results ......................................................................................................................... 159 
3.2.6 Discussion.................................................................................................................... 166 
3.2.7 Conclusion ................................................................................................................... 172 
3.2.8 References ................................................................................................................... 173 
Chapter 4 ...................................................................................................................................... 178 
Maternal adverse characteristics and ethnicity as predictors of infant body composition ........... 178 
4.1 Introduction ........................................................................................................................ 179 
4.1.1 Risk factors .................................................................................................................. 179 
4.1.2 Hypothesis ................................................................................................................... 181 




4.1.4 Outcomes ..................................................................................................................... 181 
4.1.5 Criteria ......................................................................................................................... 182 
4.1.6 Methods – Statistical analysis ...................................................................................... 182 
4.2 Results ................................................................................................................................ 184 
4.2.1 Predictors of neonatal body composition .................................................................... 184 
4.2.2 Body composition and Gender .................................................................................... 187 
4.2.3 Body composition and ethnicity .................................................................................. 192 
4.2.4 Body composition and feeding mode .......................................................................... 199 
4.3 Discussion .......................................................................................................................... 201 
4.3.1 Maternal BMI, gestational weight again and gestational age ...................................... 201 
4.3.2 Body composition and gender ..................................................................................... 203 
4.3.3 Body composition and feeding mode .......................................................................... 205 
4.3.4 Body composition and ethnicity .................................................................................. 207 
4.4 References .......................................................................................................................... 213 
Chapter 5 ...................................................................................................................................... 218 
Maternal, cord blood biomarkers and infant adiposity ................................................................. 218 
5.1 Introduction ........................................................................................................................ 219 
5.1.1 Fetal anabolic fuels ...................................................................................................... 219 
5.1.2 The role of leptin and adiponectin ............................................................................... 220 
5.1.3 Hypothesis ................................................................................................................... 220 
5.1.4 Research Questions ..................................................................................................... 220 
5.1.5 Outcomes ..................................................................................................................... 221 
5.1.6 Criteria ......................................................................................................................... 221 
5.1.7 Methods - Statistical analysis ...................................................................................... 221 
5.2 Leptin- Adiponectin assays ................................................................................................ 221 
5.2.1 Leptin Elisa .................................................................................................................. 221 
5.2.2 Adiponectin Elisa ........................................................................................................ 222 
5.2.3 Calculating the results ................................................................................................. 222 
5.3 Insulin and c-peptide assays ............................................................................................... 223 
5.3.1 Insulin and c-peptide RIA............................................................................................ 224 
5.4 Indexes of beta cell function and insulin sensitivity ........................................................... 225 
5.4.1 Homeostasis Model Assessment (HOMA) .................................................................. 226 
5.4.2 Matsuda Index ............................................................................................................. 227 
5.5 Statistical analysis .............................................................................................................. 227 
5.6 Results ................................................................................................................................ 228 
5.6.1 Maternal analysis ......................................................................................................... 229 
5.6.2 Maternal biomarkers and neonatal data ....................................................................... 232 
5.6.3 Cord adipocytokines, cord c-peptide and body composition at birth .......................... 235 
5.6.4 Cord adipocytokines and body composition at Visit 3 (4 weeks) ............................... 236 




5.6.6 Metabolic biomarkers, GDM and ethnicity ................................................................. 238 
5.7 Discussion .......................................................................................................................... 241 
5.7.1 Maternal insulin resistance: “the missing link” ........................................................... 242 
5.7.2 Development of early insulin resistance ...................................................................... 243 
5.7.3 The role of leptin and adiponectin ............................................................................... 244 
5.7.4 The role of cord c-peptide ........................................................................................... 246 
5.8 References .......................................................................................................................... 249 
Chapter 6 ...................................................................................................................................... 253 
Comparison of fat mass equations and anthropometric indexes with reference criterion (PEAPOD)
 ...................................................................................................................................................... 253 
6.1 Introduction ........................................................................................................................ 254 
6.1.1 Anthromopetric fat mass equations ............................................................................. 254 
6.1.2 Anthropometric indexes .............................................................................................. 255 
6.1.3 Hypothesis ................................................................................................................... 255 
6.1.4 Research questions ...................................................................................................... 256 
6.1.5 Outcome ...................................................................................................................... 256 
6.1.6 Criteria ......................................................................................................................... 256 
6.1.7 Methods – Statistical analysis ...................................................................................... 256 
6.2 Results ................................................................................................................................ 257 
6.2.1 Fat mass at birth ........................................................................................................... 258 
6.2.2 Fat mass at 4 weeks (visit 3) and 5 months (visit 4) .................................................... 259 
6.2.3 Prediction of body composition by anthropometric indexes ....................................... 260 
6.3 Discussion .......................................................................................................................... 262 
6.3.1 Validity of FM equations ............................................................................................. 262 
6.3.2 Anthropometric indexes as predictors of body composition ....................................... 264 
6.4 Conclusion .......................................................................................................................... 266 
6.5 References .......................................................................................................................... 267 
Chapter 7 ...................................................................................................................................... 269 
Summary and Conclusions ........................................................................................................... 269 
7.1 The origins of childhood obesity ........................................................................................ 270 
7.2 Maternal BMI, gestational weight gain (GWG) and glycaemia ......................................... 272 
7.3 What is the underlying pathogenic mechanism? ................................................................ 274 
7.4 What about maternal characteristics and childhood obesity? ............................................. 275 
7.5 Answering the hard questions ............................................................................................ 276 
7.6 Putting everything together ................................................................................................ 278 
7.7 Early postnatal life - Is it too late to intervene? .................................................................. 279 
7.8 Gestational diabetes mellitus (GDM) ................................................................................. 281 
7.9 Summary of the key messages............................................................................................ 284 
7.10 Does one size fit all? Effect of ethnicity on body composition ........................................ 285 
7.11 Conclusion – The intergenerational effect ........................................................................ 287 




7.13 References ........................................................................................................................ 290 
Ethical considerations ............................................................................................................... 295 
Consent ..................................................................................................................................... 295 
Human Biological Material ...................................................................................................... 295 
Risks and Burdens .................................................................................................................... 296 
Benefits ..................................................................................................................................... 296 
Confidentiality .......................................................................................................................... 296 
Conflicts of Interest .................................................................................................................. 297 
Funding ..................................................................................................................................... 297 
Sponsors ................................................................................................................................... 298 
Appendices ............................................................................................................................... 299 










List of illustrations 
 
Chapter 1 
Figure 1.1: Six pillars of tackling obesity  
Figure 1.2: Causes of childhood obesity  
Figure 1.3: Impact of intervening in early post natal life 
Figure 1.4: Pedersen hypothesis                                                                                                 
Figure 1.5: Developmental programming of obesity                                                                                                    
Figure 1.6: Components of gestational weight gain 
Figure 1.7: Lipogenesis and Lipolysis 
Figure 1.8: Effects of adipocyte hypertrophy in obesity 
Figure 1.9: Origin of fat cells 
Figure 1.10: Thermogenesis 
Figure 1.11: Central effects of leptin 
Figure 1.12: Leptin physiology 
Figure 1.13: Structure of adiponectin 
Figure 1.14: Adiponectin receptors  
Figure 1.15: Adiponectin receptor signaling 
Figure 1.16: Activation of PPARγ by thiazolidenidiones 
Figure 1.17: Adiponectin actions 
Figure 1.18: Two and four compartment models 
Figure 1.19: Centiles for body composition according to sex and gestational age of 
newborns enrolled in the INTERGROWTH 21st study 
Figure 1.20: Triceps and subscapular skinfold thickness assessment 
Figure 1.21: Deuterium dilution 
Figure 1.22: Infant body composition using DXA 
Figure 1.23: Inverse relationship between volume and pressure of gas under isothermic 
conditions 
Figure 1.24: PEAPOD (Infant Body Composition assessment) 
Figure 1.25: PEAPOD parts  
Figure 1.26: Lung volumes and capacities 
Figure 1.27: Steps in assessing infant body composition using PEAPOD 
Figure 1.28: Detailed display of body composition results 








Figure 2.1: Role of leptin during fetal life 
Figure 2.2: Circulating plasma levels in lambs from mothers with obesity and controls 
Figure 2.3: In utero malnourishment leads to premature leptin surge and higher weight 
gain 
Figure 2.4: Role of adiponectin during pregnancy 
Figure 2.5: Flow diagram of the study 
Figure 2.6: Forest plot showing the pooled correlation between cord blood leptin and fat 
mass at birth 
Figure 2.7: Forest plot showing the pooled correlation between cord blood adiponectin 
and fat mass at birth 
Figure 2.8: Funnel plot examining heterogeneity in the cord blood leptin and fat mass at 
birth group  
 
Chapter 3 
Figure 3.1: Steps in gaining HRA approval 
Figure 3.2: Delivery alert for midwives  
Figure 3.3: Flowchart of the study detailing recruitment and follow up visits 
Figure 3.4: Centrifugation and blood fractionation 
Figure 3.5: Flow-chart of the study showing participants’ recruitment and attendance to 
follow up visits 
Figure 3.6: Weight and body composition distribution across the three visits 
Figure 3.7: Mortality risk of expectant management versus induction of labour in GDM 
pregnancies 
Figure 3.8: Energy expenditure in infancy 
Figure 3.9: Energy intake and changes in fat free mass (FFM) 
Figure 3.10a: Active role of fat free mass (FFM)  
Figure 3.10b: Impact of weight changes in body composition 




Figure 4.1: Intergenerational programming 
Figure 4.2: Flowchart detailing infant attendance per study visit 
Figure 4.3: Predictors of weight, fat mass (FM) and fat free mass (FFM) during the first 5 
months of life 
Figure 4.4: During the first 5 months of life female offspring had consistently lower 




Figure 4.5: Body composition evolution between White Europeans and South Asians 
during the first 5 months of life 
Figure 4.6: Changes in skinfold thickness during pregnancy. Preferential central adipose 
tissue deposition 
Figure 4.7: The four core genotypes mouse model 
Figure 4.8: Sex hormones, body composition and cardiovascular risk 
Figure 4.9: Nucleotide polymorphisms associated with type 2 diabetes mellitus in SA and 
risk compared to White Europeans 
Figure 4.10: Factors associated with non communicable diseases in migrants 
 
Chapter 5 
Figure 5.1: “Sandwich” ELISA technique 
Figure 5.2a: Standard curves fitted for leptin  
Figure 5.2b: Standard curves fitted for adiponectin 
Figure 5.3a: Principles of non competitive RIA  
Figure 5.3b: Principles of competitive RIA  
Figure 5.4: Beta cell dysfunction estimated by the insulin response 
Figure 5.5a: HOMA model presented by Turner and Holmes  
Figure 5.5b: HOMA model updated by Levy et al 
Figure 5.6: Consort diagram of available biomarkers during study visits 
Figure 5.7: Outcomes of interest based on BMI categories 
Figure 5.8: Scatter plots between Matsuda index, HOMA-IR, OGTT0 glucose values, 
OGTT120 glucose values and maternal BMI 
Figure 5.9: Trends between cord leptin, cord c-peptide and percentage fat mass (%FM) 
at birth and follow up visits 
Figure 5.10a,b: Schematic representation of differences in maternal biomarkers based on 
GDM status  
Figure 5.10c,d: Schematic representation of differences in maternal biomarkers based on 
ethnicity 
Figure 5.11: Association between cord c-peptide and fat mass in offspring of GDM and 
nGDM pregnancies 
Figure 5.12: Role of metabolic hormones in the development of hypothalamic circuitry 
 
Chapter 6 
Figure 6.1: Consort diagram of available anthropometry during study visits 
Figure 6.2a: Bland Altman plot of fat mass (FM) predicted by Lingwood against reference 




Figure 6.2b: Bland Altman plot of fat mass (FM) predicted by Aris equations against 
reference criterion (PEAPOD) at birth 
 
Chapter 7 
Figure 7.1: Prevalence of childhood overweight, obesity and severe obesity in Europe 
Figure 7.2: Determinants of childhood obesity 
Figure 7.3: Insulin concentrations at different time points during OGTT at 6 years old 
children, stratified by maternal BMI according to IOM recommendations 
Figure 7.4: Fuel mediated teratogenesis 
Figure 7.5: Fetal adipose tissue development 
Figure 7.6: Preconception maternal hyperinsulinaemia and fetal overgrowth 
Figure 7.7: Structural and molecular changes as a result of adverse intrauterine 
environment 
Figure 7.8: Leptin as a predictor of future obesity 


























List of tables 
 
Chapter 1 
Table 1.1: IDF definition of metabolic syndrome in children and adolescents 
Table 1.2: Various criteria proposed for diagnosing GDM based on fasting OGTT (24-28 
weeks gestation) 
Table 1.3: Risk factors to screen for GDM as per ADA guidelines 
Table 1.4: IADSPG criteria for GDM diagnosis 
Table 1.5: Risk factors to screen for GDM as per NICE guidelines 
Table 1.6: Hormones produced by adipose tissue 
Table 1.7: Factors affecting leptin production 
Table 1.8: Leptin interactions with Insulin-glucagon  
Table 1.9: Adiponectin receptors in various human tissues 
Table 1.10: Body composition reference for children up to 3 years of age 
Table 1.11: Body composition data derived from ADP in US population 
Table 1.12: Body composition data of newborns enrolled in the INTERGROWTH 21st 
study 
Table 1.13: Body composition techniques in infancy 
 
Chapter 2 
Table 2.1: Inclusion and exclusion criteria used for the study selection  
Table 2.2: Assessment of included studies 
Table 2.3: Characteristics of studies included 
Table 2.4: Cord blood leptin and adiposity up to 5 years of age 
Table 2.5: Cord blood adiponectin and adiposity up to 5 years of age 
 
Chapter 3 
Table 3.1: Maternal characteristics 
Table 3.2: Fetal data during 20 weeks scan 
Table 3.3: Neonatal characteristics at birth 
Table 3.4a: Regression of neonatal body composition between the two groups 
Table 3.4b: Regression analysis of fat free mass (FFM) at birth adjusting for maternal 
BMI, maternal gestational weight gain (GWG) and gestational age (GA) 
Table 3.5: Infant characteristics and feeding mode at visit 3 
Table 3.6: Infant characteristics and feeding mode at visit 4 
Table 3.7: Regression analysis of fat mass index (FMI) at visit 4 adjusting for maternal 






Table 4.1: Maternal characteristics 
            Table 4.2: Results of multiple regression analysis showing predictors of body 
composition 
Table 4.3: Predictors of body composition during the first 5 months 
Table 4.4a: Maternal characteristics  
Table 4.4b: Neonatal characteristics at birth  
Table 4.4c: Infant characteristics and feeding mode at visit 3 
Table 4.5: Infant characteristics and feeding mode at visit 4              
Table 4.6: Fetal data during 20 weeks scan 
Table 4.7:  Infant anthropometric measurements based on gender    
Table 4.8: Maternal characteristics between White Europeans and South Asians (SA) 
Table 4.9: Socioeconomic and diet characteristics of White European and South Asian 
(SA) study population 
Table 4.10a: Neonatal characteristics at birth  
Table 4.10b: Regression of neonatal body composition between the two groups 
            Table 4.11a: Infant characteristics and feeding mode between White Europeans and 
South Asians (SA) at visit 3  
Table 4.11b: Infant characteristics and feeding mode between White Europeans and 
South Asians (SA) at visit 4 
Table 4.12: Fetal data during 20 weeks scan 
Table 4.13: Infant anthropometric measurements based on ethnicity 
Table 4.14: Maternal characteristics based on feeding mode 
Table 4.15a: Infant characteristics at birth based on feeding mode 
Table 4.15b: Infant characteristics at visit 4 based on feeding mode 
Table 4.16: Comparison of South Asian (SA) population participating in our cohort and 
Intergrowth 21st   
 
Chapter 5 
Table 5.1: Surrogate measures of insulin sensitivity 
Table 5.2: Maternal characteristics during OGTT at 28 weeks 
Table 5.3: Associations between maternal biomarkers and BMI at 28 weeks       
Table 5.4a: Regression analysis between maternal biomarkers (independent variable) 
and insulin sensitivity/secretion indexes  
Table 5.4b: Regression analysis between maternal biomarkers (independent variable) 




Table 5.5: Regression analysis between maternal adipocytokines at 28 weeks gestation 
and neonatal anthropometry 
Table 5.6: Correlations between maternal characteristics at 28 weeks gestation, neonatal 
body composition and cord c-peptide 
Table 5.7: Correlations between cord adipocytokines and neonatal body composition 
Table 5.8: Correlations between cord adipocytokines, cord c-peptide and neonatal body 
composition at visit 3 
Table 5.9: Correlations between cord adipocytokines, cord c-peptide and neonatal body 
composition at visit 4 
Table 5.10a: Comparison of maternal biomarkers based on GDM status  
Table 5.10b: Comparison of maternal biomarkers based ethnicity 
Table 5.11a: Comparison of anthropometric measurements and cord blood biomarkers 
between offsprings of GDM and nGDM pregnancies  
Table 5.11b: Regression analysis of cord c-peptide levels 
Table 5.12: Comparison of anthropometric measurements and cord blood biomarkers 
between offspring of SA and White European descent 
Table 5.13: Comparison of maternal and neonatal characteristics between our study 
(PEAPOD) and HAPO 
 
Chapter 6 
Table 6.1: Equations for infant fat mass (FM; kgr) estimation 
Table 6.2: Maternal-Infant characteristics and measurements by reference criterion 
(PEAPOD) 
Table 6.3: Comparison of fat mass (FM) assessment by reference method (PEAPOD) 
and equations at birth, 4 weeks and 5 months                                                                                                   
Table 6.4: Comparison of criterion method (PEAPOD) and fat mass (FM) equations using 
regression and Bland Altman analysis 
Table 6.5a: Relationship between body composition measures obtained with PEAPOD 
and anthropometric indexes at birth 
Table 6.5b: Relationship between body composition measures obtained with PEAPOD 
and anthropometric indexes at 4 weeks  
Table 6.5c: Relationship between body composition measures obtained with PEAPOD 
and anthropometric indexes at 5 months 
Table 6.6: Comparison of mean values (SD) between our cohort and data obtained by 











I would like to thank my supervisors, Professor P. Saravanan and Associate Professor O. 
Oyebode, without whom I would not have been able to finish this research. Their support, 
encouragement and patience have been invaluable throughout these three years. Their 
insight and knowledge guided me throughout my PhD and helped me develop my skills. 
Special thanks to Professor Saravanan who believed in me and introduced me to the 
“world of research”, giving me the opportunity to see medicine from a different angle.  
 
I would also like to thank the Diabetes Research Team at GEH for their collaborative 
effort during data collection, Y. Weldeselassie for reviewing the statistical accuracy of my 
analyses, J. Samavat (biotechnologist, fellow PhD student) and I. Goljan (laboratory 
assistant) for supervising and helping me with the biochemical analyses.  
 
My thanks to all participants that took part in the study. Sacrificing some of their own time 
enabled this research to be possible. Their enthusiasm for participating into research and 
contributing to public health was my drive during the long hours spent in the Maternity 
ward, at GEH. 
 
My sincere gratitude to all funding committees who helped me accomplish my PhD 
project. 
 
Finally, my biggest thanks to my family, my wife and two kids, for all the support they 


















The current thesis is an original work and is submitted to the University of Warwick in 
support of my application for the degree of Doctor of Philosophy. It has been composed 
by myself and has not been submitted in any previous application for any degree. 
 
Two papers, which have been created based on this research work, titled: i) Cord blood 
adipocytokines and body composition at birth and up to 5 years of age: A systematic 
review and ii) Impact of gestational diabetes mellitus on infant body composition, are 





























Childhood obesity has reached epidemic proportions globally. There is increasing 
evidence that factors acting during early development, such as maternal obesity, 
excessive gestational weight gain and gestational diabetes mellitus increase the chances 
of obesity and metabolic syndrome in later life. However, the major limitation of the 
available literature is the lack of accurate body composition measurement. In order to 
understand the mechanisms underpinning the developmental origins of metabolic 
diseases in adulthood, data on the evolution of body composition in early childhood is 
required. We hypothesize that offspring born to high metabolic risk mothers have altered 
body composition at birth and early infancy, which leads to adverse developmental 
programming of obesity and metabolic diseases. 
 
Objective and methods: Purpose of the current research work was to study the effect of 
maternal adverse metabolic profile on infant’s body composition. Secondary aim was to 
assess whether early life biomarkers can predict infant and early childhood adiposity, 
allowing the implementation of targeted prevention strategies on high risk groups from 
the early stages of life. A longitudinal observational study was performed. Air 
displacement plethysmography was used to assess infant body composition up to 5 
months of age. A systematic review looking at the association between cord blood leptin, 
adiponectin and infant adiposity was also conducted. 
 
Results: Maternal obesity, gestational weight gain and hyperglycaemia independently 
predict infant adiposity. Maternal insulin resistance seems to be the “missing link” 
between adverse maternal metabolic profile and neonatal adiposity. Current practices in 
the management of gestational diabetes that reduce the incidence of macrosomia 
happens at the expense of fat free mass. This may drive early adiposity rebound, which 
itself has shown to be an independent driver for metabolic diseases in adult life. Ethnic 
subgroup analysis revealed no difference in infant body composition, provided that 
maternal characteristics and intrauterine environment remain constant across ethnicity. 
Cord blood leptin is strongly and positively associated with fat mass at birth but inversely 
predicts adiposity up to 3 years of age. 
 
Conclusion: Despite genotype being determined at conception, the phenotype is 
modulated and determined by maternal and intrauterine factors. Antenatal and early 
postnatal life are critical periods of developmental plasticity for offspring fat and fat free 
mass. Such adverse body composition at birth and early infancy are setting lifelong 
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1.1 Introduction  
 
Childhood obesity has reached epidemic levels and constitutes one of the greatest Public 
Health challenges of the 21st century. It is a condition of excessive fat accumulation in 
adipose tissue to an extent that general health may be affected (4). Globally, the number 
of infants and young children (up to 5 years) who were overweight/obese was 42 million 
in 2013 with numbers expected to increase to 70 million by 2025 (5). United Kingdom’s 
(UK) obesity rate is one of the worst in Western Europe. Health survey for England in 
2015 revealed that 28% of children, between 2 and 15 years of age, were either 
overweight (14%) or obese (14%) (6). Latest data reveal that 1 in 5 children are obese 
when starting primary school with figures rising to 1 in 3 at secondary school. Most 
concerning is the fact that in 50% of cases neither children nor their parents are aware 
about the excessive weight, considering themselves as normal weight (7). By 2020, half 
children are expected to be obese or overweight. National Health Service (NHS) is 
currently spending £5.1billion/year on obesity related conditions, constituting the second 
biggest burden of the economy after smoking. If figures continue to rise, obesity related 
costs are expected to reach £10billion/year by 2050 (8). Treating obesity has proven to 
be extremely challenging, therefore is crucial to establish prevention programs at early 
stages of life. Obesity has previously been considered a high income country problem 
but increasing rates are now noted in developing countries (9). The transition from rural 
to urban lifestyle has increased the obesity rates, shifting health problems from 
malnutrition and infective diseases to cardiovascular events and diabetes. The World 
Health Organization (WHO) states that social and economic inequities are leading factors 
for the obesity epidemic, with higher prevalence in low socioeconomic and ethnic 
minority groups. Consistent with this data, 40% of children in UK deprived areas were 
obese, compared to 27% in wealthy regions (10).  
 
Recognizing the threat of childhood obesity, English Government set the ‘’Childhood 
obesity strategy’’ in 2018, aiming to halve rates within the next 10 years through 
programs as Change4Life, Living well for Longer and Healthy Lives-Healthy People (11). 
Cornerstone of the campaign is the multidisciplinary approach to the problem, requiring 
actions from the government, schools, parents and children themselves. Aim is to tackle 
the epidemic starting with maternal health and continuing into ways children are grown. 
Following the “6 pillars in ending childhood obesity” set by WHO (Figure 1.1), program 
focuses on actions starting from pre-conception and antenatal period, expanding to 





Department of Health emphasizes the correlation between maternal health and 
offspring’s well being. Normal pre-conception Body Mass Index (BMI), early diagnosis of 
maternal hyperglycaemia and gestational hypertension, gestational weight gain (GWG) 
within national recommendations and avoidance of smoking, alcohol and toxins during 
pregnancy ensure a healthy start for the baby. Following the perinatal period, UK 
government has set a pioneering plan in reducing obesity risk by creating a healthy and 
supportive environment for children to grow. The introduction of sugar levy as well as the 
plan to ban advertisements of products high in fat, sugar and salt before 9 pm aims to 
reduce excessive caloric intake. Implementation of nutritional standards to all schools 
and promotion of physical activity are other important components of the campaign. 
Audiovisual media and weight management clinics will be used to inform and support 
both parents and children on healthy nutrition and lifestyle. Finally, of great importance is 
the government’s statement on supporting and facilitating research relevant to the origins 





Figure 1.1: Six pillars of tackling obesity. Measures targeting diet and lifestyle start from 
preconception and antenatal life and extend to early childhood interventions 
 
 
1.2 Body Mass Index (BMI) 
 
BMI, defined as the body mass divided by the square of the height (kg/m2), is used as the 
reference method assessing obesity. Children are classified as obese or overweight after 
comparing their BMI with a reference population, adjusting for age and gender. BMI is a 




(12) but not in children because of the body changes in growth. It cannot distinguish Fat 
Mass (FM) to Fat Free Mass (FFM) and increased values during adolescence are more 
likely to reflect FFM rather than adiposity (13). Freedman et al (14) showed that BMI is a 
good indicator of fatness in children with obesity but in thinner subjects is strongly 
associated with FFM. Bogalusa Heart study (15) and the Pediatric Roseta study (14) 
highlighted the need for body fatness cut points, specific to age, gender and race. So far 
WHO committee has not set any cut off point for %FM in order to define obesity (16).  
Evidence suggests that higher BMI is related to short and long term adverse outcomes 
(17) but there is no data on a specific BMI value. The above has led to a number of 
reference thresholds causing confusion and inconsistency when reporting obesity rates. 
There are 4 main classification systems for childhood obesity based on age and gender 
specific BMI. These are: 
 
1. Centers for Disease Control and Prevention (CDC) growth charts, based on 
data from 4 US surveys. (18) Percentile curves were created after studying North 
American population and ensured a smooth transition from infants (birth-36 
months) to older children (2-20 years) charts. Growth patterns were set after 
considering ethnic diversity and combined (breast and formula) feeding patterns. 
Overweight was considered 85th-94th centile and obese >95th centile. 
2. International Obesity Taskforce (IOTF), based on data from 6 different 
countries (19). Data from 97,876 males and 94,851 females from birth to 25 years 
of age was retrieved in order to provide a universal “cut off” point for obesity. 
Percentile curves for BMI, sex specific, passing through the adult accepted “cut 
off” of 25 kg/m2 and 30 kg/m2 at 18 years of age were created. Children between 
2-20 years of age were categorized as normal weight/overweight/obese without 
information on BMI growth reference. 
3. World Health Organization (WHO) growth standards (20). In 2006 WHO 
published growth standards for children aged 0-5 years. Data collected between 
1997 and 2003 from 8500 children of different ethnic background was used to 
create internationally accepted growth curves. Overweight was defined as BMI-
for-age Z score ≥1 and obesity as BMI-for-age Z score ≥2. In 2007 WHO 
complimented the previous guidelines by publishing charts for children between 
5-19 years, utilizing data from 30,018 children, collected from 1963 to 1974. 
4. UK1990 thresholds. Nationally representative data from 32,222 children 
between 1978 and 1994 was used to create centile curves for British population. 
In clinical settings 91st and 98th centile were used to define overweight and 






In order to address the confusion and set clear diagnostic criteria in the UK, the Scientific 
Advisory Committee on Nutrition (SACN) and the Royal College of Paediatrics and Child 
Health (RCPCH) published a consensus report in 2009 (22). For children aged 4-18 
years, committee suggested the UK1990 criteria to define overweight and obesity, 
whereas for infants aged 0-4 years the committee recognized the new UK-WHO growth 
curves. The new charts were based on healthy children around the world who were 
exclusively breastfed for at least 4 months and have lines drawn at 91st and 98th centile to 
help clinicians during their assessment.   
 
1.3 Childhood obesity adverse outcomes 
 
The rapidly increasing numbers of children with obesity are followed by short and long 
term consequences. Metabolic syndrome in adults is known to be related with higher 
mortality, cardiovascular disease and risk of developing type 2 diabetes (23). On the 
other hand, metabolic syndrome during childhood is not well described, as the small 
numbers of children presenting with adverse metabolic profile in the past, didn’t allow for 
safe conclusions. The obesity epidemic had led the International Diabetes Federation 
(IDF) to develop diagnostic criteria in order to define metabolic syndrome in childhood 
and adolescence (24). Central obesity is mandatory to establish the diagnosis and is also 
strongly related to the other components of the syndrome which are hypertension, 




Table 1.1: IDF definition of metabolic syndrome in children and adolescents; diagnosing 
the metabolic syndrome requires the presence of central obesity plus any two of the 





A cross sectional analysis of 8579 children between 3 and 18 years of age, using data 
from the National Health and Nutrition Examination Survey (NHANES), revealed that 
children with obesity have at least two more components of the metabolic syndrome. It 
also showed that increasing levels of BMI are positively related to hypertension, 
triglycerides, HbA1c but are negative predictors of HDL cholesterol (25). Sorof et al (26) 
after studying 2460 students of mixed ethnic background showed that hypertension is 
more common in children with obesity compared to those of normal weight (33% vs 11%, 
p<0.001). In agreement with the previous results, Maggio et al (27) using 24hr 
ambulatory blood pressure monitoring at home and dual energy x-ray absorptiometry, 
confirmed that increasing levels of fat mass are related to higher systolic and diastolic 
blood pressure during childhood. Oxidative stress and low grade inflammation are 
predictors of coronary artery disease and type 2 diabetes (28). High sensitivity C 
Reactive Protein (hs-CRP), a marker of inflammation, was found to be raised in 22% of 
overweight and 25% of obese children (29). A study taking place in Turkey reviewed 72 
sex and age matched children who were either overweight or had normal weight. The 
results showed that hs-CRP is higher in children with overweight/obesity and BMI is 
positively correlated to total and LDL cholesterol but is inversely related to HDL 
cholesterol (30).  
 
Obesity is a well documented risk factor for type 2 diabetes in adults, but association with 
paediatric disease is not well studied. The increasing prevalence of type 2 diabetes in 
childhood, especially in the developing countries of Middle East and Asia, could be 
attributed to the obesity outburst (31). Al Mamun et al (32) following a cohort of 2,639 
Australian participants studied the association of BMI at 5 years of age and the risk of 
developing diabetes by the age of 21. Results confirmed the role of obesity to the rising 
incidence of diabetes, as children who were overweight at 5 years had an odds ratio of 
2.6 (95%CI: 1.29, 5.22) of experiencing future disease. In 2017, Abbasi et al (33) 
retrospectively reviewed data from 375 GP practices in the UK. In one of the largest 
cohorts in paediatric population, data from 369,362 participants, aged 2 to 15 years, was 
collected from 1994 to 2013, looking for the incidence of type 2 diabetes by the age of 
25. Results revealed that childhood obesity was related to four times higher risk for type 
2 diabetes when compared to lean subjects. The above observations confirm the role of 
childhood obesity as a modifiable factor for early onset type 2 diabetes. The obesity 
epidemic is driving the high prevalence of type 2 diabetes in children and young adults. 
The early onset of micro and macro vascular complications, characterizing diabetes, will 





Childhood obesity was once believed to have only long term cardiovascular effects. Non 
congenital cardiovascular disease is becoming more frequent, following obesity patterns 
(34). Altered cardiovascular structure and function are observed in individuals with 
obesity from the early stages of life. The increased metabolic demand by excess adipose 
tissue and hypertension lead to cardiac remodeling and left ventricular hypertrophy (LVH) 
as early as 2 years of age (35). Higher BMI is an independent factor of LVH resulting in 
impaired systolic and diastolic function (36). Up to date, there is no evidence on the 
progress of the disease and long term adverse outcomes. Furthermore, children with 
obesity are found to have increased arterial stiffness and endothelial dysfunction, both 
prognostic factors of atherosclerosis. In fact, atherosclerotic changes and fatty deposits 
are found in cadaveric samples starting from 2 years of age (37). The above data 
suggest that the duration of obesity can be a major determinant of cardiac function and 
development of heart failure. 
 
Obesity in children and adolescents has adverse effect on multiple organs and tissues of 
human body. Nonalcoholic fatty liver disease (NAFLD), the most common liver problem 
in children, can range from steatosis to steatohepatitis and fibrosis. Early development of 
hepatocellular cancer is related to NAFLD (38). BMI is an independent factor for the 
disease and is also linked to early formation of gallstones (39). Asthma prevalence is on 
the rise, currently being one of the leading chronic illnesses during childhood. A UK study 
of children between 4 and 11 years of age showed that BMI is associated with asthma 
independent of gender and ethnicity (40). Data from 4000 children in US confirmed that 
obesity at 2 years is a risk factor for asthma (41). The main pathogenic mechanisms of 
asthma, bronchial hypersensitivity and airway obstruction, are closely related to obesity. 
Inflammatory cytokines produced by adipose tissue (IL-6, PAI-1) are responsible for an 
altered immune response promoting allergic airway disease. The restrictive pattern of 
obesity causes reduced chest expansion and tidal volumes contributing further to airway 
hyper responsiveness (42). Similarly to asthma, up to 60% of children with obesity suffer 
with obstructive sleep apnoea (OSA). Severity of obesity parallels the severity of OSA 
(43) and each unit of BMI increases the risk of OSA by 12% (44). The altered 
neuromuscular tone and the mechanical load on the chest are possible explanations for 
this association. Children with OSA suffer from daytime resulting in reduced quality of life 
and physical activity, thus creating a vicious circle (45). Furthermore, OSA is linked to 
systemic hypertension, pulmonary hypertension, ventricular remodeling and arterial 






Musculoskeletal problems are common between children with overweight and obesity. 
Chronic pain, especially in weight bearing joints, secondary to increased mechanical load 
results in reduced physical activity and further weight gain (48). Excessive adipose tissue 
affects bone development leading to fractures. Children with obesity have an increased 
odd ratio of 1.23 (95% CI: 1.12, 1.35) of acquiring a low impact fracture when compared 
to normal weight (49). Mechanical reasons (increased forces due to weight) and the 
effect of cytokines produced by adipose tissue in promoting osteoclastic activity are 
possible explanations for the above observation. Childhood obesity is characterized by 
insulin resistance and an imbalance between androgens and oestrogens (50). Polycystic 
ovarian syndrome (PCOS), a common endocrinology problem in adolescents, presents 
with amenorrhoea, hirsutism and acne due to excessive androgens in female patients. 
Except from the established cardiovascular risk, girls with PCOS have a negative 
perception of their body image leading to low self esteem, depression and even suicidal 
attempts (51).  
 
Childhood obesity is related not only to medical but also to psychosocial aspects. 
Children are victimized (bullied) due to excessive weight as early as 3 years of age (52).  
Beliefs such as “obese individuals lack willpower and self-discipline” and “obesity is the 
characteristic of a weak person” are common in “obesity stigma”. Lumeng et al (53) 
showed that children with obesity are more than twice likely to be bullied compared to 
normal weight and weight discrimination rates in adolescence reach those of sexual 
orientation. Weight based victimization leads to low self esteem, depression and 
impaired social and academic performance (54). Youth with obesity are socially isolated 
because of their body habitus and find it difficult to get into a relationship. School is the 
main environment of victimization, leading children to poor attendance and performance. 
Bullied youth focus on ways to avoid public harassment instead of concentrating on 
academic requirements. Finally, discrimination during physical activities, at school or at 
the gym, leads to adverse behaviors such as binge/emotional eating and sedentary 
lifestyle, enhancing further the obesity loop (55).  
 
The correlation between obesity and medical co-morbidities is well described. Adults with 
obesity are at higher risk of type 2 diabetes mellitus, coronary artery disease and strokes, 
asthma, osteoarthritis, gallstones and all cancers except oesophageal and prostate (56). 
Children with obesity will develop adult obesity, therefore are at higher risk of adverse 
medical outcomes. Simmonds et al (57) in a meta-analysis of 200,777 participants, using 
BMI “cut off” to define obesity, showed that children with obesity are five times more 
likely to develop adult obesity when compared to normal weight. Results revealed that 




These findings are in agreement with previous work performed by Parsons et al (58) in 
1999. Risk prediction models estimate that in the next 20 years 100,000 new coronary 
events would be attributed to childhood obesity (59). In cadaveric models, obesity was 
shown to predict the extent of coronary artery atherosclerosis in adolescents and young 
adults (60). Adolescent BMI, was an independent predictor of coronary artery disease in 
a 17 years follow up study of Israeli population (61). Furthermore, in the Cardiovascular 
Risk in Young Finns study, cardiovascular disease risk factors in childhood (BMI, 
hypertension, dyslipidaemia) correlated with values in adulthood (62). Franks et al (63) 
showed that childhood obesity, glucose intolerance and hypertension increase the 
rates of premature death in an American Indian population. In summary, childhood 
obesity and the related medical, socio-economic consequences seem to persist into 
adulthood. Tackling the rising rates of obesity in the early stages of life may therefore 
reduce the obesity epidemic seen in adults.   
 
1.4 Causes of childhood obesity 
 
1.4.1 Diet and Lifestyle 
 
Obesity is difficult to treat, therefore investigating the origins of the disease and forming 
prevention strategies is critical. The phenomenal increase in childhood obesity is 
multifactorial (Figure 1.2). It is primarily caused by an imbalance between energy intake 
and expenditure. The positive energy balance is associated with the modern lifestyle 
adopted by children. Davidson et al (64) described the ‘ecological model’ where obesity 
is related to dietary intake, physical activity and sedentary behaviour.  
 
 
Figure 1.2: Causes of childhood obesity. The pathogenesis includes genetics, antenatal 




Children’s dietary patterns are central in the development of overweight. Poor diet 
containing high levels of fat or sugar is contributing to ‘unhealthy’ weight gain. Fast food, 
candy, soft drinks and convenience meals, such as canned pastas and frozen dinners 
are diet choices progressively leading to excessive fat levels in the body (65). Children 
with obesity consume 500 extra calories per day and 3 times higher sugar than 
recommended. Sugary drinks account for the 30% of daily sugar intake (66). The rapidly 
changing diet patterns are a result of “Westernization” and “Dietary Liberalization”, 
described by Gupta et al (67). Children have unrestricted access to fast foods and sugary 
drinks in shops and vending machines located close to their school. The daily “money in 
the pocket” allows them to purchase their lunch which in combination with the lack of 
knowledge on nutritional components lead to unhealthy dietary options. Children are an 
easy target group for big food companies. Aggressive advertisement and low cost 
products lead to increased consumption of energy dense foods. UK Government, 
recognizing the above hazard and in an attempt to prevent unhealthy food options, 
introduced school food standards and legislation to restrict food marketing to children.  
 
Traditional counterfactual beliefs on health and nutrition, passed from generation to 
generation, have always contributed to childhood obesity. Misconceptions such as “fat 
baby is a healthy baby”, “girl’s weight reflects her wealthiness” and “children’s fat goes 
away as they get older” have led to unhealthy diet behaviors (67). Forced feeding at any 
age group and excessive feeding of babies born small for their age are common 
practices seen in many ethnic groups. Parents and grandparents have limited knowledge 
on nutrition and even homemade food can be harmful for child’s health when wrong 
ingredients are used. For example, a study in Greece revealed that children living at 
homes where the grandmother was cooking were more prominent to obesity (68).  
 
High levels of physical activity could potentially compensate for the increased caloric 
intake, allowing the maintenance of a normal weight. The health benefits of physical 
activity are well described (69). The US Physical activity guidelines are in concordance 
with the UK guidance (8) recommending that children and adolescents aged 6 to 17 
years should have 60 minutes (1 hour) or more of physical activity each day. 
Unfortunately only 21.6% of 6 to 19 year old children and adolescents in the US and 28% 
in UK achieved this target in 2016 (70). Similar recommendations exist for children below 
5 years of age. Babies should be encouraged to pull, push, reach, grasp and spend 
tummy time on daily basis. Toddlers able to walk should be physically active (climbing, 
riding, chasing games, rolling and skipping) for at least 3 hours per day. Child 
characteristics, such as gender, age, body weight, may affect the physical activity levels. 




associated physical, emotional, and social changes (64). Females are known to be less 
active than males. Sociocultural beliefs against outdoor playing and the engagement with 
household jobs are main factors for the increased obesity rate seen in females. 
Furthermore, children are under constant pressure to perform academically, hoping for a 
better future and working potentials, neglecting at the same time sports (67). Lack of safe 
infrastructure for walking, running or cycling to school has led 53% of UK primary school 
children to commute by bus or car in 2012, compared to 80% who walked independently 
to school in 1971 (71).  
 
Sedentary lifestyle, with children spending many hours on indoor activities, such as video 
games, social media and watching television, is another important factor for obesity. In 
1995, a child spent on average 3 hours/day in front of a screen compared to 6 hours 
today. Lack of playgrounds and unsafe neighborhoods, characteristics of our modern 
society, may be driving the above observation (66). Snacking and craving for food is 
closely related to sedentary lifestyle (72). Story et al (73) showed that number of hours 
spent in front of TV correlate with consumption of most advertised goods, including foods 
high in fat, sugar and salt. The unrealistic body ideals promoted by social media, lead to 





Children with obesity tend to have parents who also suffer from excessive weight (74). 
Genetics is another factor contributing to obesity. 25-40% of BMI is heritable whereas 
50% of the way fat is distributed is attributed to heritability (75-77). Identical twins raised 
apart have a 0.7 correlation in BMI, similar to those raised together (0.74) (78). More 
than 75 genes and loci have been identified so far contributing to obesity. Leptin gene 
(Ob) deficiency, FTO and MC4R genes and mutations contributing to low basic metabolic 
rate (BMR) and low rate of lipid oxidation are some of the most well described (79, 80). 
More likely gene effects are responsible for the susceptibility of developing obesity in the 
presence of an adverse environment rather than the obesity expression itself. In this 
regard, Heitmann et al (81) showed that high fat diet resulted in weight gain only in those 
subjects who were already overweight or had parents with obesity. Furthermore, trying 
high fat diet in paired of twins resulted in higher correlation weight gain within twin pairs 
compared to “between” twin pairs, confirming the role of genetics in proneness of 
developing obesity (82). As the gene pool remains unchanged, genetic susceptibility 




obesity rates. Genetic factors need to be coupled with environmental in order to affect 
weight (83), therefore the main focus of research against the rising trends of obesity 
should be on energy balance and events occurring during early stages of life. 
 
1.4.3 Intrauterine programming 
 
For humans, in utero life is a plastic period sensitive to environmental factors resulting in 
the creation of phenotypes better matching their environment. Plasticity allows fetuses to 
get prepared for the world they are going to live in. During fetal life body goes through 
critical periods of development. “Programming” is an event that has lasting or life-long 
effects (84). Barker et al (85) was the first to describe the “fetal origins hypothesis”, 
suggesting that diseases in adult life originate from adverse intrauterine environment 
during developmental plasticity. Since then, many longitudinal studies have shown that 
despite genes and lifestyle may contribute to the development of obesity, it is the fetal 
period which remains critical for the metabolic risk (86, 87). Maternal BMI and GWG, 
ethnicity, birthweight, gestational diabetes mellitus (GDM) and postnatal feeding mode 
are factors contributing to the developmental programming of obesity and metabolic 





Figure 1.3: Impact of intervening in early post natal life. Favorable effects present when 
antenatal and postnatal environment are in concordance; Adopted from Stocker et al (89)  
 
 
The “programming factor” and the exact mechanism underpinning intrauterine 
programming are yet to be identified (90). Barker et al (84) based on the “life history 




the expense of other traits results in disease in later life. Specifically, in conditions of 
maternal undernutrition, energy is allocated to the development of brain resulting in fewer 
cells in key organs. People who were small at birth have lower numbers of renal 
glomeruli and reduced pancreatic beta cell mass leading to early glomerulosclerosis, 
hypertension (91) and diabetes (92) respectively. Hormones and metabolism may also 
explain the link between adverse fetal environment and future disease. Fetuses with 
reduced maternal supply develop peripheral insulin resistance to allow adequate glucose 
levels for brain development, sacrificing muscle growth and sensitivity to insulin action, 
leading to impaired glucose tolerance and type 2 diabetes in the future (93, 94).   
 
The role of hypothalamus in the adverse metabolic programming has drawn the attention 
of many researchers. Hypothalamus and particularly the arcuate nucleus (ARC) is the 
primary site for energy regulation. Development and maturation of hypothalamus and its 
projections occurs during fetal and immediate postnatal life in humans (95). Insulin and 
leptin receptors have been identified in the ARC neurons (96). The involvement of 
hormones in the development of hypothalamus makes it vulnerable to maternal 
metabolic state. Intrauterine obesogenic environment leads to increased fetal/neonatal 
insulin and leptin levels altering hypothalamic development. Neurogenesis of neurons 
with orexigenic effect is promoted and projections form the ARC to paraventricullar nuclei 
are reduced resulting in future hyperphagia and eventually obesity (97, 98).  
 
In terms of timing, gestation and the early post natal period are critical for “metabolic 
programming”. Adverse events during specific periods of gestation have various results 
on the offspring. In animal models, maternal undernutrition in early pregnancy is linked to 
increased adiposity after birth whereas nutrient restriction during the latter part results in 
lean phenotype (99, 100). Results are consistent with the epidemiological data from the 
Dutch Hunger Winter findings where fetuses exposed to famine during first trimester had 
higher obesity risk as adults whereas those exposed during third trimester had lower 
rates (101). Postnatal exposure to adverse environment is equally important to in utero. 
Obesity-prone pups fostered by lean dams in the immediate postnatal period show 
improved metabolic profile and on the other hand lean pups fostered by obese dams 
develop increased adiposity (102). Vogt et al (98) revealed that exposure to maternal 
obesity only in the postnatal period is enough to create adverse metabolic profile. 
Possible explanation is that the high levels of free fatty acids, glucose, insulin and leptin 
present in the milk of mothers with obesity during lactation alter hypothalamic structure, 





Prevention of obesity starting from prenatal life can have multigenerational impact. 
Children with obesity will remain obese in adolescence and adulthood. In cases of female 
adolescents, pregnancies complicated by obesity will result in offspring at high risk of 
developing future obesity, thus creating a vicious transgenerational cycle. It is therefore 
of great interest to investigate the potential epigenetic mechanisms that determine these 
risks, which will then allow to develop intervention strategies during the peri-conceptional 
and immediate postnatal period that can modify/reduce them. 
 
1.4.4 Role of maternal factors on the pathogenesis of childhood obesity 
 
1.4.4.1 Gestational Diabetes (GDM) 
 
GDM is glucose intolerance of different degrees that is first recognized during pregnancy. 
The increasing incidence of GDM, which can complicate 5-25% of pregnancies 
depending on the diagnostic criteria used and population studied, is in parallel with the 
obesity outburst. It is the commonest medical complication in pregnancy, related with 
short and long term complications and increased morbidity for both mother and the baby. 
Worldwide, 17.7 million pregnancies were complicated with GDM in 2015, with 1 in 7 
births affected in 2017 (103). South East Asian region has the highest prevalence, 
followed by Middle East and North Africa. Reduced access to maternal care, noted in low 
and middle income countries, is associated with higher rates of GDM. The growing 
burden of GDM is driven by the obesity outburst and by the fact that women tend to be 
more overweight or obese than men (104).  
 
GDM seems to be a result of the same physiological and genetic abnormalities that 
define diabetes outside pregnancy (105). There are two main key points that characterize 
normal pregnancy and play a major role in the pathophysiology of GDM. First is the 
progressively worsening insulin resistance during pregnancy that reaches a peak during 
the third trimester. Secondly is the increased insulin secretion by pancreatic β-cells in 
order to balance this high insulin resistance. The main abnormality in GDM is that insulin 
supply is not adequate to counterbalance insulin resistance and regulate the degree of 
hyperglycaemia. Β-cell dysfunction, occurring on a background of pre-existing chronic 
insulin resistance (obesity, Asian origin, polycystic ovarian syndrome) or caused by 
autoimmune or monogenic mechanisms, is the major contributing  factor  (106). Less 
than 10% of women with GDM have autoantibodies against islet cell or Glutamic Acid 
Decarboxylase (GAD) and these women are usually lean and can rapidly develop 




(107). Hormones such as estrogen, progesterone, cortisol and placental lactogen, 
progressively increase during pregnancy, peaking at the third trimester, causing higher 
insulin resistance. Adipocytokines (TNFa, adiponectin, leptin, resistin) and lipid 
concentrations have been shown to be related to changes in insulin sensitivity both in 
pregnant and non-pregnant women. Normal pregnancy is characterized by reduced 
adiponectin levels and GDM pregnancies have been found to have even less, attributing 
to higher insulin resistance. On the other hand, raised levels of TNFa, resistin and leptin 
have been correlated negatively with insulin sensitivity during pregnancy (108).  
 
1.4.4.1.1 Diagnosis of gestational diabetes 
 
There is no consensus on the optimal screening and diagnostic criteria of GDM. Despite 
extensive research, guidelines vary globally and are adjusted according to infrastructure, 
cost effectiveness and patients’ needs (109). When and how to screen for GDM, 
universal versus selective screening are still questions to be answered (Table 1.2). 
 
In 1964, O’Sullivan and Mahan formed for the first time criteria to diagnose GDM. They 
suggested a 50gr 1hr Glucose Challenge Test (GCT) to screen for GDM followed by a 
confirmatory test (in those who were GCT positive) with a 100gr 3hr Oral Glucose 
Tolerance Test (OGTT). In the following years the Somogyi-Nelson method, used by 
O’Sullivan and Mahan to measure blood glucose, was replaced by more specific enzyme 
assays based on plasma and not whole blood. The above resulted in the formation of 
new criteria and thresholds for the diagnosis of GDM.  
 
In 2004, American Diabetes Association (ADA) recommended early screening of high 
risk pregnancies (Table 1.3). A Fasting Plasma Glucose (FPG) ≥7mmol/l or a random 
plasma glucose ≥11.1mmol/l would be diagnostic of pregestational diabetes. For women 
not previously diagnosed with overt diabetes, testing for GDM should be performed at 
24-28 weeks of pregnancy following one (75gr OGTT) or two step process ( 50gr GCT 














Glucose threshold mmol/l 
(mg/dl) 
Fasting 1 h 2 h 3 h 
O’Sullivan & Mahan 1964 2 step 100 

















Carpenter & Coustan 1982 2 step 100 















American Diabetes Association (ADA) 2004 2 step 100 















International Association of Diabetes and Pregnancy 
Study Groups (IADPSG) 
2010 1 step 75 







WHO 2013 criteria (revised, same as IADPSG) 2013 1 step 75 







National Institute for Health and Care Excellence 
(NICE) 













Table 1.3: Risk factors to screen for GDM as per ADA guidelines 
 Age ≥25 years 
 BMI ≥25 kg/m2 and BMI ≥23 kg/m2 in Asian Americans 
 High risk ethnic groups: South Asian, Aboriginal, Hispanic 
 Previous history of GDM 
 Family history of type 2 diabetes 
 History of poor obstetric outcomes: congenital malformation, still birth etc 
 
The need for widely accepted criteria based on maternal and infant adverse outcomes 
triggered the Hyperglycaemia and Adverse Pregnancy Outcome (HAPO) study. 23,000 
pregnant women had OGTT between 24-32 weeks gestation and a linear relationship 
between glucose levels and adverse outcomes was demonstrated without any clear cut 
off point (111). Following the HAPO study results, the International Association of the 
Diabetes and Pregnancy Study Groups (IADSPG) suggested thresholds for the diagnosis 
of GDM and overt diabetes at first as well as third trimester (24-28 weeks gestation) 
(Table 1.4). There has been a lot of debate and controversial evidence regarding the low 
FPG cut off of 5.1mmo/l (92mg/dl) (112, 113) but general consensus to the 24-28 weeks 
criteria. World Health Organization (WHO), Endocrine Society, the Australian Diabetes in 
Pregnancy Society (ADIPS), the International Federation of Gynecology and Obstetrics 
(FIGO), the European Association for the Study of Diabetes (EASD) and the European 
Board and College of Obstetrics and Gynecology (EBCOG) have accepted 2hr 75gr 
OGTT at 24-28 weeks gestation as the optimal screening test for GDM. 
 
In 2015, National Institute of Clinical Excellence (NICE) published guidelines for the 
diagnosis of GDM. While IADSPG criteria are based on reducing maternal and offspring 
harm, NICE are based on cost effectiveness studies using health economics. It is 
recommended that women falling into one of the risk groups (Table 1.5) should have a 









Table 1.4: IADSPG criteria for GDM diagnosis. Screening includes investigations at first 
antenatal visit but also at 24-28 weeks gestation 
First prenatal visit Measure FPG, HbA1C or 
RPG 
Over diabetes if,  
FPG ≥7.0mmol/l 
(126mg/dl) or 
RPG ≥11.1mmol/l                
( 200mg/dl) or 
HbA1c  ≥6.5% 
(48mmol/mol) 
GDM if 




If the test is normal in the first prenatal visit, test for GDM during 24-28 weeks 
 
  












Table 1.5: Risk factors to screen for GDM as per NICE guidelines. NICE suggests 
selective screening based on cost-effectiveness data 
 BMI above 30kg/m2 
 Previous macrosomic baby weighing 4.5kgr or above 
 Previous gestational diabetes 
 Family history of diabetes ( first degree relative) 
 Minority ethnic family origin with a prevalence of diabetes 
 
In an ideal world, author believes that universal criteria should be used for screening and 
diagnosing GDM. Health resources, economics and cultural differences don’t allow a 








1.4.4.1.2 Gestational Diabetes consequences 
 
In 1920, Jorgen Pedersen formulated the hypothesis which states that "Maternal 
hyperglycaemia results in fetal hyperglycaemia and hence in hypertrophy of fetal islet 
cells with insulin hypersecretion, leading to greater fetal utilization of insulin" (114). The 
intrauterine hyperglycaemic state is toxic for mother and fetus, resulting in short and long 
term adverse outcomes (Figure 1.4). 
 
 
Figure 1.4: Pedersen hypothesis. Common denominator for the complex pathophysiology 
of GDM is maternal hyperglycaemia; EPO: erythropoietin, RBC: red blood cells, T2DM: 
type 2 diabetes mellitus 
 
1.4.4.1.3 Short term effects on the offspring 
 
The association between pregestational diabetes and congenital malformation is well 
established. Balsells et al (115) has shown that even women with gestational diabetes 
have a higher risk for cardiac (ventricular septal defect), neural (caudal dysplasia), 
gastrointestinal and genitourinary malformation compared with general population 
[Relative Risk (RR): 1.16, 95% CI 1.07-1.25].  
 
Chronic maternal hyperglycaemia leads to glycosylation of haemoglobin, reducing the 
capacity to carry oxygen. The hypoxic environment combined with the increased fetal 
oxygen demand due to hyperinsulinaemia leads to increased erythropoiesis and 
polycythaemia. Red blood cell breakdown will cause neonatal hyperbilirubinaemia. If the 





metabolism promotes lactate production and acidaemia, resulting in intrauterine death. 
Fetal exposure to high glucose levels cause hyperplasia of fetal pancreatic β-cells and 
hyperinsulinaemia. Raised insulin levels inhibit accumulation of Surfactant Protein A and 
B (SP-A and SP-B) messenger RNA (mRNA) and antagonize cortisol effect on the 
development of lung morphology and surfactant system in type II cells. The above effect, 
results in increased rates of neonatal Respiratory Distress Syndrome (RDS) (116).  
 
GDM diagnosis and management leads to reduced threshold for caesarian section (CS) 
as preferred method of delivery, independent of birth weight (117). GDM by itself is not 
an indication for CS though and mode of delivery should be a shared decision between 
clinician and mother. Specific conditions such as macrosomia, fetal distress and risk of 
intrauterine death are factors leading to abdominal delivery (118). Prematurity of the 
babies and the excessive retention of fluid in the lungs associated with CS are the main 
reasons for "iatrogenic RDS" (119).  Furthermore, the association of GDM with increased 
risk of stillbirth and excessive fetal growth during the latest stages of pregnancy has led 
clinical practice to earlier induction of labour. Benefits of this approach always need to be 
weighed against the possibility of higher rate of CS, maternal infection, neonatal mortality 
and morbidity (120).  
 
Macrosomia, defined as birth weight >4kgr, is the most well described complication of 
GDM. Hyperglycaemia in the fetus stimulates insulin and growth hormone production, 
promoting fat and glycogen deposition through their anabolic effect. Macrosomia 
presents in 50% of GDM pregnancies and the risk is 10 times higher than general 
population. Shoulder dystocia (SD), the impactation of neonate’s shoulder against 
maternal pelvis, is strongly related with macrosomia (121). SD and obstructed labour can 
lead to perinatal complications, like Erb’s palsy (form of brachial plexus palsy) and birth 
asphyxia. HAPO study revealed a direct association between increasing maternal 
glucose and increased risk of  large for gestational age (LGA) babies, macrosomia and 
SD (111).  
 
GDM is not only related to adverse neonatal size but also to altered body composition. 
Whitelaw in 1999 (122) was the first to demonstrate an association between maternal 
glyceamia and offspring’s skinfold thickness. Sparks et al (123) described that fat mass 
at birth is related to intrauterine environment whereas lean mass is more closely linked to 
genetic factors. Anthropometric measurements on 19,389 neonates from the HAPO 
cohort revealed a strong association between maternal glycaemia and neonatal 
adiposity. In particular, maternal glucose levels were stronger associated with 





mediated by fetal insulin, implying that adverse phenotype is present from intrauterine life 
(124). To confirm the hypothesis, Venkataraman et al (125) assessed sonographic data 
from GDM pregnancies in India at 11, 20 and 32 weeks gestation. Results showed that 
GDM fetuses had increased anterior abdominal wall thickness even at 20 weeks of 
gestation (even before GDM was diagnosed), with findings persisting to 32 weeks, 
irrespective of GDM treatment. Throughout the measurements, GDM babies were 
consistently smaller in size, having the typical “thin but fat” phenotype. The above 
findings suggest that being exposed to obesogenic and hyperinsulinaemic environment, 
fetuses show a preferential growth for the insulin sensitive adipose over fat free tissue. 
Catalano et al (126) and Lingwood et al (127) using direct measures of infant adiposity 
confirmed that adverse body composition is present at birth in the GDM group. Many 
researchers argued that increased adiposity at birth may be related to maternal BMI 
rather than the hyperglycaemia effect. Logan et al (128) performed a systematic review 
which identified 27 studies showing that GDM neonates have increased fat mass, 
percentage of body fat and similar fat free mass compared to controls, with results 
remaining unchanged after adjustment for maternal BMI. However, poor quality of 
studies, using skinfold thickness rather than direct adiposity measures and not adjusting 
for maternal HbA1c were some of the main limitations of the reviewed literature. 
Catalano et al (129) studying a subgroup of the HAPO cohort who developed GDM found 
that maternal hyperglycaemia has a higher impact on birthweight and adiposity at birth 
compared to maternal BMI, with their combination having the strongest effect. Overall, 
studies suggest that the hyperinsulinaemic intrauterine environment in GDM pregnancies 
leads to adverse body composition at birth with increased neonatal fat mass. Tracing this 
altered phenotype in childhood and adolescence will confirm the developmental origins of 
obesity and will allow intervention strategies targeting early life body composition. 
 
Intrauterine Growth Restriction (IUGR) is noted in <5% of GDM pregnancies (130). The 
exact pathogenesis remains unclear and different mechanisms have been described. 
Placental vascular insufficiency resulting in fetal malnutrition and hypoxia, as well as the 
higher rate of maternal hypertension noted in GDM mothers are the most prevalent 
explanations. 
 
Uncontrolled maternal hyperglycaemia is associated with major complications in the 
immediate postpartum period. It is well described though, that treatment of GDM reduces 
the risk of adverse outcomes. The ACHOIS trial in 2005, showed that intensive GDM 
treatment reduces the risk of perinatal complications (RR 0.33, 95% CI 0.14-0.75), 
macrosomia (RR 0.47, 95% CI 0.34-0.64), LGA and birth weight compared to routine 





Horvath et al (131) demonstrated reduced risk of SD, LGA and macrosomia with 
intensive GDM treatment  and Poolsup et al in 2014 (132) added that therapeutic 
interventions also reduce risk for gestational hypertension (RR 0.68, 95% CI 0.53-0.87) 
compared to standard care. 
 
1.4.4.1.4 Long term effects on the offspring  
 
The chronic exposure of the fetus to a hyperglycaemic environment increases the risk of 
an adverse metabolic profile in future life. There is accumulating evidence of the 
developmental origins of obesity, with incidents occurring during intrauterine or early post 
natal life having long lasting effects on the offspring (133). In a UK cohort of 42 GDM and 
44 controls adipose tissue was measured by MRI at birth and 3 months later. Despite 
similar adipose tissue volumes at birth, GDM offsprings were found to have 16% higher 
volumes at follow up visit, adjusting for maternal BMI, gender, ethnicity and mode of 
feeding and irrespective of good glycaemic control. GDM group had greater weight gain, 
driven by adipose tissue accumulation (134). The mechanisms underpinning the above 
observations remain unclear and many potential mechanisms have been suggested. The 
obesogenic environment in utero leads to higher fetal and neonatal free fatty acid, 
glucose and insulin levels.  The increased levels of these biomarkers result in altered 
hypothalamic programming causing impaired satiety and hyperphagia (90). Preliminary 
data suggests that breast milk from mothers with diabetes has altered composition with 
more glucose and insulin, thus leading to adipose phenotype (135). Plagemann et al 
(136) after comparing mothers with diabetes feeding their infants with their own milk 
against those using non diabetic banked donor breast milk found that the earlier group 
had higher risk of overweight and impaired glucose tolerance at 2 years of age.  Finally, 
factors other than hyperglycaemia which are closely related to pregnancies complicated 
by diabetes may contribute to the obesity origins. Maternal hypertriglyceridaemia and low 
HDL levels are linked to increased fetal growth (137, 138) and are consistent with the 
“fuel mediated teratogenesis” described by Freinkel (139).  
 
Gestational diabetes is linked to future obesity and metabolic dysfunction (140). 
Exposure to diabetes in pregnancy is related to increased BMI, total and abdominal 
adiposity in childhood and adolescence (141, 142). Visceral fat is one of the strongest 
predictors in the development of metabolic syndrome (143). Follow up studies from the 
HAPO cohort have confirmed that maternal hyperglycaemia is linked to impaired fasting 
glucose, impaired glucose tolerance, raised HbA1c and reduced insulin sensitivity by the 





adults exposed to GDM having two and four times higher risk for overweight and 
metabolic syndrome respectively (145). Studies on Pima Indians, confirmed that 
offsprings of pregnancies complicated by GDM have higher risk of developing adult 
obesity compared to the offsprings of mothers who developed diabetes later in their lives 
or those who never developed diabetes (146).  
 
During the last decade, researchers have been arguing whether the long term adverse 
effects of GDM are mediated by maternal BMI and birthweight in genetically predisposed 
individuals. Diabetes in pregnancy is more commonly seen in mothers with obesity and 
raised maternal BMI is linked to future metabolic dysfunction (147). Two systematic 
reviews addressing the association between GDM and future obesity provided 
inconsistent results as the majority of the studies did not adjust for maternal BMI (148, 
149). Thaware et al (150) following 1,320 participants from the HAPO study concluded 
that maternal BMI accounts for any association between mild maternal hyperglycaemia 
and obesity at 7 years of age. Consistent with these findings, the UK ALSPAC cohort 
(n=6,842) showed that the association between GDM and central/total adiposity at 10 
years of age becomes non significant after adjusting for maternal BMI (151). On the other 
hand, two large studies following a total of 28,263 children at the age of 10 provided 
strong evidence that GDM is related to increased obesity even after controlling for 
maternal BMI (152, 153). Trying to explain these contradictory results, it was suggested 
that the effects of GDM on future metabolic function may manifest later than the studied 
age groups. Consistent with this hypothesis, the HAPO follow up study at 14 years after 
delivery confirmed an impaired glucose tolerance irrespective of maternal BMI (144). 
Another potential explanation for the above findings is that studies failing to show an 
independent association between maternal glucose levels and future obesity included 
only cases with mild GDM, suggesting that a higher maternal glycaemic threshold may 
amplify the association.  
 
Offspring of pregnacies complicated by GDM are at higher risk of being SGA, LGA or 
macrosomic, as already described.  Longitudinal studies in different ethnic groups have 
described a "U" shaped association, with increased risk of developing type 2 diabetes 
and obesity at both ends of the distribution (Birth weight <2.5kgr and >4kgr) (154). Hillier 
et al (155) in a cohort of 9,439 children revealed that GDM is linked to both neonatal 
macrosomia and childhood obesity at 7 years of age. Applying multiple regression 
models showed that the GDM effect on future obesity is independent of the size of the 
offspring at birth. Finally, in order to assess the long term effects of GDM, independent of 
genetic and lifestyle contributors, two main studies have compared within siblings effect 





Indian population (n=182) offspring born after the development of GDM had higher rates 
of obesity and type 2 diabetes when compared to their siblings born before their mother’s 
diagnosis (156). As Pima Indians is a high risk group and in order to generalize the 
results to other populations, a large prospective (n=280,866) study of Swedish population 
was conducted. Consistent with findings in Pima Indians, Swedish siblings born after the 
GDM diagnosis had a greater BMI of 1.23kg/m2 (95%CI: 0.11, 2.36) compared to their 
siblings born before the diagnosis. Results remained unchanged after adjustment for 
covariates including maternal BMI and birthweight, implying that the adverse effect of 
GDM on future metabolic profile is due to intrauterine programming (157). In conclusion, 
up to date data suggests that fetal exposure to a hyperinsulinaemic environment leads to 
adverse metabolic programming, with lifestyle characteristics, common environments 
and maternal genotype being contributing factors. 
 
1.4.4.1.5 Short term effects on the mother 
 
Poor glycaemic control in pregnancies complicated by diabetes increases the risk of 
maternal urinary tract, wound and endometrial infections (158).  Increased incidence of 
hypertension is also described during GDM. Despite mothers already having co-existing 
risk factors (obesity, family history), GDM remains an independent risk, increasing the 
ratio by 1.67 and 1.54 for hypertension and pre-eclampsia respectively (159). Results 
from the HAPO cohort confirm that increasing levels of maternal glycaemia are linked to 
raised blood pressure. The exact mechanism is not well described but insulin resistance 
seems to be one of the main contributing factors. The increased incidence of CS and 
labour induction has already been discussed. 
 
1.4.4.1.6 Long term effects on the mother 
 
Pregnancy is a period in life where β-cell dysfunction can be unmasked, due to increased 
insulin resistance, leading to abnormal blood glucose levels. Mothers who develop GDM 
have seven times higher risk of developing type 2 diabetes in future (160). Incidence of 
diabetes is 3-70% depending on the diagnostic criteria used and length of follow up 
(161). Prevalence is higher during the first five years and plateaus after ten. Different 
studies have suggested various predictors with fasting blood glucose during antenatal 
OGTT (161), pre-pregnancy BMI, intrapartum and post partum weight gain and  insulin 
treatment (162) having the strongest effect. A recently published meta-analysis of 
primary care data from UK, including 9,118 women with GDM matched with 37,281 





times more likely to develop coronary disease and twice as likely to develop hypertension 
in the next 25 years (163). Mothers with GDM are at risk of diabetes recurrence in 
subsequent pregnancies, with 3 out of 5 pregnancies been complicated by maternal 
hyperglycaemia. The magnitude of the risk increases with the number of previous GDM 
episodes (164). 
 
There is global consensus that the risk of future diabetes minimizes with lifestyle 
changes. Normalization of BMI through healthy diet and graded physical activity is the 
cornerstone in the prevention of future diabetes. GDM mothers should adhere to 
postpartum diet with energy deficit of 500-1000 calories/day in order to achieve weight 
loss of 0.5-1kgr/week. Graded activity of 30 minutes for 5 days/week is also advised. 
Aerobic exercise such as brisk walking, yoga and swimming combined with strength 
training with light weights and elastic bands are also recommended. Great emphasis 
needs to be given to post-partum advice and education. All mothers require counseling 
emphasizing on ways to prevent future metabolic risks and the need to attend annual 
screening appointments for diabetes. Breast feeding advice should be provided and the 
protective role against the development of type 2 diabetes explained (165). 
 
1.4.4.1.7 Management of Gestational Diabetes 
 
Self-care is of vital importance in the management of GDM. As soon as the diagnosis is 
formed, information and education to the patient in order to facilitate self-care should be 
provided and the effects of diabetes in pregnancy should be explained. Lifestyle changes 
are the most important intervention in GDM treatment, as they provide adequate control 
in the majority of cases. Pregnant women are advised to follow a balanced diet tailored to 
their needs. Low glycaemic index foods and restriction of carbohydrates to 40% of the 
daily caloric intake are general recommendations (105). GWG should be based on the 
early pregnancy weight, as per the Institute of Medicine (IOM) guidelines (166). In the 
GDM group, target should be set 10% lower from the recommended weight gain in 
normal pregnancy. Maternal starvation and weight loss are not recommended, as they 
are linked with fetal malnutrition and IUGR (167). Regular exercise is beneficial in GDM 
by increasing insulin sensitivity and glucose absorption by the skeletal muscles. Pregnant 
women are advised to have 150 minutes of mild to moderate exercise per week. 
 
When treatment targets are not achieved with lifestyle changes, a medical approach is 





administering drugs during pregnancy, safety of both mother and fetus should be 
considered and benefits should outweigh any potential risks. 
 
Insulin treatment is globally considered the safest option for GDM treatment with an 
immediate effect on maternal glycaemia. Human insulins do not cross the placenta and 
are not related to fetal complications (168). Insulin treatment can lead to tight glycaemic 
control, but caution is required to avoid hypoglycaemic episodes as they are related to 
growth and developmental deficits. Recurrent episodes in the third trimester may be an 
indication of placental insufficiency (169).  
 
Currently, there are 2 oral agents licensed in the treatment of GDM. Glibenclamide is a 
second generation sulphonylurea which increases insulin release from the pancreatic β-
cells. It differs from the other sulphonylureas in the high protein binding (99.8%) and 
short elimination half life, resulting in very low transplacental transport (170-172). All 
published data up to date, agree that glibenclamide is non inferior to insulin treatment in 
achieving desired glycaemic control. Controversy remains regarding the safety profile for 
the fetus. A meta-analysis (173) showed no difference in macrosomia, birth weight, LGA 
and neonatal hypoglycaemia compared to insulin. On the other hand, Balsells et al. 
comparing glibenclamide to metformin and insulin revealed higher incidence of neonatal 
hypoglycaemia and macrosomia in the earlier group (174).  
 
Metformin belongs to the biguanid class. It inhibits hepatic gluconeogenesis and 
increases insulin sensitivity in peripheral tissues. It is well described that metformin 
crosses the placental barrier exposing the fetus to levels similar to maternal circulation 
(175). RCTs with insulin revealed higher rates of preterm births and less maternal weight 
gain in the metformin group. Neonatal anthropometrics were similar between treatment 
arms (176). Metformin is better received by patients but is associated with increased 
treatment failure rates, with the majority of mothers requiring the addition of insulin to 
achieve normoglycaemia (177). The increased transplacental transport of metformin 
should be considered with caution, as intrauterine programming and developmental 
effects on fetus have not been studied extensively. Follow up studies from the MiG 
cohort up to 9 years of age have not revealed any differences in BMI, body composition, 
metabolic health markers and neurodevelopmental progress between the 2 groups (178, 
179). Similar results were presented from RCTs in pregnant mothers with PCOS. 
Metformin treatment during pregnancy did not affect motor social development in infancy 
and did not alter offspring’s body composition at 9 years of age compared to the control 






1.4.4.1.8 Benefits of treating Gestational Diabetes 
 
Convincing evidence suggests that treatment of GDM improves neonatal outcomes. Two 
RCTs comparing the effect of standard antenatal care (control) versus intensified 
treatment with diet, exercise and insulin (intervention) in cases of mild GDM revealed that 
the later approach resulted in lower birth weight and macrosomia, lower neonatal fat 
mass and lower incidence of CS and SD (121, 182). Whether benefits persist beyond 
infancy is yet to be identified. Hillier et al (155) in a cohort of 9,439 offspring showed that 
GDM treatment reduces risk of neonatal macrosomia and obesity at 7 years of age 
compared to untreated cases. Applying regression models revealed that the effect on 
future obesity is independent of the effect on size at birth. In contrast, following offspring 
from the ACHOIS trial (n=199) revealed that treatment of GDM has no effect on BMI at 4 
years of age (183). Landon et al (184) showed that BMI and indices of metabolic health 
(blood pressure, cholesterol, insulin resistance) at 10 years of age are similar between 
treated and untreated cases of GDM. Inclusion of only mild GDM cases and follow up to 
10 years of age are limitations of the latest studies. Inclusion of cases with severe 
hyperglycaemia may have led to more pronounced effect on future metabolic health, an 
effect which may not be apparent by 10 years of age.  
 
Overall, the above data confirm that GDM is a complex condition leading to adverse 
metabolic profile via various pathways. Improving maternal glycaemic profile has 
significant benefits on neonatal outcomes but the adverse metabolic programming may 
not be related to hyperglycaemia only. Maternal BMI, GWG and biomarkers such as 
cytokines and lipids may be responsible for an adverse in utero environment leading to 
long term detrimental outcomes. In order to change the natural history of the disease, 
GDM pregnancies require a holistic multidisciplinary approach addressing all these risk 
factors. 
 
1.4.4.2 Maternal weight - BMI 
 
The prevalence of obesity in pregnant women follows upward trajectories in parallel with 
those of general population. Maternal nutritional state is one of the key determinants of 
offspring’s future metabolic health (147). Neonatal fat mass is strongly related to 
maternal fat mass (185) and offspring of mothers with overweight have higher fat mass 
compared to those of normal weight (186, 187). The adverse metabolic programming 
starts from the antenatal period, as high maternal BMI is related to fetal adiposity and 
insulin resistance assessed by the homeostasis model (88). On the short term, maternal 





venous thromboembolism, maternal infections and caesarian sections. Of note, high 
maternal BMI predisposes to the development of GDM, pre-eclampsia and neonatal 
macrosomia (188). Researchers have previously focused on whether these adverse 
outcomes are sustained in childhood and adulthood. 
 
Macrosomia and higher birthweight are strongly related to higher BMI in childhood and 
adulthood (189). Observational studies have provided evidence for the link between 
maternal obesity and higher offspring BMI. A large US cohort (190) studying a total of 
11,120 subjects, revealed that childhood obesity rates were two and four times higher if 
mother was overweight or obese pre-pregnancy respectively. Similar results were 
presented by the UK ALSPAC group (191) after studying children up to 7 years of age. 
Assessing body composition, Mingrone et al (192) showed that offspring of mothers with 
obesity have greater fat mass at 24 years of age. Furthermore, maternal obesity is 
related to increased risk of offspring hypertension and cardiometabolic dysfunction, type 
2 diabetes and neurodevelopmental disorders (187, 193, 194). Many researchers have 
argued that the associations revealed by observational studies are unlikely to be causal 
and may be biased by confounders. Feeding mode (women with obesity are less likely to 
breastfeed (195), rapid postnatal growth and maternal environment and 
sociodemographics may be potential contributors to the results. In order to overcome the 
problem, animal models have been used allowing for practicality of the research and 
translatability to humans. Diet induced maternal obesity in rodents programs offspring’s 
obesity, cardiometaboilc dysfunction and impaired glucose tolerance (196). Data from the 
Scotland national diabetes register has been recently reviewed and revealed that 
maternal obesity more than triples the risk of child type 2 diabetes mellitus (197).  
 
The mechanisms underpinning the developmental programming of obesity are 
summarized in Figure 1.5. The maternal obesogenic environment leads to high fetal and 
neonatal levels of insulin, leptin, inflammatory cytokines and free fatty acids resulting in 
altered hypothalamic development. The imbalance between orexigenic and anorexigenic 
neurons and the impaired response to leptin lead to hyperphagia and obesity. The fetal 
exposure to hyperglycaemia and hyperinsulinaemia causes altered peripheral insulin 
signaling and insulin secretion resulting in impaired glucose tolerance and diabetes in 
future life (198). Finally, early life hyperleptinaemia may explain the development of 
cardiovascular and neurodevelopmental disease. Specifically, high leptin levels found in 
offspring of obese mothers drive sympathetic hyperstimulation leading to hypertension 
and vascular dysfunction and also alter maturation of hippocampus leading to impaired 








Figure 1.5: Developmental programming of obesity. Maternal insulin resistance, 
hyperglycaemia and dyslipidaemia lead to adverse fetal programming through various 
mechanisms; Adopted from “Clin Endocrinology, 2013;78‐9‐16” 
 
1.4.4.3 Gestational Weight Gain (GWG) 
 
GWG is crucial for the development and viability of the fetus (Figure 1.6). The amount of 
total weight gain varies depending on the number of fetuses and maternal BMI (199). 
GWG above the IOM recommendations is also linked to adverse metabolic programming 
but strength of the effect is less than that of maternal BMI. The weak association 
described between GWG and caesarian section, GDM and hypertension during 
pregnancy is more likely due to the predominant influence of BMI than weight gain per se 
(188). Mothers with excessive weight gain during pregnancy are at high risk of retaining 
weight up to 3 years postpartum which is more likely to affect subsequent pregnancies 
(200). On the long term, Oken et al (201, 202) studying participants from two large 
cohorts (Project Viva, Growing Up Today) showed that increased GWG is positively 
related to BMI at 3 and 14 years of age. Consistent with these results, Mamun et al (203) 
extended this correlation up to 21 years of age. 
 
Improving maternal health in the peri-conceptional period is an attractive target as it 
would improve obesity rates for the next generations. In animal models, diet during 
pregnancy and lactation normalizes neonatal levels of leptin and insulin, reverses 
adverse programming of hypothalamus resulting in less hyperphagia and future obesity 
(204). In humans, siblings born before and after mother underwent bariatric surgery to 





post surgery have lower rates of macrosomia, type 2 diabetes, obesity and hypertension 
(205, 206). Muktabhant et al (207) showed that a combination of diet and exercise 
reduces GWG and macrosomia without providing evidence about potential effects on 
childhood obesity. The UPBEAT trial (208) studying a cohort of 1500 pregnancies 
complicated by obesity in the UK revealed that intense behavioural interventions lead to 
reduced GWG and offspring adiposity at 6 months of age. In contrast, Lifestyle in 
Pregnancy study (209), after randomizing 300 women with obesity to intervention versus 
standard care showed that reduction of GWG is not related to neonatal macrosomia or 
other perinatal outcomes. These results need to be considered carefully as study failed 
to achieve expected weight difference between the two groups. Furthermore, as maternal 
BMI has a greater effect on neonatal outcomes (210), it could be speculated that mothers 
with obesity have metabolically altered intrauterine environment from the early stages of 





Figure 1.6: Components of gestational weight gain. Part of the weight gain is attributed to 





Pre-eclampsia is defined as hypertension (systolic blood pressure >140mmHg or 
diastolic >90mmHg) and proteinuria (>0.3gr in 24hr) developed after 20 weeks gestation 
(212). It complicates 6-10% of pregnancies, with higher numbers noted in 





well as maternal age, BMI and previous history of pre-eclampsia are known risk factors 
(213). The pathogenesis of pre-eclampsia remains unclear. Impaired uteroplacental 
perfusion leads to maternal vascular dysfunction and hyperpermeability, eventually 
causing hypertension (214). This is related to increased fetal morbidity and mortality 
associated with prematurity secondary to placental insufficiency compromising fetal 
growth. Half of women with severe pre-eclampsia will deliver before 36 weeks gestation 
(212). The increased risk of childhood hypertension, obesity and diabetes is so far linked 
to prematurity and SGA (215) seen in pregnancies complicated with pre-eclampsia. It is 
well described that even increases in blood pressure (systolic or diastolic) not meeting 
the criteria for hypertension diagnosis are enough to increase the risk for SGA 
pregnancies (216, 217).  
 
1.4.4.5 Role of Ethnicity 
 
Some ethnic groups, in particular South Asians (SA), are at higher risk of GDM, type 2 
diabetes and cardiovascular disease (218, 219). This adverse metabolic profile is also 
seen in the SA migrant population around the world (220). SA are known to have higher 
body fat content and lower muscle mass for a given body weight/BMI compared to White 
Europeans (221), a phenotype which is present from childhood (222). They are also 
known to have higher central and visceral obesity (223). Higher body fat, lower muscle 
mass and higher central/visceral obesity have been linked to higher risk of metabolic 
disorders and cardiovascular disease in any ethnic group (224).  
 
Accumulating evidence now confirms that the adverse metabolic phenotype is present 
even at birth (219, 225), highlighting the role of intra-uterine programming. Fetal 
malnutrition, noted in SA populations, is causing redistribution of blood to brain at the 
expense of other abdominal organs and muscle. Fetal metabolic rate is reduced and 
IUGR is noted when all fetal substrates are consumed. Nutritional restriction also causes 
reduced Insulin-like Growth Factor (IGF) leading to further fetal growth retardation and 
increased cortisol levels resulting in fat accumulation (215). During fetal undernutrition, 
fat development is preserved as it is crucial for energy storage, thermoinsulation and 
providing precursors for brain development (226, 227). According to the ‘thrifty 
phenotype’ theory (228), intrauterine environment prepares the fetus for the outside 
world. If world and intrauterine conditions match, this association works as an adaptive 
mechanism. The food surplus of our modern world though, converts this association to 
harmful as high caloric intake is not processed properly and is converted to FM rather 






Yajnik et al in 2003 (229) was the first to compare infant body composition between 
Indians and Caucasians. His study revealed that babies born in Pune, India, despite 
being smaller and thinner have more adipose tissue compared to white British babies 
born in Southampton, UK. Since then, several studies using different methods of 
assessing body composition (skinfold thickness, MRI) have confirmed the “thin but fat” 
phenotype of SA babies which is characterized by LBW, small abdominal viscera and 
muscle mass but preserved fat tissue which is predominantly centrally distributed (225, 
230). Trying to identify the exact mechanism underpinning this adverse metabolic 
programming researchers studied infants of SA origin born in continents other than Asia. 
Steijn et al (231) compared 5th generation SA born in Surinam, South America, with the 
population studied in the Southampton-Pune group. Having a homogenous genetic pool, 
found that the “thin but fat” phenotype is still evident but the difference in adiposity 
compared to white Europeans is attenuated, driven by a higher maternal BMI when 
compared to the Pune population. Stanfield et al (232) compared body composition at 8 
weeks postpartum between infants of SA and European ancestry born in UK. After 
studying 30 infants in each group they reported that SA infants have lower birthweight 
and FFM but increased total FM compared to white Europeans. Of note, SA babies had 
increased subscapular (SS) and similar triceps (TR) skinfold thickness, indicating that 
ethnic origin predisposes to central but not subcutaneous fat accumulation. Analyzing 
further the previous results, SA mothers were found to be more adipose with higher rates 
of vegetarianism compared to controls. Recently, B12 deficiency secondary to 
vegetarianism was strongly linked to the development of gestational diabetes and fetal 
macrosomia (233). Thus, this adverse transgenerational effect characterizing SA could 
be due to genetics, maternal physiology and nutritional status. Identifying the exact 
factors responsible for this adverse programming will determine how early interventions 
targeting neonatal body composition need to be initiated. 
 
1.4.4.6 Psychological causes 
 
Maternal psychological well-being and physical activity status could potentially affect 
offspring’s metabolic risk. Sukumar et al (data presented in DOHaD 2017) has shown 
that maternal depression is related to sedentary lifestyle, which in turn results in higher 
maternal weight gain during pregnancy, higher incidence of gestational diabetes and 
offspring’s obesity. More studies will be required to assess the effect of these maternal 









Preterm or premature birth is a birth of a baby born less than 37 weeks gestation. It may 
be spontaneous or iatrogenic, to avoid maternal/fetal complications. Highest prevalence 
is seen in developing countries, due to infections complicating pregnancy, but increasing 
rates are now noted in developed countries secondary to assisted reproduction (234). 
Babies born preterm may be Appropriate for Gestation Age (AGA) or Small for 
Gestational Age (SGA). Prematurity is linked to developmental (respiratory, 
gastrointestinal, visual and auditory) and behavioural problems (autism) (235) (210) with 
higher mortality noted in pregnancies delivered before 32 weeks of gestation. Most of the 
published papers study the association between low birth weight and adverse metabolic 
profile in the future, without providing data to assess if prematurity (duration of gestation) 
is an independent risk factor. Since 1990, advances in medical practice have allowed the 
survival of very preterm infants who are now forming a generation of adults, allowing for 
retrospective analysis in order to assess the association between prematurity and future 
diseases. 
 
Preterm infants have low FM at birth as adipose tissue accumulates during the third 
trimester in pregnancy (236). At term equivalent age, preterm infants although being 
shorter and lighter have higher percentage of body fat compared to term (237). Of note, 
there is an increase in the intra-abdominal (visceral) fat whereas subcutaneous fat is 
reduced (238). It remains unclear if the accelerated fat deposition is secondary to 
prematurity, lower birth weight or “catch up” growth and the mechanisms underpinning 
this association are yet to be unraveled. There is no consensus regarding the body 
composition of preterm infants in late infancy and childhood (235). Methods of assessing 
body composition, quality and composition of nutrition, lifestyle and small sample 
numbers are potential confounders for the inconsistent results. On the other hand, 
researchers agree that adults born preterm have higher FM, distributed predominantly in 
the abdominal area, when compared to controls (239). Premature infants have an early 
stimulation of the hypothalamic – pituitary –adrenal axis leading to altered response to 
stress and excessive cortisol secretion. The hypercortisolaemia causes increased food 
intake and new fat deposition resulting in future obesity (240).  
 
Prematurity is also linked to hypertension in childhood and adulthood (241). Abnormal 
structure of the glomeruli and less functional nephrons seen in premature babies can 





weight to future diabetes, but data on preterm babies remain scarce. Hofman et al (243) 
showed that preterm babies have less insulin sensitivity at 4 years of age when 
compared to term. Impaired β- cell function and insulin signaling to key peripheral tissues 
are known contributing factors. Finally, available literature suggests that the association 
between preterm birth and insulin resistance in adults exists only when rapid “catch up” 
growth is present (244, 245). Overall, there is accumulating evidence that prematurity is 
linked to adverse metabolic profile but mechanisms underpinning this association are yet 
to be identified. Longitudinal studies will provide knowledge on the pathophysiology of 
preterm birth allowing the development of strategies to amend this effect.   
 
1.4.6 Small for gestational age (SGA) and Low Birth Weight (LBW) 
 
SGA and LBW are terms sometimes used interchangeably in literature. LBW is defined 
as birth weight <2.5kgr regardless of gestational age. It can be caused by fetal growth 
restriction (full term) or preterm delivery. SGA is weight <10th centile for a specific age 
and gender. Potential causes are poor maternal nutrition, infection, smoking and alcohol 
intake. Both SGA and LBW are associated with adverse metabolic profile in the future. 
Hales and Barker in 1992 (246), were the first to describe the “thrifty phenotype 
hypothesis”. They proposed that poor intrauterine environment leads to fetal metabolic 
adaptations that would allow the baby to survive postnatally in conditions of nutritional 
deprivation. However, if the environment provides nutritional excess, these adaptations 
will have long lasting detrimental effects on health. 
 
Epidemiological evidence from Europe, America and India links LBW to metabolic 
syndrome and coronary artery disease in adulthood (247, 248). Longitudinal studies in 
different ethnic groups have shown a "U" shaped association, with increased risk of 
developing type 2 diabetes and obesity at both ends of the birth weight distribution 
(<2.5kgr and >4kgr).(249). UK cohorts have shown that LBW has a stronger effect on 
future obesity compared to macrosomia. Specifically, LBW babies have seven and 
fourteen times higher risk of developing type 2 diabetes and metabolic syndrome 
respectively, when compared to macrosomic (86, 250). Furthermore, allowing for the 
control of maternal and genetic factors, studies on monozygotic twins have shown that 
the smaller twin tends to have greater susceptibility to metabolic disease (251).  
 
Evidence from animal models has shed light to the mechanism underpinning these 
correlations, with leptin having a key role in the development of future obesity. Both 





to impaired development of the hypothalamus. As a consequence, offsprings develop 
hyperphagia and obesity as adults. Timing of maternal undernutrition is also critical. 
Nutrient restriction during early pregnancy results in future adiposity (99) whereas 
undernutrition during late stages of pregnancy causes a leaner phenotype (100). These 
findings are consistent with the Dutch Hunger Winter study (101), where exposure to 
famine in different periods during pregnancy had varying outcomes. Early growth 
restriction in rat models results in altered tissue growth aiming to preserve the brain 
development at the expense of other organs (254). As a result, β-cell mass (pancreas), 
muscle mass and glomeruli (kidney) are reduced leading to future impaired glucose 
tolerance and hypertension respectively (92, 94, 255).  
 
What is not clear from current literature is if this increased risk of adverse developmental 
programming is directly associated to the size at birth or is due to “catch up growth”. Both 
SGA and LBW babies will have a ‘catch up growth’, a compensatory growth following a 
period of slower development. This ‘catch up’ takes place over 6-18 months of life with 
85% of babies completing it by 2 years of age (256). There is strong evidence that ‘catch 
up’ growth reduces hospital admissions, neurodevelopmental delay incidence and risk of 
short stature (257). On the other hand, rapid weight gain and crossing growth percentiles 
in early infancy is related to increased adiposity and insulin resistance in childhood and 
adulthood (258, 259). Tzoulaki et al (260) showed that increased weight velocity during 
the first 2 years is related to hypertension and increased BMI at 30 years of age. SGA 
have lower levels of leptin compared to AGA babies, due to lower total FM. Lower leptin 
levels predispose to hyperphagia and rapid weight gain in the immediate postnatal period 
(261). During recovery from malnutrition offspring’s FM accumulates faster than muscle 
mass (262) leading to increased abdominal adipose tissue which persists through 
adulthood. It is the therefore essential to achieve a “healthy catch-up growth”, a balance 
between adequate growth and normal body composition. Close nutritional management 
and regular monitoring of offspring’s body composition will prevent the development of 
future adverse metabolic profile.    
 
1.4.7 Feeding pattern 
 
Cesar Victora wrote that “breastfeeding (BF) is the most personalized medicine an infant 
can receive; an opportunity for health imprinting that should not be missed” (263). WHO 
recommends 6 months of exclusive BF, expanded to 2 years with additional food 
supplementation (264). Globally 38% of infants are fed as per WHO recommendations, 





months is less than 20% in high income countries, with UK having one of the lowest rates 
of <1% (260). In 2015, only 30% of UK born infants were exclusively BF at 6-8 weeks 
postpartum (265). Low maternal education, practicality, cultural and family beliefs on BF 
are known factors leading to such low levels. UK government and health services have 
been trying to increase BF rates by introducing national strategies which include 
structured postnatal support, regular Health Visitor visits and BF facilities in all public 
places (262).  
 
BF also has a protective role for mothers, as it reduces risk for breast (266) and ovarian 
cancer (267). Evidence on diabetes prevention remains weaker. The short term effects of 
BF on neonatal well-being are well described. It is linked with a reduction in 
gastrointestinal, respiratory, ear infections and hospitalization from infectious causes 
(268, 269). In the long term, BF prevents the development of non-communicable 
diseases. Despite controversial evidence in the past, several meta-analyses in the last 
few years have shown that breastfed infants have a lower risk of developing overweight 
and obesity in childhood (270, 271). Furthermore, this risk is also associated with the 
duration of BF as there is a 4% reduction for each month of BF (272). In the ALSPAC UK 
cohort, BF was related to slower weight gain and lower BMI up to 5 years of age (273). 
Weight gain and growth velocity in early infancy are negatively related to future obesity, 
as described before (258). Available studies have not revealed any association with 
future blood pressure and cholesterol levels (270).  
 
Many potential pathways involved in the beneficial effect of BF have been suggested. 
Postnatal nutrition and environment is equal important to in utero in programming future 
metabolic disease. Formula milk contains more energy, protein and micronutrients 
compared to breast milk (274). The higher caloric intake of formula fed infants leads to 
increased insulin secretion resulting in higher weight gain and growth velocity in early 
infancy, a strong indicator of future obesity. Breast milk contains many active hormones 
and peptides which may be crucial for neonatal health. Ghrelin and adiponectin are 
hormones present in breast milk which could potentially affect satiety and energy 
expenditure, but up to date leptin is the most well described bioactive component (275). 
Leptin is present in maternal (276) but not formula milk (277). In humans, leptin 
concentration in breast milk varies between people and is positively correlated to 
maternal plasma levels and maternal adiposity (276). Rat models confirm that leptin from 
maternal milk can be absorbed by the immature stomach epithelium to the infant 
circulation (278). Miralles et al (279) after studying 28 non-obese mothers showed that 
milk leptin levels at 1 month negatively predict BMI at 2 years of age, suggesting that the 





be explained by the leptin’s role on regulating appetite and energy expenditure. 
Moreover, various studies have suggested that breastfed infants have better self 
regulation of food intake both when BF and eating solids (280).  
 
In summary, early growth rate is a drive to compensate for adverse intrauterine 
environment. Formula milk lacks leptin and provides higher caloric load, leading to 
increased weight gain in early infancy and eventually childhood obesity. It would be of 
great interest to assess the effects of breast versus formula feeding on body composition 
during the first months of life using direct measures of adiposity. This would allow a 
better understanding of the mechanisms underpinning the beneficial effects of BF on 
future metabolic health. 
 
1.5 Adipose tissue: A complex cell system 
 
1.5.1 Function and types 
Adipose tissue is a loose connective tissue providing structural and metabolic support. It 
acts as the body’s fuel reservoir, storing energy in times of excess and providing fuel 
during fasting. It is the primary site for lipid mobilization and thermoregulation. Adipose 
tissue is also the largest endocrine organ. Through endocrine, exocrine and autocrine 
action adipose tissue regulates appetite, energy expenditure, metabolism, fertility and 
immunity by targeting organs as the hypothalamus, pancreas, liver, kidneys and muscle 
(281). Finally it is strategically placed in areas such as palms, soles, orbits, to provide 
mechanical support and protect from the impact of shock. 
Lipogenesis and lipolysis are the 2 main processes taking place in the adipocyte 
throughout life. A fine balance between these two, secures energy homeostasis and 
insulin sensitivity. During lipogenesis excess energy is stored in the form of triglycerides 
in the adipocyte. After a meal, triglycerides circulate in the form of Very Low Density 
Lipoproteins (VLDL) and Low Density Proteins (LDL). Via the lipoprotein lipase action, 
lipoproteins are degraded and Free Fatty Acids (FFA) are released and enter the 
adipocyte. The glycaemic component of the meal, is converted to glycerol, enabling FFA 
esterification to form triglycerides (282). During fasting, stress hormones like adrenaline 
and glucagon are secreted and insulin levels drop. This results in the activation of lipase 
breaking down triglycerides to FFA and glycerol. FFA travel bound to albumin to other 
organs for oxidization and energy production. Glycerol is absorbed from liver for either 






In periods of prolonged positive energy balance, the excessive energy stored in the form 
of triglycerides leads to increased droplet size and lipic cell hypertrophy. When the 
storage capacity of the adipocyte is saturated, cells respond with continuous lipolysis 
providing excessive amounts of glycerol and FFA to the circulation, leading to ectopic fat 
tissue deposition. The ectopic lipid accumulation, mainly affecting the liver (steatosis) 
and muscles, results in increased insulin resistance, the main risk factor for metabolic 
syndrome and cardiovascular disease (Figure 1.8) (284).  
 
 





Figure 1.8: Effects of adipocyte hypertrophy in obesity. The low grade inflammation leads 
to impaired secretion of adipocytokines resulting into ectopic fat deposition and insulin 





Adipose tissue formation starts in the antenatal period and continues throughout life. It 
consists of stem cells (or pre-adipocytes), adipocytes and the stroma vascular fraction, 
which contains mural, endothelial, neuronal and blood cells. Anatomically adipose tissue 
can be found subcutaneously, viscerally, in the bone marrow, between muscles and in 
the breast. Various adipose depots have discrete morphological and functional 
characteristics. The role of intrauterine programming in the development and distribution 
of adipose tissue has drawn the attention of research activity in the last decades (285).   
There are 3 types of adipose tissue, characterized by different origin, morphology and 
mitochondria abundance: White Adipose tissue (WAT), Brown Adipose Tissue (BAT) and 
Beige (brown in white). 
 
1.5.1.1 White Adipose Tissue 
 
WAT arises from mesenchymal progenetors and its main role is to store (in the form of 
triglycerides) or supply energy (through free fatty acid and glycerol formation) when 
required. Plays a key role in body metabolism and excess (obesity) or paucity 
(lipodystrophy) of WAT is related to metabolic abnormalities (impaired glucose 
metabolism), hypertension and carcinogenesis (286). Furthermore, presence of 
subcutaneous and dermis WAT maintains body temperature, acting as a thermal 
insulation (1).  
 
WAT can be further categorized to subcutaneous and visceral fat, each having unique 
anatomic and metabolic properties. Subcutaneous depots are found mainly in the 
interscapular and inguinal region. They contain heterogenous small adipocytes, with few 
mitochondria, resulting in low oxidative rate. High volume of interstitial tissue is a discrete 
characteristic of subcutaneous fat. On the other hand, visceral depots are found in the 
retroperitoneal, mesenteric, omental, peri-gonadal and peri-renal region and consist of 
homogenous, large adipocytes, with small number of mitochondria (287).  
 
In a simplified approach, authors describe subcutaneous as “good” and visceral as “bad” 
fat (288). The “pear” shaped phenotype often associated with female sex is characterised 
by increased deposition of subcutaneous fat around the pelvic region, resulting in lower 
risk of cardiovascular disease (289). On the other hand, the “apple” shaped phenotype 
associated with male sex, with accumulation of visceral fat around the abdominal area, is 
linked to metabolic dysfunction (290). In support of this, Tran et al in 2008, reported 
reduced insulin resistance in rodents after subcutaneous fat transplantation. Similar 





rate and adipocyte’s turnover found in subcutaneous fat may be the explanation behind 
this protective role (292). Furthermore, the 2 types respond differently to stimuli. 
Oestrogens cause increased subcutaneous fat whereas corticosteroids enhance visceral 
fat deposition, thus explaining the increased cardiovascular risk linked to long term 
endogenous or exogenous steroid exposure (293). Finally, different transcription factors 
and gene expression is found between various depots. Leptin, angiotensin, adiponectin, 
favouring metabolic health, are produced by subcutaneous fat and pro-inflammatory 
cytokines, like interleukin 6 (IL-6) and plasminogen activator inhibitor 1 (PAI-1) are 
predominantly expressed by visceral fat (285).  
 
In summary, WAT has the capacity to store energy in the form of triglycerides in times of 
positive energy balance and release it in times of fasting. Metabolic syndrome and risk 
for cardiovascular disease is associated with total FM but the distribution of adipose 
tissue plays an even more important role, with subcutaneous fat being protective for the 
metabolic well being.   
 
1.5.1.2 Brown Adipose Tissue 
 
Brown fat cells and muscle cells arise from the same stem cell population in the 
mesoderm (Figure 2.3). The progenitor cells carry the Myogenic factor 5 (Myf5), a trait 
characteristic of brown fat cells and myocytes. WAT do not activate the Myf5 (294). 
Anatomically, brown adipocytes are smaller with variable size lipid droplets. The 
presence of large numbers of mitochondria explains the increased oxidation rate 
reported. The brown colour is due to the increased vascularization and mitochondria 
presence. BAT is responsible to convert nutrients to heat by fatty acid oxidation, without 
adenosine triphosphate (ATP) production (295).  
 
BAT is predominantly found in neonates, in interscapular and perirenal regions. It is 
responsible for thermoregulation during the early stages of life. In the past it was believed 
that adults do not have any brown fat tissue. As recently as 2007, during investigations to 
trace tumor metastasis using Fluorodeoxyglucose positron emission 
tomography/computed tomography (FDG PET/CT) scan, the existence of brown fat 
depots was demonstrated in adult humans. The main depots are lower neck and 
supraclavicular areas (296). Obesity is characterized by reduced brown FM. Methods 
(BAT transplantation) and medication to increase brown fat formation and prevent/treat 







1.5.1.3 Beige (Brown in White) 
 
Beige adipocytes, are brown like thermogenic cells found mainly in subcutaneous and to 
a lesser extent visceral white fat. Despite having the same thermogenic function with 
BAT, they arise from Myf5 negative progenitor cells, like WAT (Figure 1.9) (298). Another 
theory supports that transdifferentiation of mature WAT may result in the formation of 
new beige cells (299). 
 
In conclusion, BAT and beige are responsible for the non-shivering thermogenesis. Cold, 
food intake and stress release hormones like insulin, Glucagon Like Peptide 1 (GLP-1), 
leptin and triiodothyronine (T3) which stimulate the hypothalamus (300). In return, high 
doses of noradrenaline (NA) are released through the sympathetic nerve leading to 
activation of brown and beige tissue, mobilization of lipids from other depots to brown 
and beige, increased uptake of serum circulating triglycerides and glucose from the BAT 
and “conversion” of WAT to beige by uncoupling protein 1 (UCP-1) activation. The above 
adoptive mechanism is transient and reverses back to initial state after removal of the 





Figure 1.9: Origin of fat cells. Adipocytes and myocytes share common precursor cells; 










Adipose tissue is going through dynamic changes during life, depending on energy 
balance. It is able to expand in order to accommodate increased lipid demand by 
adipogenesis, hyperplasia and hypertrophy. 
 
 Adipogenesis: Pre-adipocytes of mesenchymal origin convert to mature fat cells. 
Peroxisome proliferator activated receptor γ (PPARγ) is the master regulator of 
adipogenesis and adipose tissue maintenance (302).  
 Hyperplasia: Preadipocytes within adipose tissue, convert to fat cells in cases of 
energy excess. 
 Hypertrophy: Mature fat cells can increase their size to accommodate increased 
storage needs 
 
Obesogenesis is characterized by increased rate of all 3 pre-mentioned functions. 
Hypertrophic cells have reduced lifespan due to increased apoptosis. Macrophages 
responsible for clearance, contribute to this inflammatory state. Cytokines as IGF-1, 
Tumor Necrosis Factor a (TNFa) are released leading to altered biology of adipose tissue 
(imbalance between lipogenesis-lipolysis, impaired secretion of inflammatory-protective 
adipokines) and insulin resistance (303).  
 
1.5.2 Adipose tissue as an endocrine organ 
 
Adipose tissue was once considered to be fat storage only. Today WAT is described as 











Leptin Regulates appetite and energy expenditure, Possible role in 
intrauterine growth 
Adiponectin Reduces hepatic gluconeogenesis, reduces insulin resistance 
and increase peripheral glucose uptake 
Resistin Increases insulin resistance 
TNFa Pro-inflammatory, increases insulin resistance 
IL-6 Pro-inflammatory, participates in lipid and glucose metabolism 
PAI-1 Inhibits plasminogen activation 
Angiotensinogen Regulator of blood pressure and electrolyte homeostasis 
IGF-1 Growth hormone mediator, promotes proliferation 
FFA Oxidized to produce energy, component of triglyceride 
Glycerol Component of triglycerides and gluconeogenesis pathway  
 
Table 1.6: Hormones produced by adipose tissue. Adipocytes produce a variety of 
adipocytokines with unique metabolic profile 
 
 
Depending on the location of the fat depots, different adipocytokines (also known as 
adipokines) are secreted, with visceral fat having a more active role. Adipocytokines bind 
to receptors of target organs, triggering intracellular pathways. Adipose tissue itself is 
expressing receptors for these hormones, contributing dynamically to energy and 
metabolism homeostasis (304).  
 
During obesogenesis, the low grade inflammation described before, is contributing to 
impaired synthesis and secretion of adipocytokines. The imbalance between protective 
(leptin, adiponectin) and harmful cytokines (IL-6, TNFa, PAI-1) leads to increased insulin 
resistance resulting in metabolic syndrome, characterized by diabetes mellitus, 
hypertension and dyslipidaemia (Figure 2.2) (305).  
 
Leptin and adiponectin are 2 of the main adipocytokines related to metabolic control and 
will be described in detail for the purpose of this thesis.   
 
1.5.2.1 Leptin  
 
The discovery of leptin in 1994, established adipose tissue not only as an energy storage 
but also as an endocrine organ. Leptin originates from the Greek word “leptos”, which 
means thin. It is a 16kDa protein, consisting of 167 amino acids and produced by the Ob 
gene, located in human chromosome 7q31.3 (306). Studies, predominantly on mouse 
models, have helped understand leptin’s pathophysiology and its role in obesity. Ob/Ob 
(leptin deficient) and db/db (leptin resistant) mice are characterised by early life obesity, 
diabetes mellitus, hypothermia and infertility (307). In humans, obesity is characterized 





(308). Leptin receptor defects, inhibition of leptin signaling and reduced blood brain 
barrier transport are possible explanation of the leptin resistance noted (309). The role of 
leptin in the treatment of adult obesity has been a project of extensive research, but is 
beyond the scope of this thesis and won’t be described further (310).  
 
Adipose tissue is the main site of leptin production. WAT is the major source, whereas 
BAT was recently found to contribute to a lesser extent to the synthesis. Leptin gene is 
expressed differently in various fat depots, with subcutaneous fat producing more leptin 
when compared to visceral (311). Multiple studies have identified leptin mRNA in other 
human tissues. Ob gene was found to be expressed in ovaries, muscle (312), mammary 
cells (313) and bone marrow (314). Stomach is the only gastrointestinal tissue 
expressing the leptin gene (315). The presence of leptin production in placenta and fetal 
tissues implies the role of leptin as a growth factor (316). In summary, the production of 
leptin in tissues other than adipose, lead to the conclusion that leptin has a more 
complicated role than only being a marker of energy balance and adiposity.  
 
Leptin synthesis is affected by various factors (Table 1.7). The secretion follows a 
pulsatile pattern with diurnal variation. Higher levels are noted at midnight and early 
morning (317, 318). Obesity, overfeeding and hyperglycaemia increase leptin production. 
Oestrogens promote subcutaneous fat depots in contrast to the testosterone effect, 
leading to sex dimorphism. Females have more leptin for a given total FM compared to 
males. On the other hand, fasting, cold and long term exercise cause reduction of leptin 
production (319). In general, leptin synthesis is mediated through sympathetic nervous 
system; B-agonists, noradrenaline and isoprenaline inhibit leptin synthesis (320).  
 
Factors that increase serum leptin 
levels 
Factors that decrease serum leptin levels 
Obesity Androgens 
Overfeeding Fasting 
Impaired renal function Cold exposure 
Insulin Growth hormone 





Interleukin-1 Free fatty acids 
Alcohol β-Adrenoceptor agonists 
 





Energy homeostasis is achieved through pathways that influence feeding and metabolic 
rate. Peripheral tissues secrete hormones which reflect adipose tissue stores and 
nutritional state. Adipocytokines, insulin and gut hormones act centrally at the level of 
hypothalamus. Specifically, the ARC is the site in the hypothalamus receiving these 
signals (321). It is composed by 2 types of neurons:                   
1. anorexigenic neurons, secreting propiomelanocortin, cocaine and amphetamines 
2. orexigenic neurons, secreting neuropeptide Y and agouti-related protein 
 
Leptin’s main role is to reflect energy reserves, regulate appetite and energy expenditure 
by signaling the CNS. Its action is mediated by central and peripheral receptors (ObR) 
(322). Centrally, in conditions of positive energy balance, increased leptin levels bind to 
hypothalamus which in turn releases anorexigenic and inhibits orexigenic hormones. 
Leptin also acts to the mesolimbic dopaminergic system and the brainstem promoting 
satiety (Figure 2.5). Furthermore, hypothalamus responds to the increased energy 
expenditure demand by producing Thyrotropin Releasing Hormone (TRH), Gonadotropin 
Releasing hormone (GnRH) and IGF-1, leading to increased metabolic rate (323). Leptin 
treated mice loose more weight and develop increased metabolic rate and core 
temperature than pair-fed controls, proving that leptin regulates both appetite and energy 




Figure 1.11: Central effects of leptin. Leptin promotes the secretion of anorexigenic 
hormones and increases energy expenditure through adrenergic stimulation. Leptin 







Numerous reports have described the presence of ObR in peripheral tissues. Leptin 
receptors belong to the gp130 cytokine receptors family, expressing a CK-F3 domain as 
the binding site to leptin. Following binding, receptor degrades leading to intracellular 
activation signal (322). The ObR gene is expressed in various human tissues, including 
lungs, heart, kidney, liver, spleen, small intestine, ovaries, testis and adipose tissue 
(326). Placenta and multiple foetal organs also express ObR (327). Leptin which was one 
thought to be a marker of energy stores is now well proven to have a more complex 
physiology (Figure 1.12) participating in haemopoiesis, angiogenesis, reproduction and 
fertility, pregnancy and fetal growth, puberty and immunity (319).   
 
 
Figure 1.12: Leptin physiology. Leptin demonstrates both central (appetite regulation, 
sympatheticomimetic) and peripheral actions (increased energy expenditure, glucose - 
lipid metabolism and reproduction); Adopted from Margetic et al (319)  
 
 
1.5.2.1.1 Leptin and insulin/metabolism 
 
Of great interest is the role of leptin in human metabolism. Insulin is an anabolic 
hormone, promoting fuel storage, in contrast to leptin which mobilizes triglycerides 
leading to energy expenditure through FFA oxidization. Insulin enhances leptin 
production acting directly to the adipocyte level. The above statement is further 
supported by the presence of high leptin levels in cases of insulinoma (328). On the other 
hand, leptin inhibits insulin secretion by pancreatic islet cells (329). The main metabolic 
effect is mediated through direct action to vital organs (liver, muscle, adipose tissue) 
causing reduced lipogenesis, reduced glycogen synthesis and increased FFA oxidization 






Leptin has also other roles in reproduction (330), angiogenesis (331) and haemopoiesis . 
(332) which are beyond the scope of this thesis. 
Table 1.8: Leptin interactions with insulin-glucagon. Table demonstrates the effect of 






Adiponectin is a product of the ADIPOQ gene, located in chromosome 3q27. It was first 
described in 1995 and during the following two years various groups had successfully 
studied its molecule, leading to different names such as ARCP30 (adipocyte complement 
related protein), AdipoQ and GBP28 (gelatin binding protein 28). Adiponectin is the most 
commonly used name. Structurally full length adiponectin consists of 247 amino acids, 
posing similarities to complement and TNF-a molecules. In detail, there are 3 distinct 
compartments: i) aminoterminal peptide ii) collagen like domain at N-terminal and iii) 
globular domain at c terminal, similar to complement and facilitating binding to 
adiponectin receptors (Figure 1.13) (2).  
 
In vitro models Pathway Effect 
Leptin effect   
Muscle FFA oxidation Stimulation 
 Insulin mediated anti-oxidative and 
lipogenic effects 
Attenuation 
 Insulin mediated glucose transport No effect 
 Glycogen synthesis No effect 
Adipose Insulin binding Inhibition 
 Insulin mediated glucose transport- 
glycogen synthase activity, 
lipogenesis 
Inhibition 
Liver Insulin binding Inhibition 
 Glucagon activated cAMP 
production 
Inhibition 
Insulin effect   





After synthesis, adiponectin undergoes hydroxylation resulting in 8 isoforms. Main 
structural form is a trimer, formed by the connection of 3 monomers. 2-6 trimers combine 
to create higher molecular weight structures (hexamers, multimers). High molecular 
weight (HMW) and hexamers are the main circulating forms whereas trimers have a 
shorter half life. <1% of circulating adiponectin is the globular-adiponectin, arising from 
the proteolysis of the full length molecule and corresponding to the globular domain. 
Similar to trimers, globular-adiponectin has a short duration of life. Multimeric forms have 
different biological activity, targeting various human tissues (333). HMW adiponectin 
poses a more peripheral action, targeting predominantly the liver and muscles, having an 
insulin sensitizing effect whereas lower weight isoforms tend to act centrally at the level 




Figure 1.13: Structure of adiponectin. The aminoterminal peptide (blue), collagen like 
domain at N-terminal (green) and globular domain at c terminal (red) are color coded; 
Adopted from Achari et al (335)  
 
 
Adiponectin is almost exclusively secreted by WAT in adults. Recent studies have 
confirmed that central nervous system, bone marrow and osteoblasts, myocytes and 
cardiomyocytes, salivary gland and fetal tissues are other sources of adiponectin in 
humans (336-338). Adiponectin production in adipose tissue is regulated at the level of 
gene expression (339). Post translational changes, including hydroxylation and 
glycosylation, define the type of oligomers in circulation (340). Adiponectin gene is a 
target for peroxisome proliferator activated receptor γ (PPARγ) regulation. Activation of 
the receptor enhances adiponectin expression whereas TNFa, IL-6 and resistin inhibit it. 
PPAR is a subgroup of nuclear family receptors controlling major aspects of metabolic 
homeostasis. They are expressed in many human tissues but are predominantly found in 
WAT and BAT (341). Specifically, PPARγ are the master regulators of adipogenesis and 





lipogenesis without creating larger adipocytes, more and smaller adipose cells are 
created instead (342) and promote subcutaneous to visceral fat differentiation (343). 
Adipocyte formation is impossible without the presence of PPARγ, which are induced 
when preadipocytes convert to adipose cells (344). Deletion of PPARγ in knockout mice, 
leads to apoptosis of mature adipocytes and insulin resistance (345). The close 
relationship between PPARγ, adiponectin production and insulin resistance has led many 
researchers during the last decades in the study of substrates which could potentially 
activate the receptors, thus improving insulin sensitivity and metabolic profile. 
Thiazolidinediones (TZD), medications used in diabetes mellitus, are proven to be direct 
agonists of the receptors and will be discussed later in this chapter.  
 
Adiponectin action is mediated through 3 different receptors (Figure 1.14): 
1. AdipoR1: Transmembrane receptors, encoded by the 1p36.13-q41 gene which 
are mainly expressed in human skeletal muscle. They have high affinity for 
gAdiponectin and less for full length isoforms (346). In mice models they 
participate in energy metabolism, as R1 -/- mice are obese with low energy 
expenditure (347).  
2. AdipoR2: Transmembrane receptors encoded by the 12p13.31 gene, 67% 
homologous with R1 but having different N-terminal sequence. They are mainly 
expressed in liver but also in muscles, showing great affinity for both globular and 
full length adiponectin (346).  
3. T cadherin: Contradicting evidence exists on whether they are receptors based 
on the surface of the cell membrane or just binding proteins to adiponectin. They 
have no affinity for trimeric and globular-adiponectin but bind to HMW and 
hexameric adiponectin. They are encoded by the CDH13 gene and are mainly 
expressed in the cardiovascular system, including heart, aorta, carotids, iliac and 







Figure 1.14: Adiponectin receptors; Intracellular signaling leads to increased lipid 
oxidization, increased glucose uptake and reduced gluconeogenesis  Adopted from 
Kadowaki et al. (349)  
 
Table 1.9 demonstrates the distribution of adiponectin receptors in various human 
tissues. The presence of adiponectin receptors mRNA in various organs, reveals its 
multifactorial role in many aspects of human physiology. The adipocytokine which was 
once believed to be a marker of adipose tissue is now proven to contribute to many 
tissue functions. 
 
Interaction of adiponectin with its receptors triggers multiple signaling pathways. 
Activation of adenosine monophosphate (AMP)-activated protein kinase (AMPK) has a 
primary role in the insulin sensitizing effect of adiponectin. AMPK is a cellular energy 
sensor, which activates energy producing pathways (fat oxidation) and inhibits energy 
storing (2). AMPK important role was confirmed after the suppressed fatty acid oxidation, 
glycose uptake and lactate production seen in dominant negative mutants (350).  
Adiponectin action is also mediated by other signaling molecules such as s p38 mitogen-
activated protein kinase (p38 MAPK), peroxisome proliferator-activated receptor-a 
(PPARa) and the RAS-associated protein Rab5. Recently, the discovery of the adaptor 
protein APPL1 shed more light to the adiponectin signaling cascade. APPL1 has 3 
functional domains which include a NH2-terminal Bin1/amphiphysin/rvs167 (BAR), a 
pleckstrin homology (PH) (278–377 amino acids) and a phosphotyrosine binding (PTB) 





signaling (Figure 1.15). APPL1 deficient models, are characterized by reduced fat 
oxidation, glucose uptake and AMPK phosphorylation (351).   
 
 
  AdipoR1 AdipoR2 T-Cadherin 
Skin-Adipose Skin       
 Subcutaneous       
 Visceral       
Muscular system Muscle       
Nervous system Brain       
 Cerebral cortex     
 Medulla     
 Thalamus     
 Midbrain     
 Hypothalamus     
 Spinal Cord     
Circulation Heart       
 Blood vessels       
Endocrine Adrenal gland      
 Pituitary      
 Pancreatic cells      
 WAT      
 BAT      
GI system Stomach      
 Small Intestine      
 Large Intestine      
 Liver      
 Pancreas      
Immune system Thymus      
 Lymph nodes      
 Bone marrow      
Respiratory Lungs      
Urinary Bladder      
 Kidneys      
Reproduction Testes      
 Prostate      
 Breast      
Table 1.9: Adiponectin receptors in various human tissues. The widespread 











Figure 1.15: Adiponectin receptor signaling; Adopted from Achari et al (335)  
 
 
1.5.2.2.1 Adiponectin and liver 
 
Liver, the cornerstone organ of human metabolism, expresses adiponectin receptor 
mRNA (352). Hepatocytes express greater amount of AdipoR2 than AdipoR1. 
Adiponectin inhibits FFA synthesis and promotes oxidization by up regulating PPARa 
and AMPK mediators. It plays an important role in glucose homeostasis by suppressing 
glycogenolysis and gluconeogenesis and by increasing glucose uptake (353). Multiple 
studies have confirmed the suppressed endogenous glucose production, without 
hypoglycaemic episodes, after adiponectin infusion, even at supraphysiological doses 
(354).  
 
Adiponectin has a protective role against liver disease. In Ob/Ob mice, adiponectin 
supplementation prevented fatty liver and alcohol induced steatosis. In human models, 
chronic hepatitis and steatosis grade were negatively related to adiponectin levels. The 
above effects could be explained by the ability of adiponectin to reduce acetyl-CoA 
carboxylase and fatty acid synthase activity (355).  
 
1.5.2.2.2 Adiponectin and muscle 
 
Adiponectin is expressed in human skeletal muscle (356), another crucial tissue for 
energy metabolism. Activating AMPK and p38 MAPK, adiponectin leads to higher 
glucose uptake by the muscle and FFA oxidization (357). Moreover AdipoR1 and 
AdipoR2 are also expressed in muscle with R1 having a more predominant role (358). Of 





related to insulin levels. Thus, in conditions of fasting or insulin deficiency, adiponectin 
action is promoted by increased receptor (AdipoR1) expression. Recently, the 
association between adiponectin and muscle growth has been addressed. Fiaschi et al 
(360) showed that globular adiponectin induces muscle gene expression and cell 
differentiation in murine cells. 
 
1.5.2.2.3 Adiponectin and pancreas 
 
Human pancreatic β-cells express R1 and R2 receptors. Adiponectin deficient mice have 
low plasma insulin after glucose loading, suggesting a direct effect of adiponectin on 
pancreatic insulin secretion (361). To further support this statement, Okamoto et al (362) 
showed that the adiponectin infusion to isolated islet cells and mice increased insulin 
levels when compared to placebo. 
 
There is contradicting evidence regarding the role of adiponectin in the pathogenesis or 
prognosis of acute and chronic pancreatitis. Whether adiponectin protects pancreatic cell 
apoptosis remains to be examined further (363).  
 
1.5.2.2.4 Adiponectin and central nervous system 
 
The role of adipose tissue derived hormones, such as leptin, in regulating food intake 
and energy expenditure through CNS stimulation is well described. There is conflicting 
evidence regarding the role of adiponectin with some studies showing no effect on food 
intake and increased energy expenditure (364) whereas others revealing increased food 
intake and negative energy balance (350). Conflicting results also exist on whether 
adiponectin passes the blood-brain barrier (365). Interestingly, AdipoR1 and AdipoR2 are 
widely distributed in areas of CNS responsible to control food intake and energy balance, 
such as pituitary, hypothalamus and brainstem (366). Given the known adiponectin 
production in the CNS, a potential autocrine/paracrine role of adiponectin needs to be 
further investigated. 
 
1.5.2.2.5 Adiponectin and diseases 
 
Adiponectin has been related to the pathogenesis of various diseases and its role as a 






1.5.2.2.6 Adiponectin and inflammatory state 
 
Adiponectin exerts anti-inflammatory effects, which differ according to adiponectin 
isoforms and target cells. In vitro studies, adiponectin increased anti-inflammatory 
cytokines (IL-10) and reduced IL-6 and TNF-a production from macrophages (367). 
Tsatsanis et al (368) showed that macrophages’ immediate response to adiponectin 
exposure is to increase pro-inflammatory cytokines production. However, prolonged 
exposure leads to inhibition of further production, suggesting a form of resistance and 
adaptation. Finally, chronic inflammatory states, such as obesity, characterized by 
persistent TNF-a production by adipocytes, leads to reduced adiponectin expression 
(369).  
 
1.5.2.2.7 Adiponectin and obesity 
 
Measures of adiposity such as BMI, waist circumference and abdominal fat are 
negatively related to serum adiponectin levels (370). Despite adiponectin secretion from 
adipose tissue, humans with obesity have lower levels compared to lean (371). A 
possible explanation to this paradoxical observation is that the hyperplastic adipocytes 
seen in obesity secrete hormones like TNF-a and IL-6 which suppress adiponectin 
production. Even the expression of AdipoR1 and AdipoR2 is downregulated in cases of 
obesity (372). It looks like adiponectin has an autocrine role with negative feedback on its 
own production. The question of whether adiponectin is a “cause or consequence” of 
obesity remains to be answered. 
 
1.5.2.2.8 Adiponectin and diabetes mellitus 
 
Adiponectin exhibits its beneficial role on glucose metabolism through AMPK and PPARa 
activation, leading to reduced gluconeogenesis and increased glucose uptake (349). In 
hyperinsulinaemic-euglycaemic clamps, adiponectin negatively predicts the degree of 
insulin resistance, confirming its insulin sensitizing role (373).   
 
PPARγ is a major regulator of adipocyte gene expression and adipocyte differentiation. 
Negative PPAR-γ mutations are related to severe insulin resistance, development of type 
2 diabetes mellitus and fivefold reduction in circulating adiponectin levels (374). TZDs  
improve glucose tolerance by activation of PPAR-γ receptors. Administration of TZDs in 
insulin resistant humans has increased serum adiponectin levels by promoting 
expression of adiponectin gene, mediated by PPAR-γ activation (375). On the other 





that the benefits of the treatment are mediated by increased adiponectin production. 
Muscle and liver express less numbers of PPARγ compared to adipose tissue, therefore 




Figure 1.16: Activation of PPARγ by thiazolidenidiones (TZD). PPARγ activations leads 
to favorable metabolic effects; Adopted from Maeda et al (375)  
 
 
Multiple studies have shown that patients with diabetes have lower adiponectin levels 
(376). Both total and HMW adiponectin are negatively correlated with glucose and insulin 
levels (377). The mechanism responsible for the low adiponectin levels in insulin 
resistant states is still unclear. These observations led to the question of whether 
hypoadiponectinaemia is a cause or a consequence of insulin resistance. Yamauchi et al 
in 2001 (378), studied lipoatrophic mice with absent adiponectin and noted that 
adiponectin infusion corrected hyperinsulinaemia and hyperglycaemia. Moreover, Kubota 
et al (379) showed that despite adiponectin knockout  mice have the same insulin levels 
with controls, the glucose effect is much lower, confirming the role of adiponectin as 
insulin sensitizer. Subjects with genetic insulin receptor deficiencies, characterized by 
insulin resistance, have higher adiponectin levels (380). On the other hand, exogenous 
insulin infusion is shown to reduce adiponectin levels, questioning the cause-effect link 
between adiponectin and insulin resistance (381).  
 
In an attempt to answer the previous question, Li et al (382) performed a systematic 
review including thirteen prospective observational studies (n= 14,598 participants). 
Results of the meta-analysis revealed that higher adiponectin levels can predict reduced 
risk of future type 2 diabetes mellitus. One of the main disadvantages of his work is that 





covariates. In order to provide unbiased results Yaghootkar et al (383) performed a large 
Mendelian randomization study. Purpose of the Mendelian randomization was to 
use genetic polymorphisms with well-understood effects on exposure patterns, allowing 
safe causal effect conclusions from observational data, in the presence of confounders. 
(384) In a large cohort of 31,000 individuals, results suggested adiponectin as a marker, 
rather than a pathogenic factor of insulin resistance. In contrast to the above results, Gao 
et al (385)  applying also Mendelian randomization models in Swedish population (n=942 
individuals), showed a positive correlation between adiponectin and insulin sensitivity. All 
the above, signify that up to date, the exact pathophysiological role of adiponectin and its 
role in the development of insulin resistance and diabetes is not fully understood. Larger 
longitudinal studies, including genetic data, are required to clarify the role of this elusive 
molecule.  
 
1.5.2.2.9 Adiponectin and cardiovascular disease  
 
The link between visceral fat and increased cardiovascular disease is well established 
(386). The more visceral to subcutaneous fat the less the adiponectin levels, therefore an 
inverse correlation between cardiovascular disease and adiponectin was assumed. 
Patients with coronary artery disease have lower adiponectin levels compared to controls 
(376). Specifically it is the HMW isoforms which are reduced whereas hexameric and 
timeric forms remain the same. 
 
The above association can be explained by the anti-atherogenic role of adiponectin. In its 
presence, monocyte adhesion to endothelial cells is reduced, conversion of 
macrophages to foam cells is inhibited, binding of LDL to the sub-endothelium is limited 
and vasodilation through nitric oxide production is enhanced (387). Chronic inflammation, 
a well known risk factor for cardiovascular disease, is reduced in the presence of 
adiponectin through inhibition of TNFa and IL-6 production and enhancement of anti-
inflammatory IL-10 expression (388).  
 
1.5.2.2.10 Adiponectin and other diseases 
 
Adiponectin infusion has been linked to normalization of blood pressure in rat models 
through reduction of renal sympathetic nerve activity (389). Low adiponectin levels have 
been found to be associated with low HDL (high density lipoprotein), high VLDL (very low 
density lipoprotein) and TRG (triglycerides) levels (376) as well as increased risk of 





participate in carcinogenesis, as low levels have been linked to increased cell 
proliferation and reduced apoptosis (391).  
 
In summary, adiponectin is a complex molecule participating in the main metabolic 
pathways of humans. The presence of adiponectin receptors in various tissues, confirms 
its multifactorial role (Figure 1.17). Up to date data cannot fully explain the contribution of 
adiponectin to metabolism, low grade inflammation and atherosclerosis, the three main 
predictors of mortality. If adiponectin is a regulator or just a marker of metabolic and 
cardiovascular status remains to be confirmed. Research on ways to restore the capacity 
of adipocytes in secreting adiponectin can serve as a potential therapeutic approach to 
metabolic diseases. The prognostic value of adiponectin in the development of diabetes 
and cardiovascular morbidity and mortality remains to be clarified by further studies and 
could potentially constitute a biomarker allowing for early intervention in high risk groups.  
 
1.5.2.3 Adipocytokines in pregnancy 
 
Insulin and IGF-1 are the most well described growth factors during pregnancy (392). As 
the role of intrauterine exposure in the development of future metabolic diseases is 
established, finding a link between fetal markers and risk of adverse metabolic profile 
would enable us to understand the mechanisms underlying this association. Leptin and 
adiponectin may play an important role in fetal growth either having a direct effect or 









1.6 Body composition during early stages of life 
 
Exposures during pregnancy and early postnatal life can affect growth and determine 
metabolic milestones in future life. The majority of studies use birthweight in order to 
quantify this effect. As already described, birthweight is a rough estimate of neonatal 
wellbeing and can only partly reflect events during intrauterine life. On the other hand, 
assessing body composition provides information on the natural course of chronic 
diseases. Precise data on fat and fat free mass allows a better understanding of the 
mechanisms linking neonatal malnourishment or obesity to future adverse metabolic 
profile. Nutritional guidelines during pregnancy and postpartum and treatment 
interventions to prevent obesity can be created based on body composition information. 
 
Hydrometry, skinfold thickness, DXA, MRI and ADP are the commonest techniques for 
assessing body composition, using two, three or four compartment models. The two 
compartment model divides body to fat and fat free mass, the three compartment model 
divides FFM to water and fat free dry mass whereas the four (multicompartment model) 
further categorizes FFM to water, protein and minerals (Figure 1.18). Results derived 
from multicompartment models provide more detailed and precise information on body 










have higher cost and longer duration. In clinical settings, measuring body composition in 
neonatal population is challenging. Parents prefer non interventional and time consuming 
techniques and neonates need to be settled to complete the assessment. In this regard, 
multicompartment models are not practical and methods (MRI, DXA, and ADP) using two 
or three compartment models are preferred. Age and gender specific constants derived 
from multicompartment models can be utilized by modern techniques to convert body 
constituents into FFM. 
 
Figure 1.18: Two and four compartment models 
 
1.6.1 Infant body composition reference data 
 
Up to date, there is no consensus on the optimal body composition at birth (1). Age and 
gender specific growth charts, standardized to feeding mode and based on body 
composition do not exist. Growth charts proposed by various researchers are based on 
different techniques and cannot be used interchangeably. Each technique is based on 
theoretical assumptions, thus data obtained from different methods cannot be combined 
to create universal standards (393). So far, WHO has not defined normal growth based 
on body composition and existing charts are created on weight, length and BMI figures 
(16). The committee, after studying 8,500 children from different ethnic backgrounds, 
suggested that all humans should have an “optimal growth pattern”, pointing towards 
universal growth charts. They concluded that differences in growth are related to living 
conditions, therefore efforts should be made to minimize environmental effect on growth 
(394). On the other hand, mixed ethnicity studies have revealed that altered phenotype is 
not only a result of ecologic exposure but also of transgenerational effect (395). Already, 
in Asian adult population the threshold of BMI linked to metabolic diseases is lower 
compared to other populations (396). This adverse phenotype is also present at birth 
(“thin fat baby”) with Indian babies having more fat for a given weight when compared to 





incorporating longitudinal data on cardiovascular outcomes. Tracing body composition 
from birth to adulthood would allow a better understanding of the pathophysiology of 
chronic diseases. The acquired knowledge will eventually lead to improved clinical 
practices, starting from early stages of life, aiming to prevent development of future 
obesity.   
 
Fomon et al (397) in 1982 was the first to provide body composition reference for 
children up to 10 years of age. The author described his results as “preliminary and 
crude”, as his work was based on reports from multiple other studies and many 
assumptions. Butte et al (398) in 2000, after studying 76 newborns of different ethnic 
background produced similar body composition data up to 2 years of age (Table 1.10). 
Using multicompartment models author studied body composition in terms of FM, water, 
protein, glycogen, bone mineral content and non osseous minerals. Measurements 
included total body water (deuterium dilution), total body potassium (energy emission 
from 40K) and DXA. Up to date, her work is considered as pioneer in the study of body 
composition and newer techniques, using two compartment models, are based on 
equations derived from this dataset. 
 
 
Table 1.10: Body composition reference for children up to 3 years of age; Adopted from 





1.6.2 Body composition data using ADP 
 
Many researchers, studying various populations and using different techniques have tried 
to create reference data (399). As already described, results cannot be used 
interchangeably, therefore for the purpose of this thesis emphasis will be given to the 
studies using ADP as direct method of assessing body composition. Eriksson et al (400) 
and Carberry et al (401), studying Swedish and Australian cohorts respectively, 
presented data on body composition from birth to four months of age. Inclusion of both 
breast and formula fed neonates and mothers with raised BMI (in the Swedish cohort) 
were considered significant limitations of their work. Trying to address these limitations, 
Fields et al (402) studied 72 exclusively breastfed infants of mothers with BMI below 
25kg/m2 up to six months of age. Application of strict feeding criteria has led to great loss 
to follow up at six months, potentially biasing the results (Table 1.11). 
 
 
Table 1.11: Body composition data derived from ADP in US population. Of great interest 
are the values at one and five months of age Adopted from Fields et al (402) 
 
The current observational study (thesis) involves neonates born in UK, therefore 
population specific reference range are of great importance. Hawkes et al (403) in 2011, 
studying 743 Irish babies with similar characteristics to English population, triggered body 
composition charts at birth based on gender and gestational age. Results of his study 
also confirmed that maternal BMI and gestational age are independent predictors of 
%FM at birth. In one of the biggest cohorts, a subpopulation of the INTERGROWTH 





Oxford site were divided according to gestational age, gender and metabolic risk allowing 
for the creation of body composition centiles (Table 1.12, Figure 1.19). Postnatal body 
composition standards for UK population do not exist at present. 
 
In summary, the above-mentioned studies utilizing ADP to assess body composition 
have provided similar growth patterns with small differences in measured FM and FFM. 
The mean combined %BF for both sexes at birth is 10-12% (SD: 4%). Newborns have a 
5-10% weight loss during the first week which is driven by a reduction in FFM due to loss 
of water. After this period and up to 1 year of life FFM increases progressively. A rapid 
increase in %FM is observed during the first 6 weeks of life. Females have increased FM 




Table 1.12: Body composition data of newborns enrolled in the INTERGROWTH 









       
 
 




Anthropometric measurements include weight, length, regional body circumferences 
(arm, chest, abdominal) and skinfold thickness. Estimated body composition is derived 
by combining measured variables with population specific equations. These equations 
are based on studies using direct methods of assessing adiposity (404, 405).  
 
Circumferences provide information on body size, proportions and fat distribution. Head 
circumference is used to predict adiposity rebound and abdominal circumference to 
assess central adiposity (406). Small head circumference at birth is related to early 
adiposity rebound, a predictor of obesity later in life. It has been hypothesized that fetal 
growth restraint and small head (brain) size at birth trigger a compensatory postnatal 
“catch up growth” leading to rapid utilization of fat stores and early adiposity rebound 
(407).  In adults, abdominal circumference (circumference directly above the superior 
border of iliac crest) is a better marker of visceral fat than BMI (408) and is linked to 
diabetes, cardiovascular disease and mortality risk (409). However, studies have 
Figure 1.19: Centiles 
for body composition 
according to sex and 
gestational age of 
newborns enrolled in 
the INTERGROWTH 
21st study; Adopted 
by Villar et al (14) 
 
Blue: boys; Pink: girls 
 
Lines represent 3rd, 







revealed that use of circumferences during early stages of life has low sensitivity. Rolfe 
et al compared accuracy of ultrasound and abdominal circumference in predicting 
visceral fat in infancy against MRI derived reference data. Results revealed that waist 
circumference had a poor correlation with actual visceral fat, with ultrasound derived 
results being closely related to the MRI report (410).  
 
Skinfold thickness is measured using Holtain calipers in pediatric population. Nine 
different anatomical sites have been described with subscapular and triceps skinfolds 
being the most commonly used. The tester needs to pinch the skin creating a double 
layer which includes skin and underlying adipose tissue without muscle. Skinfold is 
measured by applying the calipers 1 cm below the pinch. Measurement should be 
repeated twice. Mean of the two measurements should be recorded as the results of the 
test. Lower angle of the scapula is used to assess subscapular skinfolds (SS) and the 
midpoint between acromial and radial for the triceps skinfolds (TR; Figure 1.20). Sum of 
triceps and sub scapular thickness is considered a marker of total adiposity, whereas the 
ratio of sub scapular to triceps skinfold thickness is used to estimate central adiposity 
(411).  
 
Anthropometric measurements are inexpensive, easy to obtain and not interventional. On 
the other hand, body composition derived from equations using skinfolds have been 
shown to have low correlation with MRI and hydrometry measurements in infants (412). 
In order to achieve low intra- and inter-observer variability testers need to undergo 
training and newborns need to be calm and cooperative allowing for precise readings to 















Isotope dilution method (hydrometry) is used to assess Total Body water (TBW). 
Deuterium (D2O or 2H2O) is the commonest tracer used. Based on the dilution principle 
(C1V1=C2V2; C1: starting concentration, V1: starting volume, C2: final concentration, 
V2: final volume) solvent (TBW) can be estimated by knowing the volume and the 
concentration of the isotope (414). Enrichment of the body water pool with deuterium 
allows the isotope dilution space to be estimated (Figure 1.21). Baseline levels are 
measured by collecting neonatal saliva or urine and the same sample is collected again 
three hours after the isotope administration. Concentration of the tracer is measured by 
spectrometry and TBW values are derived. Applying age and gender specific values of 
the FFM hydration leads to FFM calculation (FM is anhydrous). The method is based on 
the assumptions that tracer is evenly distributed in all water compartments and it is not 
metabolized after administration.  
 
Hydrometry is one of the most accurate and precise methods with a coefficient of 
variation (CV) of 1-2% (415, 416). Limitations of the method include: i) Duration of the 
test (4-5 hours) ii) Infants are not allowed to be fed during the test at it affects the 
reliability of the results iii) Duet to spillage by drooling the exact amount of tracer ingested 
may be difficult to be assessed. The above factors have limited the use of hydrometry 
during early stages of life. 
 
 
Figure 1.21: Deuterium dilution. Enrichment of the body water pool with deuterium allows 









1.6.3.3 Hydrodensiometry (underwater weighing) 
 
Archimedes, was the first to introduce the principles of hydrodensiometry, stating that 
“the object’s loss of weight in water equals the volume of water it displaces”. Individuals 
are fully submerged after a deep exhalation to minimize thoracic volume and the water 
displaced is measured. Knowledge of the water density allows the calculation of the 
volume of the body. Due to discomfort, this method is not used nowadays to assess 
neonatal body composition. 
 
1.6.3.4 Multicompartment model 
 
Assessment of body composition using multicompartment models is considered the “gold 
standard technique”. Body is divided into FM, TBW, protein, glycogen, bone mineral 
content and non osseous minerals. Each of these compartments is measured individually 
without the use of any assumptions. TBW is derived from deuterium dilution method, 
bone mineral content from DXA, nitrogen and protein from total body potassium 
(measured by energy emission from 40K) (417). Duration of the test and exposure to 
small amounts of radiation (DXA) has limited the clinical use. Multicompartment models 
are used for the creation of reference data and the validation of new techniques (398).  
 
1.6.3.5 Dual energy X-ray absorptiometry (DXA) 
 
DXA scan is based on the fact that different tissues absorb different amount of radiation 
due to variable density and chemical composition. Two X-ray beams pass through the 
body, with the subject lying flat and the attenuation of radiation is measured. Body 
structures are classified as fat, bone and muscle (3 compartment model) (418). One of 
the main strengths of the technique is the provision of both whole body and regional 
estimates (Figure 1.22). 
 
Validation of DXA in adults is well described but data in population <2 years of age is 
scarce due to radiation exposure. Radiation differs by manufacturer and a mean 
exposure from an infant scan is 1-5 milliSieverts, which equals the estimated effective 
dose of 5-25 chest x-rays (radiation dose for an infant chest x-ray is 0.02 milliSieverts) 
(417). Piglet carcasses have been used to validate the technique in pediatric population 
providing CV values for FM between 2.8 and 12.2% (419, 420). Subject movement and 
differences in hardware and software algorithms between manufacturers may further 





assessing body composition providing total and regional estimates. Factors such as lack 
of validation studies in infants, radiation exposure, costly maintenance and radiological 




Figure 1.22: Infant body composition using DXA. Babies with sim ilar weight have 
different percentage of fat mass; Adopted by Demerath et al (417)  
 
 
1.6.3.6 Magnetic Resonance Imaging (MRI) 
 
Hydrogen protons are present in all human tissues. Application of pulsed radio frequency 
causes the protons to absorb energy which is released back once the field is switched 
off. The detected signals are used by the receiver to create images (422). MRI provides 
data on both total and regional body composition volumes. The test does not involve 
radiation exposure allowing for repeatability in infants. Studies have revealed a high 
reproducibility (CV=2.6-3.4%) and accuracy for subcutaneous fat (CV=1.6%) with a lower 
precision for visceral fat (CV=8.7%) (423, 424).  
 
MRI application in infants has significant limitations. Subjects need to remain still as 
movement artifacts affect the quality of the images. Test is technically difficult as infants 
need to be scanned while sleeping and wearing earplugs. Pulse oximeter needs to be 
used during every test, monitoring baby for crying and discomfort. Limited access to MRI 
scans, high maintenance cost and need for technically trained staff reduce the 








1.6.3.7 Air displacement Plethysmography (ADP) 
 
ADP is the method of using body density to derive body composition. Based on the 2 
compartment model, body is divided into FM and FFM. Body density is calculated by 
dividing mass by volume (Density=Mass/Volume). Mass is acquired by weighing the 
subject with an accurate weighing scale whereas volume is measured in air using Boyle’s 
and Poisson’s laws.  
 
Boyle’s equation describes the behavior of air when temperature remains stable (Figure 
1.23) and is:   P1V1=P2V2, where P1, initial pressure; V1, initial volume; P2, final pressure 
and V2, final volume. 
 
When air changes temperature in response to volume changes (adiabatic conditions) the 
equation is converted to: P1/P2=(V2/V1)γ, where γ for air is 1.4 (Poisson’s law). Adiabatic 
conditions mean that there is no external factor contributing to the change in temperature 
except the heat produced by the “work”. For small volume changes P2 is always 40% 
larger than P2 in isothermic conditions, or in other words it is easier to compress air under 
isothermic conditions.  
 
 




“PEAPOD Cosmed Infant Composition system” is the only commercially available ADP 
technique for infants, first introduced in 2003 (Figure 1.24). It is licensed to measure 
infants up to 8kgr in weight, which equals approximately 6 months of age. It is safe, fast 





Operators do not require any specific training and system can accommodate infant’s 
behavior (crying, urination, defecation) without altering the accuracy of the results (see 
below). One of the main disadvantages of the technique is that the child/adult version 
(BodPod) is licensed for children above 2 years of age, leaving a gap between 6 and 24 
months of age where body composition cannot be assessed by ADP when longitudinal 
data is required. 
 
The PEAPOD components are placed on a movable cart. Test chamber, electronic scale, 
monitor are on the top while reference chamber, volume calibration container, air 
circulation, heating system, computer and printer are mounted inside the cart (Figure 
1.25). Electronic weighing scale has a capacity of 12kgr. A diaphragm separates the test 
and reference chamber whereas a pneumatic valve is between test and calibration 
chamber. Both test and reference chamber have a volume of 37 L each. Insertion of a 
subject in the test chamber causes the diaphragm to oscillate resulting in volume 
perturbations in the two chambers which have equal magnitude but opposite sign. 
Calibration chamber is smaller with a 5L volume. During calibration pneumatic valves 
















1.6.3.7.1 Operating principles 
 
Using Boyle’s and Poisson’s equations an unknown volume (Vtest) can be calculated by 
the ratio of pressures in the test (Ptest) and reference chamber (Pref). The oscillating 
diaphragm reflects the change in pressure induced by volume change. Magnitude of 
pressure change is inversely related to the volume in the chamber resulting in the 
following equation:             Vtest = (Pref/Ptest)*Vref. 
 
Air close to subject’s body, hair and within lungs behaves isothermally. PEAPOD 
assumes that all air in the test chamber is under adiabatic conditions resulting in a 40% 
overestimation of air behaving isothermally. System automatically corrects for the 
behavior close to subject’s surface (Surface Area Artifact, SAA) and within lungs 
(Thoracic Gas Volume, TGV). SAA is dependent of length and weight and is calculated 
based on Boyd equation (425) :                                                                                                                                                                                                                 
SAA = [178.27*Length (cm)0.5* Weight (kgr)0.4838]*k,  where K is a constant based on 






Lung volume is overestimated by 40% leading to equal underestimation of body volume. 
PEAPOD uses prediction algorithms to predict TGV based on pulmonary research 
literature and adjusted for weight, length and gender (426).  TGV is calculated as the 





Figure 1.26: Lung volumes and capacities 
 
Taking into considerations the above adjustments total body volume is calculated as:             
Vbody final = Vraw body volume - SAA + 40% TGV 
 
1.6.3.7.2 Calculating FM and FFM 
 
Body density is derived from mass and volume. Applying the 2-compartment model and 
considering that density is a function of the proportions and densities of its components 
lead to the following equations:                                         
1/DB = FM/DFM + FFM/DFFM   where DB, DFM and DFFM are densities of body, FM and 
FFM respectively. Replacing FFM with 1-FM leads to:                                     
%Fat = [(DFMDFFM/ DB(DFFM-DFM) –(DFM/DFFM-DFM)] *100%. 
 
Using data from Fommon et al (397) and Butte et al (398) models FFM is predicted 
based on gender and age whereas FM density remains constant at 0.9007kgr/L. Once 







%FFM= 100 - %Fat 
FM= (%Fat)(MB)/ 100% 
FFM= Total Body Mass – FM 
 
1.6.3.7.3 Test procedure 
 
To maintain the integrity of the PEAPOD system quality control needs to be performed 
daily. Users should leave at least two hours between switching on the application and 
testing allowing PEAPOD to warm up and reach desirable temperature in the test 
chamber (310C). Weighing scale should be checked against reference 5kgr phantom on 
daily basis. Every two weeks or if PEAPOD cart is moved weighing scale requires 
calibration to rule out the unlike scenario of altered gravity at different geographical 
locations. At the beginning of each test day or if there is more than 6-8 hours interval 
between tests, volume calibration needs to be performed to assess PEAPOD and 
environmental stability. The 5Lt reference phantom is inserted in the test chamber and 
six consecutive volume measurements are obtained. If standard deviation between tests 
is less than 0.003Lt calibration is considered successful. Room temperature needs to be 
maintained between 20-280C and ambient change in temperature between and during 
tests should be ≤0.50C. PCO2 levels should be checked before test and kept ≤0.45%. 
Users are allowed to proceed to subject testing when all quality control criteria are met.  
 
With electromagnetic door closed and test chamber empty automatic volume calibration 
is performed at the beginning of each test. Different pressures are applied to the 
diaphragm with the pneumatic valve open or closed. The communication between test 
and calibration chamber allows the system to perform analysis of the inverse correlation 
between different pressures and volumes. 
 
At the same time, infant is undressed and prepared for mass measurement. For sanitary 
reasons insulation material (paper, sheet) is placed and left on the scale before 
calibration, during mass measurement and post test calibration. Infants are placed 
supine and in case of urination or defecation test is repeated. Data including gestational 
age, date of birth, gender, length and unique study number is entered in the screen. By 
completion of data entry and mass measurement, volume calibration is usually finished 
and the door opens automatically. Plastic tray is pulled out and infant is placed in the 
supine position. In case of excessive hair, few drops of oil are used to flatten the hair. 
Tray is pushed back and the door is closed. During volume measurement pressure 





and door opens spontaneously. Results of the test are displayed on the screen (Figures 
1.27 and 1.28).  
 
Infant’s behavior should be monitored throughout the test. In case of excessive crying 
and increasing PCO2 levels, fitted sensor in the test chamber automatically opens the 
door and aborts the test. If during the test user or parents feel uncomfortable or are 
concerned for the infant’s behavior, test can be aborted by using one of the two safety 
buttons which allow the door to open (Figure 1.29). Test is repeated with parental 
consent once infant is settled. After each test scale and test chambers are cleaned using 




Figure 1.27: Steps in assessing infant body composition using PEAPOD. Infant is 
weighed in the electronic scale and then placed in the plastic tray for volume assessment  
 
 








Figure 1.29: PEAPOD safety buttons (indicated by red arrows) 
 
1.6.3.7.4 ADP validation 
 
Pediatric ADP has been validated against reference methods in 9 studies (Appendix 1) 
(427). For most researchers the “4 compartment” approach (4-C) is the gold standard 
method in assessing body composition. Ellis et al (428) examined 49 infants using ADP 
and compared the results with reference values from 4-C model, obtained after TBW, 
total potassium and DXA measurements. A subgroup of infants (n=31) had a repeat ADP 
assessment within 15 minutes to check reliability of the method. The two methods were 
significantly correlated (R2: 0.73, p<0.001) and a good agreement was observed with 
95% limits of agreement at -6.8 and 8.1 %FM. Mean difference of the measured %FM 
was 0.6±3.7 (p=0.62). Results also revealed reproducibility of the ADP tests, reporting a 
within subject CV of 7.9% for %BF and mean difference between first and second 
measurement of 0.4% (p>0.05).  
Detailed results of ADP reliability and accuracy were presented by Ma et al in 2004, 
(429) using deuterium solution as the reference method. Accuracy was assessed in 53 
infants of various body weight (2.7-7.4 kgr) and reliability in 36 infants after three tests in 
two consecutive days (day 1 test 1, day 2 test 1,day 2 test 2). Each ADP test included 
three volume measurements and the effect of infant’s behavior (cry, sleep, active, urinate 
or defecate) on calculated volume was assessed. In terms of reliability, results revealed 
mean %FM difference of -0.5±1.21 and 0.16±1.44 (p>0.05) for between and within days 
measurements respectively. Within days %FM CV was 5.1±0.65 and between days CV 
was 4.94±0.62. Infants behavior had no significant effect on calculated %FM (p=0.69). 
Mean %FM obtained by ADP did not differ significantly from that obtained from deuterium 
dilution (mean difference 0.07%, p=0.89). Bland Altman analysis revealed narrow 





Evaluation of ADP has also been assessed in bovine tissues against chemical analysis 
technique (430). The study included bovine phantoms of different weight and muscle to 
fat mass ratio in order to represent compositions similar to both term and preterm babies. 
Mean %FM difference between the 2 methods was 0.04 (p=0.91) with narrow agreement 
limits at -1.22 and 1.13%. Repeat ADP measurements on the phantoms revealed 
consistent CV for %FM above 10% (CV <5%) whereas precision was lower for lower fat 
mass range (CV: 18.14%). Similar results were presented by Frondas-Chauty et al using 
live piglets (431).  
 
Up to date studies confirm that ADP is an accurate and reliable method of assessing 
body composition during infancy. Poor precision noted in animal models with low range 
%FM has not been observed in inanimate phantoms (432). Furthermore, given that the 
majority of human infants have >10% FM makes ADP suitable for measurement of body 
composition in clinical practice (186). In very preterm infants, characterized by 
significantly low FM, repeated ADP measurements (2-6 tests) allows the extraction of 
very precise results (430, 433). ADP has been validated against reference techniques 
reporting narrower agreement limits than other methods (DXA) (434). Of great 
significance is the fact that results were consistent across a wide range of weight and FM 
values.  
 
In summary, numerous methods are available in assessing infant body composition. 
Clinicians should take into account the cost of the measurements, practicality, 
compliance of the studied population and the assumptions of the underlying principles of 
each technique (Table 1.13). ADP can be reliably used for the assessment of body 
composition in longitudinal studies including infants, a group where compliance is difficult 
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  
Table 1.13: Body composition techniques in infancy. One of the main disadvantages of 
the ADP technique is the lack of equipment to measure body composition in early 
childhood 
 
1.7 Study methods and main objectives 
 
Intrauterine exposures can set offspring metabolic trajectories with long lasting effects. It 
is therefore of vital importance to identify the missing link between adverse maternal 
characteristics and offspring adiposity. In order to understand the origin of metabolic 
diseases detailed data on the body composition during early stages of life is required. 
Studying the prognostic value of fetal and neonatal biomarkers in predicting future 
obesity will allow early identification of high risk groups and prompt implementation of 
prevention strategies.  
 
In order to answer the above questions we performed a systematic review (chapter 2) 
looking at the associations between early life biomarkers (cord blood leptin and 
adiponectin) and adiposity up to 5 years of age. We also performed a longitudinal, 
observational study looking at the effect of clinical and biochemical maternal 





our observational study we assessed the precision and reliability of traditional 
anthropometric equations in predicting infant adiposity, using an objective measurement 




Adverse maternal metabolic profile, such as obesity, gestational weight gain, ethnicity 
and GDM, is linked to increased risk of offspring adiposity, a strong predictor of adult 
metabolic dysfunction. We hypothesize that this altered body composition is present at 
birth and during the early stages of life in offspring born to high risk mothers, suggesting 
early life programming of obesity and metabolic disease.  
 
1.7.2 Research Questions 
 
 Is maternal adverse metabolic profile linked to altered body composition at birth 
and up to 5 months of age? (Chapters 3, 4 and 5) 
 Is there any association between cord leptin and adiponectin with body 
composition, assessed by air displacement plethysmography, at birth and up to 5 
months of age? (Chapter 5) 
1.7.3 Outcomes and criteria 
 
 Assess differences in body composition (fat and fat free mass) in newborns of 
mothers with (case) and without (control) GDM (Chapter 3; in a nested case-
control study) 
 Assess whether the common high-risk factors for GDM (BMI, age, ethnicity) could 
independently predict offspring adiposity, in the absence of GDM (Chapter 4) 
 Study if different patterns of neonatal body composition are related to mid-
pregnancy maternal markers (insulin, glucose, leptin, adiponectin) and early life 
biomarkers (cord blood leptin and adiponectin) (Chapter 5) 
 Compare if data obtained with traditional methods (anthropometry and skin-fold 
thickness) are similar to these obtained from ADP (Chapter 6) 
 
1.7.4 Inclusion criteria  
 All pregnant women between 18-45 years who delivered at George Eliot Hospital 
 All pregnant women between 18-45 years who had their antenatal care at George 






1.7.5 Exclusion criteria 





In recent years, childhood obesity has reached epidemic proportions. Children with 
obesity will remain obese as adolescents and adults, with high cardiometabolic risk. 
Given the significant co-morbidities linked to obesity, the rising rate represents one of the 
biggest social and financial burden of our days. Treating obesity has been proven to be 
challenging therefore identifying strategies for its prevention is of crucial relevance. 
Genetics are responsible for a small proportion of BMI and the rapidly increasing rates of 
obesity cannot be explained by genetic predisposition. The sedentary lifestyle and the 
plethora of food high in fat and sugars, characteristics of our modern world, are 
undoubtedly contributing to the obesity epidemic. There is increasing evidence though, 
that events occurring during in utero and early postnatal life may imprint on offspring 
leading to future adverse metabolic profile and non-communicable diseases. Adverse 
exposures, such as maternal obesity, undernutrition and GDM, during the plastic 
developmental period may program the offspring to develop obesity and metabolic 
diseases in future life. The mechanisms underpinning these associations, although not 
fully understood, appear to be related to multitude of factors including altered epigenome 
and impaired hormonal levels affecting the development of hypothalamus with long-
lasting adverse effects. Animal studies have provided some insight on the 
pathophysiology but the exact mechanisms related to developmental programming are 
yet to be identified. Defining critical developmental periods and susceptibility to diseases 
based on early life events will allow the development of prevention strategies and 
interventions with practical effect. Studying the association between adverse maternal 
environment and neonatal body composition is a promising field which will shed more 
light to the exact mechanisms of developmental origins of obesity. Weight, weight gain 
and BMI are indirect measures of obesity/adiposity, therefore defining exact levels of FM 
and FFM during early life will allow interventions targeting body composition during the 
period of developmental plasticity to avoid future adverse metabolic phenotype. Finally, 
as objective methods of assessing body composition are not yet widely available, 
discovering early life biomarkers to predict future adiposity will allow the early 






In this regard, the main aim of the current thesis is to assess how adverse maternal 
environment affects offspring’s body composition during the first months of life and to 
study whether early life biomarkers, specifically, cord blood leptin and adiponectin are 
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Role of cord blood leptin, adiponectin and 





























2.1 Introduction - Adipocytokines in pregnancy 
 
Insulin and IGF-1 are the most well described growth factors during pregnancy (1). As 
the role of intrauterine exposure in the development of future metabolic diseases is 
established, finding a link between fetal markers and risk of adverse metabolic profile 
would enable us to understand the mechanisms underlying this association. Leptin and 
adiponectin may play an important role in fetal growth either having a direct effect or 
acting as mediators and sensitizers to insulin and IGF-1. 
 
2.1.1 Leptin in pregnancy and early post natal life 
 
During pregnancy leptin is produced by maternal adipose tissue, placenta and fetal 
tissues. Maternal leptin increases as pregnancy advances with highest levels noted 
during third trimester. Levels are higher when compared to non pregnant subjects, 
adjusted for total FM (2). The above observation can be explained by increased fat 
accumulation during the pregnancy and predominantly during the last trimester. 
Researchers also believe that the higher leptin levels for a given FM could also be 
attributed to placental leptin contribution. Furthermore, the increased amount of placental 
hormones, HCG, insulin and oestradiol noted in pregnancy, factors known to promote 
leptin expression, contribute to leptin’s higher levels (3). Leptin resistance could explain 
the unique biological behavior of leptin noted in pregnancy. Hyperleptinaemia is not 
accompanied with loss of appetite and increased energy expenditure, as it would be 
expected (4). More likely, leptin plays a protective role for fetal well being, promoting 
metabolic efficiency required before delivery. In detail, during periods of maternal 
malnutrition leading to low maternal leptin, placental leptin affects maternal metabolism, 
ensuring that all reserves are utilized by the growing fetus and not used to restore 
maternal supplies. The role of leptin in mobilizing energy stores for offspring’s best 
interest is further supported by the fact that levels are higher in BF mothers compared to 
those non lactating post partum (5).  
 
Data has been controversial regarding maternal leptin and neonatal anthropometry. The 
majority of studies found no correlation between maternal leptin and birthweight (6-8) 
whereas a recent study from Brunner et al (9) showed an inverse correlation with birth 
weight and FM. Similar results were presented in two large cohorts by Retnakaran et al 
(10) and Verhaeghe et al (11). The discrepancy may be attributed to different timing of 





maternal obesity are characterized by increased cord leptin levels, a correlation which is 
more likely driven by fetal adipose tissue accumulation (12, 13).  
 
Leptin mRNA and leptin receptors have been detected in human placenta, using PCR 
(14). 98% of leptin drains in the maternal circulation whereas only small amounts are 
transferred to the fetus (15). The above observation paired with the fact that maternal 
leptin cannot cross the placenta due to high molecular weight, support the independent 
fetal leptin production. Multiple reports present that umbilical artery has higher levels of 
leptin compared to umbilical vein (7, 16), strengthening the data on the “two 
compartment model” between maternal and fetal leptin production.   
 
Fetal leptin has been detected as early as 18 weeks of gestation, with levels rising as 
pregnancy progresses, in concordance with fetal fat accumulation (17). Leptin expression 
in the fetus varies depending on environmental/external conditions. In ovine models, fetal 
hypoxia, hypercortisolaemia, hyperinsulinaemia and hypothyroidism promote leptin 
production whereas fetal hypoglycaemia and hypoinsulinaemia have the opposite results 
(18). High levels of gene expression for leptin and its receptors have been found in many 
fetal tissues, including fetal osteoblasts and chondrocytes, lungs, CNS, intestine, kidneys 
and hair follicles (19). The early detection of leptin, the presence in multiple tissues 
during fetal life and the higher levels seen in newborns than children after adjusting for 
adiposity suggest a role as growth factor (20). Multiple studies have confirmed the 
involvement of leptin in the development of many fetal tissues (Figure 2.1). Javaid et al 
(21) showed that cord leptin levels can predict bone mass at birth. His results were 
further supported by Fu et al (22) who proved that leptin regulates bone formation by 
affecting osteoblast proliferation. Leptin is also involved in fetal lung maturation. Both 
fetal lung fibroblasts and epithelial cells express leptin and its receptors and are part of a 
paracrine loop. Epithelial cells secrete parathyroid hormone related protein which 
promotes leptin expression from fibroblasts, which in return results into increased 
expression of surfactant from the epithelial cells (23). Islam et al (24) proved the 
presence of leptin receptors on rat islet cells and its role on fetal pancreatic cell 
proliferation. At the same time, the widespread presence of leptin receptors throughout 
the digestive tract shown by Aparicio et al (25) strengthens the evidence on the role of 







 Figure 2.1: Role of leptin during fetal life; CNS: central nervous system, GI: 
gastrointestinal 
 
Of great importance is the role of leptin in the development and migration of neuronal 
cells. In humans hypothalamic circuits which determine feeding behavior and satiety in 
later life develop during late antenatal and early postnatal life (26). Hormones and 
environmental factors in the early post partum can affect the ARC and mitochondria 
function, leading to changes which can persist throughout life. Several studies, 
predominantly in animal models have shown that the early post partum is a period of 
plasticity, in which interventions can imprint genotype for generations. IUGR piglets are 
born with low leptin levels resulting in reduced ObR expression in the hypothalamus and 
altered adipocyte morphology with increased lipid storage capacity. The above effect is 
reversed after leptin treatment (27). There is more evidence to support that leptin 
treatment in the early stages of life can affect neurotrophoblasts and regulate feeding 
and weight gain, thus preventing future obesity. Ob/Ob mice (28) as well as 
undernourished rats (29) have greater weight gain and measures of adiposity as adults 
when compared to controls. These associations are reversed after early leptin treatment, 
which has shown to normalize feeding behaviors and metabolic markers in future life. It is 
crucial to understand though that it is the early post natal life which can provide a window 
for interventions to modulate intrauterine programming. Bouret et al (28) showed that 
leptin treatment in Ob/Ob mice in adulthood has no effect on the neuronal connections in 
the hypothalamus, which is in contrast with early life treatment which restores structure 
(30). 
 
Leptin levels drop during the first five days of life. Cold, fasting and to a lesser extent lack 
of placental contribution lead to this observation. During suckling period (day 5-6) there is 





maturation. The timing and the duration of this peak seem to set long term feeding 
behaviors and metabolic trajectories. In particular, lambs from mothers with obesity have 
a premature peak of leptin followed by reduced amplitude and prolonged duration when 
compared to normal fed offsprings. The early post natal surge is mainly driven by raised 
cortisol levels (Figure 2.2) (31). On the other hand, undernourished offspring 
demonstrate premature leptin surge which results in greater weight gain in the following 
weeks (Figure 2.3) (32).  
 
The application of the knowledge acquired from animal models is of great importance in 
cases of SGA babies. LGA babies have higher leptin levels when compared to AGA at 
birth and cord leptin is lower in SGA when compared to AGA babies (33). These 
associations are driven by total FM. It would be interesting to adjust leptin levels for total 
FM, as it would provide evidence regarding early leptin resistance in babies born small 
for their gestational age. Preterm or SGA babies have low leptin levels at birth but by 1 
year of age their levels are higher than normal (34). The low leptin levels at birth regulate 
feeding behaviors by modulating hypothalamic connections and lead to rapid “catch up” 
growth and weight gain in infancy. As a result they are at higher risk of developing 
diabetes and obesity in future life (35). The above data once again suggest that 
intrauterine and early post natal life are crucial periods for metabolic programming and 





Figure 2.2: Circulating plasma levels in lambs from mothers with obesity (filled circles) 
and controls (open circles). The early leptin surge is driven by higher cortisol levels 










Figure 2.3: In utero malnourishment leads to premature leptin surge and higher weight 
gain (A, B). Marked body weight changes are present in NN offspring fed HFD postnataly 
(C, D). Leptin treated offspring have higher leptin levels but similar caloric intake, 
suggesting that increased energy expenditure mediates leptin’s role in early life. Dark 
and light orange lines (C, D) and columns (E, F) indicate neonatal leptin treatment; NN: 
njormal nourished, UN: undernourished, HFD: high fat diet, RCD: regular chow diet. 
Adopted from Yura et al (32)   
 
Data has shown no correlation between maternal and cord blood leptin (9, 36), 
confirming the autonomous origin of fetal leptin. On the other hand maternal BMI and 
weight gain during pregnancy positively predict leptin at birth (12, 37, 38). As more 
nutrients cross the placenta, fetal glucose and insulin levels rise, leading to adipose 
tissue accumulation and leptin production. Kadakia et al (39) focusing on the molecular 
origins of hyperleptinaemia, showed that increased pre-pregnancy BMI leads to reduced 
leptin gene methylation. DNA methylation of a gene promoter leads to decreased gene 
expression. Advancing gestational age, linked to increasing fetal FM deposition, is 
positively related to cord leptin. Many studies have tried to investigate the association 
between cord leptin and anthropometry at birth. Karakosta et al (40) published a 
systematic review including cross-sectional, observational and case control studies of 





cord leptin positively predicts birth weight (r=0.47, CI: 0.43. 0.52) and has a weaker 
correlation with length (r=0.29 CI: 0.23, 0.34) and ponderal index (r=0.36 CI: 0.31, 0.41).  
In order for leptin to be established as a marker of future obesity, longitudinal studies 
comparing cord samples with anthropometric measurements at later stages of life are 
required. As methods of assessing body composition are not widely available, 
researchers used weight/weight gain or BMI as a marker to investigate this association. 
The ALSPAC Study team in 1999 (35) was one of the first to report an adverse relation 
between cord plasma leptin and weight gain to 2 years of life. Similar results have been 
demonstrated recently by Brunner et al (9) studying a cohort of 188 newborns to 2 years 
of age. As the data was getting stronger over the years, researchers started to look into 
high risk groups and special populations. Fonseca et al (41) reviewed 96 premature 
babies and found that cord leptin could negatively predict the rate of change in BMI and 
length up to 2 years. In a big cohort of 578 Greek babies, Karakosta et al (12) found that 
cord leptin inversely predicted weight at 4 years of age in AGA but this association 
followed a positive trend in SGA. The above observation suggested earlier onset of leptin 
resistance in the SGA group. 
 
As described before, a short plasticity window for interventions in the early post natal life 
is well documented in animal models. In order to identify this optimal therapeutic period 
and the onset of leptin resistance studies looked into leptin levels and offspring’s 
anthropometry at different time points. Mantzoros et al (42), in one of the biggest cohorts 
so far (n=588), confirmed that cord leptin is inversely related to BMI at 3 years of age but 
also found that serum leptin at the age of 3 positively correlates with adiposity at this age. 
Boeke et al (43) followed participants from the above cohort (Project Viva) up to 7 years 
of age. They proved that serum leptin at 3 years is positively related with adiposity and 
BMI at 7 years of age. The latest two reports suggest that reduced leptin sensitivity or 
even leptin resistance starts within the first 3 years of life. As childhood obesity is difficult 
to treat once it is established, interventional programs to prevent the development should 
take place at the early stages of life. Early life biomarkers, such as leptin, which could be 
obtained from a single blood test and are related to future obesity, will enable the early 
identification of high risk individuals and will allow targeted approach to prevent the 
development of metabolic diseases in the future. 
 
2.1.2 Adiponectin in pregnancy and early post natal life 
 
The anti-diabetic and anti-atherogenic role of adiponectin has been the main focus of 





growth has drawn the attention of many researchers. In particular, the different metabolic 
profile and action during fetal life compared to adults has led to the hypothesis that 
adiponectin may act as a growth factor and not only as a marker of adiposity. 
 
During pregnancy, adiponectin is isolated from maternal and fetal circulation, whereas 
placental production remains controversial. Early stages of pregnancy are characterized 
by high maternal adiponectin levels, resulting in accumulation of fuels in maternal stores. 
(44) During the second half, maternal adipose tissue increases and adiponectin levels 
drop, leading to fuel mobilization (lipids, glucose) to supply the fetus in order to achieve 
normal intrauterine development and growth (45). Due to its HMW maternal adiponectin 
does not cross the placenta (44) and is not related with cord blood levels (46, 47). 
Results regarding maternal levels and birth weight remain contradictory.  Weyermann et 
al (47) studying a big cohort of newborns (n=766) found no correlation between maternal 
adiponectin and weight at birth whereas other studies, including healthy mothers with 
various BMI and pregnancies complicated with GDM, revealed a negative correlation 
(48-50).  
 
Maternal adiponectin has been associated with diseases during pregnancy. Low levels 
outside pregnancy are related to increased GDM risk in subsequent pregnancies (51) 
whereas low levels during early pregnancy positively predict the development of 
hyperglycaemia at later stages (52). Mothers with GDM are found to have lower levels 
compared to normal pregnancies (53, 54). Iliodromiti et al (55) suggested that first 
trimester adiponectin could be used as a predictive tool of GDM development. 
Performing a systematic review showed that the Area Under the Curve (AUC) of 
adiponectin for GDM is 0.78 (95%CI 0.74, 0.81). There is increasing interest on the role 
of adiponectin in the development of pre-eclampsia and gestational hypertension. 
Although the exact mechanism is not yet understood, low first trimester levels increase 
the risk of hypertension as pregnancy progresses (56). Pre-eclampsia is characterized by 
lower adiponectin levels at early pregnancy but higher during delivery when matched with 
normotensive mothers (57).  
 
Similarly to leptin, it was initially believed that placenta produces adiponectin. (58, 59) 
However recent studies, using more sensitive techniques, have shown it is unlikely that 
the placenta expresses and produces adiponectin (60, 61). This discrepancy between 
studies can be explained by the fact that studies suggesting placenta as a source of 
adiponectin used cell lines rather than fetal tissues. It is believed that the results are due 
to contamination of the cell lines from the maternal and fetal bovine serum. Sivan et al 





those four days post partum, confirming that cord adiponectin is derived from fetal and 
not from maternal or placental production.  
 
It is widely accepted that placenta expresses AdipoR1 and to a lesser extent AdipoR2 
receptors (63). Fetal growth depends on the delivery of nutrients across the placenta. 
The materno-placental transport is determined by maternal nutritional status, utero-
placental blood flow and the ability of placenta to express trophoblast nutrient 
transporters. Placenta is not only a communication canal, the presence of adiponectin 
and other adipocytokines receptors, suggests a role as a nutrient sensor, receiving 
signals from both maternal and fetal environment in order to balance fetal demand with 
maternal fuel supply. Fetal adiponectin levels reveal the nutritional status of the fetus and 
through placental signaling maternal energy stores are mobilized (64). On the other 
hand, maternal adiponectin is shown to inhibit placental proliferation in cell lines and 
attenuate the trophoblast transporter expression (65). The above observation could 
potentially explain the inverse correlation between maternal adiponectin and size at birth, 
however, as mentioned before, results are not consistent. In detail, conditions like GDM 
and maternal obesity, characterized by low maternal adiponectin levels, lead to 
hypertrophic placenta allowing more fetal nutritional supply, thus enhancing fetal growth 
and size.  
 
Cord adiponectin levels increase by 20-fold from midgestation to term and levels are 
positively related to gestational age (66). In 2005, Corbetta et al (67) using PCR and 
Western blotting in cadaveric fetuses between 14-36 weeks gestation showed that 
adiponectin is expressed in fetal tissues other than brown and white adipose tissue, 
suggesting a role as growth factor. Skin, skeletal muscle, small intestine, arterial walls 
and amniotic membranes were found to express adiponectin mRNA whereas placenta, 
consistent with previous results, was found not to produce adiponectin. It still remains 
unknown if adiponectin has a direct effect on fetal tissue or its role is mediated by other 
hormones (Figure 2.4). During antenatal life insulin is the main growth factor and the tool 
to utilize maternal glucose, therefore adiponectin may act as an insulin sensitizer. In 
favor of this hypothesis, Tsai et al (68) showed that LGA babies have higher adiponectin 
but similar insulin levels when compared to AGA. Insulin action mediated by higher levels 
in the LGA group was enough to result in increased weight and adiposity. In summary, 
the lack of correlation between maternal and cord levels, the stable adiponectin levels 
during early postnatal life and the presence of adiponectin mRNA in various fetal tissues 







Figure 2.4: Role of adiponectin during pregnancy; Adopted from Aye et al (64)  
 
Of great interest, adiponectin presents a different metabolic profile in fetal and neonatal 
life compared to this seen in adults. The inverse correlation between adipose tissue and 
adiponectin seen in adult population is not present during the early stages of life. The 
correlation between adiponectin, weight and FM during fetal and neonatal period remains 
controversial (discussed below). Furthermore, cord blood levels are significantly higher 
compared to adults, after adjusting for total FM (69, 70). There are many possible 
explanations for the shift from “positive to negative” correlation between adiponectin and 
FM, occurring around school entry age (71). The multiple sites, other than adipose 
tissue, of adiponectin expression seen in fetuses is a main contributing factor. Similar to 
anorexic adult patients, the low percentage of FM seen during the early stages of life 
leads to an impaired negative feedback to adiponectin production (72). Furthermore, as 
humans get older the structure and distribution of adipose tissue changes. Brown 
adipose tissue is reduced (73) and the subcutaneous to visceral fat ratio follows the 
same trend (74), leading to reduced adiponectin production. Fat cells become 
hypertrophic and the production of pro-inflammatory cytokines inhibits adiponectin 
expression (75). Finally, adipocytes become less “efficient” as mitochondria reduce in 
numbers or lose their function (76).  
 
Unlike leptin, the association of adiponectin with anthropometric measurements at birth 
and its role as a predictive marker of future adiposity have not been extensively 
investigated. Data on the correlation between birth weight and cord adiponectin levels 
remain controversial. Lindsay et al in 2003 (77) and Martinez et al (78) two years later 
showed no correlation between weight at birth and cord adiponectin. Similar results were 
presented by Teague et al in 2015 (79), after studying a cohort of 125 neonates. On the 
other hand, Tsai et al (68) in a big cohort of full term neonates (n=225) showed that cord 





(46) revealed a positive association in Asiatic and Caucasian populations. In a 
longitudinal study of 588 offsprings, Mantzoros et al (42) showed that cord adiponectin is 
inversely related to weight gain during the first 6 months of life but fails to predict BMI at 
3 years of age. It is difficult to explain what causes this discrepancy between various 
studies. Variability of the commercial kits used to measure adiponectin levels and the 
different adiponectin multiforms (total vs. high molecular weight vs. globular) examined in 
each study are potential contributors. Insulin is the main growth factor antenatally. 
Adiponectin is a known insulin sensitizer, enhancing the role of insulin during intrauterine 
life. The change of its metabolic profile after birth, with growth hormone taking over the 
role of the main growth factor, could potentially explain its inability to predict BMI in early 
childhood. Despite the convincing evidence of adiponectin’s role in intrauterine 
development, studies report mixed results. We therefore did a systematic review and 
metaanalysis of all the available studies that reported cord blood adipocytokines 
(specifically Leptin and Adiponectin) and their association with body composition of the 
children at birth and early childhood. 
 
 
2.2 Cord blood adipocytokines and body composition up to 5 years of age: a 




Adipose tissue in infancy is essential in ensuring adequate energy supply to the brain in 
a period of nutritional disruption and acts as thermo-insulator (white adipose tissue) and 
thermo-regulator (brown adipose tissue) (80). While it has a protective role against 
infections, intensive care unit admissions and mortality (81, 82), the recent evidences 
show that the strongest predictors of adult obesity are large for gestational age (LGA) 
and obesity in preschool children. However, the optimal range of adiposity in children 
which defines “beneficial versus metabolically harmful” levels of FM is yet to be identified 
(83). To address this, researchers proposed body composition growth charts as opposed 
to birth weight charts to improve the predictive ability of future obesity (84). Others used 
cord blood adipocytokines such as leptin and adiponectin as objective markers to predict 
future obesity compared to adiposity measurements, which are subjective and prone to 
measurement errors. 
 
As previously described, up to date, researchers have tried to find the correlation 





is convincing evidence that cord blood leptin positively predicts birthweight and is 
negatively related to BMI and weight gain up to 3 years of age. On the other hand, there 
is paucity of data regarding adiponectin’s role and the findings remain inconsistent. The 
disadvantage of this literature is that weight or BMI is not a reliable marker of adiposity. 
In order to explain the mechanisms behind intrauterine and early life programming of 
future diseases, detailed body composition is required (FM and FFM). Published studies 
examining the association between cord blood adipocytokines and adiposity at birth 
show mixed results. Most were cross-sectional and in small cohorts (9, 68, 85-96). 
Thusfar there have only been 3 moderately sized longitudinal (42, 43, 97) examining the 
link between cord blood levels and childhood adiposity up to 7 years of age. It is difficult 
to draw firm conclusions from these studies due to different ethnic groups sampled and 
different methods in assessing body composition. The purpose of this systematic review 
is to summarize these studies to improve the power and to shed light on the role of cord 




Leptin and adiponectin are key hormones for the energy homeostasis in adults. Their role 
during fetal period is less clear, with evidence suggesting that apart from mirroring 
adipose tissue, they also act as growth factors imprinting offspring’s future phenotype. 
We hypothesize that cord blood levels reflect fat mass at birth. We also hypothesize that 
cord leptin levels are related to adiposity in early childhood through adverse 
programming of hypothalamic appetite centers and increased cord adiponectin levels are 
associated with increased future adiposity. 
 
2.2.3 Research Questions 
 
 Is there any association between cord blood leptin and adiponectin with body 
composition at birth? 
 Is there any association between cord blood leptin and adiponectin with body 











2.2.4.1 Search strategy and study selection 
 
Systematic reviews collect and critically analyze primary research studies in order to 
provide answers to research questions. The increasing number of publications in health 
research combined with the limited time clinicians can spend on reading available 
literature, makes systematic reviews a very useful tool. They are the cornerstone of 
evidence-based medicine, as many of the clinical guidelines are based on reliable 
systematic reviews. Roberts et al (98) though, has shown that there is an increasing 
number of systematic reviews which are biased or even out of date when published, 
highlighting the need for universally agreed standards and guidelines.  
 
Observational, cross-sectional and longitudinal studies were examined. Studies of the 
offspring of healthy pregnant women and those with obesity were included. For studies 
involving participants with diabetes (type 1 or 2, gestational diabetes), data obtained only 
from control groups was used in the meta-analysis, as offspring of mothers with diabetes 
have higher leptin concentrations for a given FM (99, 100).  Studies of full term neonates 
of different growth patterns (AGA, LGA, SGA) and ethnic origin were considered eligible. 
Studies examining neonates born preterm or/and with congenital abnormalities 
(chromosomal disease, respiratory distress syndrome, heart and renal disease) were 
excluded (Table 2.1). Randomized control trails were not included in the current 
systematic review. Due to the different criteria used to define SGA, LGA and obesity 
across various populations, we accepted the authors’ definition.    
 
Cord blood samples, measuring leptin and adiponectin, analyzed by Enzyme-linked 
immunosorbent assay (ELISA) or radioimmunoassay (RIA) qualified for the meta-
analysis. Leptin results were reported in ng/ml and adiponectin in μg/ml. 
 
We included studies that assessed neonatal and childhood adiposity by Air Displacement 
Plethysmography (ADP), Dual Energy X-ray Absorptiometry (DXA), Magnetic Resonance 
Imaging (MRI) and anthropometric measurements (skinfold thickness). Studies using 
only ponderal index as a measure of adiposity were excluded. 
 
The review was registered on PROSPERO (CRD42017069024, Appendix 2). Meta-
analysis of Observational Studies in Epidemiology (MOOSE) guidelines were followed for 





Ethics Committee approval was not required. The individual studies included obtained 
approval from the respective local research ethics committee.  
 
A literature search was performed between January 1994 (discovery of leptin gene) and 
November 2018. Two bibliographic databases were used to conduct the searches: 
Medline/Pubmed (National Library of Medicine and National Institute of Health) and 
EMBASE (The Excerpta Medica Database). The following keywords and medical subject 
headings (MeSH) were used: “leptin”, “adiponectin”, “fetal blood”, “umbilical cord blood”, 
“adiposity”, “obesity”, “body composition”, “fetal growth” and “anthropometry”. Search 
words were combined using Boolean operators (AND, OR). The search was limited 
further to those studies published in English and performed in humans from birth to 5 
years of age. Reference lists from included studies were reviewed for further potentially 
eligible articles (Appendix 3).  
 
Inclusion criteria Exclusion 
Observational, cross-sectional Randomized control trials  
Healthy term pregnancies Preterm pregnancies 
Any ethnic background Pregnancies complicated by diabetes 
Any growth pattern (AGA, SGA, LGA) Congenital anomalies 
Adiposity assessed by DXA, MRI, 
PEAPOD and skinfold thickness 
Adiposity assessed only by ponderal index 
Table 2.1: Inclusion and exclusion criteria used for the study selection 
 
2.2.4.2 Data extraction 
 
Level one screening of search results (title and abstracts) was performed by two 
independent reviewers {Christos Bagias, Nithya Sukumar (Clinical Lecturer, Warwick 
Medical School, Warwick)], using the inclusion and exclusion criteria provided. Level two 
screening of the full manuscripts was conducted by them independently (CB and NS) 
and any discrepancy was resolved by consulting a third one (CB’s PhD supervisors: 
Ponnusamy Saravanan, Oyinlola Oyebode). 
 
For studies fulfilling the inclusion criteria, two independent review authors extracted 
details onto standard data extraction templates. This included information about type of 
study, location and time of data collection, population, sample size, type of leptin and 
adiponectin assays, statistical methods and technique to assess body composition. Any 





2.2.4.3 Statistical analysis 
 
Partial correlation and multiple regression models were used to present the results. 
Studies were reported narratively, when correlation coefficient (r) was unable to be 
extracted. Meta-analysis of correlations was performed using a random effects model. 
Cochran’s Q test was used to assess heterogeneity and I² statistics to calculate the 
percentage of variation across studies that was due to heterogeneity rather than chance. 
Different methods of assessing body composition were used, therefore the test of 
moderators was applied to investigate the effect on heterogeneity. Forest plots were 
created for each outcome. The potential for publication bias was assessed using funnel 
plots when the requirement of ten or more studies per meta-analysis was met. Egger’s 
test to assess funnel plot’s asymmetry was applied. All analyses were conducted using 
STATA version 14 in collaboration with supervisor’s institution (Warwick Medical School) 
and Dr Yonas Weldeselassie (Lead Statistician for Professor Saravanan). 
 
2.2.4.4 Assessment of risk bias 
 
The assessment of methodological quality of the studies was done using checklist 
criteria. This systematic review includes observational cohorts and cross-sectional 
studies, therefore the quality assessment tool adopted from the National Institutes of 
Health/ National Heart, Lung and Blood Institute was used (Appendix 4 and 5). After 
answering a series of 14 questions, quality of the studies was reported as poor, fair and 
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Meyer, 2018 
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Table 2.2: Assessment of included studies; Quality was assessed using quality 
assessment tool adopted from the National Institutes of Health/ National Heart, Lung and 




After applying our search criteria, 164 studies were identified, which were reduced to 148 
after removing duplicates. After title and abstract screening 118 articles were excluded, 
leaving 30 for full manuscript review. Twenty-two studies (9, 42, 43, 68, 77, 85-97, 102-
106) met all the inclusion criteria. Figure 2.5 presents the selection of the studies 








Table 2.3 provides baseline characteristics of the studies included. Most of the studies 
examined Caucasian neonates while one study (103) examined an African American 
population. Three studies (39, 88, 89, 92) included neonates of more than one ethnicity. 
In terms of maternal characteristics and risk factors, most of the studies included mothers 
without diabetes or other metabolic disorders. Two studies (78, 102) reported the 
association between adipocytokines and neonatal adiposity based on intrauterine growth 
(SGA vs AGA, AGA vs LGA).  
 
Figure 2.5: Flow diagram of the study. After screening 164 articles and removing 






2.2.5.2 Studies reporting leptin 
 
The correlation between leptin and adiposity was investigated in 17 studies (9, 42, 43, 
85-93, 97, 102-104, 106).  Eleven (9, 85-93, 102) examined the relationship at birth using 
either Pearson correlation or multiple regression analysis. Eight (9, 42, 43, , 88, 91, 97, 
103, 104) assessed the relationship between cord blood leptin and adiposity at different 
time points (3 weeks, 2 months, 2-5 years of age) using partial correlation or multiple 
regression models. Eleven studies (42, 85-87, 89, 90, 92, 93, 102, 103, 106) used 
radioimmunoassay (RIA) as the method of measuring cord blood leptin whereas six (9, 
43, 88, 91, 97, 104) used enzyme-linked immunosorbent assay (ELISA). Body 
composition was assessed using DXA (n=1) (87), ADP (n=4) (9, 89, 91, 92), MRI 
(n=1)(104) and skinfold thickness (n=12) (9, 42, 43, 85, 86, 88, 90, 93, 97, 102, 104, 
106). Total body fat was derived by measuring skinfold thickness at two [triceps(TR) and 
subscapular(SS)] (42, 43, 85, 93, 97), three [TR+SS+quadriceps(QD)] (90),four 
[TR+SS+QD+suprailiac(SI)] (9, 78, 79) or six (TR+SS+QD+SI+ biceps+gastrocnemius) 
sites (102, 104).    
 
2.2.5.3 Studies reporting adiponectin 
 
The correlation between adiponectin and adiposity at birth was examined in eight studies 
(86, 88, 89, 94-96, 102, 105), reporting correlation coefficient. Martinez et al (78) 
described no association between cord blood adiponectin and adiposity. For the purpose 
of statistical analysis this was considered as r=0. Basu et al (95) reported different 
correlation coefficients between male and female participants. Four studies (42, 88, 103, 
104) looked at the association between cord adiponectin and body composition at 
different age groups (1-3 months, 3-5 years of age). Adiponectin was measured using 
either RIA (n=6) (42, 77, 78, 89, 102, 103) or ELISA (n=5) (88, 94-96, 105). Two studies 
used ADP to calculate body composition (89, 103), one MRI (105) and the remaining 
used skinfold thickness at different sites {2 sites (n=2) (42, 105), 4 sites (n=5) (78, 88, 94, 
96), 6 sites (n=1) (102)].  
 
Two studies (77, 106) reporting association between cord plasma adipocytokines and 










2.2.5.4 Cord blood leptin and neonatal adiposity at birth 
 
All 11 studies (9, 85-93, 102), assessing 1653 pregnancies, revealed a moderate positive 
correlation between cord blood leptin and neonatal FM (r = 0.487; 95%CI: 0.444, 0.531; 
Figure 2.6). Heterogeneity between studies was assessed (I2=22.3%, p=0.14) and hence 
a random effects model was fitted. As different methods of assessing adiposity was used 
(DXA, ADP, Skinfold thickness) we included ‘method’ in the random effects model to 
examine the effect on heterogeneity. The results showed that there was no evidence for 
heterogeneity between the type of adiposity measures (QM test for moderators, p=0.50). 
Therefore, random effects model without the covariate ‘method’ was fitted. 
 
 Eight studies reported mean levels of cord blood leptin (42, 43, 88, 89, 97, 102, 104). 
Applying continuous random effects model revealed a pooled mean value of 9.1 ng/ml 




Figure 2.6: Forest plot showing the pooled correlation between cord blood leptin and fat 






Study Country (Sample 
size) 
Maternal age Maternal BMI Gestational age Birthweight Leptin                    Adiponectin 
                assessment 
Adiposity  
method 
Meyer, 2018 (104) Germany (n=89) NR NR NR NR ELISA                                  - Skinfold, MRI 
Meyer, 2017 (105) Germany (n=90) NR NR NR NR    -                                  ELISA Skinfold, MRI 
Schneider, 2017 (103) USA (n=36) 22.5 (3.7) 29.1 (8.2) 39+8 (1) 3347 (380) RIA                                 RIA ADP 
Kadakia, 2016 (92) USA (n=105) 32 (3.8) 25.0 (6.1) 39+5 (1.0) 3502 (515) RIA                                    - ADP 
Karakosta, 2016 (97) Greece (n=578) 29.5 (4.9) NR 38+0 (1.0) 3195 (442) ELISA                                - Skinfold 
Chaoimh, 2016 (91) Ireland (n=221) NR NR 40+2 (39.4, 41.4)* 3510 (3290, 3760)* ELISA                                - ADP 
Donnelly, 2015 (85) Ireland (n=147) 32.6 (4.2) 26.9 (4.7) 40+3 (1.0) 4080 (480) RIA                                    - Skinfold 
Teague, 2015 (88) USA (n=124) 24.6 (4.4) 28.2 (6.9) 39+6 (0.9) 3400 (400) ELISA                             ELISA Skinfold, DXA 
Josefson, 2014 (89) USA (n=61) NW: 32.8 (5.9) 
O: 30.2 (4.5) 
NW: 22.0 (1.8) 
O: 35.5 (4.0) 
NW:39+8 (1.1) 
O: 39+8 (1.0) 
NW: 3380 (470) 
O: 3600 (570) 
RIA                                 RIA ADP 
Brunner, 2014 (9) Germany (n=188) NR NR NR NR ELISA                                 - Skinfold 
Boeke, 2013 (43) USA (n=508) NR NR NR NR ELISA                                 - Skinfold 
Simon-Muela, 2013 
(94) 
Spain (n=96) M: 31.0 (4.6) 
F: 31.8 (5.0) 
M: 25.5 (5.9) 
F: 24.4 (4.92) 
M: 39+1 (1.7) 
F: 39+7 (1.5) 
M: 3255 (535) 
F: 3319 (487) 
     -                                 ELISA Skinfold 
Basu, 2009 (95) USA (n=121) M: 29.1 (5.6) 
F: 26.5 (5.7) NR 
M: 38+7 (0.7) 
F: 38+8 (0.6) 
M: 3406 (532) 
F: 3199 (445) 
ELISA                             ELISA Skinfold 
Mantzoros, 2009 (42) USA (n=588) 32.3 (5.1) 24.8 (5.4) 39+7 (1.5) NR RIA                                  RIA Skinfold 
Inami, 2007(96) Japan (n=52) NR NR NR 3054 )       -                                ELISA Skinfold 
Valuniene, 2007 (90) Lithuania (n=367) 
NR NR 
SGA: 38+8 (1.6) 
AGA: 39+1 (1.8) 
SGA: 2398 (374) 
AGA: 3507 (501) 
RIA                                     - Skinfold 
Martinez, 2005 (78) Mexico (n=100)    SGA: 26.5 (5.1) 
 
AGA: 25.2 (5.4) NR 
SGA: 38+0 (37, 40)* 
AGA: 39+0 (37, 41)* 
SGA: 2305 (133) 
 
AGA: 3754 (388) 
RIA                                  RIA Skinfold 
Javaid, 2005 (87) England (n=117) 
28 (5.6) NR 
M: 40+1 (1.1) 
F: 39+6 (1.3) 
M: 3506 (511) 
F: 3251 (461) 
RIA                                     - DXA 
Tsai, 2004 (102) Taiwan (n=226) 
NR NR 
LGA: 39+6 (1.2) 
AGA: 38+6 (1.0) 
LGA: 4070 (210) 
AGA: 3350 (330) 
RIA                                   RIA Skinfold 
Lindsay, 2003 (77) Scotland (n=73) NR NR NR NR -                            RIA Skinfold 
Geary, 1999 (106) England (n=39) 29.7 (6.1) 24.2 (3.8) NR 3442 (539) RIA                                      - Skinfold 
Clapp, 1998 (93) USA (n=42) NR NR NR 3600 (360) RIA                                      - Skinfold 
Table 2.3: Characteristics of studies included, maternal age is expressed in years, gestational age in weeks and birthweight in grams. Figures 
in () represent standard deviations. NR: not reported, NW: normal weight, O: obese, M: male, F: female, AGA: appropriate for gestational age, 
SGA: small for gestational age, LGA: large for gestational age, ADP: Air Displacement Plethysmography, DXA: Dual Energy Absorptiometry, 







2.2.5.5 Cord blood leptin and adiposity up to 5 years of age 
 
All studies reported a negative correlation between cord blood leptin and weight gain to 4 
years of age (9, 42, 43, 88, 91, 97, 103, 104). Schneider et al (103) studying a small 
number (n=36) of African American babies found no correlation between cord leptin and 
adiposity at 2 weeks and 3 months of life. On the other hand, Chaoimh et al (91) (n=221) 
found that cord leptin and adiposity at 2 months of age are negatively related (b= -0.021, 
p=0.003). Brunner et al (9) (n=118) and Boeke et al (43) (n=508) demonstrated an 
negative correlation between cord leptin and adiposity at 2 and 3 years of age 
respectively, after adjusting for maternal and offspring characteristics. Similarly, 
Mantzoros et al (42) (n=588) found a negative relationship with adiposity at 3 years of 
age (b=-0.24) which was not statistically significant (p=0.48). However, it is likely that this 
study and the one by Boeke et al (43) are from the same cohort (Project Viva). Meyer et 
al (104) following a cohort of 89 offsprings showed that cord leptin was negatively 
associated with total adiposity (predicted from skinfold thickness equations) at 3 and 5 
years of age, but with small effect size (3 years: b=-0.02, p=0.03; 5years: b=-0.03, 
p=0.03). The association was not observed when adipose tissue was directly assessed 
by MRI at 5 years in a subgroup of 33 children (visceral adipose tissue: b=0.26, p=0.7; 
subcutaneous adipose tissue: b-0.13, p=0.9). Studies reviewed (43, 97) revealed a 
positive, but not statistically significant, association with adiposity at 4 and 7 years of age 
(Table 2.4).  
 
Meta-analysis was not performed as results were adjusted for different maternal 





Study (Sample size) Cord leptin (ng/ml)  to Adjusted for Results P value 
Meyer, 2018 (104) 
(n=89)* 
%FM at 3 and 5 years 
VAT(cm3) and SAT(cm3) at 5 years 
Maternal BMI, gestational weight 
gain, pregnancy duration, sex, 
breastfeeding 
Β-Coef {95% CI] 
%FM at 3: -0.06                 {-
0.13,  0.01] 
%FM at 5: -0.09                    
{-0.17,  0.00] 
VAT: 0.26 {-1.71, 2.23] 
SAT: -0.13 {-9.20, 8.94] 
 
p = 0.07 
 
p = 0.04 
 
p = 0.78 
p = 0.97 
Schneider, 2017 (103) 
(n=36) 
FM(g) at 2 weeks and conditional change 
from 2 weeks to 3 months 
2 weeks: gestational age, age at 
measurement, FFM 
3 months: above+ 2 weeks 
measurement and time between 
measurements 
2 weeks: 
r = 0.27 
 
3 months: 
r = -0.19 
p>0.05 
Karakosta, 2016 (97) 
(n=578) 
SSF(mm) at 4 years of age Sex, birthweight, maternal age and 
education, parity, pre-pregnancy 
BMI and breastfeeding duration 
Β-Coef {95% CI] : 
0.2 {-1.4, 1.7] 
 
p >0.05 
Chaoimh, 2016 (91) 
(n=334) 
Conditional change to FMI(kg/m2) from birth 
to 2 months 
Maternal age-education-smoking, 
maternal BMI at 15weeks 
gestation, family income, sex, 
gestational age , breastfeeding 




Teague, 2015 (88) (n=52) %FM at 1month Diabetic status, sex, age in days r = 0.19 p = 0.19 
Brunner, 2014 (9) 
(n=90)* 
FM(g) at 2 years Maternal BMI, gestational weight 
gain, pregnancy duration, sex, 
breastfeeding 
Β-Coef {95% CI] : 
-14.86 {-29.49, -0.23] 
p= 0.04 
Boeke, 2013 (43) 
(n=508)** 
SSF(mm) at 3 years 
SSF(mm) and DXA derived FM(kg) at 7 
years 
Maternal age, weight gain, income, 
education, smoking, sex, ethnicity, 
breastfeeding 
3years Β-Coef {95% CI] : 
-1.4 {-2.7, -0.1] 
7years Β-Coef {95% CI] : 
1.1 {-1.5, 2.1] for SSF 






Mantzoros, 2009 (42) 
(n=588)** 
SS+TR(mm) and SS/TR(mm) at 3 years of 
age 
(regression per 10ng/ml of leptin) 
Maternal education, prepregnancy 
BMI, weight gain, gestational age, 
paternal BMI, sex, ethnicity, 
breastfeeding 
Β-Coef {95% CI] : 
-0.24 {-0.88, 0.41] for  
SS+TR 
-0.22 {-2.61, 2.17] for SS/TR 
 
p  = 0.48 
 
p  = 0.86 
Table 2.4: Cord blood leptin and adiposity up to 5 years of age. Table presents data on the correlation between leptin levels and 
adiposity taking into consideration different covariates. FM: fat mass, FFM: fat free mass, FMI: fat mass index, SSF: sum of skinfolds, 
SS: subscapular, TR: triceps, VAT: visceral adipose tissue, SAT: subcutaneous adipose tissue.  */** indicates that these two studies 






2.2.5.6 Cord blood adiponectin and neonatal adiposity at birth 
 
Pooled effect of the eight studies (78, 88, 89, 94-96, 102, 105) (735 pregnancies) 
revealed a weak positive correlation between cord blood adiponectin and neonatal FM (r 
= 0.201; 95% CI: 0.125, 0.277; Figure 2.7). Heterogeneity between studies was low 
(I2=26.4%, p=0.17) and a random effects model was used. Pooled mean adiponectin at 
birth was 25.6 μg/mL [95% CI: 16.5, 24.76; I2=99.77%, p<0.001] (77, 88, 89, 105).  
       
Figure 2.7: Forest plot showing the pooled correlation between cord blood adiponectin 
and fat mass at birth 
 
2.2.5.7 Cord blood adiponectin and adiposity up to 5 years of age 
 
Studies included presented inconsistent results regarding the relationship of cord blood 
adiponectin with weight gain and adiposity at different age groups. Teague et al (88) 
(n=89), studying HMW adiponectin, showed a weak positive correlation with both weight 
gain (r=0.22, p=0.004) and total adiposity (r=0.3, p=0.004) at 1 month of age. In contrast, 
cord adiponectin negatively predicted adiposity (r=-0.38, p<0.05) in 36 African American 
infants at 3 months of age (214). 
 
Mantzoros et al (42) (n=588) found that cord blood adiponectin negatively predicted 
weight at 6 months (r=-0.1, p=0.04) but not at 3 years of age (b=0.002, p=0.98). Applying 
multiple regression models for maternal, paternal and offspring characteristics showed 
that cord adiponectin is not related to total adiposity (b=0.42, p=0.12) but positively 
predicts central adiposity at 3 years of age (b=2.01, p=0.04). Meyer et al (105) examining 
both total and HMW adiponectin found a weak positive correlation with total adiposity at 3 





Table 2.5). As these studies used different covariates to adjust for the results, a meta-
analysis was not performed. 
 
2.2.5.8 Publication bias 
 
Publication bias was assessed via funnel plot only for the leptin group as the minimum 
requirement for ten studies per meta-analysis was not met in the adiponectin group. 
Application of Egger’s test did not reveal any asymmetry of the funnel plot, indicating no 




Figure 2.8: Funnel plot examining heterogeneity in the cord blood leptin and fat mass at 






Table 2.5: Cord blood adiponectin and adiposity up to 5 years of age, after adjusting for different covariates. FM: fat mass, FFM: fat 
free mass, SS: subscapular, TR: triceps, VAT: visceral adipose tissue, SAT: subcutaneous adipose tissue
Study (Sample size) Cord adiponectin (μg/ml ) 
to 
Adjusted for Results P value 
Meyer, 2017 (105) 
(n=90) 
%FM at 3 and 5 years 
VAT(cm3) and SAT(cm3) 
at 5 years 
Maternal BMI, gestational 
weight gain, pregnancy 
duration, sex, breastfeeding 
Β-Coef {95% CI] 
%FM at 3: 0.21 {0.06, 
0.35] 
%FM at 5: 0.08 {-0.10, 
0.27] 
VAT: 1.57 {-2.20, 5.34] 
SAT: 7.22 {-10.17, 24.62] 
 
p <0.05 
p = 0.36 
p = 0.39 
p = 0.40 
Schneider, 2017 (103) 
(n=36) 
FM(g) at 2 weeks and 
conditional change from 2 
weeks to 3 months 
2 weeks: gestational age, 
age at measurement, FFM 
3 months: above+ 2 weeks 
measurement and time 
between measurements 
2 weeks: 
r = 0.45 
 
3months: 





Teague, 2015 (88) (n=52) %FM at 1month Diabetic status, sex, age in 
days 
r = 0.32 p = 0.02 
Mantzoros, 2009 (42) 
(n=588) 
SS+TR(mm) and 
SS/TR(mm) at 3 years of 
age 
(regression per 10μg/ml of 
adiponectin) 
Maternal education, 
prepregnancy BMI, weight 
gain, gestational age, 
paternal BMI, sex, 
ethnicity, breastfeeding 
Β-Coef {95% CI] : 
0.42 {-0.11, 0.95] for  
SS+TR 
 
2.01 {0.09, 3.93] for 
SS/TR 
 
p = 0.12 
 








We observed three key findings in this systematic review. First, cord leptin and 
adiponectin are positively associated with adiposity at birth, suggesting these are useful 
objective markers for adiposity. The association was stronger for leptin than adiponectin. 
Second, the association between leptin with adiposity seems to reverse after the first few 
months of life and is negatively associated with adiposity at 3 years of age. Third, cord 
adiponectin levels seem to be positively associated with adiposity in young children, but 
the data is limited. 
 
2.2.6.1 Leptin and adiposity 
 
Maternal leptin cannot cross the placenta due to its high molecular weight (15). Cord 
leptin is primarily derived from fetal adipose tissue although it could also come from the 
placenta. While the majority of placental leptin drains in to the maternal circulation, small 
amounts enter the fetal circulation (16). Leptin levels are higher in the umbilical artery 
compared to umbilical vein (7). Fetal leptin is detectable as early as 18 weeks of 
gestation, with levels rising as pregnancy progresses, in concordance with fetal fat 
accumulation (17). In addition, the presence of leptin mRNA and leptin receptors in 
various fetal tissues implies its role as a growth factor during intrauterine development. 
All these findings support that cord leptin is a good marker of adiposity at birth.  
 
Our study showed that cord leptin levels are negatively related to adiposity at 3 years of 
age (9, 42, 43, 104), but this association is not sustained (43, 97) at 4 and 7 years.  
Chaoimh at al (91) showed that cord leptin is negatively associated with adiposity gain 
from birth to 2 months of age, by an objective adiposity measure, ADP. In our study, 
pooled mean leptin level at birth was at 9.1 ng/ml (n=2242). Although, there is no 
reference range for cord blood leptin levels, Karakosta et al (107) showed a mean leptin 
value of 7.7ng/ml in a cohort of 398 healthy, full term neonates, born in Greece.  Taken 
together, it appears that children born with higher leptin levels, may develop a 
‘compensatory behavior’ driven by the anorexigenic effect of leptin in early postnatal life 
which lasts up to 3 years of age. In order to maintain a positive energy balance and 
enhance vital organ development, leptin’s full metabolic effect is not exerted before the 
second post natal week (108). The above observation could potentially explain the 
positive correlation between cord leptin and adiposity during the first weeks of life, as 






The above conclusion is also supported by evidence from animal studies. Leptin plays an 
important role in brain development. Human hypothalamus develops predominantly 
during the pre-natal period. ARC, the major site for energy regulation, develops after 34 
weeks of gestation but further changes take place in the early post-natal life. 
Independent of FM accretion, leptin surge happens in the immediate post-natal period, 
which is critical for the development of projections from the ARC to paraventricular 
hypothalamic nuclei (109). Ob/ob mice have impaired projections, an effect which can be 
reversed by early life leptin administration, whereas leptin administration in adulthood 
has no effect, implying a tight window in leptin’s neurotrophic action (28).  Timing, 
amplitude and duration of the leptin surge are critical for the development of adverse 
metabolic behaviors. Obese dam’s offsprings (prolonged leptin surge) (110) and growth 
restricted pups (low amplitude surge) (111) are characterized by impaired ARC 
projections and neurogenesis of neurons with orexigenic phenotype, resulting in 
hyperphagia and obesity which can be traced to adulthood. Kirk et al (221) studying 
overfed vs. control dams in pregnancy and lactation tried to investigate the ‘transmission 
of the obesogenic trait’. Overfed pups had prolonged and amplified leptin surge and were 
heavier at birth. Weight and leptin levels were similar 30 days post birth (compensatory 
behavior) but five weeks later overfed pups developed hyperphagia resulting in increased 
weight and FM in adulthood (adverse effect of impaired leptin surge). Leptin 
administration at day 30 and 90 had no effect on overfed pups and was accompanied by 
lower neuronal activation and impaired ARC projections (leptin resistance). The study 
clearly demonstrated that leptin resistance starts prior to hyperleptinaemia and obesity. 
Thus, in our study, raised leptin levels at birth may have adversely programmed the 
hypothalamus (via impaired leptin surge), with effects becoming evident after third year 
of life. The initial negative correlation between cord leptin and adiposity may be due to 
the anorexigenic effect of leptin, followed by leptin resistance resulting in hyperphagia 
and increased adiposity. In the present systematic review, Meyer et al (215) and Boeke 
et al (155) used direct measures of adiposity (MRI, DXA) to assess the association 
between cord leptin and adiposity beyond the third year of life. Both studies 
demonstrated a trend for cord leptin to negatively predict adiposity at 3 years of life, 
which was converted to a positive association (although not reaching statistical 
significance) by the age of 5 and 7. Boeke et al (155) also showed that serum leptin at 3 









2.2.6.2 Adiponectin and adiposity 
 
Adiponectin levels increase by 20-fold from midgestation to term (112). Cord levels are 
not related to maternal adiponectin (46, 47) and placental production is not yet confirmed 
(60, 61). Sivan et al (62) showed that cord blood adiponectin levels were similar to those 
four days post partum, confirming the independent fetal production. The inverse 
correlation between adipose tissue and adiponectin observed in adult population is not 
present during the early stages of life. Evidence suggests that the shift from “positive to 
negative” correlation between adiponectin and FM occurs around school entry age (71). 
Multiple sites of adiponectin expression other than adipose tissue during fetal life (67), 
higher brown adipose tissue (73) and subcutaneous to visceral fat ratio of neonates (74) 
and the inhibition of adiponectin expression from inflammatory cytokines produced by 
hypertrophic adult adipocytes (75) could potentially explain the different metabolic profile 
between neonatal and adult life. 
 
The present report is unable to demonstrate any correlation (negative or positive) 
between cord adiponectin and future adiposity. Small sample size, different methods to 
measure adiponectin (ELISA, RIA) and different multimeric forms examined may 
contribute to the inconsistent results. Simpson et al (113) recently reviewed the 
association between adiponectin and adiposity at 9 and 17 years of age. Results showed 
no correlation with adiposity at 9 years and a positive correlation at 17 years with a very 
small effect size (b coef: 0.02, p<0.05). Major limitations of the study were the big loss to 
follow up and the small percentage of children with obesity/overweight (sample not 
representative of most populations) which could have potentially attenuated any 
associations. 
 
2.2.6.3 Strengths and weaknesses 
 
To our knowledge, our systematic review is the first to assess the correlation of cord 
blood adipocytokines with adiposity at different time points. However, while it had 
reasonable sample size to assess the independent associations of leptin and adiponectin 
with adiposity at birth, it did not have adequate sample size for early childhood.  
Publication bias was examined and selection bias was minimised by using quality 
assessment tools. As this review included observational cohorts and cross sectional 
studies, the main limitation is that correlation results do not necessitate causality. We 
also acknowledge that in the majority of the studies FM was derived from the sum of 
skinfolds and direct measures of adiposity would have minimized intra and inter subject 





understand the metabolic pathways of intrauterine programming and how early life 




The present meta-analysis reveals an association between cord blood adipocytokines 
and body fat at birth. Cord blood leptin inversely predicts adiposity up to 3 years of age 
whereas adiposity at 5 years seems to be positively predicted by cord levels. Results for 
adiponectin remain controversial and further longitudinal studies are required in order to 
draw safe conclusions 
. 
2.3 Closing Remarks 
 
Up to date knowledge on the mechanisms underpinning intrauterine programming 
remains limited (114), and the ‘gold programming factor’ is yet to be identified (115). In 
order to understand the origins of obesity and metabolic diseases we need to investigate 
growth in terms of body composition. With the National Health System under time and 
financial pressure, weight and BMI seem to be the best methods of assessing obesity. 
On the other hand, both these anthropometric measurements are not reliable during the 
early stages of life, as they cannot differentiate between fat and fat free mass. Moreover, 
it is more likely that during these developmental stages increased BMI reflects lean 
rather than adipose tissue accumulation. It is also well described that universal BMI “cut 
offs” cannot be applied as different ethnic groups have more fat for a given BMI. Skinfold 
thickness is an alternative which provides more information on the actual body 
composition. Results can be obtained in a non-interventional, non time-consuming way 
but are prone to large variations, within and between subjects. Direct methods (DXA, 
MRI, ADP) of assessing body composition allow for precise, objective measurements 
and can be used to create growth charts and identify individuals at high metabolic risk in 
order to prevent development of adverse outcomes. Measuring body composition in 
neonates is technically challenging and available methods are not yet widely accessible, 
mainly due to cost and time required for each test. Each technique is based on 
theoretical assumptions, thus data obtained from different methods cannot be combined 
to create universal standards (84, 116). Utilizing cord blood biomarkers to predict future 
adiposity is a promising field in understanding fetal programming and intervening in the 
early stages of life. Cord blood samples can be obtained easily in a non- invasive way 
with minimal training for the healthcare professionals. The high cost of the available 





evidence of their predictive value and broad universal screening would reduce the cost of 
testing. In addition, proving the utility value of these assays will also allow technology 
companies to create point of care kits at low cost, which will enable such tests can be 
performed easily even in resource-poor settings. Identifying high risk neonates from a 























































1. Milner RDG, Hill DJ. Fetal growth control: the role of insulin and related peptides. 
Clinical endocrinology. 1984;21(4):415-33. 
2. Butte NF, Hopkinson JM, Nicolson MA. Leptin in human reproduction: serum leptin 
levels in pregnant and lactating women. The Journal of Clinical Endocrinology & Metabolism. 
1997;82(2):585-9. 
3. Grattan DR, Ladyman SR, Augustine RA. Hormonal induction of leptin resistance during 
pregnancy. Physiology & behavior. 2007;91(4):366-74. 
4. Barb CR. The brain-pituitary-adipocyte axis: role of leptin in modulating neuroendocrine 
function. Journal of Animal Science. 1999;77(5):1249-57. 
5. Mukherjea R, Castonguay TW, Douglass LW, Moser-Veillon P. Elevated leptin 
concentrations in pregnancy and lactation: possible role as a modulator of substrate utilization. 
Life sciences. 1999;65(11):1183-93. 
6. Helland IB, Reseland JE, Saugstad OD, Drevon CA. Leptin levels in pregnant women and 
newborn infants: gender differences and reduction during the neonatal period. Pediatrics. 
1998;101(3):e12-e. 
7. Schubring C, Kiess W, Englaro P, Rascher W, Dotsch J, Hanitsch S, et al. Levels of leptin 
in maternal serum, amniotic fluid, and arterial and venous cord blood: relation to neonatal and 
placental weight. The Journal of Clinical Endocrinology & Metabolism. 1997;82(5):1480-3. 
8. Tamura T, Goldenberg RL, Johnston KE, Cliver SP. Serum leptin concentrations during 
pregnancy and their relationship to fetal growth. Obstetrics & Gynecology.91(3):389-95. 
9. Brunner S, Schmid D, Huttinger K, Much D, Bruderl M, Sedlmeier EM, et al. Effect of 
reducing the n-6/n-3 fatty acid ratio on the maternal and fetal leptin axis in relation to infant body 
composition. Obesity.22(1):217-24. 
10. Retnakaran R, Ye C, Hanley AJG, Connelly PW, Sermer M, Zinman B, et al. Effect of 
maternal weight, adipokines, glucose intolerance and lipids on infant birth weight among women 
without gestational diabetes mellitus. Cmaj. 2012;184(12):1353-60. 
11. Verhaeghe J, van Bree R, Van Herck E. Maternal body size and birth weight: can insulin 
or adipokines do better? Metabolism. 2006;55(3):339-44. 
12. Karakosta P, Georgiou V, Fthenou E, Papadopoulou E, Roumeliotaki T, Margioris A, et 
al. Maternal Weight Status, Cord Blood Leptin and Fetal Growth: a Prospective Mother–Child 
Cohort Study (R hea Study). Paediatric and perinatal epidemiology. 2013;27(5):461-71. 
13. Ferretti G, Cester AM, Bacchetti T, Raffaelli F, Vignini A, Orici F, et al. Leptin and 
paraoxonase activity in cord blood from obese mothers. Journal of Maternal-Fetal & Neonatal 
Medicine.27(13):1353-6. 
14. Henson MC, Swan KF, O’Neil JS. Expression of placental leptin and leptin receptor 
transcripts in early pregnancy and at term. Obstetrics & Gynecology. 1998;92(6):1020-8. 
15. Alexe D-M, Syridou G, Petridou ET. Determinants of early life leptin levels and later life 
degenerative outcomes. Clinical medicine & research. 2006;4(4):326-35. 
16. Linnemann K, Malek A, Sager R, Blum WF, Schneider H, Fusch C. Leptin production 
and release in the dually in vitro perfused human placenta. J Clin Endocrinol Metab. 
2000;85(11):4298-301. 
17. Jaquet D, Leger J, Levy-Marchal C, Oury JF, Czernichow P. Ontogeny of leptin in human 
fetuses and newborns: effect of intrauterine growth retardation on serum leptin concentrations. 
The Journal of Clinical Endocrinology & Metabolism. 1998;83(4):1243-6. 
18. Forhead AJ, Fowden AL. The hungry fetus? Role of leptin as a nutritional signal before 
birth. J Physiol. 2009;587(Pt 6):1145-52. 
19. Hoggard N, Haggarty P, Thomas L, Lea RG. Leptin expression in placental and fetal 
tissues: does leptin have a functional role? : Portland Press Limited; 2001. 
20. Hassink SG, de Lancey E, Sheslow DV, Smith-Kirwin SM, O'Connor DM, Considine 
RV, et al. Placental leptin: an important new growth factor in intrauterine and neonatal 
development? Pediatrics. 1997;100(1):e1-e. 
21. Javaid MK, Godfrey KM, Taylor P, Robinson SM, Crozier SR, Dennison EM, et al. 






22. Fu L, Patel MS, Bradley A, Wagner EF, Karsenty G. The molecular clock mediates 
leptin-regulated bone formation. Cell. 2005;122(5):803-15. 
23. Torday JS, Sun H, Wang L, Torres E. Leptin mediates the parathyroid hormone-related 
protein paracrine stimulation of fetal lung maturation. American Journal of Physiology-Lung 
Cellular and Molecular Physiology. 2002;282(3):L405-L10. 
24. Islam MS, Sjöholm Å, Emilsson V. Fetal pancreatic islets express functional leptin 
receptors and leptin stimulates proliferation of fetal islet cells. International journal of obesity. 
2000;24(10):1246. 
25. Aparicio T, Kermorgant Sp, Darmoul D, Guilmeau S, Hormi K, Mahieu-Caputo D, et al. 
Leptin and Ob-Rb receptor isoform in the human digestive tract during fetal development. The 
Journal of Clinical Endocrinology & Metabolism. 2005;90(11):6177-84. 
26. Desai M, Gayle D, Han G, Ross MG. Programmed hyperphagia due to reduced 
anorexigenic mechanisms in intrauterine growth-restricted offspring. Reproductive sciences. 
2007;14(4):329-37. 
27. Attig L, Djiane J, Gertler A, Rampin O, Larcher T, Boukthir S, et al. Study of 
hypothalamic leptin receptor expression in low-birth-weight piglets and effects of leptin 
supplementation on neonatal growth and development. American Journal of Physiology-
Endocrinology and Metabolism. 2008;295(5):E1117-E25. 
28. Bouret SG, Draper SJ, Simerly RB. Trophic action of leptin on hypothalamic neurons that 
regulate feeding. Science. 2004;304(5667):108-10. 
29. Vickers MH, Gluckman PD, Coveny AH, Hofman PL, Cutfield WS, Gertler A, et al. 
Neonatal leptin treatment reverses developmental programming. Endocrinology. 
2005;146(10):4211-6. 
30. Bouret SG, Simerly RB. Development of leptin‐sensitive circuits. Journal of 
neuroendocrinology. 2007;19(8):575-82. 
31. Long NM, Ford SP, Nathanielsz PW. Maternal obesity eliminates the neonatal lamb 
plasma leptin peak. The Journal of physiology. 2011;589(6):1455-62. 
32. Yura S, Itoh H, Sagawa N, Yamamoto H, Masuzaki H, Nakao K, et al. Role of premature 
leptin surge in obesity resulting from intrauterine undernutrition. Cell metabolism. 2005;1(6):371-
8. 
33. Cinaz P, Şen E, Bideci A, Ezgü FS, Atalay Y, Koca E. Plasma leptin levels of large for 
gestational age and small for gestational age infants. Acta Paediatrica. 1999;88(7):753-6. 
34. Jaquet D, Leger J, Tabone MD, Czernichow P, Levy-Marchal C. High serum leptin 
concentrations during catch-up growth of children born with intrauterine growth retardation. The 
Journal of Clinical Endocrinology & Metabolism. 1999;84(6):1949-53. 
35. Ong KKL, Ahmed ML, Sherriff A, Woods KA, Watts A, Golding J, et al. Cord blood 
leptin is associated with size at birth and predicts infancy weight gain in humans. The Journal of 
Clinical Endocrinology & Metabolism. 1999;84(3):1145-8. 
36. Tamura T, Goldenberg RL, Johnston KE, Cliver SP. Serum leptin concentrations during 
pregnancy and their relationship to fetal growth. Obstetrics & Gynecology. 1998;91(3):389-95. 
37. Starling AP, Brinton JT, Glueck DH, Shapiro AL, Harrod CS, Lynch AM, et al. 
Associations of maternal BMI and gestational weight gain with neonatal adiposity in the Healthy 
Start study. The American journal of clinical nutrition. 2014;101(2):302-9. 
38. Linabery AM, Nahhas RW, Johnson W, Choh AC, Towne B, Odegaard AO, et al. 
Stronger influence of maternal than paternal obesity on infant and early childhood body mass 
index: the F els L ongitudinal S tudy. Pediatric obesity. 2013;8(3):159-69. 
39. Kadakia R, Zheng Y, Zhang Z, Zhang W, Hou L, Josefson JL. Maternal pre‐pregnancy 
BMI downregulates neonatal cord blood LEP methylation. Pediatric obesity. 2017;12:57-64. 
40. Karakosta P, Chatzi L, Plana E, Margioris A, Castanas E, Kogevinas M. Leptin levels in 
cord blood and anthropometric measures at birth: a systematic review and meta-analysis. Paediatr 
Perinat Epidemiol. 2011;25(2):150-63. 
41. Fonseca VM, Sichieri R, Moreira MEL, Moura AS. Early postnatal growth in preterm 
infants and cord blood leptin. Journal of perinatology. 2004;24(12):751. 
42. Mantzoros CS, Rifas-Shiman SL, Williams CJ, Fargnoli JL, Kelesidis T, Gillman MW. 
Cord blood leptin and adiponectin as predictors of adiposity in children at 3 years of age: a 





43. Boeke CE, Mantzoros CS, Hughes MD, S LR-S, Villamor E, Zera CA, et al. Differential 
associations of leptin with adiposity across early childhood. Obesity.21(7):1430-7. 
44. Mazaki-Tovi S, Kanety H, Pariente C, Hemi R, Wiser A, Schiff E, et al. Maternal serum 
adiponectin levels during human pregnancy. Journal of Perinatology. 2007;27(2):77. 
45. Catalano PM, Hoegh M, Minium J, Huston-Presley L, Bernard S, Kalhan S, et al. 
Adiponectin in human pregnancy: implications for regulation of glucose and lipid metabolism. 
Diabetologia. 2006;49(7):1677-85. 
46. Chan T-F, Yuan S-SF, Chen H-S, Guu C-F, Wu L-C, Yeh Y-T, et al. Correlations 
between umbilical and maternal serum adiponectin levels and neonatal birthweights. Acta 
obstetricia et gynecologica Scandinavica. 2004;83(2):165-9. 
47. Weyermann M, Beermann C, Brenner H, Rothenbacher D. Adiponectin and leptin in 
maternal serum, cord blood, and breast milk. Clinical Chemistry. 2006;52(11):2095-102. 
48. Jansson N, Nilsfelt A, Gellerstedt M, Wennergren M, Rossander-Hultheén L, Powell TL, 
et al. Maternal hormones linking maternal body mass index and dietary intake to birth weight. The 
American journal of clinical nutrition. 2008;87(6):1743-9. 
49. Lowe LP, Metzger BE, Lowe Jr WL, Dyer AR, McDade TW, McIntyre HD, et al. 
Inflammatory mediators and glucose in pregnancy: results from a subset of the Hyperglycemia 
and Adverse Pregnancy Outcome (HAPO) Study. The Journal of Clinical Endocrinology & 
Metabolism. 2010;95(12):5427-34. 
50. Ategbo JM, Grissa O, Yessoufou A, Hichami A, Dramane KL, Moutairou K, et al. 
Modulation of adipokines and cytokines in gestational diabetes and macrosomia. The Journal of 
Clinical Endocrinology & Metabolism. 2006;91(10):4137-43. 
51. Hedderson MM, Darbinian J, Havel PJ, Quesenberry CP, Sridhar S, Ehrlich S, et al. Low 
prepregnancy adiponectin concentrations are associated with a marked increase in risk for 
development of gestational diabetes mellitus. Diabetes care. 2013;36(12):3930-7. 
52. Lain KY, Daftary AR, Ness RB, Roberts JM. First trimester adipocytokine concentrations 
and risk of developing gestational diabetes later in pregnancy. Clinical endocrinology. 
2008;69(3):407-11. 
53. Pala HG, Ozalp Y, Yener AS, Gerceklioglu G, Uysal S, Onvural A. Adiponectin levels in 
gestational diabetes mellitus and in pregnant women without glucose intolerance. Advances in 
clinical and experimental medicine: official organ Wroclaw Medical University. 2015;24(1):85-
92. 
54. Xu J, Zhao YH, Chen YP, Yuan XL, Wang J, Zhu H, et al. Maternal circulating 
concentrations of tumor necrosis factor-alpha, leptin, and adiponectin in gestational diabetes 
mellitus: a systematic review and meta-analysis. The Scientific World Journal. 2014;2014. 
55. Iliodromiti S, Sassarini J, Kelsey TW, Lindsay RS, Sattar N, Nelson SM. Accuracy of 
circulating adiponectin for predicting gestational diabetes: a systematic review and meta-analysis. 
Springer; 2016. 
56. D'Anna R, Baviera G, Corrado F, Giordano D, Di Benedetto A, Jasonni VM. Plasma 
adiponectin concentration in early pregnancy and subsequent risk of hypertensive disorders. 
Obstetrics & Gynecology. 2005;106(2):340-4. 
57. D’Anna R, Baviera G, Corrado F, Giordano D, De Vivo A, Nicocia G, et al. Adiponectin 
and insulin resistance in early‐and late‐onset pre‐eclampsia. BJOG: An International Journal of 
Obstetrics & Gynaecology. 2006;113(11):1264-9. 
58. Caminos JE, Nogueiras R, Gallego R, Bravo S, Tovar S, García-Caballero T, et al. 
Expression and regulation of adiponectin and receptor in human and rat placenta. The Journal of 
Clinical Endocrinology & Metabolism. 2005;90(7):4276-86. 
59. Lappas M, Yee K, Permezel M, Rice GE. Release and regulation of leptin, resistin and 
adiponectin from human placenta, fetal membranes, and maternal adipose tissue and skeletal 
muscle from normal and gestational diabetes mellitus-complicated pregnancies. Journal of 
endocrinology. 2005;186(3):457-65. 
60. McDonald EA, Wolfe MW. Adiponectin attenuation of endocrine function within human 
term trophoblast cells. Endocrinology. 2009;150(9):4358-65. 
61. Wang Y, Lu G, Wong WPS, Vliegenthart JFG, Gerwig GJ, Lam KSL, et al. Proteomic 






62. Sivan E, Mazaki-Tovi S, Pariente C, Efraty Y, Schiff E, Hemi R, et al. Adiponectin in 
human cord blood: relation to fetal birth weight and gender. The Journal of Clinical 
Endocrinology & Metabolism. 2003;88(12):5656-60. 
63. Kharroubi I, Rasschaert J, Eizirik DL, Cnop M. Expression of adiponectin receptors in 
pancreatic β cells. Biochemical and biophysical research communications. 2003;312(4):1118-22. 
64. Aye ILMH, Powell TL, Jansson T. adiponectin–the missing link between maternal 
adiposity, placental transport and fetal growth? Placenta. 2013;34:S40-S5. 
65. Benaitreau D, Dieudonné M-N, Santos ED, Leneveu M-C, Mazancourt Pd, Pecquery R. 
Antiproliferative effects of adiponectin on human trophoblastic cell lines JEG-3 and BeWo. 
Biology of reproduction. 2009;80(6):1107-14. 
66. Kajantie E, Hytinantti T, Hovi P, Andersson S. Cord plasma adiponectin: a 20-fold rise 
between 24 weeks gestation and term. Journal of Clinical Endocrinology & 
Metabolism.89(8):4031-6. 
67. Corbetta S, Bulfamante G, Cortelazzi D, Barresi V, Cetin I, Mantovani G, et al. 
Adiponectin expression in human fetal tissues during mid-and late gestation. The Journal of 
Clinical Endocrinology & Metabolism. 2005;90(4):2397-402. 
68. Tsai PJ, Yu CH, Hsu SP, Lee YH, Chiou CH, Hsu YW, et al. Cord plasma concentrations 
of adiponectin and leptin in healthy term neonates: positive correlation with birthweight and 
neonatal adiposity. Clinical endocrinology. 2004;61(1):88-93. 
69. Weiss R, Dufour S, Groszmann A, Petersen K, Dziura J, Taksali SE, et al. Low 
adiponectin levels in adolescent obesity: a marker of increased intramyocellular lipid 
accumulation. The Journal of Clinical Endocrinology & Metabolism. 2003;88(5):2014-8. 
70. Pinar H, Basu S, Hotmire K, Laffineuse L, Presley L, Carpenter M, et al. High molecular 
mass multimer complexes and vascular expression contribute to high adiponectin in the fetus. The 
Journal of Clinical Endocrinology & Metabolism. 2008;93(7):2885-90. 
71. Asayama K, Hayashibe H, Dobashi K, Uchida N, Nakane T, Kodera K, et al. Decrease in 
serum adiponectin level due to obesity and visceral fat accumulation in children. Obesity research. 
2003;11(9):1072-9. 
72. Pannacciulli N, Vettor R, Milan G, Granzotto M, Catucci A, Federspil G, et al. Anorexia 
nervosa is characterized by increased adiponectin plasma levels and reduced nonoxidative glucose 
metabolism. The Journal of Clinical Endocrinology & Metabolism. 2003;88(4):1748-52. 
73. Viengchareun S, Zennaro M-C, Pascual-Le Tallec L, Lombes M. Brown adipocytes are 
novel sites of expression and regulation of adiponectin and resistin. FEBS letters. 
2002;532(3):345-50. 
74. Milan G, Granzotto M, Scarda A, Calcagno A, Pagano C, Federspil G, et al. Resistin and 
adiponectin expression in visceral fat of obese rats: effect of weight loss. Obesity Research. 
2002;10(11):1095-103. 
75. Kamon J, Yamauchi T, Waki H, Uchida SK, Ito Y, Suzuki R, et al. Mechanism for the 
regulation of adiponectin expression. Diabetes. 2002;51:A87. 
76. Bullen Jr JW, Bluher S, Kelesidis T, Mantzoros CS. Regulation of adiponectin and its 
receptors in response to development of diet-induced obesity in mice. American Journal of 
Physiology-Endocrinology and Metabolism. 2007;292(4):E1079-E86. 
77. Lindsay RS, Walker JD, Havel PJ, Hamilton BA, Calder AA, Johnstone FD. Adiponectin 
is present in cord blood but is unrelated to birth weight. Diabetes care. 2003;26(8):2244-9. 
78. Martínez-Cordero C, Amador-Licona N, Guízar-Mendoza JM, Hernández-Méndez J, 
Ruelas-Orozco G. Body fat at birth and cord blood levels of insulin, adiponectin, leptin, and 
insulin-like growth factor-I in small-for-gestational-age infants. Archives of medical research. 
2006;37(4):490-4. 
79. Teague AM, Fields DA, Aston CE, Short KR, Lyons TJ, Chernausek SD. Cord blood 
adipokines, neonatal anthropometrics and postnatal growth in offspring of Hispanic and Native 
American women with diabetes mellitus. Reproductive Biology and Endocrinology. 
2015;13(1):68. 
80. Kuzawa CW. Adipose tissue in human infancy and childhood: an evolutionary 
perspective. American Journal of Physical Anthropology: The Official Publication of the 





81. Pelletier DL, Frongillo Jr EA, Habicht J-P. Epidemiologic evidence for a potentiating 
effect of malnutrition on child mortality. American journal of public health. 1993;83(8):1130-3. 
82. Victora CG, Barros FC, Kirkwood BR, Vaughan JP. Pneumonia, diarrhea, and growth in 
the first 4 y of life: a longitudinal study of 5914 urban Brazilian children. The American journal of 
clinical nutrition. 1990;52(2):391-6. 
83. anthropometry Wtuaio. WHO | Physical status: the use and interpretation of 
anthropometry. WHO. 2013. 
84. Wells JCK. Toward Body Composition Reference Data for Infants, Children, and 
Adolescents–. Advances in nutrition. 2014;5(3):320S-9S. 
85. Donnelly JM, Lindsay KL, Walsh JM, Horan M, Molloy EJ, McAuliffe FM. Fetal 
metabolic influences of neonatal anthropometry and adiposity. BMC Pediatrics.15:175. 
86. Martinez-Cordero C, Amador-Licona N, Guizar-Mendoza JM, Hernandez-Mendez J, 
Ruelas-Orozco G. Body fat at birth and cord blood levels of insulin, adiponectin, leptin, and 
insulin-like growth factor-I in small-for-gestational-age infants. Archives of Medical 
Research.37(4):490-4. 
87. Javaid MK, Godfrey KM, Taylor P, Robinson SM, Crozier SR, Dennison EM, et al. 
Umbilical cord leptin predicts neonatal bone mass. Calcified Tissue International.76(5):341-7. 
88. Teague AM, Fields DA, Aston CE, Short KR, Lyons TJ, Chernausek SD. Cord blood 
adipokines, neonatal anthropometrics and postnatal growth in offspring of Hispanic and Native 
American women with diabetes mellitus. Reproductive Biology & Endocrinology.13:68. 
89. Josefson JL, Zeiss DM, Rademaker AW, Metzger BE. Maternal leptin predicts adiposity 
of the neonate. Hormone research in paediatrics. 2014;81(1):13-9. 
90. Valuniene M, Verkauskiene R, Boguszewski M, Dahlgren J, Lasiene D, Lasas L, et al. 
Leptin levels at birth and in early postnatal life in small- and appropriate-for-gestational-age 
infants. Medicina (Kaunas, Lithuania).43(10):784-91. 
91. Chaoimh CN, Murray DM, Kenny LC, Irvine AD, Hourihane JO, Kiely M. Cord blood 
leptin and gains in body weight and fat mass during infancy. European Journal of 
Endocrinology.175(5):403-10. 
92. Kadakia R, Zheng Y, Zhang Z, Zhang W, Hou L, Josefson JL. Maternal pre-pregnancy 
BMI downregulates neonatal cord blood LEP methylation. Pediatric Obesity.12 Suppl 1:57-64. 
93. Clapp Iii JF, Kiess W. Cord blood leptin reflects fetal fat mass. Journal of the Society for 
Gynecologic Investigation. 1998;5(6):300-3. 
94. Simon-Muela I, Naf S, Ballesteros M, Vendrell J, Ceperuelo-Mallafre V, de la Flor M, et 
al. Gender determines the actions of adiponectin multimers on fetal growth and adiposity. 
American Journal of Obstetrics & Gynecology.208(6):481.e1-7. 
95. Basu S, Laffineuse L, Presley L, Minium J, Catalano PM, Hauguel-De Mouzon S. In 
utero gender dimorphism of adiponectin reflects insulin sensitivity and adiposity of the fetus. 
Obesity. 2009;17(6):1144-9. 
96. Inami I, Okada T, Fujita H, Makimoto M, Hosono S, Minato M, et al. Impact of serum 
adiponectin concentration on birth size and early postnatal growth. Pediatric research. 2007;61(5, 
Part 1):604. 
97. Karakosta P, Roumeliotaki T, Chalkiadaki G, Sarri K, Vassilaki M, Venihaki M, et al. 
Cord blood leptin levels in relation to child growth trajectories. Metabolism. 2016;65(6):874-82. 
98. Roberts I, Ker K, Edwards P, Beecher D, Manno D, Sydenham E. The knowledge system 
underpinning healthcare is not fit for purpose and must change. Bmj. 2015;350:h2463. 
99. Persson B, Westgren M, Celsi G, Nord E, Ortqvist E. Leptin concentrations in cord blood 
in normal newborn infants and offspring of diabetic mothers. Hormone & Metabolic 
Research.31(8):467-71. 
100. Gross GA, Solenberger T, Philpott T, Holcomb WL, Landt M. Plasma leptin 
concentrations in newborns of diabetic and nondiabetic mothers. American journal of 
perinatology. 1998;11(04):243-7. 
101. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-
analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of 





102. Tsai PJ, Yu CH, Hsu SP, Lee YH, Chiou CH, Hsu YW, et al. Cord plasma concentrations 
of adiponectin and leptin in healthy term neonates: positive correlation with birthweight and 
neonatal adiposity. Clinical Endocrinology.61(1):88-93. 
103. Schneider CR, Catalano PM, Biggio JR, Gower BA, Chandler‐Laney PC. Associations of 
neonatal adiponectin and leptin with growth and body composition in African American infants. 
Pediatric obesity. 2018. 
104. Meyer DM, Brei C, Stecher L, Much D, Brunner S, Hauner H. Leptin in Maternal Plasma 
and Cord Blood as a Predictor of Offspring Adiposity at 5 Years: A Follow‐up Study. Obesity. 
2018;26(2):279-83. 
105. Meyer DM, Brei C, Stecher L, Much D, Brunner S, Hauner H. Cord blood and child 
plasma adiponectin levels in relation to childhood obesity risk and fat distribution up to 5 y. 
Pediatric research. 2017;81(5):745. 
106. Geary M, Pringle PJ, Persaud M, Wilshin J, Hindmarsh PC, Rodeck CH, et al. Leptin 
concentrations in maternal serum and cord blood: relationship to maternal anthropometry and fetal 
growth. BJOG: An International Journal of Obstetrics & Gynaecology. 1999;106(10):1054-60. 
107. Karakosta P, Georgiou V, Fthenou E, Margioris A, Castanas E, Kogevinas M, et al. 
Gender-specific reference intervals for cord blood leptin in Crete, Greece. European journal of 
pediatrics. 2012;171(10):1563-6. 
108. Mistry AM, Swick A, Romsos DR. Leptin alters metabolic rates before acquisition of its 
anorectic effect in developing neonatal mice. American Journal of Physiology-Regulatory, 
Integrative and Comparative Physiology. 1999;277(3):R742-R7. 
109. Bouret SG, Draper SJ, Simerly RB. Formation of projection pathways from the arcuate 
nucleus of the hypothalamus to hypothalamic regions implicated in the neural control of feeding 
behavior in mice. Journal of Neuroscience. 2004;24(11):2797-805. 
110. Kirk SL, Samuelsson A-M, Argenton M, Dhonye H, Kalamatianos T, Poston L, et al. 
Maternal obesity induced by diet in rats permanently influences central processes regulating food 
intake in offspring. PloS one. 2009;4(6):e5870. 
111. Delahaye F, Breton C, Risold P-Y, Enache M, Dutriez-Casteloot I, Laborie C, et al. 
Maternal perinatal undernutrition drastically reduces postnatal leptin surge and affects the 
development of arcuate nucleus proopiomelanocortin neurons in neonatal male rat pups. 
Endocrinology. 2007;149(2):470-5. 
112. Kajantie E, Hytinantti T, Hovi P, Andersson S. Cord plasma adiponectin: a 20-fold rise 
between 24 weeks gestation and term. The Journal of Clinical Endocrinology & Metabolism. 
2004;89(8):4031-6. 
113. Simpson J, Smith AD, Fraser A, Sattar N, Lindsay RS, Ring SM, et al. Programming of 
Adiposity in Childhood and Adolescence: Associations With Birth Weight and Cord Blood 
Adipokines. J Clin Endocrinol Metab. 2017;102(2):499-506. 
114. Dearden L, Ozanne SE. Early life origins of metabolic disease: Developmental 
programming of hypothalamic pathways controlling energy homeostasis. Frontiers in 
neuroendocrinology. 2015;39:3-16. 
115. Cottrell EC, Martin-Gronert MS, Fernandez-Twinn DS, Luan Ja, Berends LM, Ozanne 
SE. Leptin-independent programming of adult body weight and adiposity in mice. Endocrinology. 
2011;152(2):476-82. 































The impact of Gestational Diabetes Mellitus 



































Exposures during antenatal and early post natal life can metabolically imprint the 
offspring with long lasting effects. Birthweight is a rough estimate of body composition 
which doesn’t precisely reflect nutritional status during intrauterine life. In order to 
understand the mechanisms underpinning the “intrauterine origins of metabolic diseases” 
detailed data on neonatal body composition is required.  
 
Gestational diabetes mellitus rises in parallel with adult obesity, constituting one of the 
commonest metabolic problems in pregnancy. Pregnancies complicated by diabetes face 
short and long term adverse consequences, for both mother and the offspring. Despite 
convincing evidence suggesting the beneficial effects of maintaining normoglycaemia on 
short term outcomes, data reveals that glucose control on its own is not adequate to 
prevent future offspring obesity. The exact reason remains unknown and various 
mechanisms (epigenetics, environmental exposures, maternal dyslipidaemia) have been 
proposed. Taking a closer look at the body composition evolution during early life may 
provide insight on the pathogenesis of obesity and metabolic diseases. In this regard, we 
performed a longitudinal, observational study looking at the effects of maternal GDM on 
offspring body composition up to 5 months of age. 
 
 
3.2 The role of maternal adverse/risk outcomes on offspring's body composition: 





GDM is linked to increased risk of offspring obesity, impaired glucose tolerance and 
metabolic syndrome. This association persists despite optimal glycaemic control. We 
hypothesize that events occurring during prenatal, antenatal and immediate postnatal life 
metabolically imprint offspring’s health. This adverse effect may be potentially reflected in 
altered infant body composition. 
 
3.2.2 Research Questions 
 Is maternal GDM linked to altered body composition at birth and up to 5 months 






3.2.3 Outcomes and criteria 
 Assess differences in body composition (fat and fat free mass) in newborns of 
mothers with (case) and without (control) GDM  
 
3.2.3.1 Inclusion criteria  
 All pregnant women between 18-45 years who delivered at George Eliot Hospital 
 All pregnant women between 18-45 years who had their antenatal care at George 
Eliot Hospital and had a home birth 
 
3.2.3.2 Exclusion criteria 




3.2.4 Study design 
 
3.2.4.1 Sample size calculation 
 
We estimated the sample size for the outcomes based on 5% significance. We 
calculated that a minimum of 40 neonates in the GDM group would provide 80% power 
to detect a mean difference of 10% in total adipose tissue between cases and controls. 
We considered these differences to be clinically significant as they are similar to those 
between preterm and healthy term infants (47); the former group is known to have higher 
risk for future metabolic diseases. 
 
At GEH (recruitment site) 15% of pregnancies are complicated by GDM. Allowing for a 
30% drop out from the follow up studies, we aimed to recruit at least 400 participants in 
order to achieve the required targets.  
  
3.2.4.2 Application and Approvals 
 
In order to start the research project author, who is also the co-investigator of the study, 
had to sign an honorary contract with GEH allowing him to approach NHS patient-service 
users for research purposes (Appendix 6). Project was then discussed with local 
Research and Development (R&D) office and details on duration, expected level of 





consideration GEH R&D department consented for the research project to be 
accommodated at GEH premises (Appendix 7). 
 
Following the completion of a Health Research Authority (HRA) Statement of Activities 
template a co-sponsorship agreement was signed between the University of Warwick 
(UoW; Lead Research Sponsor) and GEH (Co-sponsor) setting the terms for their 
respective duties. In specific, UoW held the Public and Products Liability insurance, 
Clinical Trial insurance and had the PEAPOD ownership. It was also responsible to 
ensure all the research staff who had access to the GEH facilities had all the up to date 
research training. GEH was responsible for all the study related clinical procedures, 
maintaining standard operating procedures, updating protocols, training of staff, 
maintaining study related documents in safe areas as per Good Clinical Practice (GCP) 
guidelines and making all the above available for audit and inspection as necessary .  
 
As the research project took place and involved users of the NHS England, HRA 
approval was mandatory. The process involved the following steps (Figure 3.1): 
I. Completion of the portfolio application form, found in the Integrated Research 
Application System (IRAS), for inclusion of the study on the National Institute for 
Health Research – Clinical Research Network (NIHR-CRN) portfolio  
II. Completion of the Research Application form found in IRAS, stating the nature 
and the process of the research project  
III. Uploading of all research relevant documents to the IRAS database, including 
protocol, patient information sheet, consent form, questionnaires, study flow 
chart, sponsorship and equipment agreements, honorary contract and 
investigators’ curriculum vitae 
IV. Booking of an “application review” date with Research Ethics Committee (REC), 
examining the ethical aspects of the study 
V. Application for HRA approval, assessing the governance and legal compliance of 
the study 








Figure 3.1: Steps in gaining HRA approval 
 
 
3.2.4.3 Preparing for the study initiation 
 
One of the most challenging parts in setting up the study was finding the room to host the 
PEAPOD machine. The room had to be close to maternity ward (for newborn’s 
measurement), accessible to parents (measurements during follow up visits), spacious 
(due to PEAPOD size) and with relatively stable ambient temperature (PEAPOD 
requirements). After considering available options it was decided that the PEAPOD room 
would be based on maternity ward, next to the paediatric assessment room, allowing 
easy access to mothers and newborns in the immediate postpartum period. For the 
follow up appointments it was decided that participants should report to maternity main 
reception and accompanied to the PEAPOD room by a member of the research team. It 
was instantly noted that the geographical direction of the room did not allow stable and 
within target range temperatures during summer period (hot weather), therefore after 
liaising with hospital Estates services a portable Air Conditioning unit was installed in the 
room. 
 
The current research project was part of a larger longitudinal study (PEAPOD study), 
with a predicted recruitment of 3,000 participants over a 5 years period. In order to 
maintain high quality standards and keep up with the requirements of the study a fully 
qualified research team was formed which included two research midwives (Karen 
Shorthose, Judith Plester), one research associate (Gail Pounder), one research 
bioscientist (Ilona Goljan), a statistician (Yonas Weldeselassie) and a research 





Investigator and the author was the Co-Investigator. Author was responsible for the study 
set up, organization and delegation of job roles to the team members. The 
responsibilities of each member were stated in the study delegation logbook (Appendix 
10).  
 
Instructions on operating, troubleshooting and maintaining PEAPOD were provided by a 
company’s (COSMED) representative to the research team. Members responsible for 
performing maternal and neonatal measurements (author and midwives) had further 
training on obtaining anthropometric measurements. Anthropometry protocol of the WHO 
Multicentre Growth Reference Study (MGRS) and INTERGROWTH-21st anthropometry 
handbook (48) were used as reference techniques. Audiovisual material was also used 
for better understanding of the process in an attempt to minimize intra- and inter-
observer variability. 
 
In order to raise awareness of the study among the public and midwifery, posters were 
used in General Practice (GP) waiting rooms, community rooms and libraries. The study 
was also advertised on social media through GEH account. Advertising material 
contained brief information about the study and advised potential participants to contact 
the research team for more information (Appendix 11). Three multidisciplinary team 
forums were organized in the local areas and the study protocol was presented in detail. 
Author working in collaboration with Primary Care, Diabetes & Endocrinology Local 
Research Networks and the research team were responsible for organizing these 
meetings. 
 
For “out of hours” deliveries, the participation of non-research midwives in collecting cord 
blood samples was necessary. After approaching the Head of Midwifery and explaining 
the purpose and the structure of the study we got approval for training midwives in the 
delivery unit on how to collect, centrifuge and store cord blood samples. Posters 
providing a brief description of the study and detailed instructions on how to perform cord 
blood collection and storage were placed in the delivery unit and sluice room (Figure 
3.2). Author and the research bioscientist performed regular quality inspections and 








Figure 3.2: Delivery alert for midwives. Contact details for research team and instructions 
for collecting the samples are clearly indicated  
 
 
3.2.4.4 STUDY INITIATION AND VISITS 
 
The prospective observational case-control study involved pregnant women planning to 
deliver at GEH and involved four study visits (Figure 3.3). Study was officially launched 








 Figure 3.3: Flowchart of the study detailing recruitment and follow up visits 
 
 
3.2.4.4.1 Visit 1/ Recruitment 
 
Vast majority of the participants were recruited during their OGTT (24-28 weeks 
gestation). OGTT appointment lists were screened by the research team one week in 
advance identifying potential participants for the study. On arrival to the Antenatal ward 
mothers were approached by a member of the research team and were provided with 
information about the study. A participant information sheet was given to all potential 
candidates (Appendix 12). Main priority during the consent was to ensure that mothers 
had capacity to make a well informed decision. It was also always highlighted that 
participation was entirely voluntary and decision not to participate would not compromise 
their medical/obstetric care. Mothers who were happy to participate were recruited at the 
same appointment (Appendix 13). For those requiring more time to consider their 
participation an extra visit was offered (none of the participants involved in the current 
thesis/study required the extra visit). Mothers who expressed their interest in participating 





group, thus not requiring an OGTT, were recruited during their booking visit (12 weeks) in 
the Antenatal clinic (during this thesis/study only two participants were recruited in early 
pregnancy).   
 
During the recruitment visit an additional 10ml were withdrawn with each blood sampling 
of the OGTT (OGTT0 and OGTT120). Blood samples were pseudoanonymised with a 
unique study ID number and immediately centrifuged. Using pipettes, samples were 
further divided to four aliquots containing serum, four containing plasma, one blood and 
one buffy coat (Figure 3.4). All aliquots were then placed in an ultra low freezer at -800C, 




Figure 3.4: Centrifugation and blood fractionation (Copyright 2004, Pearson Education, 
Inc., Benjamin Cummings) 
 
 
During the two hours waiting between the OGTT sampling, basic maternal 
anthropometric measurements were obtained, including height, weight, abdominal 
circumference and skinfold thickness (Appendix 14). Participants were also asked to 
complete questionnaires assessing their physical activity, well-being, socioeconomic 
status, anxiety and depression levels (Appendix 15). Ethnicity was self-selected by 
participants and in cases of migrant population further information on the ethnicity of their 
parents and grandparents was collected. The following categories were available for 
selection: White British, South Asian, African and “other”. A “delivery pack” which 
included two blood bottles for cord blood sample collection and an information note to the 
midwives (identifying mother as a study participant) was handed over to all participants. 
A sticker with the study logo was placed on the right top corner of the maternal notes, 
enabling prompt identification of study participants. A copy of the consent form was 






Following the OGTT results, participants were further categorized to GDM and non-GDM 
group (controls) based on the NICE 2015 criteria (49). GDM group had regular reviews 
(every one or two weeks) in the antenatal clinic, as dictated by NICE and hospital 
guidelines. Dietary and exercise advice were provided and target blood glucose levels 
were set at <5.5mmol/l premeal and <7.8mmol/l 1hr postprandial. Diet, metformin and 
insulin were used to achieve glycaemic targets. Fetal growth was assessed by 
ultrasound scans every 4 weeks or earlier if clinically indicated. Controls had standard 
antenatal care.  
 
3.2.4.4.2 Visit 2/ Delivery 
 
Research team kept a logbook of estimated delivery date of each participant. 
Furthermore Delivery Unit capacity was checked on a daily basis for names participating 
in the study. Midwives on the Delivery Unit, were notifying research team about the 
delivery of a participant on a daily basis. In case of “within working hours” deliveries a 
member of the research team performed cord blood centrifugation whereas staff 
midwives centrifuged and stored cord samples for “out of hours’ deliveries. Samples 
were then allocated to four aliquots containing serum, four containing plasma, one blood 
and one buffy coat and were stored at -800C. Women who had a home birth were still 
eligible to continue in the study, even without having cord blood samples collected. 
 
Author or one of the research midwives approached participants within five days after 
delivery, optimally during their stay in the Maternity ward, checking if they were still 
happy to continue in the study. Birth weight and anthropometric measurements (chest 
and waist circumference, length, triceps and sub scapular skinfold thickness) were 
collected for offsprings whereas mothers had their weight and skinfold thickness 
measured. Perinatal outcome data (mode of delivery, complications/birth injury, genetic 
anomaly, Apgar score, head circumference) was collected from obstetric notes. For 
pregnancies complicated by GDM, mode of treatment and last HbA1c were also 
acquired. Offsprings had their body composition assessed using PEAPOD (Appendix 
16). Principles and methods of assessing skinfold thickness and body composition using 
PEAPOD have been previously described. 
 
After completion of the assessment participants were asked again if they were happy to 
continue with the follow up visits. Appointments were booked for a day and time 
convenient to them (weekdays, working hours) and a text reminder was sent one week 






3.2.4.4.3 Visit 3 (4 weeks post partum) and Visit 4 (5 months post partum) 
 
Participants were asked to attend their follow up visits at 4 weeks and 5 months post 
partum. Offsprings had anthropometric measurements (length, triceps and sub scapular 
skinfold thickness) and body composition assessment via PEAPOD (Appendix 17). 
Mothers had their weight checked and were asked to complete two questionnaires, 
regarding feeding mode and sleep quality (Appendix 18). Mean duration of each visit was 
ten minutes. 
 
The breastfeeding questionnaire was used to categorize feeding patterns to 
predominantly breastfeeding, predominantly formula feeding and mixed feeding by 
addressing mode and duration of feeding. The “Pittsburgh Sleep Quality Index” (PSQI) 
questionnaire was used to differentiate “poor from good” sleep quality by measuring 
subjective sleep quality, sleep latency, sleep disturbances, daytime somnolence and use 
of sleeping medication during the last one month. 
 
3.2.4.5 Data extraction 
 
After study completion all the data was converted into electronic form. For analysis, no 
personal identifiable data was required. Hence this was carried out using the anonymous 
data with the link secured stored in NHS and University computers. Anthropometric 
measurements (weight, length, body's fat content) were transferred from the PEAPOD 
database to password protected computers. Demographic, maternal and neonatal 
characteristics documented in paper report forms were transferred to an electronic 
database and linked to the pre-mentioned PEAPOD information. All analysis took place 
either at GEH or at UoW using laptops/computers which remained locked in password 
protected areas. Only research staff had access to these areas. 
 
In order to explore the pathophysiology of GDM in depth and its effects on fetal 
development, GEH electronic imaging database was used to extract information from 
ultrasound anomaly scans at 20 weeks. Data on estimated fetal weight (EFW), head 
(HC)-abdominal (AC) circumference and femur length (FL) was retrieved. Hadlock 
formula was used to calculate EFW (50).  
 
Due to the nature of study, the participants’ personal data will be kept for 15-20 years 





the offspring. This data will be kept in a separate file and stored under strict secure 
conditions as mentioned above. 
 
3.2.4.6 Statistical analysis 
 
Data was analyzed using SPSS version 22. Statistical analysis was performed using “t 
test” or “Mann-Whitney U test” depending on data distribution (parametric or not). 
Independent one-way and mixed multi-factorial ANOVA was used to compare data 
across three or more independent variables. Chi-squared test was used to compare 
categorical data. For the primary outcome linear regression analyses was used to assess 
whether GDM independently predicts the risk of increased adiposity in the offspring. 
Results were adjusted for maternal and neonatal characteristics. As %FM adjusts only 
for body weight, statistically optimal indices were used to adjust fat and fat free mass for 
infant size. These were FM/length (cubed) and FFM/length (cubed) in the neonatal 
period (visit 2); FM/length (squared) and FFM/length (squared) for the follow up visits 
(visit 3 and 4) (51). Risk factors for GDM were considered as covariates and their 
independent effect on body composition was assessed. The author performed all 
statistical analyses. The accuracy of the methods and results were reviewed by the Chief 




508 mothers were approached from February 2017 to July 2018 at George Eliot Hospital 
NHS Trusts, Nuneaton, UK. 18% refused to take part in the study, whereas 417 were 
happy to be recruited and signed the consent form. The main reasons for refusing to take 
part in the study were lack of time (45%), lack of interest in participating into research 
(20%) and hesitation about the use of PEAPOD (35%). Participants completed their 
follow up visits by February 2019, allowing data to be analyzed and presented before 
August 2019 (thesis submission). 255 participants and their offspring undertook 
assessment at birth, 220 attended visit 3 and a total of 192 participants completed all four 
visits. A detailed flowchart of the study is presented in Figure 3.5. In order to assess the 
effect of intrauterine environment on body composition, data from all newborns measured 
at birth (n=255) was considered. The evolution of body composition during infancy was 
assessed using data from infants who completed all four visits (n=192). Maternal, fetal 
and neonatal characteristics were similar between the group who completed only visit 2 









3.2.5.1 Maternal Characteristics 
 
Following the 75gr OGTT at 28 weeks, participants were categorized into GDM (n=47) 
and nGDM (n=208) groups. GDM group had higher BMI (32.4 ± 5.5 vs. 29.5 ± 6.9 kgr/m2, 
p<0.01) at booking visit (12 weeks gestation), lower gestational weight gain (3.851 ± 
2.687 vs. 7.208 ± 4.375 kgr, p=0.02) and were delivered 9 days earlier (p=0.02). 
Maternal age and ethnic variation were similar between the two groups (Table 3.1).  
 
The GDM group achieved good glycaemic control, with a mean (SD) third trimester 
HbA1c of 34.9mmol/mol (4.3). 23 participants were diet controlled, 13 were treated with 







Figure 3.5: Flow-chart of the study showing participants’ recruitment and 
attendance to follow up visits. A total of 192 participants were included for final 






 GDM (n=47) nGDM (n=208) p value 
Maternal Age 
(years) 
32.3  (5.8) 32.1 (5.4) 0.8 
Ethnicity 40 White Europeans 
6 Asians 
1 African 




BMI (kgr/m2) 32.4 (5.5) 29.5 (6.9) <0.01 
GWG (kgr) 3.851 (2.687) 7.208 (4.375) 0.02 
Gestational Age 
(weeks) 
38.0 (1.1) 39.3 (2.4) 0.02 
Delivery 18 (38.1%) CS 
29 (62%) normal 
56 (27%) CS 
152 (73%) normal 
0.1 
Table 3.1: Maternal characteristics. The GDM group had higher BMI, lower gestational 
weight gain and was delivered earlier. p<0.05 is considered statistically significant 
 
3.2.5.2 Fetal characteristics based on 20 weeks scan 
 
Gestational age was similar between the two groups during fetal scan (20.3 ± 0.6 vs. 
20.3 ± 0.4 weeks, p=0.6). GDM group fetuses were found to have higher EFW (372.1 ± 
52.3 vs. 355.8 ± 38.5 grams, p=0.01) and larger HC (17.8 ± 0.8 vs. 17.6 ± 0.7 cm, 
p=0.01). There was no difference in AC or FL between groups (Table 3.2). After 
adjustment for maternal BMI and age, gestational age and gender of the fetus, EFW and 
HC remained significantly higher in the GDM group.  
 
 
 Fetal scan 







20.3 (0.6) 20.3 (0.4) 0.6 
EFW (grams) 372.1 (52.3) 355.8 
(38.5) 
0.01 
HC (cm) 17.8 (0.8) 17.6 (0.7) 0.01 
AC (cm) 15.8 (1.2) 15.6 (0.8) 0.08 
FL (cm) 3.3 (0.2) 3.2 (0.2) 0.4 
Table 3.2: Fetal data during 20 weeks scan. GDM fetuses tended to be heavier with 






3.2.5.3 Neonatal Characteristics at birth (visit 2) 
 
Mean time (SD) of neonatal body composition measurement was 42 (9.8) hours after 
birth for both groups. GDM group neonates had lower birth weight (3.078 ± 0.407 vs. 
3.322 ± 0.514 kgr, p<0.01) and were shorter (48 ± 2 vs. 49 ± 2 cm, p=0.02). There was 
no difference in gender between groups. Babies born to mothers with GDM were born 
slightly earlier than the non-GDM (38.0 ± 1.1 vs. 39.3 ± 2.4; p=0.02; table 3.3). 
 
PEAPOD assessment revealed similar %FM (9.9 ± 4.4% vs. 10.7 ± 4.1%, p=0.7) and FM 
(0.317 ±0.171 vs. 0.369 ± 0.171 kgr, p=0.06) between the two groups. GDM group 
neonates had lower FFM (2.761 ± 0.295 vs. 2.954 ± 0.405 kgr, p<0.01). Adjustments for 
neonatal size (FMI, FFMI) didn’t alter the results (Table 3.7). After adjustments for 
maternal BMI, maternal weight gain and gestational age at delivery, FM results between 
the two groups remained unchanged whereas the FFM difference attenuated and 
became non significant (Table 3.4).  
 
 
Visit 2 (birth) GDM (n=47) nGDM (n=208) P VALUE 






Birthweight (kgr) 3.078 (0.407) 3.322 (0.514) <0.01 
Gestational age  38.0 (1.1) 39.3 (2.4) 0.02 
Length (m) 0.48 (0.02) 0.49 (0.02) 0.02 
%FM1 9.9 (4.4) 10.7 (4.1) 0.2 
FM (kgr) 0.317 (0.171) 0.369 (0.171) 0.06 
FFM (kgr) 2.761 (0.295) 2.954 (0.405) <0.01 
FMI (kgr/m3) 2.6 (1.2) 2.9 (1.2) 0.1 
FFMI (kgr/m3) 22 (4.7) 23.9 (2.9) <0.01 
Table 3.3: Neonatal characteristics at birth. GDM neonates were shorter but also lighter. 
The difference in birthweight was driven by lower FFM whereas FM was similar; p<0.05 














Model 1  Model 2 
 B coef. Sig.  B coef. Sig. 
%FM -0.790 0.2  -0.639 0.3 
FM (kgr) -0.052 0.06  -0.039 0.1 
FFM (kgr) -0.193 <0.01  -0.119 0.06 
 
Table 3.4: a) Regression of neonatal body composition between the two groups; Model 
1: unadjusted, Model 2: adjusted for maternal BMI, maternal weight gain and gestational 
age b) Regression analysis of fat free mass (FFM) at birth adjusting for maternal BMI, 
maternal gestational weight gain (GWG) and gestational age (GA) revealing gestational 
weight gain and gestational age as independent predictive factors. 
 
 
3.2.5.4 Body composition at visit 3 (4 weeks) 
 
Mean age (SD) at the second assessment was similar for both groups (GDM: 32 ± 3 
days; nGDM: 33 ± 6 days, p=0.6). During visit 3 GDM group infants remained shorter (53 
± 2 vs. 54 ± 2 cm, p=0.1) with lower total body weight (4.206 ±0.468 vs. 4.388 ± 0.639 
kgr, p=0.08). PEAPOD assessment revealed that both %FM (16.7 ± 5.3% vs. 17.6 ± 
4.7%) and FFM (3.487 ± 0.302 vs. 3.602 ± 0.471 kgr) remained numerically lower in the 
GDM group, although not reaching statistical significance (p>0.05; Table 3.5). Results 









Model B SEE Beta p value 
GDM -0.119 0.061 -0.118 0.06 
BMI 0.008 0.004 0.130 0.07 
GWG 0.008 0.003 0.185 0.02 






Visit 3 (4 weeks) GDM (n=42) nGDM (n=150) P VALUE 
Age (Days) 32 (3) 33 (6) 0.6 
Weight (kgr) 4.206 (0.468) 4.388 (0.659) 0.08 
Weight gain (kgr) 1.086 (0.396) 1.061 (0.453) 0.7 
Length (m) 0.53 (0.02) 0.54 (0.02) 0.1 
%FM 16.7 (5.3) 17.6 (4.7) 0.2 
FM (kgr) 0.718 (0.269) 0.785 (0.285) 0.1 
FFM (kgr) 3.487 (0.302) 3.602 (0.471) 0.1 
FMI (kgr/m2) 2.5 (0.9) 2.6 (0.8) 0.4 
FFMI (kgr/m2) 12.1 (1.1) 12.1 (1.1) 0.9 
Feeding mode n (%) n (%) 0.4 
Breastfeeding 15 (35.7) 55 (36.6)  
Formula-feeding 23 (54.7) 70 (46.6)  
Mixed 4 (9.5) 25 (16.6)  
Table 3.5: Infant characteristics and feeding mode at visit 3. There was no between 
groups difference noted. 
 
 
3.2.5.5 Body composition at visit 4 (5 months) 
 
Offspring of both groups had the same age during their last assessment. GDM group 
demonstrated a more rapid growth with higher weight gain between visits 3 and 4 (3.226 
± 0.694 vs. 3.078 ± 0.670 kgr, p=0.2). As a result weight at visit 4 was similar between 
the 2 groups (GDM: 7.432 ± 0.825 vs. 7.461 ± 0.918 kgr, p=0.6; Table 3.6). The 
accelerated growth noted was driven by FM accumulation, as GDM group continued to 
have lower FFM (Figure 3.6).  
 
After adjusting for infant size using FMI, a mixed 3 x 2 multi-factorial ANOVA revealed a 
significant interaction between GDM and FMI, F (2, 387)= 5.235, p=0.01. Further 
examination with three independent “t-tests” and after adjusting for significance reveled 
that GDM group had higher FMI at visit 4 (p=0.015). FMI remained higher in the GDM 










Visit 4 (5 months) GDM (n=42) nGDM (n=150) P VALUE 
Age (days) 158 (20) 159 (13) 0.5 
Weight (kgr) 7.432 (0.825) 7.461 (0.918) 0.6 
Length (m) 0.65 (0.02) 0.65 (0.02) 0.73 
%FM 26.7 (5.7) 25.8 (5.6) 0.6 
FM (kgr) 2.003 (0.554) 1.945 (0.566) 0.9 
FFM (kgr) 5.428 (0.636) 5.515 (0.644) 0.8 
FMI (kgr/m2) 5.1 (1.9) 4.5 (1.3) 0.015 
FFMI (kgr/m2) 12.7 (1.2) 12.8 (1.3) 0.7 
Weight gain  Visits2-4 4.312 (0.836) 4.138 (0.831) 0.2 
Weight gain  Visits 3-4 3.226 (0.694) 3.078 (0.670) 0.2 
Feeding mode n (%) n (%)  
Breastfeeding 11 (26.1) 34 (22.6) 0.1 
Formula feeding 31 (73.8) 103 (68.6)  
Mixed 0(0) 13 (8.6)  
Breastfeeding duration 
(weeks)* 
5.5 (0-20) 3.5 (0-20) 0.7 
 Table 3.6: Infant characteristics and feeding mode at visit 4. GDM infants develop an 
early adiposity rebound, still having lower FFM.                                                                












t Sig. B Std. Error Beta 
1 (Constant) 4.758 1.821  2.612 .010 
GDM .639 .288 .175 2.216 .028 
BMI .010 .018 .045 .559 .577 
GWG .002 .017 .010 .118 .906 
GA  -.013 .045 -.022 -.292 .771 
a. Dependent Variable: FMI at visit 4 
 
 Figure 3.6: Weight and body composition distribution across the three visits  (V2: 
birth, V3: 4 weeks, V4: 5 months). GDM offspring have an early adiposity rebound 
















      
      
 
Table 3.7: Regression analysis of fat mass index (FMI) at visit 4 (5 months) adjusting for 
maternal BMI, maternal gestational weight gain (GWG) and gestational age (GA). GDM 
is an independent factor for offspring FMI at 5 months 
 
 
3.2.6 Discussion  
 
Results of our study revealed three key findings:  
1. Treatment of GDM resulted in lower birthweight, which was driven by lower FFM, 
whereas FM was similar between groups;  
2. Timing of delivery and gestational weight gain are independent predictors of FFM in 
the GDM group and  
3. Offspring of GDM pregnancies, despite optimal maternal glycaemic control 
(indicated by HbA1c), have greater adiposity at 5 months. 
To our knowledge, this is the first study to assess the evolution of adiposity in cases of 
treated GDM up to 5 months post partum. We have used fetal scan data in an attempt to 
track the origins of the disease from the antenatal period and we adjusted all our body 
composition measurements for infant size by using FMI and FFMI in order to provide 
statistically robust data. 
 
Sonographic estimation of AC and EFW during the third trimester has been shown to 
have a sensitivity of 80% in detecting neonatal macrosomia (52, 53). Recent data 
suggests that abnormal fetal growth is present even before the biochemical diagnosis of 
GDM, which is usually at 28 weeks of gestation following OGTT. Sovio et al (54) in a UK 
cohort (85% White Caucasians, 15% Asians and Africans) showed that GDM fetuses 
have higher AC at 28 weeks and an accelerated growth velocity between 20 and 28 






t Sig. B Std. Error Beta 
1 (Constant) 4.758 1.821  2.612 0.01 
GDM 0.639 0.288 0.175 2.216 0.02 
BMI 0.010 0.018 0.045 0.559 0.57 
GWG 0.002 0.017 0.010 0.118 0.90 
GA  -0.013 0.045 -0.022 -0.292 0.77 





abdominal wall thickness as a marker of abdominal adiposity showed that adverse body 
composition is present from 20 weeks of gestation in GDM pregnancies of Asian origin. 
One of the latest studies assessing fetal growth in both European and Asian population 
suggested a biphasic trend in the fetal development of GDM cases (56). Specifically, 
fetuses tend to be smaller between 12-16 weeks of gestation but demonstrate higher 
EFW, HC and AC by 24 weeks. In our cohort data was available from the 20 weeks 
anomaly scan. Consistent with findings from Brand et al (56) fetuses of GDM 
pregnancies were found to have higher EFW and HC. AC, although numerically higher in 
GDM cases, was only approaching statistical significance. We assume that the 
pathophysiology underpinning the biphasic fetal growth in GDM pregnancies is similar to 
this in cases of pre-existing diabetes (57). Hyperglycamia leads to low grade oxidative 
stress and pro-inflammation which in turn causes inhibition of trophoblast and placental 
growth. This growth restriction up to 16 weeks of gestation is followed by an accelerated 
“catch up” growth due to the hyperinsulinaemic environment (58).  
 
Diagnostic criteria and management of GDM are predominantly based on the findings of 
HAPO study (59). This landmark study revealed a linear association between maternal 
hyperglycaemia and adverse perinatal outcomes without proposing a clear diagnostic or 
therapeutic threshold. As a result, various diagnostic criteria and therapeutic targets have 
been proposed, as already described in chapter 1. Common denominator for all the 
criteria is the aim to minimize perinatal outcomes without compromising healthy fetal 
growth. NICE 2015 criteria on GDM were adopted in our study (49). Strong evidence 
suggests that treatment of GDM, as proposed by current guidelines, significantly reduces 
LGA, macrosomia and shoulder dystocia (60, 61). On the other hand, despite maternal 
antenatal treatment, offspring of GDM pregnancies remain at higher risk of childhood 
obesity (62, 63). The exact mechanism remains unclear and genetic, epigenetic, 
maternal and environmental factors have been suggested as possible explanations.  
 
NICE guidelines on GDM suggest to allow pregnancies up to 41 weeks of gestation 
provided that fetal growth and maternal glucose control is stable (47). Diabetes during 
pregnancy increases the risk of stillbirth by 4-6 times. In 50% of the cases stillbirths are 
described as idiopathic but maternal obesity, high maternal age and macrosomia are 
known risk factors (64). Rosenstein et al (65) in a retrospective analysis of over a million 
pregnancies (193,000 GDM) showed that GDM pregnancies are at higher risk of stillbirth 
between 36-39 weeks, with a relative risk ranging from 1.45 to 1.84. Results suggested 
that the risk of expectant management compared to delivery in GDM cases is higher after 
38 weeks (Figure 3.7). These results should be interpreted with caution as the GDM 





eclampsia, all known risk factors for stillbirth. Furthermore, the incidence of stillbirth was 
extremely low, not exceeding 0.06% of cases. A RCT assessing the optimal delivery time 
for insulin treated GDM cases, suggested that induction of labor at 38 weeks reduces 
incidence of macrosomia and SD without increasing the CS rate (66, 67). RCOG adopts 
NICE guidelines but recommends to “consider personal circumstances” when deciding 
about the time of delivery. 
 
 
Figure 3.7: Mortality risk of expectant management versus induction of labour in GDM 
pregnancies. Risk increases significantly after 38 weeks gestation; Adopted from 
Rosenstein et al (65)  
 
 
Our study compares a cohort of pregnant women without GDM receiving standard 
antenatal care with treated GDM pregnancies as per NICE guidelines. Maternal 
glycaemic control was optimal in the GDM group as indicated by a mean HbA1c of 34.9 
mmol/mol. Intensified care of the GDM group with nutritional advice, close blood glucose 
monitoring, regular antenatal appointments resulted in lower gestational weight gain and 
earlier induction of labour. Offspring of GDM group were lighter with similar %FM with 
nGDM group but with significantly lower FFM. After adjusting for maternal characteristics 
and gestational age difference in FFM became nonsignificant indicating that the earlier 
induction and lower weight gain noted in the GDM group resulted in lower neonatal FFM. 
Gestational age had a higher effect size on FFM than weight gain pregnancy, as 
indicated by the standardized B co-efficient (GA: 0.378 vs. Wt gain: 0.185). The effect 
size of gestational age on FM and FFM in our cohort is consistent with findings from the 
INTERGROWTH 21st study (1). After analyzing a sample of 1,000 neonates using 





increases by a mean value of 33-36 gr/week and FFM by 155-169 gr/week (combined 
data for both sexes). In our study, GDM pregnancies were delivered 9 days earlier 
resulting in a mean FM difference of 52 gr and a mean FFM difference of 193 gr.  
 
One of the most striking differences in the maternal characteristics of our cohort is the 
significantly less gestational weight gain noted in the GDM group. Regular antenatal 
appointments with dietician input, maternal education on healthy diet options and lifestyle 
changes implemented as part of the GDM management are more likely to be the cause 
for this difference. In 2009, IOM developed guidelines on optimal gestational weight gain 
based on prepregnacy maternal BMI (68). Purpose of the guidance was to balance the 
risks of having LGA infants, SGA infants, preterm births and postpartum weight 
retention. Publications of the guidelines triggered reactions, as many physicians claimed 
that targets are too high and contributing to obesity epidemics. Up to date results remain 
controversial, with some studies suggesting no harm in setting lower targets (69) and 
other linking weight gain below the recommendations with higher proportion of SGA, 
especially in obese and morbidly obese population (70). To our knowledge there is no 
study assessing the impact of weight gain below IOM recommendations on neonatal 
body composition using direct techniques. In our study, based on mean maternal booking 
BMI, GDM group had less weight gain than IOM targets (IOM based on BMI>30 kgr/m2: 
5-9 kgr vs.GDM group: 3.8 kgr). We believe that in addition to earlier iatrogenic delivery, 
this significantly lower gestational weight gain has also contributed to the lower 
birthweight, with a more prominent effect, worryingly, on FFM. 
 
By 5 months of age, we presented significant body composition differences between the 
two groups. GDM offsprings had higher weight gain which was driven by FM 
accumulation, as they continued to have lower FFM. We used statistically and clinically 
appropriate indices to adjust for infant size. Our analysis revealed that GDM group had 
higher adiposity at 5 months. Findings remained unchanged after adjusting for maternal 
characteristics, indicating a direct effect of GDM on infant body composition. 
  
Our results are consistent with previous studies. Logan et al (71) assessing body 
composition with MRI in a UK cohort found no differences at birth between well controlled 
GDM pregnancies and nGDM. Similarly, Au et al (72) in an Australian cohort using 
PEAPOD and Brumbaugh et al (73) in US cohort using MRI failed to show any between 
group differences. We suggest that tight maternal glycaemic control, present in all 
studies, attenuated any differences in neonatal adiposity. Logan et al (71) after 
reassessing body composition at 10 weeks showed a 16% higher adiposity in the GDM 





hypothalamic development and altered breast milk composition in the GDM group. Our 
study assessed infants at 4 weeks and 5 months post partum. There was no difference 
observed at 4 weeks but clearly, at 5 months, our GDM group demonstrated accelerated 
infant growth with excessive fat mass accumulation. We strongly believe that this altered 
growth is driven by the lower FFM at birth. 
 
Our study is the first to look at FFM differences as the majority of literature focuses on 
the effect on FM. FFM is the most important factor of energy expenditure and accounts 
for 75% of Basic Metabolic Rate (BMR). Brain and liver are responsible for 58-70% of 
BMR whereas muscles account for 5% (Figure 3.8) (74). Dulloo et al (75) has nicely 
described the “active and passive” role of FFM on energy metabolism and body 
composition. Although appetite is predominantly adipocentric because of the close 
relationship between fat cells and leptin, FFM remains a physiological source of hunger 
(Figure 3.9). Increasing amount of FFM results in increased BMR which in turn leads to 
higher energy intake to match the requirements (passive role). On the other hand, loss of 
FFM triggers a feedback mechanism to increase intake in an attempt to restore FFM 
(active role; Figure 3.10). The Minnesota experiment (76) showed that human body in 
periods of starvation loses FM at greater rate compared to FFM. During refeeding 
though, FFM takes longer to restore leading to excessive weight gain and FM 
accumulation, a condition known as “collateral fattening”. In other words, despite FM and 
weight recovery hyperphagia persists until FFM is completely restored (Figure 3.11). In 
our cohort, we suggest that the reduced FFM noted at birth in the GDM group, leads to 
hyperphagia and weight gain in an attempt to restore FFM resulting in FM accumulation 
by 5 months of age. Rapid weight gain and higher FM are both independently linked to 





Figure 3.8: Energy 
expenditure in infancy ;  
Basic Metabolic Rate (BMR) 
is the main contributor of total 
energy expenditure. Growth 
is the anabolic process 
requiring energy; Thermic 
effect of feeding is the energy 
required for food digestion 
and absorption   











           
      
Figure 3.10: a) Active role of fat free mass (FFM; EE: energy expenditure, EIN: energy 
intake), b) Impact of weight changes in body composition. Weight changes are 




Figure 3.11: Changes in body composition during starvation and refeeding period 
(Minnesota experiment). During refeeding, hyperphagia persists, despite FM restoration, 







One of the main limitations of our study is the lack of a healthy control group, a cohort 
which does not fulfill any of the high metabolic risk criteria. According to our study 
protocol, recruitment of low risk pregnancies could happen during booking visit, at 12 
weeks of gestation. In real life though, recruitment of this low risk group proved to be 
challenging, as only two participants were recruited during early pregnancy. First 
trimester is a very sensitive period for mothers, with most of them not disclosing their 
pregnancy until the viability of the fetus is confirmed at booking visit. The above 
observation could potentially explain the small numbers expressing their wish to 
participate into research through their general practitioner or community midwife. 
Furthermore, low risk antenatal clinics tend to be larger and busier, making it difficult for 
private conversations between mothers and research staff. Potential participants may 
feel uncomfortable by the time limitations and the waiting room environment, thus 
deciding not to take part in the suggested study. Although our research staff always tried 
to respect privacy when talking to mothers about a very sensitive topic, the external 
impacts described before, seemed to have grossly affected their final decision. On the 
other hand, the comparison of the GDM group with a low risk group would have amplified 
the differences found in our study; therefore, we suggest that the lack of a healthy control 




Our study is the first to follow the body composition evolution in pregnancies complicated 
by GDM up to 5 months of age. We showed that treatment of GDM results in a reduction 
of neonatal macrosomia at the cost of reduced FFM. This adverse phenotype at birth 
leads to rapid weight gain and FM accumulation by 5 months of age. The above indicate 
that maternal glycaemic control on its own may not be sufficient to prevent long term 
adverse outcomes and the correlation between GDM and childhood obesity is traced 
back in the antenatal and early post natal periods. The “gold standard” approach to 
pregnancies complicated by GDM, from preconception to the postnatal period, is yet to 
be identified and further studies are required to shed light into ways of preventing the 
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Prevalence of childhood obesity has reached an alarming rate constituting one of the 
most serious Public Health challenges globally (1). In chapter 1 we described the 
multifactorial origins of the disease and the higher risk of non-communicable diseases at 
a younger age. There is accumulating evidence that the origins of obesity can be traced 
as back as early postnatal life, antenatal and even prenatal health of the mother (2). 
Events occurring during this “plastic period” of development have multigenerational 
impact on human metabolism (Figure 4.1).  
 
 
Figure 4.1: Intergenerational programming. The metabolic syndrome trait passes from 
generation to generation Adopted from Drake et al (3)  
 
 
4.1.1 Risk factors  
 
4.1.1.1 Maternal Obesity and gestational weight gain (GWG) 
 
Maternal BMI has been considered one of the strongest predictors of offspring obesity in 
childhood and adulthood (4, 5). Neonatal body composition is closely linked to maternal 





excessive fat mass (FM) (6). GWG has less effect, compared to BMI, on adverse 
metabolic profile (7). Although the majority of studies reveal an association between 
excessive weight gain during pregnancy and childhood obesity (8-10), few failed to show 
any link with offspring body composition and BMI (11, 12).  
 
4.1.1.2 Gender and ethnic differences 
 
Gender and ethnic inequities in obesity are well described. Females are known to have 
higher %FM and lower FFM for a given BMI compared to males and are characterized by 
the “pear shaped” phenotype with increased subcutaneous fat deposition around the 
pelvic area. On the other hand, males despite having lower %FM are at higher risk of 
cardiometaboilc diseases, as their fat is predominantly centrally distributed (“apple 
shaped”) (13). Sex specific genetic variants and sex hormones (estrogens, testosterone) 
are the main determinants of this gender dimorphism (14).  
 
The Asian population is known to have a more adipose body composition for a given 
weight with increased central and visceral fat deposition (15). Evidence suggests that this 
adverse phenotype is present at birth (16). Countries of the South Asian (SA) continent 
are currently facing the “double burden” of the obesity epidemic: The problem of 
malnutrition is still present, especially in rural areas, but at the same time, in urban 
settings, risk factors of obesity and non-communicable diseases continue to rise. 
However, in the last decade a gradual “urbanization” of rural areas is noted. As such, 
fetal and early post natal periods, characterized by inadequate nutrition, are followed by 
exposure to high fat and energy dense foods as children grow older. This diet pattern 
coupled with lack of physical activity and sedentary lifestyle leads to an adipose 
phenotype and increased cardiometaboilc diseases. Of great interest, studies taking 
place during the first decade of our century revealed that the “thin fat” phenotype is 
evident also in SA migrants to high-income countries, but differences from populations 
native to the high-income countries are attenuated when compared to residents of the SA 
continent  (17).  
 
4.1.1.3 Feeding patterns 
 
BF during infancy is shown to reduce childhood obesity as well as having many other 
benefits for child health and wellbeing (18). The global recommendation is exclusive 
breast feeding for the first 6 months of life. Despite the beneficial effects of BF, only 30% 





evidence suggests that exclusive BF beyond five months reduces the risk of obesity at 
15 years of age in children with increased genetic risk (FTO gene) (20). Data on the 
effect of BF on body composition during the neonatal period remain scarce. A single US 
cohort study revealed that breastfed infants gained less weight than formula-fed infants 
up to 7 months, but interestingly this difference was driven by lower FFM accumulation, 
measured by DXA (21). At the same time, evidence from small cohorts reveal that 
breastfed infants have lower FFM and higher %FM during the first months of life, with the 




Adverse maternal characteristics, such as obesity and increased gestational weight gain, 
are linked to increased offspring adiposity in childhood. Similarly, Asian populations and 
females are known to have higher percentage of fat mass for a given weight when 
compared to those of white European descent and males respectively. We hypothesize 
that this altered body composition is present at birth and early infancy. 
 
4.1.3 Research questions 
 Is maternal adverse metabolic profile linked to altered body composition at birth 
and up to 5 months of age? 
 Is the “thin-fat” phenotype present in infants of South Asian origin born in UK? 
 Is there any difference in body composition between breastfed and formula-fed 
infants? 
 Is gender dimorphism in body composition present during early infancy? 
 
 4.1.4 Outcomes  
 Assess whether higher maternal BMI and gestational weight gain are linked to 
increased infant adiposity 
 Assess ethnic-specific body composition variability 
 Assess body composition differences between breastfed and formula-fed infants 









 4.1.5 Criteria 
 
The current analysis includes participants of the longitudinal, cohort study assessing 
body composition differences between offspring of GDM and non GDM mothers, 
described in chapter 3. For this reason inclusion and exclusion criteria remain the same 
as previously described. 
 
4.1.6 Methods – Statistical analysis 
 
In order to assess the impact of maternal and infant characteristics on offspring body 
composition without the confounding effect of GDM treatment, we included data obtained 
only from the control group (ie. participants without GDM; n=211, Figure 4.2). We 
assessed the effect of maternal characteristics on infant body composition at three 
different time points, using data obtained from PEAPOD measurements. In order to 
assess the effect of intrauterine exposures on body composition at birth, data from all 
newborns (except cases of GDM) measured at birth was considered. The effect of 
maternal characteristics on the evolution of body composition during infancy was 
assessed using data from infants who completed all three study visits (n=150). In an 
attempt to detect differences originating from early fetal life we assessed fetal size data 
from the 20 weeks anomaly scan. Finally we used anthropometric measurements, in 
specific skinfold thickness, in order to determine differences in fat distribution. The ratio 
of sub scapular to triceps (SS/TR) skinfold thickness was used as a marker of central 







Figure 4.2: Flowchart detailing infant attendance per study visit. 150 nGDM infants were 
included for final analysis 
 
We used multiple linear regression analysis and Generalized Linear Models (GLM) to 
assess the effect of maternal characteristics on body composition at birth and over a 
period of five months respectively. GLM can analyze the simultaneous effects of multiple 
variables, including mixtures of categorical and continuous variables. Ordinary linear 
regression assumes that a constant change in a predictor leads to a constant change in 
the response variable. We know that early postnatal life is a developmental period 
sensitive to environmental characteristics during which body composition undergoes 
dynamic changes (25), therefore GLM was used to describe the patterns of interactions 
and associations (26).  
 
We assessed the effect of ethnicity, gender and feeding mode on body composition by 
separate regression models. Maternal and infant characteristics and offspring body 
composition were described separately according to the variable studied. Depending on 
feeding mode during the first 5 months participants were categorized into predominantly 
breastfeeding (BF), predominantly formula feeding (FF) and mixed feeding (similar 
proportions of breast and formula milk). Maternal ethnicity was determined using 
questionnaires which asked participants to indicate which ethnic category best described 
their ethnic origin. Women were classified as either White Europeans or South Asians 
(SA). The first group included mothers who were White British or of other White 





Nepal, India, Pakistan and Sri Lanka. We restricted the cohort to women of White 
European and SA origin, as numbers from other ethnic backgrounds were not adequate 
to be analyzed separately (n=3). We used the terms “first generation migrant” to describe 
a native born participant (mother) whose parents were born in another country and 
“second generation” if both participant and her parents were native born citizens. The 
ethnicity of the participant’s partner and grandparents was not captured in our dataset. 
 
Statistical analysis was performed using “t test” or “Mann-Whitney U test” depending on 
data distribution (parametric or not). Independent one-way and mixed multi-factorial 
ANOVA was used to compare data across three or more independent variables. Chi-
squared test was used to compare categorical data. For multivariable analysis, linear 
regression models were applied to adjust for maternal and infant characteristics. %FM 
was used to adjust absolute number of fat mass for infant weight whereas optimal indices 
(FMI, FFMI) were used to adjust for infant size. 
 
Statistical analysis was performed using SPSS version 22. The accuracy of the methods 




4.2.1 Predictors of neonatal body composition 
 
Data from 208 participants was available and considered for the final analysis (Table 
4.1). Maternal BMI, GWG, gestational age, ethnicity and gender were the variables 
examined. Maternal, fetal and neonatal characteristics were similar between the group 
who completed only visit 2 and those who completed all study visits. 
 
 
n =208 Mean values (SD) 
Maternal BMI (kgr/m2) 29.5 (6.9) 
GWG (kgr) 8.1 (3.6) 
Gestational age (wks) 39.3 (2.4) 
Gender Male: 94, Female: 114 
Maternal Ethnicity  White: 178, Asian: 30 
Table 4.1: Maternal characteristics. Our study cohort included infants of different ethnic 
background and gender   






4.2.1.1 At birth 
 
Maternal BMI, GWG and gestational age independently predicted birthweight. Maternal 
BMI was the strongest predictor of FM at birth; GWG, gestational age and gender also 
significantly contributed to the model examined (BW, FM and FFM). Gestational age, 
GWG, gender but not BMI predicted FFM at birth. Females were found to have higher 
FM and lower FFM at birth. Mother’s ethnicity was not a predictor of any of the outcomes 
examined. Detailed effect size is shown in Table 4.2. 
 
4.2.1.2 During the first 5 months of life 
 
Maternal BMI and GWG were the only variables which independently predicted all 
outcomes (weight, FM, FFM). Gestational age was linked to weight and FFM, whereas 
the association with FM was approaching statistical significance (p=0.08). Male sex was 
related to higher weight and FFM. Ethnicity and breastfeeding duration were not found to 


























Birthweight (n=208) β-coefficient Standardized B 
Maternal BMI (kgr/m2) 0.012* 0.162 
GWG (kgr) 0.011* 0.194 
Gestational age (wks) 0.077* 0.384 
Gender  -0.115 -0.111 
Ethnicity -0.178 -0.121 
b) 
FM at birth (n=208) β-coefficient Standardized B 
Maternal BMI (kgr/m2) 0.006* 0.250 
GWG (kgr) 0.004* 0.196 
Gestational age (wks) 0.014* 0.219 
Gender  0.059* 0.175 
Ethnicity -0.063 -0.131 
c) 
FFM at birth (n=208) β-coefficient Standardized B 
Maternal BMI (kgr/m2) 0.006 0.107 
GWG (kgr) 0.007* 0.167 
Gestational age (wks) 0.063* 0.397 
Gender -0.172* -0.210 
Ethnicity -0.118 -0.102 
Table 4.2: Results of multiple regression analysis showing predictors of body 
composition (a: birthweight; b: FM; c: FFM) at birth. Gestational age and weight gain 
independently predicted all studied outcomes, whereas BMI only birthweight and FM;         
* p value <0.05 





    
                       






n=147 Weight (kgr) FM (kgr) FFM (kgr) 
Maternal BMI 0.021* 0.009* 0.011* 
GWG (kgr) 0.017* 0.006* 0.012* 
Gestational age (wks) 0.069* 0.01 0.058* 
Gender 0.52* - 0.06 0.583* 
Ethnicity 0.07 - 0.02 0.107 
Breastfeeding duration 
(wks) 
0.006 0.004 0.002 
Table 4.3: Predictors of body composition during the first 5 months, values 
represent β co-efficient. Maternal BMI and gestational weight gain 










Figure 4.3: Predictors of weight, fat mass (FM) and fat free mass (FFM) during the first 5 




4.2.2 Body composition and Gender 
 
Maternal characteristics and ethnic variation were similar between the two groups. 
Despite a similar weight at birth, females were found to have higher %FM (11.6 ± 4.3% 
vs. 9.5 ± 3.8%, p<0.01), higher FM (0.40 ± 0.171 vs. 0.334 ± 0.163 kgr, p<0.01) and FMI 
(3.2 ± 1.3 vs. 2.5 ± 1.1 kgr/m3, p<0.01) but lower FFM (2.886 ± 0.373 vs. 3.043 ± 0.421 
kgr, p<0.01). Body composition differences attenuated and became non significant at 4 





































 Male (n=94) Female (n=114) p value 
Maternal Age (years) 33.6 (5.4) 31.2 (5.1) 0.2 
Maternal height (m) 1.64 (0.06) 1.65 (0.07) 0.4 
Ethnicity White European: 81 
Asian: 13 
White European: 97 
Asian: 17 
0.9 
BMI (kgr/m2) 29.9 (6.7) 29.2 (7.0) 0.5 
GWG (kgr) 8.454 (4.891) 6.295 (4.358) 0.09 
Gestational Age (wks)  39.2 (3.3) 39.4 (1.3) 0.6 
b) 
Visit 2 (birth) Male(n=94) Female(n=114) p value 
Birthweight (kgr) 3.374 (0.522) 3.284 (0.499) 0.2 
Length (m) 0.5 (0.02) 0.49 (0.02) 0.1 
%FM 9.5 (3.8) 11.6 (4.3) <0.01 
FM (kgr) 0.334 (0.163) 0.400 (0.171) <0.01 
FFM (kgr) 3.043 (0.421) 2.886 (0.373) <0.01 
FMI (kgr/m3) 2.5 (1.1) 3.2 (1.3) <0.01 
FFMI (kgr/m3) 23.9 (2.8) 24.0 (3.0) 0.5 
c) 
Visit 3 (4-5 weeks) Male(n=68) Female(n=79) p value 
Age (Days) 33.4 (6.5) 33.0 (5.7) 0.6 
Weight (kgr) 4.470 (0.670) 4.321 (0.653) 0.1 
Length (m) 0.54 (0.03) 0.54 (0.02) 0.06 
%FM           17.0 (4.3) 18.2 (5.0) 0.1 
FM (kgr) 0.776 (0.262) 0.798 (0.307) 0.6 
FFM (kgr) 3.694 (0.484) 3.523 (0.452) 0.02 
FMI (kgr/m2) 2.5 (0.7) 2.7 (0.9) 0.2 
FFMI (kgr/m2) 12.2 (1.0) 12.0 (1.1) 0.4 
Feeding mode n (%) n (%) 0.07 
Breastfeeding  21 (31) 32 (41)  
Formula-feeding 31 (45.5) 39 (49)  
Mixed 16 (23.5) 8 (10)  
 
 
Table 4.4: a) Maternal characteristics b) Neonatal characteristics at birth c) Infant 
characteristics and feeding mode at visit 3 (4 weeks). Maternal characteristics were similar 






Weight gain (males: 4.225 ± 0.776kgr, females: 4.028 ± 0.863kgr; p=0.1) and age 
(males: 159 ± 12.9 days, females: 160 ± 14.8 days; p=0.6) at visit 4 (5 months) were 
similar between the two groups, thus male infants remained numerically heavier (7.595 ± 
0.826 vs. 7.323 ± 0.980 kgr, p=0.7). Mixed 3 x 2 multi-factorial ANOVA revealed a 
significant interaction between gender and %FM [F (1, 144)= 14.724, p<0.01], FFM [F (1, 
144)= 12.738, p<0.01], FMI [F (1, 144)= 10.897, p<0.01) and FFMI [F (1, 144)= 2.988, 
p=0.05]. Further examination with three independent “t-tests” and after adjusting for 
significance (p<0.016) revealed that %FM (p<0.01), FMI (p=0.011) and FFM (p<0.01) 
remained significantly different between groups (Table 4.5, Figure 4.4).  
 
 
Visit 4 (5 
months) 
Male(n=68) Female(n=79) p value 
Age (days) 159 (12.9) 160 (14.8) 0.6 
Weight (kgr) 7.595 (0.826) 7.323 (0.980) 0.7 
Length (m) 0.66 (0.02) 0.65 (0.02) 0.02 
%FM 23.9 (4.8) 27.2 (5.7) <0.01 
FM (kgr) 1.834 (0.489) 2.025 (0.615) 0.04 
FFM (kgr) 5.760 (0.592) 5.298 (0.600) <0.01 
FMI (kgr/m2) 4.2 (1.1) 4.7 (1.3) 0.011 
FFMI (kgr/m2) 13.1 (1.0) 12.5 (1.3) 0.08 
Feeding mode n (%) n (%) 0.2 
Breastfeeding 13 (19) 20 (25)  
Formula feeding 47 (69) 55 (70)  




4 (0-20) 4.2 (0-20) 0.8 
Table 4.5: Infant characteristics and feeding mode at visit 4 (5 months). Female infants 
continued to show higher adiposity and lower FFM                                                                








Figure 4.4: During the first 5 months of life female offspring had consistently lower 
weight, lower fat free mass (FFM) but higher percentage of fat mass (%FM) 
 
 
4.2.2.1 Fetal and infant anthropometric measurements 
 
Fetal scan at 20 weeks revealed that male fetuses had higher HC (177.6 ± 7.0 vs. 174.6 
± 7.5 mm, p<0.01) and higher AC (157.1 ± 8.3 vs. 154.3 ± 8.1, p=0.05), which remained 
significant even after adjusting for maternal BMI, gestational age and ethnicity. Rest of 
the measurements were similar between the 2 groups (Table 4.6).  
 
 Fetal scan 





20.3 (0.4) 20.2 (0.4) 0.6 
EFW (grams) 359.0 (39.1) 352.9(38.2) 0.2 
HC (mm) 177.6 (7.0) 174.6 (7.5) <0.01 
AC (mm) 157.1 (8.3) 154.3 (8.1) 0.05 
FL (mm) 32.7 (1.9) 33.0 (2.0) 0.2 
Table 4.6: Fetal data during 20 weeks scan. Female fetuses were found to have    
lower head and abdominal circumference 
 
Male neonates continued to have higher HC at birth. The remaining anthropometric 
measurements, including TR and SS skinfold thickness as well as waist (WC) – chest 

























PEAPOD measurements, females were found to have numerically, but not statistically, 
higher total adiposity without any differences in the distribution of adipose tissue during 















HC (cm) 35 (1.5) 34.2 (1.3) <0.01 <0.01 
TR (mm) 6.9 (3.9) 7.1 (1.9) NS NS 
SS (mm) 6.9 (3.4) 6.9 (1.7) NS NS 
SS/TR 1.03 (0.02) 0.98 (0.01) NS NS 
SS+TR (mm) 13.9 (7.2) 14 (3.5) NS NS 
WC (cm) 33.6 (2.8) 34.9 (2.1) NS NS 
CC (cm) 34.6 (2.3) 34.9 (2.1) NS NS 
ARC (cm) 13.1 (1.2) 11.2 (1.3) NS NS 
Visit 3 (4-5 weeks) (n=68) (n=79)   
TR (mm) 8.4 (1.9) 9.2 (2.2) <0.01 0.02 
SS (mm) 8.3 (1.8) 8.9 (1.8) <0.01 0.02 
SS/TR 1.00 (0.17) 0.99 (0.16) NS NS 
SS+TR (mm) 16.8 (3.5) 18.1 (3.8) 0.2 0.002 
WC (cm) 38.1 (2.8) 37.8 (3.1) NS NS 
CC (cm) 38.7 (2.6) 38.0 (2.6) NS NS 
ARC (cm) 12 (1.3) 11.8 (1.3) NS NS 
Visit 4 (4-5 months) (n=68) (n=79)   
TR (mm) 12.1 (3.1) 11.9 (3.2) NS NS 
SS (mm) 9.80 (3.3) 10.80 (2.9) NS NS 
SS/TR 0.82 (0.24) 0.90 (0.28) NS NS 
SS+TR (mm) 21.9 (5.9) 22.8 (5.6) NS NS 
WC (cm) 44 (3.1) 43.7 (3.4) NS NS 
CC (cm) 44.9 (2.4) 44.0 (2.9) NS NS 
ARC (cm) 14.9 (1.4) 14.7 (1.5) NS NS 
Table 4.7:  Infant anthropometric measurements based on gender, Anthropometrc 
indexes dd not reveal any sustained difference between groups TR: triceps skinfold 
thickness; SS: sub scapular skinfold thickness; WC: waist circumference; CC: chest 
circumference; ARM: arm circumference: NS : non significant (p>0.05);  Model 1: 






4.2.3 Body composition and ethnicity 
 
Maternal characteristics of the two groups can be found in Table 4.8. Both groups shared 
similar maternal and gestational age but SA group had lower BMI (30.3 ± 6.9 vs. 24.7 ± 
5.3 kgr/m2, p<0.01) and higher weight gain during gestation (7.931 ± 4.312 vs. 9.270 ± 
3.643, p=0.5). There was no difference in maternal total adiposity (SS+TR) or adipose 










Maternal Age (years) 32.4 (5.5) 31.5 (4.5) 0.8 
Maternal height (m) 1.65 (0.06) 1.65 (0.08) 0.9 
BMI (kgr/m2) 30.3 (6.9) 24.7 (5.3) <0.01 
GWG (kgr) 7.931 (4.312) 9.270 (3.643) 0.5 
Gestational Age 
(weeks) 
39.3 (2.6) 39.3 (1.2) 0.7 
SS+TR (mm) 53.6 (13) 48.1 (11) 0.07 
SS/TR (mm) 1.07 (0.2) 1.10 (0.2) 0.6 
Table 4.8: Maternal characteristics between White Europeans and South Asians (SA). 
SA mothers had lower BMI but similar measures of adiposity 
 
 
Socioeconomic data and diet patterns were retrieved from the study questionnaires. SA 
participants had higher educational qualifications and the vast majority was married. 
There were no between group differences in employment status, annual income and diet 













Socioeconomic White European 
(n=178) 
SA (n=30) p 
value 
Education        Higher 
(MD,PhD,PGCE)   Professional 
                         Entry level  
                         No qualifications 











Marital status           Married 







Employment            Yes 






Income                     >52,000 
                             36,400-51,999 
                             26,000-36,339 











Diet                          Vegetarian 






Generation               First 
                                  Second 














4.2.3.1 Body composition at birth 
 
There was no difference in gender between the two groups. Neonates of SA group were 
found to have a lower birthweight (3.368 ± 0.501 vs. 3.065 ± 0.497 kgr, p<0.01) which 
was driven by lower %FM (11.0 ± 4.0 vs. 8.7 ± 4.0%, p<0.01), as FFM was similar 
between the two groups (2.985 ± 0.396 vs. 2.830 ± 0.441 kgr, p=0.1). Difference in FM 
remained after adjusting for neonatal length as there was a statistically significant 
difference in FMI between the two groups (White Europeans: 3.0 ± 1.2 kgr/m3, SA: 2.0 ± 
1.1 kgr/m3, p<0.01). After applying multiple regression models adjusting for maternal 
BMI, educational and marital status the correlation between FM, %FM, FMI and ethnicity 
slightly attenuated but remained significant whereas differences in birthweight were no 







Table 4.9: Socioeconomic and diet characteristics of White European and South 
Asian (SA) study population. Of note the high percentage of higher education and 
marital status in the SA group; NA: Not Applicable, NR: Not Reported; p values 



















Birthweight (kgr) 3.368 (0.501) 3.065 (0.497) <0.01 
Length (m) 0.5 (0.02) 0.49 (0.02) 0.4 
%FM1 11.0 (4.0) 8.7 (4.0) <0.01 
FM (kgr) 0.385 (0.170) 0.276 (0.145) <0.01 
FFM (kgr) 2.985 (0.396) 2.830 (0.441) 0.1 
FMI (kgr/m3) 3.0 (1.2) 2.3 (1.1) <0.01 















4.2.3.2 Body composition at 4-5 weeks and 5 months 
 
Maternal, fetal and neonatal characteristics were similar between the group who 
completed only visit 2 (birth) and those who completed all study visits. SA infants 
demonstrated numerically higher weight gain during the first 5 months of life (4.095 ± 
0.850 vs. 4.272 ± 0.654 kgr, p=0.3) but still remained lighter than the White European 
cohort. Of great interest, the weight gain was predominantly driven by a more rapid 
accumulation of FM resulting in numerically, but not statistically, higher FM% at 5 months 
(25.6 ± 5.5% vs, 26.6 ± 6.2, p=0.4). FFM remained lower in the SA group throughout the 
Visit 2 (Birth) Model 1 Model 2 
 B coef. Sig. B coef. Sig. 
Birthweight 
(kgr) 
-0.303 <0.01 -.251 NS 
%FM -2.36 <0.01 -1.83 0.02 
FM (kgr) -0.109 <0.01 -0.083 0.01 
FMI (kgr/m3) -0.7 <0.01 -0.5 0.02 
FFM (kgr) -0.155 0.1 -0.132 NS 
FFMI (kgr/m3) -0.6 0.4 -0.5 NS 
Table 4.10: a) Neonatal characteristics at birth b) Regression of neonatal body 
composition between the two groups; SA infants presented lower weight and adiposity 
at birth, even after adjusting for maternal characteristics; Model 1: unadjusted, Model 2: 






study. Results remained unchanged after adjusting for infant size (Figure 4.5, Table 
4.11). 
 
BF data revealed that SA mothers were more likely to breastfeed their infants 
postpartum, having a higher total median duration of BF (White European median: 3.0, 
IQR [0-20] weeks; SA median: 10.0, IQR [3.0- 20] weeks). After adjusting for maternal 
BMI, socioeconomic status and BF duration, body composition differences remained non 






Figure 4.5: Body composition evolution between White Europeans and South Asians 
during the first 5 months of life. Both groups demonstrated similar body composition 



















Age (Days) 37.8 (6.0) 35.5 (6.3) 0.07 
Weight (kgr) 4.405 (0.640) 4.290 (0.814) 0.4 
Length (m) 0.54 (0.02) 0.54 (0.02) 0.6 
%FM 17.5 (4.4) 18.2 (6.4) 0.5 
FM (kgr) 0.784 (0.274) 0.811 (0.367) 0.7 
FFM (kgr) 3.620 (0.460) 3.478 (0.554) 0.2 
FMI (kgr/m2) 2.6 (0.8) 2.7 (1.1) 0.7 
FFMI (kgr/m2) 12.2 (1.1) 11.7 (1.0) 0.09 
Feeding mode n (%) n (%) 0.04 
Breastfeeding 43 (33.5) 10 (52.5)  
Formula-feeding 66 (51.5) 4 (21)  
Mixed 19 (15) 5 (26.5)  
 
b) 





Age (days) 160.5 (13.4) 153.5 (15.9) 0.04 
Weight gain       
V2-V4 (kgr) 
4.095 (0.850) 4.272 (0.654) 0.3 
Weight (kgr) 7.462 (0.923) 7.368 (0.924) 0.6 
Length (m) 0.65 (0.02) 0.65 (0.02) 0.5 
%FM 25.6 (5.5) 26.6 (6.2) 0.4 
FM (kgr) 1.931 (0.565) 1.981 (0.590) 0.7 
FFM (kgr) 5.529 (0.629) 5.382 (0.693) 0.3 
FMI (kgr/m2) 4.4 (1.3) 4.6 (1.3) 0.6 
FFMI (kgr/m2) 12.8 (1.2) 12.6 (0.9) 0.4 
Feeding mode n (%) n (%) 0.01 
Breastfeeding 24 (19) 9 (47.5)  
Formula feeding 92 (72) 10 (52.5)  
Mixed 12 (9) 0  
Table 4.11: Infant characteristics and feeding mode between White Europeans and 
South Asians (SA) at a) 4 weeks b) 5 months. After adjusting for maternal characteristics 
and feeding mode ethnic background did not affect infant body composition                                                                                                                 






4.2.3.3 Fetal and infant anthropometric measurements 
 
Fetal scan revealed that SA group had a lower estimated fetal weight at 20 weeks of 
gestation (348.3 ± 43.5 vs. 356.8 ± 37.8grams, p=0.3) with similar HC and FL. AC was 
smaller in the SA group (154.8 ± 9.2 vs. 156.2 ± 8.8 mm, p=0.4). Results remained 
unchanged after adjusting for maternal BMI and height (Table 4.12).  
 
 









20.3 (0.4) 20.2 (0.6) 0.9 
EFW (grams) 356.8 (37.8) 348.3 
(43.5) 
0.3 
HC (mm) 176.0 (7.3) 176.2 (8.4) 0.9 
AC (mm) 156.1 (8.8) 154.8 (9.2) 0.4 
FL (mm) 32.8 (1.9) 33.1 (1.8) 0.7 




After adjusting for infant’s weight or length, neonatal anthropometry revealed a lower WC 
(32.2 ± 2.6 vs. 34.3 ± 2.6 cm, p=0.02) and lower SS/TR ratio (0.9 ± 0.1 vs. 1.02 ± 0.1, 
p=0.01) in the SA group at birth, with the remaining measurements being similar between 
the two groups. There were no differences noted at visit 3. During visit 4, markers of total 
and central adiposity were similar between the groups and interestingly, SA were found 




























HC (cm) 34.7 (1.5) 33.9 (1.5) 0.02 NS 
TR (mm) 7.2 (3.1) 6.0 (1.3) NS NS 
SS (mm) 7.1 (2.7) 5.5 (1.3) 0.01 NS 
SS/TR 1.02 (0.1) 0.9 (0.1) 0.01 0.01 
SS+TR (mm) 14.3 (5.7) 11.5 (2.4) 0.04 NS 
WC (cm) 34.3 (2.6) 32.2 (2.6) <0.01 0.02 
CC (cm) 35.0 (2.2) 33.4 (2.1) <0.01 NS 
ARC (cm) 12.3 (8.7) 10.7 (1.1) NS NS 
Visit 3 (4-5 weeks) (n=128) (n=19)   
TR (mm) 8.9 (2.1) 8.6 (2.0) NS NS 
SS (mm) 8.7 (1.8) 8.4 (1.2) NS NS 
SS/TR 0.99 (0.1) 0.99 (0.1) NS NS 
SS+TR (mm) 17.6 (3.7) 17.1 (3.) NS NS 
WC (cm) 38.0 (2.7) 37.4 (4.4) NS NS 
CC (cm) 38.4 (2.5) 38.1 (3.5) NS NS 
ARC (cm) 11.8 (1.3) 12.1 (1.4) NS NS 
Visit 4 (5 months) (n=128) (n=19)   
TR (mm) 11.9 (3.2) 12.8 (2.4) NS NS 
SS (mm) 10.1 (3.1) 11.6 (2.6) NS 0.03 
SS/TR 0.87 (0.2) 0.9 (0.1) NS NS 
SS+TR (mm) 22.07 (5.8) 24.5 (4.9) NS NS 
WC (cm) 43.9 (3.2) 43.7 (3.8) NS NS 
CC (cm) 44.4 (2.7) 44.4 (3.3) NS NS 
ARC (cm) 14.6 (1.5) 15.5 (1.3) 0.02 <0.01 
Table 4.13: Infant anthropometric measurements based on ethnicity. Infant 
anthropometry did not reveal any sustained between groups difference; TR: triceps, 
SS: sub scapular, WC: waist circumference, CC: chest circumference, ARM: arm 






4.2.4 Body composition and feeding mode 
 
Data from 147 participants was reviewed and considered for final analysis. The majority 
of our participants were found to predominantly FF their offspring (n=102), followed by 
BF (n=33) and mixed feeding (n=12). Maternal characteristics were similar across the 
three groups. There was a trend for mothers who opted to formula feed their infants to be 
younger (BF: 33.5 ± 4.6, FF: 31.7 ± 5.4, Mixed: 31.3 ± 6.4 years; p=0.2) with higher BMI 












33.5 (4.6) 31.7 (5.4) 31.3 (6.4) 0.2 
Maternal 
height (m) 
1.63 (0.07) 1.64 (0.17) 1.62 (0.06) 0.9 
BMI (kgr/m2) 28.3 (6.9) 30.2 (7.1) 29.9 (4.7) 0.4 
GWG (kgr) 8.236 (6.414) 8.500 (8.192) 3.600 (5.063) 0.1 
Gestational 
Age (weeks) 
39.4 (1.4) 39.2 (3.2) 39.6 (1.0) 0.8 









Table 4.14: Maternal characteristics based on feeding mode 
 
 
4.2.4.1 Body composition at birth and 5 months post partum (visit 4) 
 
There was no significant gender dimorphism across the three groups. Neonatal 
characteristics were similar at birth. 36.5% of our participants were predominantly BF at 4 
weeks and only 22.6% at 5 months. A mixed 2X3 multifactorial ANOVA revealed a 
significant interaction between FFMI [F(2,148)=4.149, p=0.01]at visit 4 and mode of 
feeding. BF infants had significantly lower FFMI from both FF and mixed fed infants 
(FFMI: 12.2 ± 0.9 vs. 12.9 ± 1.3 vs. 13.2 ± 1.7). Although not reaching statistical 
significance there was a clear trend for BF infants to gain less weight but have higher 
























3.408 (0.604) 3.296 (0.506) 3.351 (0.358) 0.5 
Length (m) 0.50 (0.02) 0.49 (0.02) 0.50 (0.01) 0.1 
%FM1 10.8 (4.9) 10.7 (4.0) 9.2 (3.9) 0.4 
FFM (kgr) 3.013 (0.450) 2.932(0.406) 3.024 (0.283) 0.5 
FMI (kgr/m3) 2.9 (1.4) 2.9 (1.2) 2.5 (1.0) 0.6 
FFMI (kgr/m3) 23.1 (2.4) 23.8 (3.1) 23.4 (2.9) 0.4 
 
b) 











Weight (kgr) 7.419 (0.921) 7.451 (0.938) 7.652 (0.785) 0.7 
Weight gain 
(kgr) 
4.011 (0.886) 4.159 (0.827) 4.300 (0.731) 0.5 
Length (m) 0.65 (0.03) 0.65 (0.04) 0.65 (0.02) 0.8 
%FM1 27.7 (5.4) 25.1 (5.6) 25.8 (5.2) 0.06 
FFM (kgr) 5.332 (0.588) 5.559 (0.678) 5.646 (0.419) 0.1 
FMI (kgr/m3) 4.8 (1.2) 4.4 (1.3) 4.6 (1.4) 0.3 
FFMI (kgr/m3) 12.2 (0.9) 12.9 (1.3) 13.2 (1.7) 0.01 
Solid food* n=3 (10) n=6 (7) n=4 (7)  
Table 4.15: Infant characteristics at a) birth and b) visit 4 based on feeding mode. Body 
composition at 5 months revealed that BF infants had lower FFM, after adjusting for nfant 
size.                                                                                                                                                      
* Data indicate the number of participants who introduced solid food before the follow up 
assessment, data in () indicate the mean duration of solid food intake in days, before the 










We have presented a comprehensive analysis of the maternal and infant characteristics 
predicting body composition showing the following key findings:  
1. Increase in fetal weight during the late stages of gestation is driven by FFM, 
rather than FM, accumulation;  
2. Maternal BMI and GWG independently predict offspring adiposity during the first 
5 months of life;  
3. Sex differences in body composition are present at birth; 
4. BF infants tend to have lower weight gain but higher %FM and lower FFM at 5 
months post partum and  
5. Infants of SA origin have similar body composition with infants of European 
descent. 
 
4.3.1 Maternal BMI, gestational weight again and gestational age 
 
The increasing maternal obesity rates parallel the childhood obesity epidemic raising the 
question of developmental programming (27). Data from multiethnic cohorts reveal that 
maternal obesity is related to increased childhood and adulthood adiposity (4, 5). 
Accumulating evidence suggest that this adverse phenotype is present at birth, with 
offspring of mothers with overweight and obesity having higher FM compared to those 
born to women of a normal weight (28, 29). At the same time, well designed randomized 
control trials have shown that GWG is inversely related to offspring adiposity at 6 months 
of age. Observational studies have shown that these adverse outcomes are maintained 
in childhood and adulthood (8, 30, 31).  
 
During pregnancy, adipose tissue is used as storage which continuously provides energy 
to the fetus, matching the requirements of intrauterine growth. Maternal fat accumulation 
parallels GWG (32), with adipose tissue being predominantly centrally deposited (Figure 
4.6). Central adiposity is linked to reduced insulin sensitivity and hyperlipidaemia, even in 
pregnancy (33). Insulin resistance leads to hyperglycemia and hypertriglyceridaemia due 
to unopposed lipolysis. In cases of preexisting maternal obesity, the above effect is 
exaggerated due to increased peripheral insulin resistance (34). As a result, maternal 
obesity and high GWG lead to excessive transplacental transport of nutrients (glucose, 
free fatty acids and amino acids) to the fetus, stimulating fetal insulin secretion. The 







Figure 4.6: Changes in skinfold thickness during pregnancy. Graph demonstrates the 
preferential central adipose tissue deposition; Adopted from Taggart et al (35)  
 
Using an objective body composition technique (PEAPOD) to describe offspring 
adiposity, we managed to demonstrate that maternal BMI and GWG are related to higher 
adiposity at birth and up to 5 months of age, with BMI having a greater effect. Similarly to 
the effect of GDM on body composition, we believe that the small effect size noted may 
be due to a delayed effect, which will become more prominent after 5 years of age (36). 
Furthermore, evidence from the Project Viva has shown that modest differences in body 
composition during the early postnatal period may be amplified as child gets older (37). 
Our data also show that GWG is independently related to FFM. To date, there is paucity 
of data regarding the metabolic significance of FFM at the early stages of life as most 
studies focus on the quantification of FM. We suggest that FFM is an important 
component of metabolic imprinting and more studies are required to clarify its association 
with maternal characteristics. Specifically, we believe that GWG below the IOM 
recommendations could lead to compromised FFM development contributing to adverse 
cardio-metabolic outcomes in later life.  We were unable to demonstrate any association 
between maternal BMI and FFM at birth. We speculate that the weak association 
between BMI and FFM during the first 5 months post partum is driven by the higher 
weight of the offspring of mothers with obesity.  
 
As expected, we have shown that increasing gestational age is related to higher weight, 
FM and FFM. Consistent with the Newborn Body Composition Study (Intergrowth 21st) 
(38) data we have shown that the rate of FFM accumulation is higher than that of FM 
during the late stages of pregnancy. After assessing 1000 infants, Intergrowth study team 
showed a mean increase of FM by 35gr/week and FFM by 162gr/week after 34 weeks of 
gestation, with great variability between subjects. Although the effect size on both FM 





FFM/FM accretion with increasing gestational age is similar. Furthermore, our study 
involved participants with high metabolic risk whereas the Intergrowth sub study included 
low to medium risk pregnancies (mean BMI in our study: 29.8 ± 7 kg/m2 vs. Intergrowth 
BMI: 24.9 ± 4.9 kg/m2). The exact effects of maternal obesogenic intrauterine 
environment remain unknown, therefore comparison of the two groups by means of 
absolute FM and FFM values may not be reliable. 
 
4.3.2 Body composition and gender 
 
We performed a subgroup analysis to assess gender differences in body composition 
during the early stages of life. We used PEAPOD as a direct measure of body 
composition to describe differences in FM and FFM between sexes. We reviewed data 
from fetal anomaly scans at 20 weeks of gestation to identify any early impact of gender 
on fetal growth and we used skinfold thickness to assess any difference in FM 
distribution in our study groups. Our results show that gender dimorphism in body 
composition is present at birth but not during early pregnancy. We found that females 
have a more adipose phenotype with higher %FM, higher FMI and lower FFM. We were 
unable to demonstrate any difference in adipose tissue distribution during the first 5 
months of life. Our results are consistent with findings from two large studies which also 
used PEAPOD technique to assess neonatal body composition. The Intergrowth 21st 
study team (38) assessed body composition in 1019 infants born in Oxford, UK, after 34 
weeks of gestation.  Norris et al (39) combined data from 4 different multi ethnic (US, 
Ireland, Italy) cohorts (n= 1457) in order to create body composition charts from 30 
weeks of gestation up to 6 months post partum. Both studies showed that females have 
consistently higher %FM and lower FFM when compared to males. 
 
Gender differences in body composition are well described in adult populations. Females 
are known to have higher %FM and lower FFM for a given BMI.  Despite the higher total 
adiposity females have lower cardiometaboilc risk which is related to the adipose tissue 
distribution (40). Males have central adiposity whereas females are characterized by the 
“pear shaped” phenotype, with subcutaneous fat accumulation around the pelvic region 
(13). Body composition differences arise from sex chromosomes and sex hormones (14). 
In order to distinguish the contribution of chromosomes and hormones to adipose tissue 
formation animal models have been used. In mice models, in an attempt to eliminate the 
gonadal effect, the testis determining gene (Sry) was deleted from the Y chromosome 
and a transgene was inserted to an autosome. As a result, four core genotype models 





or female gonads (Figure 4.7). Presence of the XX genotype was related to higher total 
body fat and greater appetite. The same genotype when exposed to high fat diet 
demonstrated larger subcutaneous inguinal adipose tissue deposition whereas XY mice 




Figure 4.7: The four core genotypes mouse model. Differences between gonadal females 
and gonadal males are attributed to sex hormone effects, while differences between XX 
and XY mice are attributed to the sex chromosome; Adopted by Link et al (14)  
 
 
The role of sex hormones has been widely described (Figure 4.8). Various expression of 
oestrogen receptors within different depots of WAT is responsible for adipose tissue 
distribution. Oestrogen receptors are predominantly expressed in subcutaneous rather 
that visceral fat. Furthermore, gluteal subcutaneous fat has more receptors that 
abdominal subcutaneous are which explains the preferential deposition of adipose tissue 
around the pelvic region in females (41). To further support this theory, post menopausal 
women have increased central adiposity when compared to premenopausal. This relation 
is attenuated in postmenopausal women receiving hormone replacement therapy (42). 
Finally, in cases of PCOS which are characterized by an imbalance between oestrogens 








Figure 4.8: Sex hormones, body composition and cardiovascular risk; Adopted from 
Ethun et al (44)  
 
In our cohort, we demonstrated higher adiposity in female infants. Consistent with animal 
studies described before, we believe that these differences are driven by the sex 
chromosomes. We were unable to find any difference in adipose tissue distribution. As 
previously explained, adipose tissue depot formation is strongly linked to sex hormones. 
We believe that the sexual dimorphic pattern of reproductive hormone levels described 
during early infancy (45) is not strong enough to create different patterns in adipose 
tissue deposition. To further support our hypothesis, Kanehisa et al (46) has previously 
shown that mild body composition differences between sexes in childhood are amplified 
during puberty, a period of “sex hormone prosperity”. 
 
4.3.3 Body composition and feeding mode 
 
We utilized data from our observational study to compare body composition based on 
different feeding modes. Consistent with national data (19), 36.5% of our participants 
were found to predominantly BF at 4 weeks and only 22.6 at 5 months. Similarly to Oddy 
et al (47) we observed that maternal BMI was associated with reduced duration of BF. In 
our cohort, BF was related to lower weight gain but higher %FM and lower FFMI at 5 
months. 
 
The long term benefits of BF on non-communicable diseases are well established. Data 
from seven systematic reviews, including 81 studies, has shown that BF reduces the risk 
of childhood obesity (48). Based on this evidence, BF has received the unanimous 





mechanism underpinning the protective effect of BF is yet to be identified. The number of 
studies on non-nutritional components of milk, such as leptin, adiponectin, insulin and 
ghrelin has been progressively increasing in the last decade, but the causal link to 
metabolic outcomes remains unknown (48).  
 
At the same time, data on the effect of breast milk on infant body composition remains 
controversial. In our study we showed that BF infants have lower weight gain at 5 
months. The reduced concentration of energy, protein and micronutrients in breast milk 
compared to formula can explain the above findings (49, 50). Consistent with our results, 
Butte et al (22) and Anderson et al (23), using DXA and PEAPOD respectively, have 
shown that BF infants have higher %FM and lower FFM during the first months of life. In 
contrast, results from UK (51) and Italian (52) cohorts  suggest that BF is related to 
consistently lower weight gain, lower BMI and FM up to 5 months of age. We believe that 
the higher energy density of formula milk and specifically the higher protein/energy ratio 
may be responsible for the lower FFM observed in BF infants (53). We hypothesize that 
the increased adiposity observed in BF infants may be related to bioactive components 
of breast milk, such as leptin, adiponectin and insulin. For example, maternal BMI is 
related to breast milk insulin concentration (54). Given the preferential effect of insulin on 
FM, we speculate that levels above a normal “cut off” could potentially lead to increased 
FM accumulation. Overall, current literature is sparse and the exact effects of breast milk 
are difficult to be established. There are both known and unknown factors influencing 
maternal breast milk composition, and these factors may, in turn, affect infant outcomes 
independent of their effect on breast milk composition (48). More studies are required to 
explore these hypotheses to ascertain the link between breatfeeding and early childhood 
body composition. This may help to understand its beneficial effects on metabolic 
disorders in latter life. 
 
Interestingly, one of the most recent studies suggested that breast milk is not related to 
the quantity of adipose tissue but the type (55). In specific, researchers have shown that 
lipids [alkylglycerol-type (AKG-type) ether lipids] present only in breast milk delay the 
conversion of beige to white adipose tissue which usually takes place during late infancy. 
Knowing that beige adipose tissue is inversely correlated to childhood obesity, authors 
have suggested that the prolonged presence of the metabolically active beige adipocytes 
could be the causal link between BF and reduced future obesity. To further investigate 
this hypothesis, studies using glucose uptake scans will be required as other body 
composition techniques (PEAPOD, DXA, MRI) are unable to differentiate between 






There are several limitations in the studies described above, including our study. 
Observational studies are not able to infer causation, therefore well designed RCTs 
would be required to assess the true effect of BF. These would be unethical when the 
weight of evidence for BF as being beneficial for both mother and child is considerable, 
and because, carrying out RCTs during the perinatal period is very sensitive. The 
definition of BF varies between different studies, therefore comparison of the results may 
not be reliable. In our cohort we categorized participants as predominantly breastfeeding 
(BF), predominantly formula feeding (FF) and mixed feeding based on the total duration 
of feeding mode over a period of 5 months (e.g. mixed: similar proportions of breast and 
formula milk). We were unable to capture data regarding the number of participants who 
fed their infants pumped breast milk. This could have potentially biased the results as 
pumped breast milk is also coming under the category of BF without however the non-
nutritional benefits of BF, such as skin to skin contact, slower suckling rate and improved 
satiety. Furthermore, data on feeding mode is gathered based on maternal report. 
Cultural, religious and social stigma could potentially lead mothers to false reporting of 
feeding patterns. Finally, the inability to control for confounders is a common critique of 
available literature. In our trial, due to the size/weight limitations of PEAPOD, participants 
were followed only up to 5 months post partum. Only a very small percentage (8.6%) of 
our cohort reported introduction of very small amounts of solid food by that point 
(irrespective of ethnicity), which ensures that our data is free from the confounding effect 
of caloric intake through solid food. 
 
4.3.4 Body composition and ethnicity 
 
Our study presents unique data on body composition based on ethnic origin. We showed 
that SA and White European infants have similar body composition and adipose tissue 
distribution up to 5 months of age. This is contrary to existing literature which show that 
SA infants have higher adiposity than White Europeans (16).  
 
SA are at higher risk of type 2 diabetes and cardiovascular disease than populations 
descended from White Europeans (56). They are known to have higher FM and lower 
FFM for a given BMI when compared to other populations (57). Furthermore, they have a 
tendency to store adipose tissue centrally (visceral fat) rather than peripherally 
(subcutaneous fat), which increases their cardiovascular risk further (15).  This adverse 
body composition has been shown to be present in childhood and even at birth (58, 59). 
Interestingly, this increased metabolic risk has been seen in SA migrants around the 





onset is ten years earlier than native population (56). UKPDS suggested that increased 
insulin resistance is the main cause of the observed cardiometaboilc risk (61). It was 
previously suggested that central adiposity is the link between ethnic origin and 
increased risk of insulin resistance. The above hypothesis is not enough to explain the 
pathophysiology observed as SA continue to exhibit higher insulin resistance even if they 
are matched for central adipose tissue amount (62). The above results led to the 
assumption that SA are genetically predisposed to have adverse metabolism as 
compared with people descended from white European populations. A recent systematic 
review on ethnic genetic heterogeneity using global data from DIAGRAM (Diabetes 
Genetics Replication And Meta-analysis) showed that presence of nucleotide 
polymorphisms predisposes SA to type 2 diabetes (Figure 4.9) but evidence is not strong 




Figure 4.9: Nucleotide polymorphisms associated with type 2 diabetes mellitus in SA and 
risk compared to White Europeans. KCNQ1 seems to have the strongest correlation; 
Adopted by Sohani et al (63) 
 
 
When studying the association between migration and non communicable diseases there 
are many factors that need to be taken into account (Figure 4.10). Except genes, 
exposures of subjects in pre-migration need to be carefully reviewed. In specific, the role 
of intrauterine exposure to malnutrition and its adverse effect on future metabolic 
diseases need to be considered, as the metabolic imprinting can be profound for many 





retained by migrants for many years before becoming acculturated to local customs and 
way of life (66). Therefore, although someone may consider that both native and migrant 
populations are exposed to the same environment, this may not be entirely true. Finally, 
data in the past has shown that migrants had limited access to education and healthcare 
services, suggesting that lower screening rates and preventative measures could be 




Figure 4.10: Factors associated with non communicable diseases in migrants. Genes 
and pre-migration status as well as post-migration lifestyle dictate the risk for non-
communicable diseases (NCD); Adopted from Montesi et al (68)  
 
 
Yajnik et al (16, 59) has extensively investigated body composition of SA infants living in 
India. After comparing newborns in Pune, India with White Europeans born in the UK 
concluded that SA infants are more centrally adipose resulting in increased insulin 
resistance from the early stages of life. These findings were further confirmed by Modi et 
al (69) who used MRI to show increased visceral and reduced subcutaneous adiposity in 
infants born in Asia compared with White European newborns in UK. These findings are 
not comparable with the results of our cohort. The above-mentioned studies, reviewed a 
high risk population prone to maternal malnutrition giving birth in Pune, India. Findings of 
these studies could be explained by the “thrifty phenotype” model which is closely related 
to maternal nutritional status (70). Our cohort consists of SA population with completely 
different maternal characteristics, both anthropometric (higher BMI and height) and 
socioeconomic (higher educational and socioeconomic status). Furthermore, antenatal 







The first large cohort to compare body composition differences between migrant and 
native population was published in 2009 (17). The study team assessed body 
composition in infants born in Pune, infants of SA origin born in Surinam (South America) 
and infants born to the population native to Surinam. Findings suggested that the “thin-
fat“ phenotype was still present in 4th-5th generation migrants but body composition 
differences with native population were attenuated when compared with infants born in 
Pune. In 2012, The London Mother and Baby study (71) assessed body composition 
differences between UK born infants of SA origin and White European infants using 
PEAPOD, showing that SA have lower FFM and higher central adiposity at 8 weeks post 
partum. The team suggested that the lower FFM is the potential link to the future adverse 
cardiometaboilc risk. Our study cohort has many similarities with the Surinam study. 
Maternal BMI (our study: 23.7, Surinam: 23.4), maternal diet patterns (majority non 
vegetarians), neonatal birthweight (our study: 3.090 kgr, Surinam: 3.159) and length (our 
study: 49 cm, Surinam: 48.7 cm) were similar between the SA populations. The authors 
of Surinam study describe the community of SA migrants as “closely knit” and genetically 
homogenous. Furthermore, the authors do not provide any data on the socioeconomic 
status of the participants which is relevant to the access to the local health system. We 
speculate that the difference in findings from our cohort is due to lifestyle and eating 
habits which may create an obesogenic intrauterine environment. We also question 
whether study participants had full access to healthcare services, including regular 
screenings, diet advice and educational sessions in the Surinam study. Regarding the 
London cohort we are able to identify many differences with our study which could 
explain the results. Mothers of SA origin in the London cohort were significantly shorter 
(our study: 1.65 m, London: 1.58) compared to our study. When compared to White 
Europeans, SA mothers were found to be more adipose in the London cohort (SA: 
SS=21, TR= 26.5 mm; Europeans: SS= 17, TR= 22.2 mm) whereas there was no 
between groups difference in our study. Of great importance half of the mothers were 
vegetarians as opposed to only 5% in our cohort. Finally, there was a statistical 
significant difference in GA between the two groups (SA: GA=39.4 weeks; Europeans: 40 
weeks, p<0.05), which was not observed in our study. We have previously showed in our 
study that maternal adiposity is related to offspring FM and also that lower gestational 
age is related to lower FFM at birth. Using data from the Minnesota experiment we 
proved that lower FFM can lead to rapid weight gain driven by predominantly FM 
accumulation (Chapter 3). Vegetarian diet is linked to low B12 levels and reduced protein 
intake (72). Given the link of low maternal B12 with offspring adiposity and insulin 
resistance we suggest that maternal diet could have directly affected neonatal body 
composition. Finally, low protein intake could have potentially contributed to lower FFM 






In one of the largest cohorts so far, cord leptin levels and skinfold thickness were 
compared between 4,649 Pakistani and 4,055 White British neonates born in Bradford, 
UK (74). Authors concluded that based on adjusted cord blood leptin levels offspring of 
Pakistani origin were more adipose at birth. Large sample size and definition of 
offspring’s ethnicity taking into account both maternal and paternal place of birth were the 
major strengths of the study. A closer look at the results though, puts the credibility of the 
conclusion under question. After adjusting for birthweight, authors were unable to show 
any between group differences in skinfold thickness. The difference in cord leptin levels 
was demonstrated after adjusting for birthweight. The higher leptin levels found in the 
Pakistani group doesn’t necessarily imply higher FM at birth. The raised leptin levels may 
be due to increased leptin expression by adipocytes as a result of adverse epigenetic 
programming. In favor of this hypothesis, authors present data revealing that differences 
in cord leptin levels attenuate (or even become non significant) after adjusting for 
maternal characteristics which could potentially affect  intrauterine programming (BMI, 
height, socioeconomic status). The Born in Bradford cohort has significant demographic 
differences to our study group. Mothers were only from Pakistani origin, had low 
socioeconomic status, had higher BMI and were shorter when compared to the SA 
population of our study.  
 
Findings of our study are in agreement with the Intergrowth 21st (75) and WHO 
multicentre Growth Reference study (76). After analyzing fetal and infant data across 8 
different populations it was suggested that growth is affected more by health, 
socioeconomic and environmental factors rather than ethnic and genetic characteristics 
which account only for <3% of total variability. Based on this evidence the above 
committees suggested universal growth standards in low risk populations, as defined by 
demographic, clinical, social and educational criteria. Our SA cohort shares many similar 
characteristics with the “low risk” Indian population studied in the Intergrowth trial (Table 
4.16). Maternal BMI was marginally higher in our site and mothers were taller. 
Birthweight was slightly higher in our cohort, likely due to higher maternal BMI. Birth 
length and HC at birth were identical to Intergrowth data suggesting that fetal 











 SA in our cohort Intergrowth 21st 
Maternal BMI (kgr/m2) 23.7 22.9 
Maternal Height (m) 1.65 1.57 
Birthweight (kgr) 3.065 2.900 
Birth length (cm) 49 48.6 
HC (cm) 33.9 33.1 
Table 4.16: Comparison of South Asian (SA) population participating in our cohort and 
Intergrowth 21st.In our study cohort mothers of SA origin were taller with higher BMI 
resulting in higher birthweight    
 
Our cohort involves participants of SA origin with good socioeconomic and educational 
status. 40% of the participants (mothers) were born in the UK (first generation migrants) 
and the remaining moved into the country at a very young age. The high educational 
status of our cohort may have raised the awareness of maternal imprinting to offspring, 
thus leading to healthier lifestyle options during the pre and antenatal periods. Of great 
importance, NHS has evolved during the last few years and a health policy regarding 
immigrants has been created (77). Ethnic minority groups share equal rights and time 
during consultations and the presence of translators, when required, ensures that all 
information provided is retained by the patients. Furthermore, leaflets translated in 
various languages have helped to raise awareness regarding the obesity epidemic and 
ways to prevent it. The high stature of our participants confirms the “healthy migrant 
effect”. According to this SA with greater financial means for maternal and child nutrition 
are more likely to migrate. The height of our participants reveals that they were free from 
the” maternal constraint effect” (78) as fetuses, in other words mothers of our cohort 
experienced an optimal intrauterine environment as fetuses. The similar total adiposity 
and adipose tissue distribution compared to native population is another clue of the non-
obesogenic intrauterine environment. 
 
In conclusion, we strongly believe that despite genotype being determined at conception, 
the phenotype is modulated and determined by environmental factors known as 
epigenetic mechanisms. Imprinted genes can be modified by environmental factors 
acting during the “plastic” period of preconception to early post natal life. Maternal 
behaviors can affect structural and functional development of tissues and determine the 
transgenerational transmission of non communicable diseases. As epigenetic effects 
may not be evident until later in life, it would be of great interest to examine the evolution 
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In our previous chapters we have demonstrated that adverse maternal characteristics, 
such as obesity, increased GWG and GDM are associated with increased infant 
adiposity up to 5 months post partum. Our results show that the link between adverse 
intrauterine environment and risk of future metabolic diseases is traced back to the early 
postnatal life, supporting the theory of intrauterine programming. Our findings suggest 
that intervention strategies to prevent the development of obesity and metabolic 
syndrome should be implemented during antenatal or even prenatal life, a period of 
developmental plasticity. Finding the link between maternal and fetal biomarkers with 
adverse infant anthropometry would allow a better understanding of the pathophysiology 
of intrauterine programming and would enable the identification of high risk individuals 
requiring targeted approach.  
 
5.1.1 Fetal anabolic fuels 
 
In 1952, Pedersen postulated that maternal hyperglycaemia is transferred to the fetal 
circulation via the placenta, which in turn stimulates fetal hyperinsulinaemia. Given the 
anabolic action of insulin and the preferential effect on FM, excessive exposure of the 
fetus to insulin leads to deposition of large amounts of body fat and neonatal macrosomia 
(2). The HAPO study, in a multinational cohort, confirmed the “Pedersen hypothesis” by 
showing that maternal glycaemia during OGTT is related to infant adiposity and 
macrosomia, a relationship mediated by increased fetal insulin (3). As maternal BMI is 
related to higher fasting and postprandial glucose levels (4) the HAPO research group 
tried to investigate if the observed relationship was driven by the effect of maternal BMI 
rather than hyperglycaemia per se. Data revealed that both maternal obesity and 
hyperglycaemia are independent risk factors of neonatal adverse outcomes with their 
combination having a stronger impact (5, 6). The independent relationship between 
maternal BMI and neonatal size highlighted the importance of nutrients other than 
glucose. Lipids, free fatty acids and amino acids which are also related to insulin 
resistance and are found to be raised in mothers with high BMI (7) may contribute to 
neonatal fat accretion (8). Data from animal studies and cell lines reveal that maternal 
adiponectin inhibits placental proliferation and attenuates the trophoblast transporter 
expression (9). The association between maternal obesity and hypoadiponectinaemia 
may lead to placental hypertrophy allowing more nutrients to fetal circulation and 







5.1.2 The role of leptin and adiponectin 
 
The role of leptin and adiponectin in human metabolism and during pregnancy has been 
extensively described in chapter 2. Leptin promotes energy expenditure by inhibiting 
lipogenesis and glycogenesis and by enhancing free fatty acid oxidization. Levels are 
positively correlated with adiposity and maternal BMI (11). On the other hand, 
adiponectin improves insulin sensitivity and low levels are observed in non-pregnant 
adults with type 2 diabetes mellitus and obesity (12). Data suggests that high molecular 
weight adiponectin (HMWA), rather than total, is implicated in the risk of metabolic 
syndrome, insulin resistance and cardiovascular disease in adults and children (13). Both 
leptin and adiponectin are present in fetal circulation from the early stages of pregnancy. 
The presence of mRNA and their receptors in many fetal tissues implies a role during 
intrauterine development (14, 15). Results of our systematic review, although not 
conclusive, revealed that both adipocytokines are positively correlated to adiposity at 
birth, with cord leptin levels negatively predicting weight gain and fat mass accretion up 




Mid gestation maternal biomarkers reflect maternal metabolic profile and intrauterine 
environment. While HAPO study concluded that maternal glucose levels and BMI at 28 
weeks of gestation were independently associated with infant adiposity and is likely to be 
mediated by increased fetal hyperinsulinaemia, the role of maternal insulin, leptin and 
adiponectin were not investigated. In addition the effects of these on FFM is not known. 
We hypothesise that the following two relationship exist between: 1) maternal BMI may 
mediate infant adiposity through hyperleptinemia, low adiponectin and raised insulin 
levels; and 2) cord blood leptin and adiponectin are reliable markers of neonatal adiposity 
at birth and early childhood (up to 5 months of age). If proven, these biomarkers may 
enable to identify children who are at risk of adverse metabolic intrauterine programming 
and develop strategies to minimize the risk. 
 
5.1.4 Research Questions 
 Is there any association between mid gestation maternal biomarkers (leptin, 
adiponectin, insulin, glucose) and infant body composition? 
 Is there any association between cord leptin and adiponectin with body 
composition, assessed by air displacement plethysmography (PEAPOD), at birth 






 Study if different patterns of neonatal body composition are related to mid-
pregnancy maternal metabolic markers (leptin, adiponectin, insulin, glucose) and 
early life biomarkers (cord blood leptin and adiponectin) 
5.1.6 Criteria 
 The current analysis includes participants from the main longitudinal, 
observational study described in chapter 3. For this reason inclusion and 
exclusion criteria remain the same as already described before 
 
5.1.7 Methods - Statistical analysis 
 
Paired maternal and infant data from the main observational, longitudinal cohort study 
was utilized. Maternal samples obtained during the 75 gr OGTT at 26-28 weeks of 
gestation were retrieved. Baseline samples during the OGTT (OGTT0) were analyzed for 
maternal leptin, adiponectin, glucose, insulin and c-peptide. Samples obtained 2 hours 
after the 75 gr glucose load (OGTT120) were analyzed for glucose, insulin and c-peptide. 
We utilized data obtained from the OGTT analysis to calculate beta cell insulin secretory 
capacity and insulin resistance using HOMA2 and HOMA-IR/ Matsuda index respectively. 
Cord blood samples were tested for leptin, adiponectin and c-peptide levels. Infant body 
composition was assessed at birth, 4 weeks and 5 months post partum using PEAPOD.  
 
5.2 Leptin- Adiponectin assays 
 
Leptin and adiponectin levels in both maternal and cord samples were measured using 
Enzyme-Linked Immunosorbent Assay (ELISA). This technique allows the detection and 
quantification of an antigen (protein) by using antibodies (Abs) directed against the 
antigen (Figure 5.1). All analyses were performed at the Clinical Sciences Research 
Laboratories (CSRL) at University Hospital of Coventry. 
 
5.2.1 Leptin Elisa 
 
All samples were removed from the freezer (-800C) and allowed to rest at room 
temperature for at least 30 minutes. 10 μL of sample were retrieved and analyzed using 
‘sandwich” ELISA (Quantikine ELISA, R&D systems, 3.5 hours assay). Leptin specific 
Abs had been pre-coated in each well. After the addition of the sample, leptin molecules 
were bound to the immobilized Abs. The plate was then washed to remove any unbound 





the new Ab allowed the “sandwich reaction” due to the ability to bind to different leptin 
epitopes.  The plate was then washed to remove any unbound enzyme linked Abs. 
Finally, a substrate (chromogen) was added to each well which was linked to the 
enzyme, resulting in a colour development (positive reaction) in proportion to the amount 
of bond leptin. The optic density of each plate was then measured using microplate 
reader at 450nm (spectrophotometer). 
 
5.2.2 Adiponectin Elisa 
 
Adiponectin was measured using “sandwich” ELISA (HMW and Total adiponectin ELISA, 
ALPCO, 4.5 hours assay). The same process described before was followed for 
adiponectin quantification. In addition, in order to quantify HMWA, a treatment enzyme 
(protease) to degrade total to HMWA (“digest low and medium weight adiponectin) was 
added to each sample. 
 
 




5.2.3 Calculating the results 
 
In order to extract the results a “standard curve” from the standards was created for each 
plate. The mean absorbance of the standards was plotted on the y axis and the 
concentration on the x axis. A best fit curve was fitted. For the leptin ELISA the curve 
was linear whereas for the adiponectin a 4 Parameter Logistic (sigmoid) curve was used. 
Concentrations extracted from the standard curves were multiplied by the dilution factor 
(100 for leptin, 5000 for adiponectin) in order to get the concentration present in each 
sample. Intra and inter assay co-efficient of variation was <5% for leptin and <10% for 







a)                                                               b) 
  
Figure 5.2: Standard curves fitted for a) leptin and b) adiponectin 
 
 
5.3 Insulin and c-peptide assays 
 
Maternal samples were analyzed for both insulin and c-peptide whereas cord samples 
only for c-peptide. We chose to use cord blood c-peptide as a marker of fetal beta cell 
function rather than insulin, as c-peptide is not affected (degraded) by haemolysis which 
is present in 15% of cord samples (16). C-peptide is an amino acid connecting the insulin 
A and B chains in the proinsulin molecule. Proteolysis of proinsulin results in equal 
amounts of insulin and c-peptide formation. Insulin, which is the active product, is 
metabolized in the liver having a short half life of 3 minutes. On the other hand, c-
peptide, the inactive para-product, is not extracted in the liver resulting in longer half life 
(35 minutes) and ten times higher plasma concentrations (17).  
 
Measurements of both insulin and c-peptide were performed using “sandwich” (non 
competitive) Radioimmunoassay (RIA) at George Eliot Hospital biochemistry department. 
Catherine Wood, principal clinical biochemist, was supervising the process. RIA is the 
technique of using radiolabelled Ag/Ab complexes to determine the concentration of an 
Ag (Figure 5.3). ROCHE assays were used for both insulin (Elecsys Insulin, cobas) and 
c-peptide (Elecsys c-peptide, cobas). Inter and intra assay co-efficient of variation was 









a)                                                                                                  
 
  
b)             
 
 
Figure 5.3: Principles of a) non competitive and b) competitive RIA 
 
5.3.1 Insulin and c-peptide RIA 
 
Standard curves were created using known quantity of radioactive Ag mixed with known 
amount of Ag specific Ab. The first step was to mix 20 μL of sample with Ag specific Ab 
and labeled Ag specific Ab in order to form a “sandwich reaction”. In order to separate 
the Ab bound Ag from the free particles, streptavidin microparticles were added to the 
solution allowing the Ab-Ag-labelled Ab complex to bind to the solid phase. The 
microparticles were then magnetically captured on the surface of an electrode and the 
radioactivity of the complex was measured using gamma sensors. Using the standard 
curves created we were able to calculate the concentration of the Ag (insulin or c-





5.4 Indexes of beta cell function and insulin sensitivity 
 
Insulin sensitivity or resistance underlies the development of type 2 diabetes or any 
degree of glucose intolerance. Elements of insulin sensitivity are the absorption of 
glucose by the peripheral tissues and the insulin mediated suppression of hepatic 
glucose production. Hyperinsulinaemic – euglycaemic clamp (HEC) is considered the 
“gold standard” method in assessing peripheral insulin sensitivity but the method is 
costly, invasive and not appropriate for large scale studies. For this reason many indexes 
based on either fasting or OGTT derived glucose/insulin levels have been created (Table 
5.1). Fasting indexes reflect hepatic insulin sensitivity whereas OGTT derived reflect both 
hepatic and peripheral sensitivity. During the OGTT, hepatic glucose production is more 
prominent within the first hour and glucose uptake by peripheral tissues during the 
second hour (18). In our study, maternal glucose and insulin/c-peptide levels were 
available at OGTT0 and OGTT120. We opted to use both a fasting (HOMA-IR) and an 
OGTT derived index (Matsuda index) to assess insulin sensitivity in our cohort. Both 
indexes used have a high correlation with reference HEC (HOMA-IR: r=-0.6, Matsuda: 
r=0.67) (19, 20).  
Table 5.1: Surrogate measures of insulin sensitivity. Fasting indexes reflect hepatic 
insulin sensitivity whereas OGTT derived reflect both hepatic and peripheral sensitivity; 
Adopted from Otten et al (19); I0 and I120: insulin levels at baseline and 120 minutes after 
75gr glucose administration; G0, G90 and G120: glucose levels at baseline, 90 and 120 
minutes after 75gr glucose administration; Gmean and Imean: mean glucose and insulin 





Stumvoll MCR (21) 18.8 − 0.271 × BMI − 0.0052 × I120 − 0.27 × G90 
Gutt (22) [75,000 + (G0-G120) × 0.19 × BW]/(120 × log [(I0 + I120)/2] × [(G0 + 
G120)/2]) 
Stumvoll ISI (21) 0.226 − 0.0032 × BMI − 0.0000645 × I120 − 0.00375 × G90 
OGIS (23) http://webmet.pd.cnr.it/ogis/ 
Matsuda (24) 10,000/√G0 x I0 x Gmean x Imean 
Fasting indexes  
HOMA-IR (25) (G0 × I0)/22.5 
QUICKI (26) 1/(log G0 + log I0) 
Revised QUICKI 
(27) 
1/(log G0 + log I0 + log NEFA) 
HOMA-%S (25) www.dtu.ox.ac.uk/homacalculator/index.php 





5.4.1 Homeostasis Model Assessment (HOMA) 
 
HOMA estimates pancreatic beta cell function (%B) and insulin sensitivity (%S) as 
percentage of a normal population. Model is based on the Turner and Holman 
assumption (1) that fasting glucose and insulin levels are determined by a hepatic-
pancreatic interaction (Figure 5.4). Healthy population and even patients with type 2 
diabetes mellitus (mild forms) have equal fasting insulin levels but fasting glucose levels 
vary at the individual level. Fasting hyperinsulinaemia is in proportion to increased insulin 
resistance whereas fasting hyperglycaemia is the “sensor” to stimulate deficient 
pancreatic cells to secrete normal basal insulin. In other words, fasting glucose reflects 
the pancreatic secretory capacity and fasting insulin reflects the insulin resistance (Figure 
5.5).  
 
In 1985, Matthews et al (25) expanded the model producing a linear equation of %B and 
introduced the term of insulin resistance (HOMA-IR) as the reciprocal of %S (100/%S). 
Ten years later, Levy et al (29) implemented in the formula values obtained by more 
advanced insulin/c-peptide assays and accounted for variations in hepatic and peripheral 
insulin resistance (Figure 5.5). Since 2004 HOMA2 calculator is widely available 
(https://www.dtu.ox.ac.uk/homacalculator/) and used in large scale studies defining 
insulin resistance as HOMA-IR>2.5 [(Glucose0 x Insulin0)/22.5]. Estimates from the 
HOMA2 correspond well (r= -0.6) with reference methods, such as HEC (19).   
 
 
 Figure 5.4: Beta cell dysfunction estimated by the insulin response. Adopted from 







Figure 5.5: HOMA model a) presented by Turner and Holmes and b) updated by Levy et 
al; Adopted from Tara et al (30) 
 
 
5.4.2 Matsuda Index 
 
In 1999 Matsuda and De Fronzo (24) compared OGTT derived insulin indexes with 
results obtained by reference HEC. Purpose of the clamp is to suppress liver 
gluconeogenesis and assess peripheral insulin resistance by infusing high doses of 
intravenous insulin, maintaining at the same time stable glucose levels by intravenous 
variable rate infusion. The rate of the glucose infusion mirrors the glucose uptake by 
tissues, indicating insulin sensitivity. After studying 153 subjects, who underwent both 
HEC and OGTT, they developed a model (http://mmatsuda.diabetes-
smc.jp/2pointssi.html) which was highly correlated (r= 0.73) with the glucose disposal 
obtained from the clamp. A Matsuda Index <2.5 (10,000/√Go x I0 X Gmean x Imean) is 
indicative of insulin resistance. 
 
5.5 Statistical analysis 
 
Data was analyzed using SPSS version 22. Statistical analysis was performed using “t 
test” or “Mann-Whitney U test” depending on data distribution (parametric or not). Results 
of the biochemical analysis were checked for potential outliers. Bivariate and partial 





interest. A subgroup analysis was performed comparing maternal biomarkers adjusting 
for GDM status and ethnicity. Regression models were used to assess any association 
between maternal and cord biomarkers with infant body composition. Data which was not 
normally distributed were log transformed and the effect size was presented as 
“percentage change”. Results were further adjusted for potential confounders. In order to 
eliminate the effect of GDM treatment, association between maternal biomarkers and 
neonatal data was examined only in the nGDM participants. The author performed all 
statistical analyses. The accuracy of the methods and results were reviewed by the Chief 




Maternal and cord blood data was available for 109 participants for all the biomarkers 
except HMWA. Due to an error (stop solution not added on time) during the ELISA 
analysis of HMWA, only 95 maternal and cord blood HMWA pairs were available for the 
final analysis (Figure 5.6). GDM was diagnosed in 16.5% of our participants who 




Figure 5.6: Consort diagram of available biomarkers during study visits; SA: South 





5.6.1 Maternal analysis 
 
Maternal characteristics are presented in Table 5.2. Our cohort included mothers with 
increased metabolic risk, fulfilling at least one of the risk factors for GDM, as indicated by 
NICE guidelines (31). Mean (SD) maternal BMI at 28 weeks of gestation (during OGTT) 
was 33.2 (6.9). After utilizing OGTT0 and OGTT120 glucose and insulin levels %B, HOMA-
IR and Matsuda indexes were calculated. Median (IQR) maternal leptin was 32.5 (23.3, 
42.8) ng/ml, mean (SD) of total and HMW adiponectin were 4.1 (1.6) μg/ml and 1.8 (0.9) 
μg/ml respectively. 
 
Table 5.2: Maternal characteristics during OGTT at 28 weeks gestation. Table provides 
information regarding maternal adipocytokines, glucose values and insulin resistance.                                        
*Median values with Interquartile range 
 
 
Maternal BMI positively predicted glucose levels at OGTT0 and OGTT120. Higher levels of 
BMI were positively correlated with higher insulin resistance, as indicated by HOMA-IR 
and Matsuda indexes. Higher leptin levels were noted with raising maternal BMI (r=0.62, 
p<0.01). Both total (r= -0.2, p=0.1) and HMW (r= -0.1, p=0.9) adiponectin were negatively 
related to BMI, without reaching statistical significance (Figure 5.7, Figure 5.8, Table 5.3).  
 
Maternal characteristics during 
OGTT (n=109) 
Mean (SD) 
Age (yrs) 32.2 (5.1) 
BMI (kg/m2) 33.2 (6.9) 
Gestational age (weeks) 27.9 (1.2) 
Leptin (ng/ml)* 32.5 (23.3, 42.8) 
Total adiponectin (μg/ml) 4.1 (1.6) 
HMWA (μg/ml) (n=95) 1.8 (0.9) 
OGTT0 glucose (mmol/L) 4.5 (0.4) 
OGTT120 glucose (mmol/L) 6.0 (1.4) 
%B 182.8 (51) 
HOMA-IR* 2.9 (2, 4.3) 






Figure 5.7: Outcomes of interest based on BMI categories. Higher BMI was correlated 
with higher insuln resitance, higher leptin and lower adiponectin levels 
 
 
 Figure 5.8: Scatter plots between Matsuda index, HOMA-IR, OGTT0 glucose 






 BMI at 28 weeks 
Dependent variables β co-efficient r value p values 
Matsuda index -0.127 -0.40 <0.01 
HOMA-IR* 1.9% 0.57 <0.01 
%B 3.55 0.45 <0.01 
OGTT0 glucose (mmol/L) 0.02 0.35 <0.01 
OGTT120 glucose 
(mmol/L) 
0.03 0.20 0.07 
Leptin (ng/ml)* 4.4% 0.62 <0.01 
Total adiponectin (μg/ml) -0.04 -0.15 0.1 
HMWA (μg/ml) -0.001 -0.1 0.9 
Table 5.3: Associations between maternal biomarkers and BMI at 28 weeks. BMI shows 
a moderate correlation with insulin resistance, pancreatic secretion and leptin levels. 
There is a weak correlation with glucose values at OGTT0 but not at OGTT120                                     
* Values represent percent increase (or decrease) in the response variable for every one-




In order to assess the metabolic effect of maternal adipocytokines, specifically their effect 
on insulin metabolism, we investigated their correlations with indexes of insulin 
sensitivity. Increased maternal leptin was weakly associated with increased insulin 
resistance (p<0.01). A weak negative association between both total and HMW 
adiponectin and insulin resistance was noted (p<0.05). After adjusting for maternal BMI, 
all associations attenuated except HMWA which remained statistically significant. 
Detailed data is presented in Table 5.4. Looking at the relationship between glucose 
measurements during OGTT as continuous variable and maternal adipocytokines we 

















Leptin (log.) Unadj. β p value Adjusted β p value partial r 
Matsuda* -0.03 <0.01 -0.01 0.2 -0.2 
HOMA-IR** 0.6 <0.01 0.3 0.6 0.3 
%B* 0.8 <0.01 0.2 0.3 0.1 
Total adip. 
(μg/ml) 
     
Matsuda 0.3 0.02 0.2 0.08 0.17 
HOMA-IR*** -1.2 0.4 -0.02 0.8 -0.1 
%B -4.3 0.2 -2 0.5 -0.1 
HMWA (μg/ml)      
Matsuda 0.41 0.05 0.44 0.02 0.2 
HOMA-IR*** -2.4 0.4 -2.2 0.2 -0.2 
%B -10.1 0.05 -10.3 0.02 -0.3 
 
b) 
Leptin (log.) Unadj. β p value Adjusted β p value partial r 
OGTT0* 0.57 <0.01 0.25 0.2 0.1 
OGTT120* -0.26 0.9 -1.1 0.1 -0.1 
Total adip. 
(μg/ml) 
     
OGTT0 -0.15 0.5 -0.002 0.9 -0.1 
OGTT120 -0.02 0.8 0.01 0.8 0.1 
HMWA (μg/ml)      
OGTT0 0.01 0.8 0.008 0.8 0.1 
OGTT120 0.01 0.9 0.04 0.8 0.1 
 
Table 5.4: Regression analysis between maternal biomarkers (independent variable) and 
a) insulin sensitivity/secretion indexes b) glucose values during OGTT (dependent 
variables); Unadjusted and adjusted for maternal BMI at 28 weeks. The correlation 
between maternal leptin and insulin resistance disappears after adjusting for maternal 
BMI                                                                                                                                                           
* 1% increase in the independent variable increases (or decreases) the dependent 
variable by x units                                                                                                                                                                            
** Values represent percent increase (or decrease) in the dependent variable for every 
1% increase in the independent variable                                                                                                                                            
*** Values represent percent increase (or decrease) in the response variable for every 




5.6.2 Maternal biomarkers and neonatal data 
 
In order to eliminate the effect of GDM treatment, analysis included mothers without the 
diagnosis of GDM (n=91). There was no correlation between maternal and cord 
adipocytokines (r=0.1, p>0.05) except a weak positive correlation in the case of total 
adiponectin (r=0.3, p=0.01). Maternal leptin was positively correlated with infant 





total and HMW adiponectin were negatively correlated with adiposity and birthweight, but 
once again without reaching statistical significance (Table 5.5).  
 
 




















19.7,                  
p=0.8 
Model 2 p=0.6 p=0.7 p=0.2 p=0.2 p=0.8 













0.731,                
p=0.9 
Model2 p=0.5 p=0.3 p=0.9 p=0.7 -1.0,  p=0.9 













Model 2 p=0.4 p=0.5 p=0.3 p=0.2 -4.5,  p=0.8 
 
Table 5.5: Regression analysis between maternal adipocytokines at 28 weeks gestation 
and neonatal anthropometry; Model 1: unadjusted, Model 2: adjusted for maternal BMI at 
28 weeks, maternal age, gestational weight gain, gestational age, gender and ethnicity                                                                                                    




Higher beta cell function (%B) and higher insulin resistance (HOMA-IR, Matsuda) at 28 
weeks gestation were correlated with higher adiposity and birthweight. Correlations 
became non significant after adjusting for maternal BMI. Glucose values during OGTT0 
and OGTT120 were positively related to neonatal FM and %FM. Maternal BMI at 28 
weeks was independently related to neonatal adiposity and birthweight, even after 
adjusting for maternal glycaemia. Cord c-peptide was strongly correlated with maternal 
insulin resistance and OGTT120 glucose levels, but not with maternal BMI or glucose 






















Birth FM (kgr) %FM FFM (kgr) Weight 
(kgr) 
Cord c-
peptide   
(pmol/lt) 
28 weeks gestation Β co-efficient (p value)  
BMI      
Model 1 0.008 (0.01) 0.157 (0.01) 0.009 (0.1) 0.017 (0.03) 0.1 (0.9) 
Model 2 0.007 (0.01) 0.126 (0.02) 0.004 (0.4) 0.011 (0.1) -0.2 (0.9) 
Model 3** 0.007 (0.01) 0.125 (0.02) 0.0013 (0.06) 0.02 (0.02) -1.5 (0.9) 
OGTT0      
Model 1 0.108 (0.01) 2.6 (0.01) -0.09 (0.4) 0.01 (0.9) 61.1 (0.1) 
Model 2 0.109 (0.01) 2.6 (0.01) -0.1 (0.1) 0.01 (0.9) 67.1 (0.1) 
Model 3 0.075 (0.1) 2.1 (0.03) 0.007 (0.2) 0.006 (0.6) 76.4 (0.1) 
OGTT120      
Model 1 0.036 (0.02) 0.86 (0.9) 0.009 (0.8) 0.04 (0.3) 31.2 (0.03) 
Model 2 0.036 (0.01) 0.8 (0.03) 0.020 (0.5) 0.06 (0.1) 30.1 (0.05) 
Model 3 0.032 (0.02) 0.7 (0.02) 0.004 (0.4) 0.05 (0.2) 30.3 (0.05) 
Matsuda      
Model 1 -0.012 (0.2) -0.2 (0.2) -0.04 (0.5) -0.05 (0.04) -19.6 (0.02) 
Model 2 -0.020 (0.01) -0.4 (0.04) -0.04 (0.04) -0.06 (0.01) -19.2 (0.03) 
Model 3 -0.013 (0.09) -0.3 (0.1) -0.03 (0.07) -0.05 (0.05) -22.8 (0.01) 
HOMA- IR*      
Model 1 0.002 (0.01) 0.04 (0.02) 0.001 (0.3) 0.003 (0.1) 159.3 (0.04) 
Model 2 0.002 (0.01) 0.05 (0.03) 0.001 (0.09) 0.003 (0.1) 154.3 (0.06) 
Model 3 0.001 (0.9) 0.04 (0.07) 0.001 (0.9) 0.002 (0.5) 253.9 (0.01) 
%B      
Model 1 0.001 (0.05) 0.01 (0.2) 0.002 (0.03) 0.003 (0.02) 0.5 (0.1) 
Model 2 0.001 (0.01) 0.014 (0.06) 0.001 (0.1) 0.002 (0.04) 0.5 (0.1) 
Model 3 0.006 (0.04) 0.008 (0.3) 0.001 (0.9) 0.002 (0.1) 0.7 (0.08) 
Table 5.6: Correlations between maternal characteristics at 28 weeks gestation, neonatal body composition and cord 
c-peptide. Maternal BMI and glucose levels independently predict neonatal adiposity. Insulin resistance, but not BMI, 
predict cord c-peptide levels Model 1: unadjusted, Model 2: adjusted for gestational weight gain, maternal age, 
gestational age, gender and ethnicity, Model 3: Model 2 + maternal BMI at 28 weeks gestation;                                                                                                                
* 1% increase in the independent variable increases (or decreases) the dependent variable by (coefficient/100) units;    





5.6.3 Cord adipocytokines, cord c-peptide and body composition at birth 
 
Cord c-peptide and body composition were available for 109 newborns. Mean (SD) BW 
was 3.368 (0.510) kgr and mean (SD) %FM was 11.3 (4.0) %. Median (IQR) cord leptin 
level was 7.3 (4.2, 11.8) ng/ml. Mean (SD) total and HMW adiponectin levels were 19.3 
(8.5) μg/ml and 10.7 (5.2) μg/ml respectively. Females were found to have numerically 
higher leptin [7.9 (4.6, 12.3) vs. 5.8 (3.1, 11.0) ng/ml, p=0.1] and adiponectin levels (19.5 
± 9.6 vs. 18.9 ± 8.8 μg/ml, p=0.7). Mean (SD) cord c-peptide levels were 500 (185) 
pmol/lt. Cord c-peptide was moderately related with all cord adipocytokines (r=0.3, 
p<0.01). Table 5.7 shows correlations between cord adipocytokines, cord c-peptide and 
measures of neonatal body composition. 1% increase in cord leptin levels were related to 
0.04% increase in %FM and 0.006 kgr increase in BW. Similarly both total and HMW 
adiponectin were positively related with neonatal adiposity. Adjustments for maternal 
characteristics and gender did not alter the results. Partial correlation (r) for %FM was 
0.3 for cord leptin, 0.2 for total and 0.3 for HMW adiponectin. Cord c-peptide levels were 
positively correlated with neonatal anthropometry without reaching significance and they 
revealed moderate positive correlation with cord adipocytokines (r=0.4, p<0.01) 
Table 5.7: Correlations between cord adipocytokines and neonatal body composition. 
Data suggests a weak correlation between cord adipocytokines and neonatal adiposity.                               
Model 1: unadjusted, Model 2: adjusted for gestational age, maternal BMI at 28 weeks, 
gestational weight gain, gender and ethnicity                                                                                                                                   
*1% increase in the independent variable increases the dependent variable by x units 
 
 
Cord samples FM %FM FFM BW 
Leptin (log)* Β co-efficient (p value) 
Model 1 0.003 (0.01) 0.04 (0.01) 0.004 (0.01) 0.006 (0.01) 
Model 2 0.002 (0.01) 0.03 (0.01) 0.003 (0.01) 0.005 (0.01) 
Total adip. (μg/ml)     
Model 1 0.005 (0,01) 0.1 (0.01) 0.004 (0.4) 0.005 (0.01) 
Model 2 0.004 (0,03) 0.08 (0.03) 0.003 (0.4) 0.003 (0.5) 
HMWA (μg/ml)     
Model 1 0.009 (0.01) 0.2 (0.01) 0.006 (0.4) 0.015 (0.1) 
Model 2 0.009 (0.01) 0.18 (0.01) 0.005 (0.6) 0.013 (0.1) 
C-peptide 
(pmol/lt) 
    
Model 1 0.0001 (0.1) 0.003 (0.3) 0.0001 (0.1) 0.0001 (0.08) 





5.6.4 Cord adipocytokines and body composition at Visit 3 (4 weeks) 
 
Mean (SD) neonatal age at visit 3 assessment was 34 (6) days. Cord adipocytokines and 
c-peptide remained positively correlated with measures of adiposity, weight and weight 
gain since birth, but p value was not reaching statistical significance. Adjustments for 




Cord samples FM %FM FFM Weight Weight 
gain 
Leptin (log)* Β co-efficient (p value)  
Model 1 0.002 
(0.02) 












     
Model 1 0.004 (0.2) 0.06 (0.2) 0.002 (0.7) 0.005 (0.4) 0.001 (0.8) 
Model 2 0.00 (0.2) 0.06 (0.2) 0.002 (0.7) 0.005 (0.4) 0.002 (0.6) 
HMWA (μg/ml)      
Model 1 0.005 (0.3) 0.06 (0.5) 0.009 (0.3) 0.014 (0.2) -0.001 
(0.9) 





     
Model 1 0.0001 
(0.2) 
0.003(0.2) 0.001 (0.5) 0.001 (0.9) 0.0001 
(0.2) 
Model 2 0.0001 
(0.5) 
0.001(0.7) 0.001 (0.5) 0.001 (0.8)  
Table 5.8: Correlations between cord adipocytokines, cord c-peptide and neonatal body 
composition at visit 3 (4 weeks). Cord biomarkers are not associated with body 
composition 4 weeks post partum;                                                                                                                       
Model 1: unadjusted, Model 2: adjusted for maternal age, gestational age, maternal BMI 
at 28 weeks, gestational weight gain, gender, ethnicity and feeding mode                                                                                                                                                  








5.6.5 Cord adipocytokines and body composition at Visit 4 (5 months) 
 
Mean (SD) neonatal age at visit 4 assessment was 161 (17) days. There was a shift from 
positive to negative correlation between cord leptin, cord c-peptide and infant 
anthropometry at 5 months post partum (Figure 5.9). After adjusting for covariates the 
correlation between cord leptin and %FM became significant (p=0.03). We were unable 
to demonstrate any association between total, HMW adiponectin and infant 
anthropometry at visit 5. All cord adipocytokines were negatively correlated with weight 
gain from birth to 5 months of age, with c-peptide reaching statistical significance (Table 
5.9). Subgroup analysis excluding cases with GDM did not alter the results.  
 
 
Figure 5.9: Trends between cord leptin, cord c-peptide and percentage fat mass (%FM) 
at birth and follow up visits. At visit 4 (5 months) relationship between cord biomarkers 
















Cord samples FM %FM FFM Weight Weight gain 
Leptin (log)* Β co-efficient (p value)  
Model 1 -0.002 (0.3) -0.03 (0.1) 0.003 (0.08) 0.001 (0.6) -0.004 (0.1) 
Model 2 -0.003 (0.1) -0.04 (0.03) 0.004 (0.05) 0.001 (0.8) -0.004 (0.2) 
Total adip. (μg/ml)      
Model 1 -0.001 (0.9) -0.007 (0.9) 0.002 (0.7) 0.0002 (0.8) -0.002 (0.8) 
Model 2 0.001 (0.8) 0.002 (0.9) 0.002 (0.7) 0.004 (0.7) -0.001 (0.9) 
HMWA (μg/ml)      
Model 1 0.004 (0.7) -0.01 (0.9) 0.012 (0.3) 0.014 (0.4) -0.001(0.9) 
Model 2 0.007 (0.5) 0.02 (0.8) 0.008 (0.4) 0.015 (0.4)  0.001 (0.9) 
C-peptide(pmol/lt)      
Model 1 -0.0001 (0.2) -0.002 (0.5) -0.0001 (0.3) -0.001 (0.1) -0.001 (0.03) 
Model 2 -0.001 (0.1) -0.005 (0.1) -0.0001 (0.6) -0.001 (0.1) -0.001 (0.03) 
Table 5.9: Correlations between cord adipocytokines, cord c-peptide and neonatal body 
composition at visit 4 (5 months). Cord leptin is correlated negatively with adiposity 
whereas adiponectin seems to have no predictive value in body composition evolution in 
the first 5 months of life;                                                                                                                                         
Model 1: unadjusted, Model 2: adjusted for gestational age, maternal BMI at 28 weeks, 
gestational weight gain, gender, ethnicity and feeding mode                                                                                                                                                  
*1% increase in the independent variable increases the dependent variable by x units 
 
 
5.6.6 Metabolic biomarkers, GDM and ethnicity 
 
We performed a subgroup analysis looking at maternal biomarkers’ patterns at 28 weeks 
of gestation after adjusting for GDM and ethnicity (Table 5.10). Participants with GDM 
(n=18) were found to have higher insulin resistance (HOMA-IR, Matsuda) and higher 
beta cell function when compared to the nGDM group (n=88). Serum leptin was noted to 
be significantly higher in the GDM group after adjusting for maternal BMI, age, 
gestational age and ethnicity (33.8 vs 32.5 ng/ml, p=0.05). On the other hand, there was 
no statistically significant difference between the groups for serum total and HMW 
adiponectin, with the GDM group though having consistently numerically lower levels 
(total: 3.9 vs. 4.2 μg/ml, p=0.8; HMWA: 1.8 vs. 2 μg/ml, p=0.3, Figure 5.10).  
 
At birth, offspring of GDM pregnancies had lower weight (3.201±0.288 vs. 3.407±0.538 
kgr, p=0.1), driven predominantly by lower FFM (2.820±0.205 vs. 3.011±0.419 kgr, 
p=0.06). Cord levels of leptin, adiponectin and HMWA were similar between the two 
groups. Despite no differences in measures of adiposity, offspring of GDM pregnancies 
were found to have higher c-peptide levels (610±245 vs. 478±164 pmol/lt, p=0.007). After 





remained significant. Addition of insulin resistance indexes (Matsuda, HOMA-IR) to the 
regression models attenuated the results (Table 5.11, Figure 5.11).  
 
We further assessed differences between South Asian (SA, n=15) and White European 
(n=87) population. After adjusting for confounders (including GDM status), markers of 
beta cell function and insulin resistance were similar between the two groups. There was 
no difference in maternal serum adipocytokines (Table 5.10, Figure 5.10).  
Neonatal data revealed that offspring of SA origin were lighter at birth (3.257±0.454 vs. 
3.405±0.504 kgr, p=0.2), with lower FM (0.302±0.148 vs. 0.411±0.176 kgr, p=0.02) and 
%FM (9.0±3.9% vs. 11.7±3.9, p=0.01). There was no difference in cord leptin and c-
peptide levels between the two groups, but the SA group was found to have lower 
adiponectin and HMWA. Results remained unchanged after adjusting for maternal and 
neonatal characteristics (Table 5.12).  
 
a) 
During OGTT GDM (n=18) nGDM (n=88) p value adjusted p 
Matsuda 2.5 (1.2) 4.8 (2.1) <0.01 <0.01 
HOMA-IR* 4.9 (3.5, 5.4) 2.7 (1.8, 3.7) <0.01 <0.01 
%B 199 (69) 181 (51) 0.2 0.8 
Leptin (ng/ml)* 33.8 (22.8, 
47.6) 
32.5 (24.6, 42.8) 0.9 0.05 
Total adip. 
(μg/ml) 
3.9 (1.6) 4.2 (1.6) 0.5 0.8 
HMWA (μg/ml) 1.8 (0.9) 2.0 (1.9) 0.5 0.3 
 
b) 
During OGTT SA (n=15) White 
Europeans 
(n=87) 
p value adjusted p 
Matsuda 4.5 (2.0) 4.3 (2.1) 0.7 0.2 
HOMA-IR* 2.4 (2, 3) 3 (2, 4.6) 0.1 0.2 
%B 175 (34) 186 (58) 0.4 0.3 
Leptin (ng/ml)* 29.8 (20.4, 
38.2) 
32.5 (23.3, 46.4) 0.3 0.09 
Total adip. 
(μg/ml) 
4.3 (2.1) 4.1 (1.5) 0.6 0.9 
HMWA (μg/ml) 1.7 (1.0) 1.8 (0.9) 0.6 0.6 
Table 5.10: Comparison of maternal biomarkers based on a) GDM status b) ethnicity. 
Mothers wth GDM have higher insulin resistance and leptin levels. Subgroup analysis 
based on ethnic background did not reveal any differences; data represent mean (SD) 
values                                                                                                                                    









Figure 5.10: Schematic representation of differences in maternal biomarkers based on a, 
b) GDM status and c, d) ethnicity. Asterisk suggests statistically significant difference 
 
a) 
 GDM (n=18) nGDM (n=88) p value 
Birthweight (kgr) 3.201 (0.288) 3.407 (0.538) 0.1 
%FM 11.6 (4.3) 11.2 (3.9) 0.7 
FM (kgr) 0.380 (0.160) 0.396 (0.181) 0.7 
FFM (kgr) 2.820 (0.205) 3.011 (0.419) 0.06 
Leptin (ng/ml) 10.8 (8.2) 8.8 (6.1) 0.2 
Total adip. 
(μg/ml) 
21.2 (13.1) 18.8 (8.2) 0.3 
HMWA (μg/ml) 10.9 (6.8) 10.8 (5.4) 0.9 
c-peptide (pmol/lt) 610 (245) 478 (164) 0.007 
 
b) 
Cord c-peptide (pmol/lt) β  co-efficient p value 
Model 1 140 0.005 
Model 2 150 0.003 
Model 3 110 0.03 
Table 5.11: a) Comparison of anthropometric measurements and cord blood biomarkers 
between offspring of GDM and nGDM pregnancies b) Regression analysis of cord c-
peptide levels. Infants of GDM pregnancies have higher cord peptide levels even after 
adjusting for maternal characteristics and infant anthropometry ; Model 1: adjusted for 
gender, birthweight, %FM, FFM, gestational age; Model 2: model 1 + booking maternal 










Figure 5.11: Association between cord c-peptide and fat mass (FM) in offspring of GDM 






 SA (n=15) White Europeans 
(n=87) 
p value 
Birthweight (kgr) 3.257 (0.454) 3.405 (0.504) 0.2 
%FM 9.0 (3.9) 11.7(3.9) 0.01 
FM (kgr) 0.302 (0.148) 0.411 (0.176) 0.02 
FFM (kgr) 2.954 (0.374) 2.994 (0.391) 0.7 
Leptin (ng/ml) 8.3 (5.6) 9.3 (6.6) 0.6 
Total adip. 
(μg/ml) 
14.4 (7.6) 20.1 (9.2) 0.02 
HMWA (μg/ml) 6.7 (3.5) 11.6 (5.6) 0.03 
c-peptide (pmol/lt) 470 (182) 506 (186) 0.5 
Table 5.12: Comparison of anthropometric measurements and cord blood biomarkers 
between offspring of SA and White European descent. SA infants have lower leptin 
(numerically) and adiponectin levels, driven by lower FM. There are no signs of early 






Our study reveals five key findings: i) Increased insulin resistance, characterizing 
maternal obesity and GDM, is positively related to increased fetal adiposity and mediated 
by higher cord c-peptide levels; ii) Offspring of GDM pregnancies have higher c-peptide 
levels for a given FM, which is suggestive of early development of insulin resistance; iii) 


























and neonatal adiposity; iv) Maternal glycaemia in the sub diabetic range and maternal 
BMI independently predict neonatal adiposity and v) Cord blood adipocytokines are 
markers of neonatal adiposity, with cord leptin and c-peptide levels negatively predicting 
adiposity and weight gain at 5 months of age. 
 
5.7.1 Maternal insulin resistance: “the missing link” 
 
Maternal BMI and GDM are factors contributing to the developmental programming of 
obesity and metabolic disease (32), with adverse phenotype being present at birth (6, 
33). Maternal obesity is characterized by higher fasting and postprandial glucose levels 
(4) raising the question of whether the association between hyperglycaemia and neonatal 
fat mass is due to BMI rather than hyperglycaemia per se. Performing a subgroup 
analysis in the nGDM group in an attempt to eliminate the effect of GDM treatment, we 
showed that maternal glycaemia in the sub diabetes range during OGTT (OGTT0 and 
OGTT120) and maternal obesity independently predict neonatal adiposity. Regarding 
maternal hyperglycaemia, we observed a stronger effect size of glucose levels at OGTT0 
on neonatal %FM (β co-efficient: OGTT0= 2.1 %FM vs. OGTT120=0.7 %FM). Using 
surrogate markers of insulin sensitivity (HOMA-IR, Matsuda) we showed that insulin 
resistance is the common denominator for both conditions, leading to hyperfunctioning of 
beta cells (raised %B) in order to overcome the resistance and maintain euglycaemia. 
Furthermore, we demonstrated that higher insulin resistance is linked to higher neonatal 
hyperinsulinaemia (indicated by cord c-peptide levels), increased neonatal adiposity and 
birthweight.  
 
In an attempt to investigate the missing link between maternal intrauterine environment 
and neonatal body composition we looked at associations between maternal metabolic 
profile and cord blood biomarkers. Of great interest is the fact that despite the correlation 
between insulin resistance and fetal hyperinsulinaemia we were unable to demonstrate 
any direct association between maternal BMI, glucose levels during OGTT and cord c-
peptide, except a borderline correlation with OGTT120 values (β=30.3, p=0.05). Given the 
fact that maternal insulin does not cross the placenta (34) the above observation can be 
explained by the “fuel mediated teratogenesis” hypothesis developed by Freinkel (35). 
According to this, a variety of nutrients in addition to glucose may be transported from 
maternal to fetal circulation across the placenta, stimulating fetal insulin production and 
leading to increased adiposity. Insulin resistance is related to raised serum glucose, 
triglycerides, free fatty acids and amino acids levels in maternal circulation. The 





and adiposity (36). Studies from Schaefer et al (7) and Di Cianni et al (37) have 
supported the above hypothesis by showing that maternal lipids and amino acids are 
linked to macrosomia independent of maternal glucose levels and BMI. In our cohort, 
cord c-peptide levels were positively related to neonatal fat mass and weight, albeit not 
reaching statistical significance. We speculate that this is due to sample size and a 
clinically important correlation between fetal hyperinsulinaemia and adiposity at birth 
really exists. Evidence from the HAPO study supports our theory (3). After examining the 
association between 19,885 cord c-peptide samples and neonatal anthropometry they 
suggested an approximate effect size of 0.4gr in birthweight and 0.003% in %FM for 
every 1pmol/L increase in cord c-peptide levels. Results of our cohort are very similar 
suggesting an effect size of 0.1 gr for birthweight and 0.002% for %FM. Overall, we 
report that the effect of adverse intrauterine environment on neonatal body composition 
is mediated by increased fetal hyperinsulinaemia.  
 
5.7.2 Development of early insulin resistance 
 
Treatment of GDM is known to reduce perinatal adverse outcomes (38) but not the risk of 
future obesity (39). Catalano et al (40) has shown that pregravid BMI is related to 
increased fetal insulin resistance even after adjusting for neonatal FM. Consistent with 
these findings, Luo et al (41) proved that insulin resistance during OGTT is related to 
increased cord insulin and reduced fetal glucose to insulin ratio. The above results 
suggest that insulin resistance may be present even at birth in pregnancies complicated 
by maternal adverse outcomes. Our study is the first to assess the association between 
maternal and neonatal biomarkers with offspring’s body composition obtained by 
objective measures of adiposity. We reveal that optimal glycaemic control in pregnancies 
complicated by GDM reduces neonatal macrosomia and adiposity but fails to improve 
offspring’s metabolic trajectories. We report that offspring of pregnancies complicated by 
GDM, despite maternal glucose optimization, have higher cord c-peptide levels for a 
given FM compared to the nGDM group, suggesting the presence of in utero beta-cell 
dysfunction and/or insulin resistance. Fetal exposure to adverse maternal intrauterine 
environment before the diagnosis of GDM seems to alter structural and functional 
development of organs leading to early life insulin resistance. It is interesting to note that 
recent HAPO follow-up study showed that maternal fasting and post-load glucose levels 
at OGTT predicts offspring fasting and post-glucose levels, respectively (42).  
 
Cord blood glucose levels were not available in our study therefore we used cord c-





insulin does not cross the placenta (43) and fetal insulin is the main growth and anabolic 
factor during intrauterine development, favoring fat to fat free mass deposition (44). 
However, cord blood c-peptide levels except pancreatic insulin secretion may also reflect 
insulin sensitivity (8). One of the main limitations of this approach is that administration of 
intravenous glucose (in cases of GDM pregnancies) during delivery could potentially bias 
the results by transiently increasing fetal insulin secretion. Although we recognize the 
above limitation we speculate that it is unlikely to contribute to our findings.  In our study, 
all pregnancies were delivered at the Delivery Suite of George Eliot Hospital, in 
Nuneaton, UK. Trust guidelines dictate that all pregnancies complicated by GDM should 
have a very tight glucose control during delivery, achieved by the implementation of 
variable rate insulin infusion (VRII). Purpose of the protocol is to maintain maternal 
glucose levels between 4-7.8 mmol/lt by simultaneous infusion of glucose solutions and 
insulin.   
 
5.7.3 The role of leptin and adiponectin 
 
Adipose tissue has been recognized as an endocrine organ contributing to the 
complexity of the “obesity genesis” (45). The most biological active and well described 
adipocytokines are leptin and adiponectin. Leptin inhibits the anabolic effect of insulin, 
causing reduced lipogenesis, reduced glycogenesis and increased fattyacid oxidation 
(46). Raised leptin levels has a direct, suppressive effect of pancreatic insulin production 
(47). Obesity is characterized by insulin and leptin resistance, with levels being in 
proportion with BMI and visceral adiposity (48). Our results are in agreement with the 
above literature. We found that maternal BMI is positively related to leptin levels during 
pregnancy. We also demonstrated that higher leptin levels are related to higher insulin 
resistance. The presence of leptin resistance is confirmed by the positive correlation 
between leptin and beta cell secretory function, indicated by %B. We were unable to 
demonstrate any correlation between maternal leptin levels and cord leptin levels or 
neonatal anthropometry. Our findings confirm the “two compartment model” between 
maternal and fetal circulation suggesting that maternal leptin cannot cross the placenta 
due to its high molecular weight (49).  
 
Adiponectin has a pivotal role in energy homeostasis, inflammation and cell proliferation. 
Low levels are observed in cases of obesity, insulin resistance, type 2 diabetes mellitus 
and GDM. The HMW isoform has been shown to be more metabolically active and more 
closely related to insulin sensitivity when compared to total adiponectin (13). In our 





shown a negative correlation with insulin resistance but not with glucose levels during 
OGTT. After assessing indexes of maternal metabolic health we were unable to 
demonstrate any superiority of HMW over total adiponectin. In contrast to our results, 
Fisher et al (50) showed that in Indo-Asian males (n=34), adiponectin was negatively 
correlated with OGTT120 values (stronger association with HMWA). Hara et al (51) 
showed that both total and HMWA are related to insulin resistance in Japan adult 
population (n=171) but after adjusting for maternal BMI and gender only HMWA 
remained significant. Ethnic variability and small sample size are the most likely 
contributing factors for these discordant results. Furthermore, the physiology of 
adiponectin is different during pregnancy and affected by placental signaling (fetal 
adiponectin levels reveal the nutritional status of the fetus through placental signaling), 
thus direct comparison may not be reliable (52). Adiponectin values in serum and 
adipose tissue drop after mid pregnancy in an attempt to promote nutrient mobilization to 
the growing fetus (53).  
 
Following the results of our systematic review we tried to assess the predictive value of 
cord blood biomarkers in neonatal adiposity up to 5 months of age. One of the main 
strengths of our study was the use of objective measure of adiposity (PEAPOD) to 
calculate body composition. Mean cord blood adiponectin (19.3 μg/ml) was almost five 
times higher compared to maternal levels (4.18 μg/ml), findings consistent with current 
literature (54). Although our mean cord blood leptin level was higher, the median levels in 
our study (7.3ng/ml) were similar to the results of our systematic review (mean cord 
leptin = 9.1ng/ml) and to those presented by Karakosta et al (mean cord leptin = 7.7 
ng/ml). Our results reveal that cord leptin and adiponectin are positively associated with 
adiposity at birth, suggesting these are useful objective markers for adiposity. The 
association between cord leptin, infant FM and weight gain remained positive at 4 weeks 
but shifted to negative at 5 months post partum. This was similar to what was seen in our 
systematic review. As already extensively described in chapter 2, we speculate that 
infants with higher leptin levels develop a ‘compensatory behavior’ driven by the 
anorexigenic effect of leptin in early postnatal life. In order to maintain positive energy 
balance ensuring adequate brain and visceral organ development leptin’s full metabolic 
effect is not exerted until two weeks post partum (55), observation which could potentially 
explain the positive correlation with body composition at 4 weeks. We were unable to 
show any consistent patterns between cord adiponectin levels and body composition 








5.7.4 The role of cord c-peptide 
 
One of the notable findings of our analysis is the correlation between cord c-peptide and 
body composition in the early post natal life. C-peptide seems to parallel leptin, having a 
positive correlation with adiposity in the first 4 weeks, shifting to negative at 5 months of 
age. The effects of fetal and neonatal insulin on hypothalamic development have not 
been extensively studied in vivo due to the hypoglycaemia cross effect. In humans, 
hypothalamic development occurs during gestation and early post natal life. One of the 
most important components of hypothalamus is the arcuate nucleus (ARC), playing an 
important role in energy homeostasis and appetite regulation. Projections from ARC 
develop during pregnancy with further refinements occurring in the early post natal period 
(56). Similarly to leptin, data from neuronal cell lines suggest that insulin has a 
neurotrophic action participating in neurite outgrowth development (57). Perinatal 
hyperinsulinaemia may be a programming factor causing malformation of hypothalamic 
structures and future obesity. Animal studies showed that early post natal insulin 
administration leads to increased hyperphagia, obesity and insulin resistance in 
adulthood (58, 59). Blockage of central insulin signal in genetically modified rodents 
exposed to high maternal diet led to restoration of ARC projections and normalization of 
metabolic profile (60). In cases of adverse intrauterine environment, insulin seems to be 
one of the metabolic hormones affecting hypothalamic development (Figure 5.12) (61). 
Maternal diabetes and obesity, resulting in fetal hyperinsulinaemia, have been shown to 
impact on the structure of the ARC by promoting orexigenic to anorexigenic neuron 
formation (62). We speculate that the negative correlation with infant adiposity observed 
at 5 months is predominantly driven by higher leptin levels rather than a direct effect of c-
peptide per se, as cord c-peptide and leptin levels are weakly-positively correlated 
(r=0.35, p=0.01). It would be of great interest to follow this cohort in the future to 
investigate whether cord c-peptide can predict future adiposity through adverse 









Figure 5.12: Role of metabolic hormones in the development of hypothalamic circuitry; 
ARC: arcuate nucleus; GIT: gastrointestinal tract; PVN: paraventricular nucleus; LHA: 
lateral hypothalamic area; DMH: dorsomedial nucleus; NTS: nucleus of solitary tract; 
Adopted from Cottrell et al (63)  
 
 
Limitation of our study is the fact that cord HMWA levels were not available for 14 
neonates due to laboratory error during ELISA analysis. The main strength of our study is 
the use of PEAPOD, a direct method of assessing body composition, instead of fat mass 
equations derived by skinfold thickness measurements. Our study, despite the relative 
small number, shares common characteristics and findings with the landmark HAPO trial 
(Table 5.13) (3). Basic demographics are common between the two groups and both 
results support the theory that maternal hyperglycaemia and BMI independently predict 
neonatal adiposity, a relationship mediated by fetal hyperinsulinaemia. The discordance 
between %FM and cord c-peptide in the two studies can be attributed to the different 
methods of assessing neonatal adiposity (PEAPOD vs. FM equations). 
Table 5.13: Comparison of maternal and neonatal characteristics between our study 
(PEAPOD) and HAPO. Our cohort included high risk pregnancies with higher maternal 
BMI. Despite similar FM at birth, cord c-peptide levels were discordant. HAPO study 
used anthropometric indexed to derive infant adposity; Data represent mean (SD) values 
 PEAPOD study (n=109) HAPO (n=19,885) 
Maternal BMI (kgr/m2) 32.6 (6) 27.5 (5) 
OGTT0 (mmol/l) 4.5 (0.4) 4.5 (0.4) 
OGTT120 (mmol/l) 6.0 (1.4) 6.2 (1.3) 
Gestational age (weeks) 39.2 (1.4) 39.4 (1.6) 
Birthweight (kgr) 3.368 (0.510) 3.308 (0.505) 
%FM at birth 11.3 (4) 11.3 (3.7) 





In conclusion, we showed that maternal hyperglycaemia in the sub diabetes range and 
maternal obesity independently predict neonatal adiposity, a correlation mediated by fetal 
hyperinsulinaemia. We demonstrated that despite optimal glycaemic control, offspring of 
pregnancies complicated by GDM are metabolically compromised at birth, suggesting 
that adverse metabolic programming has already taken place by the time of GDM 
diagnosis. We also revealed that cord leptin and c-peptide may be useful markers in 
predicting future adiposity by adverse intrauterine programming, thus allowing early 
identification of high risk groups with a single blood test. Follow up studies of our cohort 
with body composition assessment in childhood and adolescence is crucial in order to 
understand the long term effects of maternal metabolic environment and the predictive 
value of cord blood biomarkers in future obesity. If prevention is the key to tackle the 
obesity epidemic, preconception and early postpartum periods may be an important 
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Comparison of fat mass equations and 































Birthweight and BMI have been widely used to identify risk of future obesity and 
metabolic diseases. Evidence suggests a “U” shaped association between weight at birth 
and future obesity (1), with low birthweight having a stronger effect when compared to 
macrosomia (2). BMI is derived from two simple anthropometric measurements (weight, 
height) allowing for precision, accuracy and repeatability of the results. Higher BMI 
values are related to higher prevalence of type 2 diabetes mellitus, hypertension and 
dyslipidaemia, traced from childhood to adulthood (3, 4). Both birthweight and BMI are 
poor indicators of nutrition and growth as they are unable to differentiate between FM 
and FFM. BMI changes during childhood are more likely to reflect changes in FFM rather 
than FM (5). Furthermore, the relationship between BMI or weight and percentage of FM 
differs between various populations. Asian adults are known to have up to 5% higher FM 
for a given BMI when compared to White Europeans (6).  
In previous chapters, we have extensively described the role of intrauterine programming 
on the development of future diseases. In order to understand the pathogenic 
mechanisms and natural course of diseases data on body composition is required. 
Objective techniques of assessing neonatal body composition, such as MRI, DXA and 
ADP, have been shown to provide accurate and reliable results. The majority of these 
methods incorporate assumptions (e.g. density of FFM, total lung volume) but as the 
results are derived after a combination of measurements, the importance of these 
assumptions is minimized (7, 8). Despite the recent progress in mapping body 
composition during the early post natal period, objective techniques remain not widely 
available and are predominantly used for research purposes. To address these 
limitations, anthropometric equations, based on epidemiological data, have been created 
and are currently cited in many studies (9, 10).  
6.1.1 Anthromopetric fat mass equations 
 
There are currently four commonly used equations to estimate FM in infancy (Table 6.1). 
Variables such as gender, ethnicity, gestational age, length, weight and skinfold 
thickness are taken into account. Catalano et al (11) used Total Body Electrical 
Conductivity as the reference method, whereas others (12, 13, 14) have used Air 
Displacement Plethysmography (ADP). Despite being widely cited, there is limited data 
on the validation of these equations in specific age groups. As a general rule, equations 






Table 6.1: Equations for infant fat mass (FM; kgr) estimation. Weight, length and skinfold 
thickness from different sites are used to derive FM; Adopted from Cauble et al (15)                                                                                                                                                                                       
ADP: Air Displacement Plethysmography, TOBEC: Total Body Electrical Conductivity 
 
6.1.2 Anthropometric indexes 
Anthropometric indexes have been used as practical alternatives and as a proxy to body 
composition. To be used as a measure of adiposity indexes need to fulfill two criteria: i) 
they should be correlated with adiposity and ii) they should be independent of association 
with the denominator (16). Although the first criterion is widely investigated, studies 
addressing the second are limited (17, 18). BMI (weight/length2), ponderal index 
(weight/length3), weight for length, waist circumference for length and the sum (total 
adiposity) or ratio (central adiposity) of sub scapular and triceps skinfold thickness are 
the most commonly used body composition indexes  (19).  
 
6.1.3 Hypothesis 
Defining body composition during the early stages of life would allow a better 
understanding of intrauterine programming and the association with future metabolic risk. 
As objective measures of assessing body composition are not yet widely available, fat 
mass equations using skinfold thicknesses and anthropometric indices are used as 
surrogate markers of adiposity. We hypothesize that these markers are closely related 
and in agreement with body composition measurements obtained by a reference method, 
PEAPOD. 







−0.012 – 0.064*gender(1 = male; 0 = female) + 0.0024*age 
(days) – 0.150*body weight (kg) + 0.055*body weight2 
(kg)2 + 0.046*ethnicity (1 = Hispanic; 0 = not Hispanic) + 
0.020*sum of 3 skinfolds (triceps, subscapular and thigh) 




0.54657 + 0.39055 * Birth weight (g) + 0.0453*Flank 
Skinfold (mm) – 0.03237* Length (cm) 
TOBEC 194 1-3 
Lingwood 
(13) 
FFM = 0.057 + 0.646 * weight (kg) - 0.089 * gender (1 = 
male; 2 = female) + 0.009 * length (cm)                                                        
FM = weight – FFM 
ADP 77 0-4 
Aris (14) −0.022 + 0.307 * weight (kg) - 0.077 * gender (1 = male; 0 = 
female) - 0.019 * gestational age (week) + 0.028 * 
subscapular skinfold (mm) 





6.1.4 Research questions 
 How good are the associations between the commonly used fat mass equations, 
anthropometric indices and measurements obtained by PEAPOD? 
6.1.5 Outcome 
 Compare the data derived from the use of fat mass equations and anthropometric 
indexes are similar to these obtained from PEAPOD 
6.1.6 Criteria 
The current analysis includes participants from the main longitudinal, observational 
cohort study described in chapter 3. For this reason inclusion and exclusion criteria 
remain the same as already described before. 
 
6.1.7 Methods – Statistical analysis 
Data from the main longitudinal, observational cohort study was reviewed. 
Anthropometric measurements obtained at birth and follow up visits were analyzed and 
combined to calculate anthropometric indexes and FM equations. 
Two different FM estimation equations (13, 14) were validated at birth, 4 weeks and 5 
months against data obtained from ADP measurements (PEAPOD measurements at 
birth and during follow up visits). Due to lack of data in our dataset (flank and thigh 
skinfold thickness) we were unable to validate Deierlein (12) and Catalano (11) 
equations. All data was assessed for normality. Paired-sample t test was used to detect 
differences between the estimation equations and the reference criterion. Regression 
analysis was used to assess the accuracy of each estimation equation against the 
reference method. To be considered accurate, the regression line should be the same 
with the line of equality (x=y) or in other words the slope of the regression line should not 
deviate significantly from 1.0. Precision of the equations was assessed using Lohman’s 
criteria (20). R2 and Standard Error of Estimate (SEE) were calculated for each equation. 
A SEE between 2 and 3% of fat mass is desirable and classified as very good whereas a 
SEE >4.0% is considered poor. A R2 value <0.64 was considered the cut off to define 
poor agreement between the two methods. Agreement of the methods was also 
assessed using Bland Altman analyses. Mean difference and 95% limits of agreement 
were calculated (21).  
In order to evaluate which anthropometric index best predicted FM and FFM at birth, 4 
weeks and 5 months, multiple linear regression models were created. %FM, FM and 
FFM values measured by PEAPOD were assessed for normality and constituted the 





index (PI), weight to length (Wt/length), waist circumference to length (WC/length) and 
sum of triceps and subscapular skinfold thickness (TR+SS) were examined. Models were 
adjusted for gender, gestational age or postnatal age at estimation. Statistical analysis 




A consort diagram of available data is detailed in Figure 6.1. Infant anthropometry at 
birth, 4 weeks and 5 months is presented in Table 6.2. 
 
  
Figure 6.1: Consort diagram of available anthropometry during study visits. Data fro 192 








Table 6.2: Maternal-Infant characteristics and measurements by reference criterion 
(PEAPOD) at birth, visit 3 (4 weeks) and visit 4 (5 months) 
 
 
6.2.1 Fat mass at birth 
 
At birth, significant mean difference was found between the reference criterion and 
Lingwood equation (p<0.01), whereas Aris equation provided similar results to reference 
method (p=0.1; Table 6.3). After applying regression to assess accuracy and precision, 
we found that regression slope differed from 1.0 for both equations. Poor agreement was 
found between criterion and the two equations with very low R2 values and high SEE 
values ranging from 0.175 to 0.172 (Table 6.4).  
 
Agreement was further checked applying Bland-Altman analysis (Table 6.4). The mean 
difference between criterion and Lingwood equation was -0.4 kgr with 95% limits of 
agreement of -0.85 kgr, 0.05 kgr. Mean difference between criterion and Aris equation 
was 0.02 kgr. 95% limits of agreement were -0.488 kgr, 0.448 kgr. There was no 






 Birth (n=225) Visit 3 (n=218) Visit 4 (n=192) 
Age (days) 2 ± 0.3 32 ± 4 158 ± 20 
Gender M: 102, F: 123 M: 99, F: 119 M: 90, F:102 
Ethnicity Europeans: 191 
Asians: 30                 
Africans: 4 
Europeans: 188 
Asians: 26                 
Africans: 4 
Europeans: 164 
Asians: 24                 
Africans: 4 
Length (cm) 49 ± 2 54 ± 2 65 ± 2 
Triceps (mm) 7.0 ± 2.8 8.8 ± 2.1 12.1 ± 3.1 
Subscapular 
(mm) 
6.8 ± 2.5 8.6 ± 1.9 10.4 ± 2.9 
%FM  10.6 ± 4.2 17.4 ± 4.8 26 ± 5.6 
FM (kgr) 0.361 ± 0.175 0.770 ± 0.282 1.958 ± 0.562 





6.2.2 Fat mass at 4 weeks (visit 3) and 5 months (visit 4) 
 
Mean differences (p<0.05) were found between the criterion and the equations at 4 
weeks and 5 months measurements. The slope measured by regression differed by 1.0 
for both equations at both time points. R2 values remained consistently very low with very 
high (>4%) SEE values. Bland-Altman analysis revealed no agreement between either of 




Method FM (kgr) 




ADP (reference) 0.361 ± 0.175 0.770 ± 0.282 1.958 ± 0.562 
Lingwood 0.792 ± 0.166 1.130 ± 0.205 2.113 ± 0.357 
Aris 0.334 ± 0.169* 0.699 ± 0.220 1.681 ± 0.355 
Table 6.3: Comparison of fat mass (FM) assessment by reference method (PEAPOD) 
and equations at birth, 4 weeks (visit 3) and 5 months (visit 4). Aris equation provided 
similar FM values with PEAPOD at birth but not at follow up visits                                                                                                










Regression analysis Bland-Altman 
Slope  R2 SEE Mean dif. 95% limits of 
agreement 
Birth      
Lingwood  0.02 0.001 0.175 -0.40 -0.85, 0.05 
Aris 0.01 0.001 0.172 0.02 -0.44, 0.48 
4 weeks      
Lingwood  0.09 0.005 0.282 -0.35 -0.99, 0.29 
Aris 0.1 0.008 0.283 0.68 0.02, 1.34 
5 months      
Lingwood  0.07 0.002 0.497 -0.15 -1.42, 1.12 
Aris 0.2 0.016 0.568 0.27 -0.90, 1.44 Table 6.4: Comparison of criterion method (PEAPOD) and fat mass (FM) equations 
using regression and Bland Altman analysis. Data revealed persistently low R2 and 








a)                                                                  b)  
 
Figure 6.2: Bland Altman plot of fat mass (FM) predicted by a) Lingwood and b) Aris 
equations against reference criterion (PEAPOD) at birth. Middle line represents the mean 
difference between equation studied and reference criterion and upper/lower lines 
represent 95% limits of agreement  
 
6.2.3 Prediction of body composition by anthropometric indexes 
We used multiple regression models adjusted for gender, gestational age and age at 
assessment. Five different indexes were compared at birth, 4 weeks and 5 months post 
partum. FM, %FM and FFM obtained from PEAPOD measurements were used as 
reference values.  
Table 6.5 shows the relationship between anthropometric indexes and body composition. 
At birth, PI was the best predictor of FM (R2=0.07) and %FM (R2=0.06) whereas 
WC/length best predicted FFM (R2=0.21).  At 4 weeks, WC/length remained the best 
predictor of FFM (R2=0.03) but was also superior in predicting FM (R2=0.02) and %FM 
(R2=0.03). At 5 months, the analysis revealed SS+TR as the best predictor of FM 
(R2=0.03) and %FM (R2=0.03). 
Data in Table 6.5 reveal that the relationship between anthropometric indexes and body 
composition was very weak at all time points, with values ranging from 0.006 to 0.22. 
Consistent with the above observation, the effect size on body composition remained 
extremely low for all indexes, as indicated by the β co-efficient value. All indexes 








Index FM %FM FFM 
Birth β coef. R2 Β coef. R2 Β coef. R2 
BMI (kg/m2) 0.01 0.05 0.28 0.04 0.01 0.19 
PI (kg/m3) 0.005 0.07 0.14 0.06 0.006 0.19 
Wt/length 
(kg/m) 
0.01 0.05 0.38 0.04 0.03 0.19 
SS+TR (mm) 0.003 0.05 0.05 0.04 0.005 0.20 
WC/length 
(cm/m) 
0.003 0.04 0.06 0.03 0.01 0.21 
 
b) 
Index FM %FM FFM 
4 weeks (visit 3) β coef. R2 Β coef. R2 Β coef. R2 
BMI (kg/m2) 0.02 0.01 0.49 0.02 0.019 0.03 
PI (kg/m3) 0.01 0.01 0.22 0.02 0.008 0.033 
Wt/length 
(kg/m) 
0.01 0.006 0.27 0.009 0.002 0.02 
SS+TR (mm) 0.003 0.004 0.05 0.001 0.01 0.005 
WC/length 
(cm/m) 
0.01 0.02 0.19 0.03 0.003 0.035 
 
c) 
Index FM %FM FFM 
5 months (visit 
4) 
β coef. R2 Β coef. R2 Β coef. R2 
BMI (kg/m2) 0.001 0.004 0.19 0.03 0.05 0.148 
PI (kg/m3) 0.001 0.005 0.05 0.03 0.01 0.130 
Wt/length 
(kg/m) 
0.01 0.006 0.28 0.03 0.03 0.125 
SS+TR (mm) 0.01 0.03 0.14 0.05 0.007 0.125 
WC/length 
(cm/m) 
0.003 0.007 0.003 0.03 0.02 0.141 
Table 6.5: Relationship between body composition measures obtained with PEAPOD 
and anthropometric indexes at a) birth, b) 4 weeks (visit 3) and c) 5 months (visit 4). All 
indexes presented low R2 values with weak effect size on FM and %FM at three different 







In this chapter we assessed the validity of FM equations against a reference method, 
PEAPOD. We also sought to investigate which anthropometric index best predicts body 
composition components up to 5 months of age. Our results show: i) Poor agreement 
between Lingwood (13) and Aris (14) FM equations and the reference criterion ii) PI is a 
better predictor of FM at birth but WC/length ratio has a stronger correlation with FM at 4 
weeks iii) All anthropometric indexes examined have a very low effect size on body 
composition and consistently explain a higher variation in FFM compared to FM. 
 
6.3.1 Validity of FM equations 
 
In this analysis we assessed the validity of Lingwood et al (13) and Aris et al (14) 
equations in predicting FM against PEAPOD measurements, which was used as the 
reference method. At birth, there was no mean difference between Aris equation and the 
criterion. At follow up assessments, mean differences were detected for both equations 
and the reference method. Both equations had low accuracy and precision for all time 
points as indicated by regression analysis. Results revealed that slope was different from 
1.0 at all assessments and the R2 and SEE values were consistently low and high 
respectively. Bland-Altman analysis revealed poor agreement between the equations and 
the criterion with wide 95% limits of agreement. 
 
As objective measurements of body composition are not yet widely available, prediction 
equations have been created to provide useful tools during clinical assessment. 
Equations presented in Table 6.1 have been recently developed and are increasingly 
cited when assessing infant FM. Deierlein et al (12) equation incorporates data from 
thigh skinfold thickness whereas Catalano et al (11) uses data from flank skinfold 
thickness. In our cohort skinfold thickness was assessed only at two sites, sub scapular 
and triceps, therefore due to lack of data in our dataset we were unable to assess those 
two equations. To our knowledge, Lingwood and Aris equations have only been validated 
once, using PEAPOD measurements as the reference method. Similar to our results, 
Cauble et al (15) showed poor agreement between the equations and the criterion.  
 
In an attempt to explain our results, we explored the main principles of the equations. 
Anthropometric equations are created based on large epidemiological studies. One of the 
main limitations is that equations should be applied only to groups which share similar 
characteristics (age group, ethnicity) to the reference population.  Both equations 





validated in older infants. This could explain the poor agreement found at 4 weeks and 5 
months follow up assessments but not the discrepancy at birth. Lingwood equation was 
based on a study on Australian population, of which 90% were of white European 
descent, whereas Aris equation was developed from Asian population living in 
Singapore, including Chinese, Indians and Malay neonates. Neither of these equations 
takes ethnicity into account. Our cohort comprises neonates from a multi ethnic 
background with 85% being White British and 15% Asians and Africans.  Ethnic diversity 
in body composition is well described (22), therefore the mismatch between the studied 
and validation population could have potentially biased the results.  
 
Finally, FM equations are based on anthropometric measurements, such as height, 
weight and skinfold thickness. Measurements are prone to intra- and inter-observer 
variability and infancy is a challenging period to acquire precise readings. Small 
deviations from the actual infant size would cause great diversity in the estimated FM. A 
detailed comparison between our study and data presented from the Kansas cohort (15) 
proves our hypothesis (Table 6.6). Neonates in the Kansas group were found to have 
lower triceps (5.6 ± 1.5 vs. 7.0 ± 2.8 mm) and sub scapular (5.3 ± 1.4 vs. 6.8 ± 2.5 mm) 
skinfold thickness compared to our study but the absolute (0.374 ± 0.170 vs. 0.361 ± 
0.175 kgr) and %FM (11.2 ± 4.3% vs. 10.6 ± 4.2%)  were found to be disproportionally 
higher when measured by PEAPOD. Assuming that PEAPOD measurements were 
performed under adiabatic conditions and as per operating protocols at both sites, 
differences can be explained by experimenter error or bias in obtaining the skinfold 
results. In our study, skinfold measurements were performed by the author, two research 
midwives and a research assistant. All staff was trained to obtain anthropometric 
measurements as indicated by WHO Multicentre Growth Reference Study (MGRS) and 
















 PEAPOD study Kansas Group 
Maternal age (yrs) 32.1 (5.4) 28.9 (4.8) 
Maternal BMI (kgr/m2) 30.3 (6.7) 25.8 (6.1) 
Gestational age (weeks) 39.0 (2.6) 39.2 (2.8) 
Birthweight (kgr) 3281 (0.499) 3497 (0.404) 
Triceps skinfold (mm) 7.0 (2.8) 5.6 (1.5) 
Subscapular skinfold (mm) 6.8 (2.5) 5.3 (1.4) 
%FM 10.6 (4.2) 11.2 (4.3) 
FM (kgr) 0.361 (0.175) 0.374 (0.170) 
Table 6.6: Comparison of mean values (SD) between our cohort and data obtained by 
the Kansas group (15). The discordant results between skinfold thickness and objectively 




6.3.2 Anthropometric indexes as predictors of body composition 
 
We have presented data showing that PI and WC/length are the best predictors of FM 
and FFM at birth respectively. We were unable to demonstrate consistency of the results 
found at birth across other age groups. Specifically, we found that WC/length ratio best 
predicted all body composition components during the 4 weeks assessment but SS+TR 
was a better predictor of FM at 5 months. We have also shown that anthropometric 
indexes explain only a small proportion of the variation in body composition as indicated 
by the low R2 values, therefore their use in clinical practice remains questionable. 
Furthermore we have shown that these indexes are more closely correlated to FFM 
rather than FM across all age groups. 
 
In 1970 Keys et al (24) was the first to evaluate weight-height indexes as measures of 
adiposity. Ten years later the International Dietary Energy Consultancy Group (IDECG) 
task force introduced BMI as a marker of “energy deficiency” (25). Since then, there has 
been a lot of controversy regarding the ideal index to describe adiposity. An 
anthropometric index should be able to identify any positive or negative correlation with 
adiposity but at the same time needs to be statistically robust to allow risk stratification. In 
other words, the ideal index should be closely related to adiposity and be independent of 
association with denominator (16). BMI and PI use the power of height in an attempt to 
eliminate any correlation with the denominator. BMI is highly correlated with weight but 
increasing evidence suggests that it is a poor index of fat, especially in children (26). 





FFM rather than FM changes, an observation more likely explained by the rapid 
developmental growth up to adolescence (5). Furthermore, both indexes cannot be used 
interchangeably across all age and ethnic groups. The optimal exponent for 
weight/lengthp ratio changes from 3 (PI) at birth to 2 (BMI) in adulthood (27).  
 
Evidence from cross-sectional studies confirms that the optimal anthropometric index is 
yet to be identified. Data from the INTERGROWTH 21st study suggests that the 
weight/length ratio is the best predictor of FM and FFM at birth in one of the largest, 
multi-ethnic cohorts studied ever (19). On the other hand, Cole et al. suggested that BMI 
is superior to simple weight/length ratio after studying 40,500 Dutch children (28). The 
same group described the weight/length ratio as statistically inappropriate due to high 
correlation with the denominator (29). Finally, reports from two smaller cohorts suggest 
the use of WC/length ratio (18) and the skinfold thickness (17) as optimal markers of 
adiposity. 
 
In our cohort we were unable to find a FM equation agreeing with our reference criterion 
and we failed to demonstrate an index which can strongly predict body composition 
throughout infancy. We strongly believe that our findings, as well as the controversial 
data derived from the studies described before, are due to the dynamic changes 
occurring in the early post natal period. Infancy is a period of rapid growth with great 
inter-individual variability. Infants are expected to increase their length by 30% by 5 
months and by 50% by 12 months. At the same time, they are expected to lose up to 
10% of their weight during the first 5 days and regain it by the end of the second week. 
Birthweight typically doubles by 5 months and triples by 12 months (30). Gender, 
ethnicity and feeding mode could be potential contributors to this variability. Females are 
known to have more FM and less FFM for a given weight when compared to males (31). 
In our previous chapters we have demonstrated that this gender dimorphism in body 
composition is present from the early stages of life. At the same time, specific 
populations, such as South Asians, are known to have higher FM for a given BMI (32), 
implying that universal application of FM equations and anthropometric indexes is 
unlikely to provide reliable findings. Feeding mode has not been addressed in any of the 
equations examined. Although data on body composition and feeding mode remain 
controversial, it is widely accepted that formula fed infants are more likely to lose less 
weight during the first 5 days of life (33). Finally, to further support our theory evidence 
shows a better agreement between equations and actual body size in childhood, 
adolescence and adulthood, periods were growth and body composition are more stable 








Currently used FM equations lack validation studies and are inappropriately used to 
estimate body composition. Our findings suggest that these equations lack accuracy and 
precision, leading to unreliable results during clinical assessment. The “gold standard” 
anthropometric index is yet to be identified. Commonly used indexes are not consistently 
correlated with adiposity across various study groups and some of them may be 
statistically flawed. Both FM equations and anthropometric indexes rely on 
measurements which are prone to intra- and inter-observer variability.  Tracking the 
origins of adult disease from the early stages of life requires better understanding of body 
composition and objective measurements of adiposity, such as ADP and DXA, could be 
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7.1 The origins of childhood obesity 
 
Childhood obesity is one of the major public health concerns of our century and is related 
to immediate (1, 2) and long term cardiovascular, metabolic and psychological adverse 
outcomes (3). Latest data from the European Childhood Obesity Surveillance Initiative 
(COSI) reveals that 25-30% of 13.7 million children aged 6-9 years are either overweight 
or obese (4). Severe obesity affects 400,000 children of school age in 21 European 
countries (Figure 7.1). Results are similar in England where 20% of children are affected 
by obesity by the age of 6 years (5). Secondary analysis of the data shows that parental 
obesity, low educational and socioeconomic status are linked to higher rates of childhood 
obesity. On the other hand, countries experiencing nutritional transition have lower rates. 
Longitudinal evidence support that childhood obesity is related to adverse phenotype and 
metabolism in adulthood (6). Data from 2017-2018 in England reveals that 10,660 
hospital admissions were attributed to obesity causing substantial costs to the NHS, with 
16 billion a year spent to conditions related to obesity (5). Currently in the UK, the 
number of adults with obesity is two times higher than those who are smoking. Given that 
childhood obesity has a huge impact on health, well being and economy it is of vital 
importance to tackle the epidemic by various approaches, from prevention to early 
diagnosis and treatment. 
 
 
Figure 7.1: Prevalence of childhood overweight, obesity and severe obesity in Europe; 
Adopted from Spinelli et al (4)  
 
 
The development of obesity is complex and multifactorial (Figure 7.2). It is a result of 





of modern societies such as unhealthy diet, low levels of physical activity and sedentary 
lifestyle have contributed to the obesity outburst. However, neither all people living in 
these environments will become obese nor all obese people will develop same adverse 
outcomes. The above observations suggest a role of genetic predisposition, with adverse 
phenotype developing when subjects are exposed to “obesogenic challenges”. Indeed, 
up to 40% of offspring BMI may be heritable (7) and epidemiological data suggests that 
in 25% of cases of childhood obesity at least one of the two parents is also obese or 
overweight (5). As genetic pool remains unchanged (or changes with very slow rate) the 
current obesity epidemic cannot be entirely attributed to genetic factors. Compared with 
siblings born before mother underwent bariatric surgery, siblings born after maternal 
weight loss display lower rates of obesity and better metabolic profile (8). The above 
highlight the role of intrauterine programming. Events occurring in the “plastic 
developmental period” metabolically imprint offspring for the rest of life. 
 
 
Figure 7.2: Determinants of childhood obesity. Genes, antenatal and postnatal exposures 
contribute to the pathogenesis of adverse phenotype 
 
 
Fetal growth is dependent on maternal environment and changes in nutritional, hormonal 
and metabolic conditions can affect the development of organs and gene expression. 
Barker et al (9) was the first to focus on the effects of maternal undernutrition and chronic 
cardiovascular disease. The “thrifty phenotype” hypothesis was further supported by 
epidemiological data from the Dutch famine (10). More recently, maternal overnutrition 
has been added to the developmental Origins of Health and Disease (DOHaD) concept 
(11). Maternal characteristics consistent with the lifestyle of modern days, such as 





future obesity and metabolic disorders. The early life programming of future diseases is a 
strong indicator that prevention strategies should be implemented in the pre-conception 
and antenatal period. The success of a pioneering prevention program aiming to improve 
offspring health via improving maternal health depends on the understanding of the 
pathophysiological mechanisms underpinning the developmental origins of metabolic 
diseases. Therefore it is of great importance to answer the following questions:  
 What is the missing link between adverse maternal characteristics and offspring 
obesity? 
 What are the mechanisms involved in the process of intrauterine programming? 
 How can we identify high risk groups from the early stages of life? 
 When is the best period to prevent or reverse adverse intrauterine programming? 
Purpose of the current thesis was to shed light to these questions and provide insight for 
further research. 
 
7.2 Maternal BMI, gestational weight gain (GWG) and glycaemia 
 
The parallel increase of maternal and childhood obesity was the first clue that maternal 
BMI may be a developmental factor (12). Higher maternal BMI translates to higher 
birthweight (BW), which in turn is strongly related to childhood obesity (13). Of great 
interest though is the fact that maternal BMI has a greater predictive value on future 
obesity than BW (14). The above observation confirms that BW is a rough estimate of 
fetal growth and detailed neonatal body composition is required to better understand the 
programming effect of maternal obesity. Up to date, the majority of studies assess the 
effect of maternal obesity using BW or skinfold derived FM equations as the outcome 
variable. In our study we assessed infant body composition using a direct measure, 
PEAPOD. We demonstrated that maternal BMI predicts higher neonatal adiposity up to 5 
months of age, independent of other maternal factors (GWG, glycaemic status).  
 
The optimal GWG has been an area of controversy for many years.  In 2009, IOM 
published guidelines on optimal weight gain to support adequate fetal growth and 
optimize maternal and neonatal outcomes (15). The role of GWG on adverse metabolic 
programming has received a lot of attention in the last decade but data on the effect of 
neonatal body composition remains scarce. Combined data from Europe, North America 
and Australia suggests that GWG above IOL recommendations explains up to 20% of 
childhood obesity (16). Results were consistent with subgroup analysis of the HAPO 
participants in China which demonstrated that excessive GWG is related to childhood 





to have increased adiposity and cord c-peptide levels at birth. Our study provides strong 
evidence that independent of maternal BMI, GWG is related to FM accumulation during 
the first 5 months of age. The vast majority of our participants were either overweight or 
obese therefore we were unable to assess the effect size of GWG based on maternal 
BMI. Previous studies consistently have shown that the effect of GWG on offspring 
outcomes attenuates as maternal BMI increases (16). One of the striking findings of our 
study is that GWG below IOM recommendations is related to lower FFM at birth.  
Similarly, Catalano et al, using neonatal anthropometry, showed that GWG < 5kgr is 
related to lower neonatal FFM (18). The fact that FFM is the most metabolically active 
tissue in human body (19) paired with the theory of collateral fattening in cases of FFM 
deficit (20) (theory will be analyzed later in this session) could potentially explain the 
increased adiposity and insulin resistance at 6 years of age, showed by the HAPO 
subgroup analysis from Hong Kong (Figure 7.3).  
 
 
Figure 7.3: Insulin concentrations at different time points during OGTT at 6 years old 
children, stratified by maternal BMI according to IOM recommendations. Gestational 
weight gain below recommendations has been proven to be equally harmful to excessive 
weight gain; Black circles: within recommendations; Triangles: below recommendations; 
Squares: exceeding recommendations; Adopted from Tam et al (17)  
 
 
The effect of maternal hyperglycaemia on fetal growth has been widely reviewed with the 
most robust data presented from the HAPO study (21). Maternal BMI is closely linked 
with glucose metabolism with maternal obesity related to higher fasting and post-prandial 
glucose levels (22). The above observation has raised the suspicion that increased 
adiposity at birth is not related to glycaemic status per se but more likely reflects the 
effect of maternal obesity. Our data confirms the independent effect of fasting and post 
prandial hyperglycaemia on neonatal FM, after adjusting for maternal characteristics 





diabetic glucose levels, showing a continuous relationship between maternal glucose and 
adiposity at birth. In our cohort, fasting glucose levels (OGTT0) seem to have a stronger 
effect on FM at birth when compared to post glucose load (OGTT120). 
 
7.3 What is the underlying pathogenic mechanism? 
 
In an attempt to identify the missing link between maternal adverse characteristics and 
neonatal adiposity we examined maternal and cord blood biomarkers. We demonstrated 
that maternal BMI is associated with higher glucose levels, higher insulin resistance and 
higher leptin levels. We also observed a trend between maternal adipocytokines and 
neonatal adiposity, which is positive in the case of leptin and negative in the case of 
adiponectin. We have shown that maternal BMI, glucose levels during OGTT and insulin 
resistance independently predict neonatal body composition. 
 
After examining cord blood biomarkers we found that cord adipocytokines and c-peptide 
are related to each other and with neonatal adiposity. Given that insulin is the main 
growth factor during fetal development (23) and maternal insulin cannot cross the 
placenta (24) we looked at associations between maternal factors and fetal insulin status. 
Fetal hyperinsulinaemia was correlated with maternal insulin resistance but not with 
maternal BMI or glucose levels during OGTT. Taking into consideration the above 
observations we support that insulin resistance is the major metabolic factor 
underpinning the relationship between maternal intrauterine environment and body 
composition at birth. 
 
Pregnancy is a period of “hormonal challenges” for the human body. Placental 
hormones, such as estradiol, progesterone and placental lactogen promote insulin 
resistance in order to secure adequate nutritional supply to the growing fetus (25). In 
cases of maternal obesity the insulin resistance is exaggerated due to the maternal pre-
pregnancy metabolic status. Similarly, excessive GWG is related to higher insulin 
resistance. Although weight gain in pregnancy occurs to support the developing fetus, 
excessive weight gain results in central fat accumulation which promotes insulin 
resistance (26). As a result of reduced insulin sensitivity, lipogenesis and protein 
synthesis are suppressed and hepatic gluconeogenesis is enhanced. Circulating levels of 
glucose, amino acids and free fatty acids cross the placenta and stimulate fetal insulin 
secretion. Given the anabolic effect of insulin and the preferential action on FM rather 
than FFM (27), fetal hyperinsulinaemia leads to adiposity and macrosomia, an effect 





independent of maternal BMI and glucose tolerance, on neonatal adiposity has been 
previously shown by other researchers (28-30). Of great importance, transmission of 
obesity to offspring post bariatric surgery is reduced even if mothers remain overweight, 
suggesting that insulin resistance, rather than maternal BMI, is the responsible 
pathogenetic factor (31).  
 
 
Figure 7.4: Fuel mediated teratogenesis. Glucose, proteins and lipids transplacental 
transport affects offspring adiposity 
 
 
7.4 What about maternal characteristics and childhood obesity? 
 
The correlation between maternal BMI, GWG and future risk of obesity is complex. 
Maternal metabolic status can affect offspring metabolic trajectories via genetic factors, 
intrauterine programming, epigenetic effects and shared post natal obesogenic 
environment.  Furthermore, it is difficult to quantify the effect of GWG as it reflects not 
only maternal nutritional affluence but also the growth of fetus, placenta and uterus. In 
addition, a great proportion of GWG is attributed to fluid retention. On the other hand, the 
correlation between maternal adverse characteristics and future obesity, traced from 
infancy to adulthood suggests a role of developmental programming.   
 
We demonstrated that cord leptin and c-peptide levels reflect fetal FM and are also 
related to maternal insulin resistance. We suggest that fetal/neonatal hyperleptinaemia 
and hyperinsulinaemia are important programming factors of future obesity. In humans, 
hypothalamus, the main centre for satiety and energy expenditure control, develops 





actions and are required for the correct formation of neuronal projections (32). Evidence 
from animal models suggests that prolonged exposure to supraphysiological levels of 
leptin (33) or insulin (34) alter hypothalamic structure and function, promoting the 
development of orexigenic over anorexigenic neurons in the ARC. As a result, offspring 
develop hyperphagia, obesity and impaired glucose metabolism.  At the same time, data 
reveals that the early post natal period is characterized by “plasticity and reversibility” 
and exposure to favorable environment could potentially revert any adverse metabolic 
programming (35). We speculate that maternal insulin resistance adversely programs the 
hypothalamus via increased fetal hyperleptinaemia and hyperinsulinaemia leading to 
future metabolic dysfunction. 
 
7.5 Answering the hard questions 
 
Interventions during pregnancy (diet, physical activity), despite reduction in GWG, have 
little effect on pregnancy outcomes (GDM, HTN) and fetal overgrowth (birthweight, LGA). 
It has been suggested that wide variability of the interventions and their intensity, poor 
compliance of the case group and cross-motivational effect on the control group may 
explain the results. At the same time, interventions starting at the pre-conception period 
have shown promising results (36, 37). In animal models diet interventions before 
pregnancy normalize neonatal adiposity, leptin and insulin levels leading to improved 
metabolic profile in adulthood (38, 39). The above observations lead to the following 
questions: i) Do we intervene too late? ii) Does maternal adverse metabolism affect 
developmental programming during early pregnancy? 
 
The intrauterine development of adipose tissue is summarized in Figure 7.5. Adipose 
tissue is not present before 14 weeks of gestation. At that point aggregation of 
mesenchymal cells starts form the head to the trunk and finally to the limbs. Around 16 
weeks of gestation the first pre-adipocytes are formed. The period between 19-28 weeks 
of gestation is characterized by maturation of adipocytes, followed by a period of rapid 
adipose tissue accumulation until term (40). Of importance, between 23 and 28 weeks of 
gestation the number of adipocytes remains constant and it is only the size which 
changes. Therefore, the window between 14-23 weeks of gestation may be 
characterized by developmental plasticity with adverse events affecting proliferation and 
differentiation of adipocytes (41, 42). In fact, evidence from animal models suggest that 
nutritional and hormonal signals in early pregnancy upregulate proliferation and PPARγ 








Figure 7.5: Fetal adipose tissue development. Adipocytes present at 14 weeks of 
gestation and accumulate rapidly during the third trimester 
 
 
In the last decade, accumulating evidence suggests that maternal metabolic status 
during preconception and early pregnancy plays a crucial role in offspring metabolic 
imprinting through altered placental growth and epigenetic modifications (45). Placenta is 
a complex organ which acts as a nutrient sensor in an attempt to match maternal supply 
with fetal requirements. Placental weight is strongly related to neonatal adiposity (46) and 
mothers with obesity are known to have heavier placentas (47). Once again, the link 
underpinning the above association is increased maternal insulin resistance (Figure 7.6). 
Maternal hyperinsulinaemia affects mitochondrial function (48) and leads to hyperplastic 
placenta (49). In turn, the excess of placental hormones increases maternal insulin 
resistance further, leading to unopposed transfer of nutrients to fetal circulation and 
macrosomia. Furthermore, hyperinsulinaemia is related to placental over-expression of 
amino acid and lipid transporters contributing further to the excessive fetal supply (50).  
 
Human’s phenotype is determined not only by the DNA sequence but also by information 
inherited due to gene expression, the later mechanism known as “epigenome”. During 
gametogenesis genes are expressed or silenced leading to the inheritance of a new 
regulatory state. DNA methylation is the most described epigenetic mechanism (51). 
Maternal obesity is linked to altered methylation of the PPARγ promoter in fetuses 
resulting in increased adipogenesis (52, 53). Children born to mothers before and after 
bariatric surgery present differences in the methylation of the glucoregulatory gene. (54) 
Furthermore, maternal hyperglycaemia is related to altered DNA methylation in the fetal 
liver and pancreas, causing adverse epigenetic programming (55, 56). Tracing epigenetic 
modifications in offspring with obesity from birth to early adulthood has revealed that 
methylation sites at birth may attenuate, disappear or be replaced by new sites (57). The 





and can also be mediated by environmental factors. Body composition and metabolic 
changes at birth, such as neonatal insulin resistance and adiposity may drive 
physiological pathways causing obesity later in life, even if the related epigenetic 
mechanisms attenuate. At the same time, early post natal life is the right period to 
intervene to reverse any adverse metabolic programming. 
 
 
Figure 7.6: Preconception maternal hyperinsulinaemia and fetal overgrowth. 
Hyperinsulinaemia can affect placental growth but also transplacental nutrient transport 
resulting in fetal macrosomia and adiposity; Adopted from Catalano et al (45)  
 
 
7.6 Putting everything together 
 
Maternal obesity is characterized by metabolic derangements and through genetic and 
lifestyle differences is linked to increased adiposity, gestational weight gain, 
hyperglycaemia and insulin resistance. The developmental programming occurs 
throughout pregnancy and early postnatal life and lifelong metabolic imprinting is 
mediated through altered tissue structure and function (Figure 7.7). Exposure to maternal 
obesity and increased insulin resistance in early gestation causes altered placental 
growth and epigenetic alterations to key organs (liver, muscle, adipose tissue) setting 
adverse metabolic trajectories for the offspring. Throughout pregnancy, the increased 





macrosomia and adiposity. The increased fetal insulin and leptin levels, caused either by 
nutritional stimulation and fat mass accretion or by overexpression of genes (epigenetic 
mechanism), alter hypothalamic structure leading to hyperphagia, obesity and impaired 
metabolism in the future. 
 
 




7.7 Early postnatal life - Is it too late to intervene? 
 
In humans, hypothalamic circuits develop during late pregnancy and early postnatal life. 
Arcuate nucleus is the regulatory centre of appetite and energy. Metabolic hormones, 
such as leptin and insulin are crucial for the formation of the hypothalamic circuitry (32). 
Animal studies suggest that early postpartum is a period of plasticity where interventions 
can determine future metabolic trajectories (58).  Of great importance evidence suggest 
that “favorable” conditions during early life can alter adverse intrauterine programming 
leading to better metabolic health in future (35). Knowledge obtained from animal studies 
provides insight into ways to prevent childhood obesity. Early identification of high risk 
groups with implementation of prevention strategies from the early stages of life could be 
the way to tackle the epidemic. 
 
Birthweight and BMI have been traditionally used as markers of obesity. Although easy to 
obtain, both markers don’t precisely reflect intrauterine growth and body composition of 





skinfold thicknesses have been extensively used by researchers to estimate body 
composition. However, these measurements are prone to inter and intra observer 
variability and have not been validated in all age groups (e.g. neonates) (60). Using 
PEAPOD as the reference method to assess infant body composition we revealed no 
agreement between the reference method, skinfold thickness and FM equations. Direct 
techniques of assessing adiposity, such as PEAPOD, MRI and DXA are not widely 
available due to cost of the equipments (all) and time required (MRI and DXA) for each 
test and their use is currently restricted to research purposes.  
 
The above observations led us to investigate the role of cord blood biomarkers in 
predicting future adiposity. Our results show that cord blood leptin, adiponectin and c-
peptide are useful objective markers of neonatal FM. Using data from our cohort and 
evidence from our systematic review we showed that cord leptin is negatively related to 
adiposity up to 3 years of age with the association becoming positive thereafter. Of great 
interest, we found that cord blood c-peptide seems to follow the same trend with leptin, at 
least up to 5 months of age. The negative correlation during the first 3 years of life can be 
explained by the metabolic profile of leptin. Infants with increased adiposity, thus higher 
leptin levels, develop a “compensatory behavior” driven by the leptin’s effect on appetite 
and energy expenditure. The “honeymoon” period of negative energy balance is followed 
by hyperphagia and fat mass accretion leading to increased weight gain and adiposity by 
7 years of age. In animal models, there is evidence that the obesogenic offspring 
behavior is a result of adverse hypothalamic programming and leptin resistance. 
Abnormal levels or abnormal surge of leptin and c-peptide during early postnatal life lead 
to altered hypothalamic structure favoring the development of orexigenic over 
anorexigenic neurons (33, 34). At the same time, intrauterine exposure to adverse 
maternal environment leads to altered organ development resulting into increased leptin 
resistance in liver, muscle and adipose tissue (61). This adverse programming becomes 
clinically evident in early childhood (Figure 7.8).  
 
The concept of using cord blood biomarkers to identify neonates at high risk of obesity is 
promising. Samples are obtained directly from the cord, not from the neonate, without 
requiring any special training for staff. The potential development of “point of care” kits to 
measure cord blood levels will allow the identification of high risk groups within minutes 
after birth. Extending our findings to a larger cohort with follow up assessment of body 
composition in early childhood will provide robust data for the predictive value of cord 
biomarkers. This will allow targeted implementation of prevention strategies aiming to 






Figure 7.8: Leptin as a predictor of future obesity. Abnormal leptin levels affect 
hypothalamic development, resulting in early leptin resistance, hyperphagia and 
adiposity. Neonatal hyperleptinaemia leads to a compensatory behavior during the first 3 
years of life 
 
 
7.8 Gestational diabetes mellitus (GDM) 
 
GDM is defined as glucose intolerance of different degrees that is first diagnosed during 
pregnancy. The pathogenesis of GDM is a combination of increased insulin resistance 
and insufficient insulin secretion. In other words, beta cell function is not able to 
overcome the level of insulin resistance in order to maintain euglycaemia. GDM parallels 
the obesity epidemic, complicating 2-6% and 9% of pregnancies in Europe (62) and US 
(63) respectively. There is no universal consensus on optimal screening and diagnostic 
criteria but it is widely accepted that pregnancies complicated by GDM are related to 
short and long term adverse outcomes for both mother and offspring. Women who 
develop diabetes during gestation may already have an impaired metabolic profile which 
is unmasked due to the stressogenic effect of pregnancy on metabolism. They comprise 
a high risk population having two times higher risk for cardiovascular disease (64) and at 
least seven times higher risk for type 2 diabetes mellitus (65). Uncontrolled maternal 





outcomes (21). Strong evidence from the HAPO study suggests that offspring of 
pregnancies complicated by GDM have higher adiposity and impaired glucose 
metabolism at 10-14 years of age (66). Treatment of GDM (lifestyle interventions, 
metformin and insulin) has been shown to improve maternal and offspring perinatal 
outcomes (67) but fails to prevent childhood obesity (68). The exact mechanism leading 
to future obesity in cases of treated GDM remains unclear. 
 
In our study, we assessed the effect of GDM on infant body composition up to 5 months 
of age. We diagnosed GDM based on NICE criteria (69) following OGTT at 28 weeks of 
pregnancy. Women diagnosed with GDM received regular antenatal care, lifestyle advice 
and treatment with metformin and/or insulin. Treatment interventions in the GDM group 
resulted in optimal glycaemic control, as indicated by the levels of HbA1c (mean value: 
34.9 mmol/mol). We observed that GDM group gained less weight (mean weight gain 
was 3 kgr) than IOM recommendations (15) and was delivered ten days earlier than the 
control group of nGDM pregnancies. Using an accurate technique of measuring body 
composition (70), PEAPOD, we assessed infants at three time points: birth, 4 weeks and 
5 months postpartum. We used statistically robust indexes (FMI, FFMI) to allow 
adjustments for infant size. We presented data showing that treatment of GDM prevents 
neonatal macrosomia at the cost of reduced FFM. After adjusting for maternal 
characteristics we showed that reduced GWG and earlier induction of labour were the 
main determinants of low FFM in the GDM group. Finally, we demonstrated that by 5 
months of age offspring of the GDM group, despite optimal maternal glycaemic control, 
develop accelerated growth driven by FM accretion. 
 
Our study supported the observation of early adiposity rebound shown by Logan et al 
(71) in GDM offspring despite optimal maternal glycaemic control and exclusive breast 
feeding. Using paired MRI scans at 11 days and 10 weeks of post partum, they revealed 
that offspring exposed to maternal GDM have increased adiposity at 10 weeks despite 
similar adiposity levels at 11 days after delivery. Authors suggested that this observation 
may be due to altered hypothalamic signaling leading to hyperphagia or differences in 
the composition of breast milk. They did recognize though that data on breast milk 
composition in mothers with GDM are scarce and they suggested future research on this 
field. Our study not only supported this observation using another objective measure of 
adiposity but extend this observation to 5 months of postpartum in a much larger sample 
size. 
 
The role of maternal hyperglycaemia in adverse metabolic programming is beyond doubt. 





glucose leads to fetal hyperinsulinaemia, macrosomia and adiposity. We have previously 
presented data that maternal hyperglycaemia in early pregnancy is related to altered 
placental growth and epigenetic modifications which in turn result to altered tissue 
structure and function. Of great importance, maternal hyperglycaemia leads to lower 
leptin gene methylation in fetal adipocytes, resulting in higher cord blood leptin levels 
(Figure 7.9) (73). Recent ultrasound findings suggest that adverse fetal growth is present 
even at 20 weeks of gestation, preceding the diagnosis of GDM (74-76). Consistent with 
these findings, we showed that fetuses whose mothers will eventually develop GDM 
have higher estimated fetal weight and head circumference during the 20 weeks scan. In 
this study, we showed that despite optimal glycaemic control, offspring of pregnancies 
complicated by GDM have higher insulin resistance at birth, indicated by higher c-peptide 
levels for a given FM. The above observations suggest that adverse metabolic 
trajectories may be set prior to the diagnosis of GDM by causing some form of beta-cell 
dysfunction and optimization of intrauterine environment during early pregnancy is crucial 
to prevent future obesity.  
  
We believe that the effect of developmental programming on offspring phenotype is 
unlikely to present during infancy, therefore we suggest that early adiposity rebound 
cannot be due to adverse hypothalamic programming, as proposed by Logan et al. 
Results of our systematic review and analysis of cord blood biomarkers in our cohort 
support the above statement. Cord blood leptin seems to be negatively related to 
adiposity up to 3 years of age, shifting to a positive correlation thereafter. Instead, we 
propose that the increased adiposity noted in early infancy in our GDM group is driven by 
low FFM at birth, a phenomenon known as “collateral fattening” (20). FFM is the most 
metabolically active tissue in our body and is responsible for 70% of Resting BMR. Data 
suggests a feedback system between FFM and satiety center. In cases of FFM excess 
hunger is increased to match the requirements (passive role) and in cases of FFM 
deficiency hunger is triggered to restore the deficit (77). “Collateral fattening” describes 
the excessive fat mass accretion as a result of body’s attempt to correct FFM deficit 
through hyperphagia. The concept was first described following the Minnesota 
Experiment at the end of World War II (78). Healthy adults after 24 weeks of semi-
starvation followed by 20 weeks of re-feeding regained more weight and FM than they 
initially lost. Hyperphagia and fat mass accretion continued until FFM was completely 
restored (Figure 3.23). The imbalance in FM/FFM partitioning could be explained as an 
adaptive mechanism in which body stores higher amounts of FM in order to be prepared 
for the next nutritional scarcity. Furthermore, hyperphagia may exceed the synthetic 
capacity of FFM causing the excess calories to be deposited as FM. In summary, 





macrosomia at the cost of FFM. The FFM deficiency triggers a “reactive mechanism” 
which results in “fat overshoot”. Rapid postnatal weight and FM accretion contribute 
further to the adverse metabolic programming and the development of future obesity. 
 
7.9 Summary of the key messages 
 
Diagnostic criteria and therapeutic approach of pregnancies complicated by GDM aimed 
to reduce perinatal outcomes and identify women at risk for type 2 diabetes mellitus.  
HAPO study revealed a continuous association between maternal glucose, adverse 
perinatal outcomes and neonatal adiposity without any clear “cut off” (21). Latest results, 
highlighting the association between GDM and childhood adverse metabolism, add 
further to the need of amending our approach in order to reduce the risk of future obesity 
for the offspring (66). In other words, management of GDM, from preconception to 
diagnosis and treatment, should be tailored not only to prevent short term but also long 
term adverse outcomes. Accumulating data suggests that we may interfere too late, 
when metabolic trajectories are already set by the effect of impaired glucose metabolism 
(namely insulin resistance or impaired glucose tolerance or hyperglycaemia) during the 
early stages of life (79). Ideally, we would like all mothers to have optimal metabolic 
profile in early pregnancy, therefore, we should implement lifestyle interventions in the 
preconception period. As a big percentage of pregnancies are unplanned and women do 
not see their doctors until the end of the first trimester it would be difficult to identify 
potential candidates (80). Considering the difficulties of engaging mothers during 
preconception or early pregnancy, researchers have turned their attention in creating risk 
models (using maternal characteristics and biomarkers) to identify high risk mothers 
during the first trimester. Results of ongoing studies (PRiDE and STRiDE) are highly 
anticipated as they will allow selective and targeted approach to those most needing it. 
On the other hand, raising public awareness on the importance of preconception care 
could potentially lead more women to seek medical advice. A pregnancy complicated by 
GDM, should not be considered as a catastrophic event for maternal and offspring 
metabolism but as a chance to improve maternal health for consequent pregnancies. 
Therefore, lifestyle interventions and follow up care should be implemented in the 
immediate postnatal period. 
 
The term “Health Technologies” describes every intervention aiming to promote public 
health by preventing and treating diseases. Health Technology Assessment” assesses 
the cost-effectiveness and the impact of every implemented intervention. As such, 





perinatal outcomes (e.g caesarian section) via controlling fetal growth (81). However, real 
life data suggests that induction of labor and rate of caesarian sections are higher in 
pregnancies complicated by GDM (74). Our results are consistent with these findings 
with our GDM group delivered on average 9 days earlier. Furthermore, we showed that 
intensified management of GDM led to weight gain below IOM recommendations. Early 
induction of labor and inadequate weight gain in our cohort was associated with reduced 
FFM, potentially causing early adiposity rebound and high cardiovascular risk in the 
future. Our findings are in agreement with data presented by Catalano et al (18) and 
suggest that “weight reduction” should be replaced by “weight gain limitation”. We 
propose that GWG targets should comply with IOM recommendations until new robust 
data is available. We hope that our data provides insight on the optimal timing of delivery 
and raise queries regarding current practices. New studies (Big Baby) looking at the 
association between time of delivery, short (still birth) and long (low FFM driving future 
obesity) term adverse outcomes will enable RCOG and NICE to develop evidence based 
guidance to direct clinical practice. The cost-effectiveness approach which is currently 
adopted by NICE shouldn’t be based solely on immediate perinatal outcomes but also 
take into account long term adverse outcomes and the impact of childhood obesity on 
NHS resources. 
 
7.10 Does one size fit all? Effect of ethnicity on body composition 
 
There has been a long standing controversy regarding the optimal way to monitor fetal 
growth. Despite the universal agreement regarding customized growth charts based on 
gender and gestational age, there is no consensus regarding maternal ethnicity (82). The 
close relationship between rates of SGA and perinatal mortality seen when ethnic-
specific standards are used has led many to support that growth charts should be also 
customized for maternal ethnicity (83). On the other hand, Intergrowth 21st study has 
recently shown that growth is affected more by health, socioeconomic and environmental 
factors rather than ethnic and genetic characteristics. The team suggested that variability 
in fetal/neonatal characteristics is <3% between ethnic groups, provided that maternal 
health and fetal intrauterine conditions are optimal (84). If we take a closer look at both 
approaches, we will realize that they convey the same message. Ethnic-specific 
standards do not take into account intrauterine environment and heavily rely on genetics. 
For example, a mother of SA origin born in Asia will come under the same category with 
a mother of SA origin born in a European country (first or second generation migrant). On 
the other hand, participants of the Intergrowth study had to fulfill very strict inclusion 





the fetus. The “gap” between developed and developing countries, rural and urban areas 
sets the generalizability of these results under question. Overall, combined messages 
from both approaches reveal that fetal/ neonatal characteristics should be similar, 
provided that maternal characteristics and intrauterine environment remain constant.  
 
Our study provides unique data on body composition of infants of SA and white 
European descent as we revealed no between group differences up to 5 months of age. 
Our data strongly suggests that the role of intrauterine programming is far more 
significant than this of genetic predisposition. In our cohort, both groups shared same 
maternal characteristics, except lower BMI in the SA cohort, which could potentially 
explain the lower birthweight observed in their offspring. We further examined surrogate 
markers of maternal metabolism and we remarkably showed that both groups shared 
similar insulin resistance and adipocytokines levels. Based on maternal demographics, 
we speculate that the improved metabolic and antenatal health of our SA cohort 
compared with SA residing in Asia could be a result of higher socioeconomic status, 
higher education, balanced diet and better access to healthcare services. We also 
hypothesize, that due to the “healthy migrant effect” mothers of SA origin experienced a 
favorable intrauterine environment as fetuses, resulting in higher height, higher weight 
and improved metabolic status (85). As a result, exposures and environments 
experienced by one generation (SA mothers) relate to the health development of the next 
generation (SA offspring) and the convergence of adiposity rates similar to native (White 
British) population. 
 
In conclusion, we support that maternal intrauterine environment, irrespective of maternal 
ethnic background, can set offspring metabolic trajectories. Imprinted genes can be 
modified by antenatal fetal exposures and favorable intrauterine environment can affect 
structural and functional development of organs responsible for future metabolic health. 
Although of reasonable size (and the largest for having serial objective adiposity 
measurements until 5 months of age), the size of our cohort is one of the main limitations 
in the generalizability of our results. However, the use of detailed maternal 
demographics, maternal biomarkers and the assessment of infant composition with 
PEAPOD add to the validity and credibility of our results. It would be of great importance 
to follow up our cohort and assess metabolic markers in order to examine whether these 









7.11 Conclusion – The intergenerational effect 
 
Intergenerational effect can be summarized as “those factors and conditions experienced 
by one generation that relate to the development and health of subsequent generations”. 
Intergenerational programming is a combination of three mechanisms:  
i) shared genes between mother and the offspring;  
ii) environmental conditions which may be similar across different generations and  
iii) intrauterine programming.  
The latter mechanism describes the sequence of female fetuses exposed to adverse 
intrauterine environment becoming mothers with adverse metabolism and subsequently 
giving birth to offspring with impaired metabolic trajectories (Figure 7.9). We have 
previously described the role of intrauterine programming and provided evidence to 
suggest that what appears to be genetic may in fact be a programming influence that has 
been running through several generations. From conception to early postnatal life the 
future of every cell, every tissue is dictated by “developmental programming”. Human’s 
physiology, in other words, is programmed by the intrauterine conditions the fetus is 
growing. Understanding the timing of tissue development is crucial to assess whether 
interventions can affect the metabolic function in the future.  
 
 
Figure 7.9: Developmental programming and intergenerational effect; Red boxes 
represent pathogenetic mechanisms; Green boxes represent intervention strategies. 







Pregnancy, from preconception to early postpartum, is the ideal opportunity to intervene 
as mothers are highly motivated to adopt behaviors which will protect their offspring. A 
temporary improvement in maternal health could potentially improve health of 
succeeding generations. Interventions, such as lifestyle changes, need to be 
implemented in the preconception period and continue throughout pregnancy. The 
development of risk assessment models to identify high risk pregnancies will allow 
targeted approach to those most in need, constituting a cost-effective way in tackling the 
obesity epidemic from its routes. The importance of early postpartum, a period of 
developmental plasticity, should not be ignored. For mothers, it should be an opportunity 
to improve their metabolic health and well being as they will be getting ready for 
subsequent pregnancies. For offspring, the potential use of early life biomarkers to 
identify those at high risk of future obesity, will allow implementation of early intervention 
strategies, such as parental education on the benefits of exclusive breastfeeding, healthy 
diet options and physical activity. 
 
7.12 Future plans and recommendations 
 
The current thesis is part of a larger study taking place at GEH, aiming to recruit 3,000 
participants by 2022. It would be of great interest to see if findings from our cohort are 
consistent with these of a larger population. Our data suggests that insulin resistance is 
the missing link between maternal adverse characteristics and neonatal adiposity. The 
observational design of our study can only establish associations, but not causality. To 
further support the theories of “insulin resistance” and “fuel teratogenesis” we suggest 
the analysis of additional maternal biomarkers, such as triglycerides, free fatty acids and 
amino acids, looking at their correlation with maternal insulin resistance and neonatal 
adiposity. We strongly suggest follow up studies of our cohort looking at offspring body 
composition and metabolic markers in early childhood. We encourage the use of 
objective measures to assess body composition, in specific the child/adult version of 
PEAPOD, BODPOD. Data obtained could potentially shed light on the role of intrauterine 
programming on long term offspring metabolic trajectories and the predictive value of 
cord blood biomarkers on future obesity.  
 
We presented unique data supporting that intrauterine exposures can override genetic 
predisposition. Specifically, we showed that offspring of SA origin born in the UK share 
similar infant body composition with White Europeans when maternal characteristics and 
intrauterine exposures are matched. In order to provide evidence on the generalizability 





suggest that ethnicity questionnaires should also capture information on the paternal 
ethnicity in an attempt to better characterize offspring’s ethnic background. Fathers could 
potentially have an indirect epigenetic effect on offspring by influencing their partner’s 
diet, thus influencing intrauterine environment. 
 
Finally, we speculate that the timing of intervention strategies is crucial in the prevention 
of adverse outcomes. Therefore, we provide the following recommendations for future 
research and clinical practice:  
i) design of randomized control trials looking at the association of preconception 
interventions with maternal metabolism and objectively measured offspring 
adiposity;  
ii) creation of early pregnancy individualized risk models to identify pregnancies 
at high risk of developing GDM or adverse perinatal outcomes and  
iii) development of postnatal strategies aiming to improve maternal health for 
subsequent pregnancies to potentially reverse adverse intrauterine 
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Throughout our study, all participants had to sign a written consent form prior to being 
recruited. This consent form explicitly asked for the mothers’ permission to carry out 
genetic and molecular tests on the blood and tissue samples (maintaining anonymity), 
even after the completion of the study, for medical and research purposes in the future. 
Research staff was always present during consenting in order to answer any questions 
or clarify further any statements on the form. 
 
Only competent pregnant mothers with capacity to understand information about the 
study and give their valid consent were recruited. Due to the ethnic diversity of the study 
group we came across participants who did not have a good understanding of the 
English language. As we highly value the contribution of ethnic minorities in our study we 
made provisions for participants to understand information provided and give informed 
consent. In such cases, a qualified interpreter went through the patient information sheet 
and assisted in the informed consent process. Participants were also offered the choice 
of interpreter’s presence in the subsequent study visits. During the study, we did not 
identify any participant with other communication barriers, such as reading or hearing 
difficulties. 
 
Human Biological Material 
 
Consent form clearly asked participants consent on collecting and storing serum and 
cord blood samples for further analysis, including gene tests. It also firmly stated that 
results would be kept confidential and not revealed to the individual. Purpose of storing 
samples was to analyze further biomarkers during the course of the study, on top of the 
initial biochemical tests, in an attempt to understand the underlying mechanisms and 
pathophysiology of GDM. 
 
All samples were stored in the pathology laboratories at GEH under the local pathology 
network and under the custody of Prof. Saravanan (Chief Investigator). Only laboratory 
and research staff assigned to carry out investigations from the blood samples was given 






Risks and Burdens 
 
As this was a non-interventional study, the risks to the participants were minimal. All of 
the study visits coincided with participants’ routine pregnancy visits with midwives or 
hospital clinics. However, some participants may have been inconvenienced by the two 
extra visits (4 weeks and 5 months postpartum), therefore we tried to arrange a suitable 
day and time for them, reimbursing any extra costs like transport or parking. Participants 
would usually spent 15 additional minutes during their recruitment visit in completing 
questionnaires for the study. However, they were asked to complete them during their 
two hours wait for the repeat OGTT test. 
 
Maternal blood sampling also coincided with routine blood testing (OGTT) and samples 
at birth were obtained from the cord and not from the mother. Anthropometric data 
collection was painless, aside from the use of calipers which was felt as “a pinch of the 
skin”. ADP principles (utilizing circulating air and body’s volume) ensured the safety of 
the PEAPOD measurement. 
 
Non-research staff was asked to collect and centrifuge cord blood samples when 
participants delivered out of working hours. In order to thank them for their kind 
participation and reimburse them for the extra time spent in collecting samples for our 
study a £5 voucher was provided for every ten cord blood samples collected. 
Furthermore souvenirs, like pens, mugs and bags with the study logo, were provided to 




As this was an observational study, there were no direct benefits for the participants. 
Knowing that their participation in the study would help raise awareness on the effect of 
maternal adverse risk factors on offspring’s body fat mass and future health was on its 
own rewarding for the majority of participants. Furthermore, instant access to the body 





Recommendations from the NHS Code of Confidentiality and University of Warwick data 





participant was given a unique study ID which followed them throughout the study. Data 
and bloods obtained were labeled with that ID number. Only the research team members 
who came into direct contact with the participants had access to their personal data, 
whilst everyone else had only access to their pseudoanonymised data via the unique 
study ID. The former group included the author and the two research midwives who had 
to take informed consent and carry out anthropometric measurements. Since this was a 
prospective longitudinal study, following up the participants throughout the pregnancy 
and immediate postpartum was an essential part of it. This is the reason why author and 
research midwives had access to the participants’ obstetric records for the duration of the 
study. 
 
Paper case report forms and files were stored in the Diabetes Research office. Access to 
the office was through a password protected door and allowed only to authorised 
members of the staff. After completion of the study all paper data was converted to 
electronic using password protected computers at GEH or University of Warwick 
premises. PEAPOD database was transferred to these computers using encrypted 
(password protected) USB sticks provided by the university or the hospital. Personal 
identifiable data was not required for the analysis, thus not entered to the electronic 
database. 
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observational study involving pregnant patients, George Eliot Hospital (GEH) acted as 
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Appendix 5: Quality assessment score of the included studies; Y: yes, N: no, NA: 
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